{"ref-id":"A202103","pubmed-id":32117299,"citation":"Deveuve Q, Lajoie L, Barrault B, Thibault G: The Proteolytic Cleavage of Therapeutic Monoclonal Antibody Hinge Region: More Than a Matter of Subclass. Front Immunol. 2020 Feb 11;11:168. doi: 10.3389/fimmu.2020.00168. eCollection 2020.","parent_key":"BE0002094"}
{"ref-id":"A202103","pubmed-id":32117299,"citation":"Deveuve Q, Lajoie L, Barrault B, Thibault G: The Proteolytic Cleavage of Therapeutic Monoclonal Antibody Hinge Region: More Than a Matter of Subclass. Front Immunol. 2020 Feb 11;11:168. doi: 10.3389/fimmu.2020.00168. eCollection 2020.","parent_key":"BE0002095"}
{"ref-id":"A202103","pubmed-id":32117299,"citation":"Deveuve Q, Lajoie L, Barrault B, Thibault G: The Proteolytic Cleavage of Therapeutic Monoclonal Antibody Hinge Region: More Than a Matter of Subclass. Front Immunol. 2020 Feb 11;11:168. doi: 10.3389/fimmu.2020.00168. eCollection 2020.","parent_key":"BE0002096"}
{"ref-id":"A1713","pubmed-id":17139284,"citation":"Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.","parent_key":"BE0002097"}
{"ref-id":"A1715","pubmed-id":17016423,"citation":"Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.","parent_key":"BE0002097"}
{"ref-id":"A13078","pubmed-id":17704420,"citation":"Zhang W, Gordon M, Schultheis AM, Yang DY, Nagashima F, Azuma M, Chang HM, Borucka E, Lurje G, Sherrod AE, Iqbal S, Groshen S, Lenz HJ: FCGR2A and FCGR3A polymorphisms associated with clinical outcome of epidermal growth factor receptor expressing metastatic colorectal cancer patients treated with single-agent cetuximab. J Clin Oncol. 2007 Aug 20;25(24):3712-8.","parent_key":"BE0002097"}
{"ref-id":"A13079","pubmed-id":7547242,"citation":"Negri DR, Tosi E, Valota O, Ferrini S, Cambiaggi A, Sforzini S, Silvani A, Ruffini PA, Colnaghi MI, Canevari S: In vitro and in vivo stability and anti-tumour efficacy of an anti-EGFR/anti-CD3 F(ab')2 bispecific monoclonal antibody. Br J Cancer. 1995 Oct;72(4):928-33.","parent_key":"BE0000710"}
{"ref-id":"A1713","pubmed-id":17139284,"citation":"Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.","parent_key":"BE0002098"}
{"ref-id":"A1715","pubmed-id":17016423,"citation":"Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.","parent_key":"BE0002098"}
{"ref-id":"A13078","pubmed-id":17704420,"citation":"Zhang W, Gordon M, Schultheis AM, Yang DY, Nagashima F, Azuma M, Chang HM, Borucka E, Lurje G, Sherrod AE, Iqbal S, Groshen S, Lenz HJ: FCGR2A and FCGR3A polymorphisms associated with clinical outcome of epidermal growth factor receptor expressing metastatic colorectal cancer patients treated with single-agent cetuximab. J Clin Oncol. 2007 Aug 20;25(24):3712-8.","parent_key":"BE0002098"}
{"ref-id":"A1723","pubmed-id":10206649,"citation":"Park YC, Burkitt V, Villa AR, Tong L, Wu H: Structural basis for self-association and receptor recognition of human TRAF2. Nature. 1999 Apr 8;398(6727):533-8.","parent_key":"BE0000704"}
{"ref-id":"A1725","pubmed-id":10338381,"citation":"Sandborn WJ, Hanauer SB: Antitumor necrosis factor therapy for inflammatory bowel disease: a review of agents, pharmacology, clinical results, and safety. Inflamm Bowel Dis. 1999 May;5(2):119-33.","parent_key":"BE0000704"}
{"ref-id":"A1727","pubmed-id":10357816,"citation":"Grell M, Zimmermann G, Gottfried E, Chen CM, Grunwald U, Huang DC, Wu Lee YH, Durkop H, Engelmann H, Scheurich P, Wajant H, Strasser A: Induction of cell death by tumour necrosis factor (TNF) receptor 2, CD40 and CD30: a role for TNF-R1 activation by endogenous membrane-anchored TNF. EMBO J. 1999 Jun 1;18(11):3034-43.","parent_key":"BE0000704"}
{"ref-id":"A1729","pubmed-id":10375846,"citation":"Moreland LW: Inhibitors of tumor necrosis factor: new treatment options for rheumatoid arthritis. Cleve Clin J Med. 1999 Jun;66(6):367-74.","parent_key":"BE0000704"}
{"ref-id":"A1731","pubmed-id":10405518,"citation":"Calabrese LH: Rheumatoid arthritis and primary care: the case for early diagnosis and treatment. J Am Osteopath Assoc. 1999 Jun;99(6):313-21.","parent_key":"BE0000704"}
{"ref-id":"A9","pubmed-id":11752352,"citation":"Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5.","parent_key":"BE0000704"}
{"ref-id":"A202010","pubmed-id":27463856,"citation":"Hofmann HP, Kronthaler U, Fritsch C, Grau R, Muller SO, Mayer R, Seidl A, Da Silva A: Characterization and non-clinical assessment of the proposed etanercept biosimilar GP2015 with originator etanercept (Enbrel((R))). Expert Opin Biol Ther. 2016 Oct;16(10):1185-95. doi: 10.1080/14712598.2016.1217329. Epub 2016 Aug 16.","parent_key":"BE0000710"}
{"ref-id":"A203909","pubmed-id":19128982,"citation":"Arora T, Padaki R, Liu L, Hamburger AE, Ellison AR, Stevens SR, Louie JS, Kohno T: Differences in binding and effector functions between classes of TNF antagonists. Cytokine. 2009 Feb;45(2):124-31. doi: 10.1016/j.cyto.2008.11.008. Epub 2009 Jan 6.","parent_key":"BE0000710"}
{"ref-id":"A13085","pubmed-id":15457442,"citation":"Criswell LA, Lum RF, Turner KN, Woehl B, Zhu Y, Wang J, Tiwari HK, Edberg JC, Kimberly RP, Moreland LW, Seldin MF, Bridges SL Jr: The influence of genetic variation in the HLA-DRB1 and LTA-TNF regions on the response to treatment of early rheumatoid arthritis with methotrexate or etanercept. Arthritis Rheum. 2004 Sep;50(9):2750-6.","parent_key":"BE0002098"}
{"ref-id":"A13086","pubmed-id":15526004,"citation":"Hughes LB, Criswell LA, Beasley TM, Edberg JC, Kimberly RP, Moreland LW, Seldin MF, Bridges SL: Genetic risk factors for infection in patients with early rheumatoid arthritis. Genes Immun. 2004 Dec;5(8):641-7.","parent_key":"BE0002098"}
{"ref-id":"A202010","pubmed-id":27463856,"citation":"Hofmann HP, Kronthaler U, Fritsch C, Grau R, Muller SO, Mayer R, Seidl A, Da Silva A: Characterization and non-clinical assessment of the proposed etanercept biosimilar GP2015 with originator etanercept (Enbrel((R))). Expert Opin Biol Ther. 2016 Oct;16(10):1185-95. doi: 10.1080/14712598.2016.1217329. Epub 2016 Aug 16.","parent_key":"BE0002098"}
{"ref-id":"A203909","pubmed-id":19128982,"citation":"Arora T, Padaki R, Liu L, Hamburger AE, Ellison AR, Stevens SR, Louie JS, Kohno T: Differences in binding and effector functions between classes of TNF antagonists. Cytokine. 2009 Feb;45(2):124-31. doi: 10.1016/j.cyto.2008.11.008. Epub 2009 Jan 6.","parent_key":"BE0002098"}
{"ref-id":"A202010","pubmed-id":27463856,"citation":"Hofmann HP, Kronthaler U, Fritsch C, Grau R, Muller SO, Mayer R, Seidl A, Da Silva A: Characterization and non-clinical assessment of the proposed etanercept biosimilar GP2015 with originator etanercept (Enbrel((R))). Expert Opin Biol Ther. 2016 Oct;16(10):1185-95. doi: 10.1080/14712598.2016.1217329. Epub 2016 Aug 16.","parent_key":"BE0002099"}
{"ref-id":"A203909","pubmed-id":19128982,"citation":"Arora T, Padaki R, Liu L, Hamburger AE, Ellison AR, Stevens SR, Louie JS, Kohno T: Differences in binding and effector functions between classes of TNF antagonists. Cytokine. 2009 Feb;45(2):124-31. doi: 10.1016/j.cyto.2008.11.008. Epub 2009 Jan 6.","parent_key":"BE0002099"}
{"ref-id":"A13083","pubmed-id":10800083,"citation":"Hart SP, Ross JA, Ross K, Haslett C, Dransfield I: Molecular characterization of the surface of apoptotic neutrophils: implications for functional downregulation and recognition by phagocytes. Cell Death Differ. 2000 May;7(5):493-503.","parent_key":"BE0002100"}
{"ref-id":"A13087","pubmed-id":7535196,"citation":"Ranheim EA, Kipps TJ: Tumor necrosis factor-alpha facilitates induction of CD80 (B7-1) and CD54 on human B cells by activated T cells: complex regulation by IL-4, IL-10, and CD40L. Cell Immunol. 1995 Apr 1;161(2):226-35.","parent_key":"BE0002100"}
{"ref-id":"A203909","pubmed-id":19128982,"citation":"Arora T, Padaki R, Liu L, Hamburger AE, Ellison AR, Stevens SR, Louie JS, Kohno T: Differences in binding and effector functions between classes of TNF antagonists. Cytokine. 2009 Feb;45(2):124-31. doi: 10.1016/j.cyto.2008.11.008. Epub 2009 Jan 6.","parent_key":"BE0002100"}
{"ref-id":"A13085","pubmed-id":15457442,"citation":"Criswell LA, Lum RF, Turner KN, Woehl B, Zhu Y, Wang J, Tiwari HK, Edberg JC, Kimberly RP, Moreland LW, Seldin MF, Bridges SL Jr: The influence of genetic variation in the HLA-DRB1 and LTA-TNF regions on the response to treatment of early rheumatoid arthritis with methotrexate or etanercept. Arthritis Rheum. 2004 Sep;50(9):2750-6.","parent_key":"BE0002097"}
{"ref-id":"A13086","pubmed-id":15526004,"citation":"Hughes LB, Criswell LA, Beasley TM, Edberg JC, Kimberly RP, Moreland LW, Seldin MF, Bridges SL: Genetic risk factors for infection in patients with early rheumatoid arthritis. Genes Immun. 2004 Dec;5(8):641-7.","parent_key":"BE0002097"}
{"ref-id":"A202010","pubmed-id":27463856,"citation":"Hofmann HP, Kronthaler U, Fritsch C, Grau R, Muller SO, Mayer R, Seidl A, Da Silva A: Characterization and non-clinical assessment of the proposed etanercept biosimilar GP2015 with originator etanercept (Enbrel((R))). Expert Opin Biol Ther. 2016 Oct;16(10):1185-95. doi: 10.1080/14712598.2016.1217329. Epub 2016 Aug 16.","parent_key":"BE0002097"}
{"ref-id":"A203909","pubmed-id":19128982,"citation":"Arora T, Padaki R, Liu L, Hamburger AE, Ellison AR, Stevens SR, Louie JS, Kohno T: Differences in binding and effector functions between classes of TNF antagonists. Cytokine. 2009 Feb;45(2):124-31. doi: 10.1016/j.cyto.2008.11.008. Epub 2009 Jan 6.","parent_key":"BE0002097"}
{"ref-id":"A1754","pubmed-id":15898717,"citation":"Dhalluin C, Ross A, Huber W, Gerber P, Brugger D, Gsell B, Senn H: Structural, kinetic, and thermodynamic analysis of the binding of the 40 kDa PEG-interferon-alpha2a and its individual positional isomers to the extracellular domain of the receptor IFNAR2. Bioconjug Chem. 2005 May-Jun;16(3):518-27.","parent_key":"BE0000661"}
{"ref-id":"A1755","pubmed-id":16953837,"citation":"Yano H, Ogasawara S, Momosaki S, Akiba J, Kojiro S, Fukahori S, Ishizaki H, Kuratomi K, Basaki Y, Oie S, Kuwano M, Kojiro M: Growth inhibitory effects of pegylated IFN alpha-2b on human liver cancer cells in vitro and in vivo. Liver Int. 2006 Oct;26(8):964-75.","parent_key":"BE0000661"}
{"ref-id":"A1758","pubmed-id":19955815,"citation":"Ishii K, Shinohara M, Sawa M, Kogame M, Higami K, Sano M, Morita T, Sumino Y: Interferon alpha receptor 2 expression by peripheral blood monocytes in patients with a high viral load of hepatitis C virus genotype 1 showing substitution of amino Acid 70 in the core region. Intervirology. 2010;53(2):105-10. doi: 10.1159/000264200. Epub 2009 Dec 3.","parent_key":"BE0000661"}
{"ref-id":"A9","pubmed-id":11752352,"citation":"Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5.","parent_key":"BE0000661"}
{"ref-id":"A1713","pubmed-id":17139284,"citation":"Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.","parent_key":"BE0000661"}
{"ref-id":"A1715","pubmed-id":17016423,"citation":"Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.","parent_key":"BE0000661"}
{"ref-id":"A1762","pubmed-id":10822464,"citation":"Krown SE: Interferon treatment of renal cell carcinoma. Current status and future prospects. Cancer. 1987 Feb 1;59(3 Suppl):647-51.","parent_key":"BE0000661"}
{"ref-id":"A37","pubmed-id":17911465,"citation":"Siberil S, Elluru S, Graff-Dubois S, Negi VS, Delignat S, Mouthon L, Lacroix-Desmazes S, Kazatchkine MD, Bayry J, Kaveri SV: Intravenous immunoglobulins in autoimmune and inflammatory diseases: a mechanistic perspective. Ann N Y Acad Sci. 2007 Sep;1110:497-506.","parent_key":"BE0000710"}
{"ref-id":"A13124","pubmed-id":20441428,"citation":"Baerenwaldt A, Biburger M, Nimmerjahn F: Mechanisms of action of intravenous immunoglobulins. Expert Rev Clin Immunol. 2010 May;6(3):425-34. doi: 10.1586/eci.10.9.","parent_key":"BE0000710"}
{"ref-id":"A13125","pubmed-id":17351760,"citation":"Negi VS, Elluru S, Siberil S, Graff-Dubois S, Mouthon L, Kazatchkine MD, Lacroix-Desmazes S, Bayry J, Kaveri SV: Intravenous immunoglobulin: an update on the clinical use and mechanisms of action. J Clin Immunol. 2007 May;27(3):233-45. Epub 2007 Mar 11.","parent_key":"BE0000710"}
{"ref-id":"A37","pubmed-id":17911465,"citation":"Siberil S, Elluru S, Graff-Dubois S, Negi VS, Delignat S, Mouthon L, Lacroix-Desmazes S, Kazatchkine MD, Bayry J, Kaveri SV: Intravenous immunoglobulins in autoimmune and inflammatory diseases: a mechanistic perspective. Ann N Y Acad Sci. 2007 Sep;1110:497-506.","parent_key":"BE0002098"}
{"ref-id":"A13124","pubmed-id":20441428,"citation":"Baerenwaldt A, Biburger M, Nimmerjahn F: Mechanisms of action of intravenous immunoglobulins. Expert Rev Clin Immunol. 2010 May;6(3):425-34. doi: 10.1586/eci.10.9.","parent_key":"BE0002098"}
{"ref-id":"A13125","pubmed-id":17351760,"citation":"Negi VS, Elluru S, Siberil S, Graff-Dubois S, Mouthon L, Kazatchkine MD, Lacroix-Desmazes S, Bayry J, Kaveri SV: Intravenous immunoglobulin: an update on the clinical use and mechanisms of action. J Clin Immunol. 2007 May;27(3):233-45. Epub 2007 Mar 11.","parent_key":"BE0002098"}
{"ref-id":"A37","pubmed-id":17911465,"citation":"Siberil S, Elluru S, Graff-Dubois S, Negi VS, Delignat S, Mouthon L, Lacroix-Desmazes S, Kazatchkine MD, Bayry J, Kaveri SV: Intravenous immunoglobulins in autoimmune and inflammatory diseases: a mechanistic perspective. Ann N Y Acad Sci. 2007 Sep;1110:497-506.","parent_key":"BE0002099"}
{"ref-id":"A13124","pubmed-id":20441428,"citation":"Baerenwaldt A, Biburger M, Nimmerjahn F: Mechanisms of action of intravenous immunoglobulins. Expert Rev Clin Immunol. 2010 May;6(3):425-34. doi: 10.1586/eci.10.9.","parent_key":"BE0002099"}
{"ref-id":"A13125","pubmed-id":17351760,"citation":"Negi VS, Elluru S, Siberil S, Graff-Dubois S, Mouthon L, Kazatchkine MD, Lacroix-Desmazes S, Bayry J, Kaveri SV: Intravenous immunoglobulin: an update on the clinical use and mechanisms of action. J Clin Immunol. 2007 May;27(3):233-45. Epub 2007 Mar 11.","parent_key":"BE0002099"}
{"ref-id":"A37","pubmed-id":17911465,"citation":"Siberil S, Elluru S, Graff-Dubois S, Negi VS, Delignat S, Mouthon L, Lacroix-Desmazes S, Kazatchkine MD, Bayry J, Kaveri SV: Intravenous immunoglobulins in autoimmune and inflammatory diseases: a mechanistic perspective. Ann N Y Acad Sci. 2007 Sep;1110:497-506.","parent_key":"BE0002100"}
{"ref-id":"A13124","pubmed-id":20441428,"citation":"Baerenwaldt A, Biburger M, Nimmerjahn F: Mechanisms of action of intravenous immunoglobulins. Expert Rev Clin Immunol. 2010 May;6(3):425-34. doi: 10.1586/eci.10.9.","parent_key":"BE0002100"}
{"ref-id":"A13125","pubmed-id":17351760,"citation":"Negi VS, Elluru S, Siberil S, Graff-Dubois S, Mouthon L, Kazatchkine MD, Lacroix-Desmazes S, Bayry J, Kaveri SV: Intravenous immunoglobulin: an update on the clinical use and mechanisms of action. J Clin Immunol. 2007 May;27(3):233-45. Epub 2007 Mar 11.","parent_key":"BE0002100"}
{"ref-id":"A37","pubmed-id":17911465,"citation":"Siberil S, Elluru S, Graff-Dubois S, Negi VS, Delignat S, Mouthon L, Lacroix-Desmazes S, Kazatchkine MD, Bayry J, Kaveri SV: Intravenous immunoglobulins in autoimmune and inflammatory diseases: a mechanistic perspective. Ann N Y Acad Sci. 2007 Sep;1110:497-506.","parent_key":"BE0002097"}
{"ref-id":"A13124","pubmed-id":20441428,"citation":"Baerenwaldt A, Biburger M, Nimmerjahn F: Mechanisms of action of intravenous immunoglobulins. Expert Rev Clin Immunol. 2010 May;6(3):425-34. doi: 10.1586/eci.10.9.","parent_key":"BE0002097"}
{"ref-id":"A13125","pubmed-id":17351760,"citation":"Negi VS, Elluru S, Siberil S, Graff-Dubois S, Mouthon L, Kazatchkine MD, Lacroix-Desmazes S, Bayry J, Kaveri SV: Intravenous immunoglobulin: an update on the clinical use and mechanisms of action. J Clin Immunol. 2007 May;27(3):233-45. Epub 2007 Mar 11.","parent_key":"BE0002097"}
{"ref-id":"A1863","pubmed-id":18230610,"citation":"Cironi P, Swinburne IA, Silver PA: Enhancement of cell type specificity by quantitative modulation of a chimeric ligand. J Biol Chem. 2008 Mar 28;283(13):8469-76. doi: 10.1074/jbc.M708502200. Epub 2008  Jan 29.","parent_key":"BE0000661"}
{"ref-id":"A1943","pubmed-id":12044041,"citation":"Lorenz HM: Technology evaluation: adalimumab, Abbott laboratories. Curr Opin Mol Ther. 2002 Apr;4(2):185-90.","parent_key":"BE0000704"}
{"ref-id":"A1946","pubmed-id":14532145,"citation":"Flendrie M, Creemers MC, Welsing PM, den Broeder AA, van Riel PL: Survival during treatment with tumour necrosis factor blocking agents in rheumatoid arthritis. Ann Rheum Dis. 2003 Nov;62 Suppl 2:ii30-3.","parent_key":"BE0000704"}
{"ref-id":"A1948","pubmed-id":15022409,"citation":"Aguillon JC, Contreras J, Dotte A, Cruzat A, Catalan D, Salazar L, Molina MC, Guerrero J, Lopez M, Soto L, Salazar-Onfray F, Cuchacovich M: [New immunological weapons for medicine in the 21st Century: biological therapy based on the use of the latest generation monoclonal antibodies]. Rev Med Chil. 2003 Dec;131(12):1445-53.","parent_key":"BE0000704"}
{"ref-id":"A1951","pubmed-id":15046527,"citation":"Bang LM, Keating GM: Adalimumab: a review of its use in rheumatoid arthritis. BioDrugs. 2004;18(2):121-39.","parent_key":"BE0000704"}
{"ref-id":"A11615","pubmed-id":11804648,"citation":"Gresele P, Agnelli G: Novel approaches to the treatment of thrombosis. Trends Pharmacol Sci. 2002 Jan;23(1):25-32.","parent_key":"BE0001151"}
{"ref-id":"A11616","pubmed-id":15252033,"citation":"Pineda AO, Chen ZW, Caccia S, Cantwell AM, Savvides SN, Waksman G, Mathews FS, Di Cera E: The anticoagulant thrombin mutant W215A/E217A has a collapsed primary specificity pocket. J Biol Chem. 2004 Sep 17;279(38):39824-8. Epub 2004 Jul 13.","parent_key":"BE0001151"}
{"ref-id":"A11617","pubmed-id":1660324,"citation":"McCachren SS, Diggs J, Weinberg JB, Dittman WA: Thrombomodulin expression by human blood monocytes and by human synovial tissue lining macrophages. Blood. 1991 Dec 15;78(12):3128-32.","parent_key":"BE0001151"}
{"ref-id":"A11618","pubmed-id":2836377,"citation":"Shirai T, Shiojiri S, Ito H, Yamamoto S, Kusumoto H, Deyashiki Y, Maruyama I, Suzuki K: Gene structure of human thrombomodulin, a cofactor for thrombin-catalyzed activation of protein C. J Biochem. 1988 Feb;103(2):281-5.","parent_key":"BE0001151"}
{"ref-id":"A11619","pubmed-id":3039877,"citation":"Boffa MC, Burke B, Haudenschild C: [Different localization of thrombomodulin]. Ann Biol Clin (Paris). 1987;45(2):191-7.","parent_key":"BE0001151"}
{"ref-id":"A13218","pubmed-id":7509291,"citation":"Ericson SG, Benoit NE, Mills LE, Fanger MW: The effect of recombinant human interleukin-3 and recombinant human granulocyte-macrophage colony-stimulating factor on Fc gamma receptor expression and antibody-dependent cellular cytotoxicity of hematopoietic progenitor cells during in vitro myeloid maturation. Exp Hematol. 1994 Mar;22(3):283-9.","parent_key":"BE0002097"}
{"ref-id":"A13218","pubmed-id":7509291,"citation":"Ericson SG, Benoit NE, Mills LE, Fanger MW: The effect of recombinant human interleukin-3 and recombinant human granulocyte-macrophage colony-stimulating factor on Fc gamma receptor expression and antibody-dependent cellular cytotoxicity of hematopoietic progenitor cells during in vitro myeloid maturation. Exp Hematol. 1994 Mar;22(3):283-9.","parent_key":"BE0000710"}
{"ref-id":"A14065","pubmed-id":10049744,"citation":"Russell-Harde D, Wagner TC, Perez HD, Croze E: Formation of a uniquely stable type I interferon receptor complex by interferon beta is dependent upon particular interactions between interferon beta and its receptor and independent of tyrosine phosphorylation. Biochem Biophys Res Commun. 1999 Feb 16;255(2):539-44.","parent_key":"BE0000661"}
{"ref-id":"A16953","pubmed-id":16912135,"citation":"van Koetsveld PM, Vitale G, de Herder WW, Feelders RA, van der Wansem K, Waaijers M, van Eijck CH, Speel EJ, Croze E, van der Lely AJ, Lamberts SW, Hofland LJ: Potent inhibitory effects of type I interferons on human adrenocortical carcinoma cell growth. J Clin Endocrinol Metab. 2006 Nov;91(11):4537-43. Epub 2006 Aug 15.","parent_key":"BE0000661"}
{"ref-id":"A16954","pubmed-id":12034032,"citation":"Dupont SA, Goelz S, Goyal J, Green M: Mechanisms for regulation of cellular responsiveness to human IFN-beta1a. J Interferon Cytokine Res. 2002 Apr;22(4):491-501.","parent_key":"BE0000661"}
{"ref-id":"A16955","pubmed-id":11747625,"citation":"Runkel L, De Dios C, Karpusas M, Baker D, Li Z, Zafari M, Betzenhauser M, Muldowney C, Miller S, Redlich PN, Grossberg SE, Whitty A, Hochman PS: Mapping of IFN-beta epitopes important for receptor binding and biologic activation: comparison of results achieved using antibody-based methods and alanine substitution mutagenesis. J Interferon Cytokine Res. 2001 Nov;21(11):931-41.","parent_key":"BE0000661"}
{"ref-id":"A1993","pubmed-id":17642244,"citation":"Mimura T: [Selection of one of the TNF blockers; infliximab and etanercept]. Nihon Rinsho. 2007 Jul;65(7):1282-6.","parent_key":"BE0000704"}
{"ref-id":"A1994","pubmed-id":16052578,"citation":"Braun J, Baraliakos X, Listing J, Sieper J: Decreased incidence of anterior uveitis in patients with ankylosing spondylitis treated with the anti-tumor necrosis factor agents infliximab and etanercept. Arthritis Rheum. 2005 Aug;52(8):2447-51.","parent_key":"BE0000704"}
{"ref-id":"A1996","pubmed-id":16456024,"citation":"Danese S, Sans M, Scaldaferri F, Sgambato A, Rutella S, Cittadini A, Pique JM, Panes J, Katz JA, Gasbarrini A, Fiocchi C: TNF-alpha blockade down-regulates the CD40/CD40L pathway in the mucosal microcirculation: a novel anti-inflammatory mechanism of infliximab in Crohn's disease. J Immunol. 2006 Feb 15;176(4):2617-24.","parent_key":"BE0000704"}
{"ref-id":"A1998","pubmed-id":15674127,"citation":"Magro F, Pereira P, Carneiro F, Veloso FT: Reactive hepatitis in a patient with Crohn's disease successfully treated with infliximab: does tumor necrosis factor alpha play a role in reactive hepatitis? Inflamm Bowel Dis. 2005 Jan;11(1):88-90.","parent_key":"BE0000704"}
{"ref-id":"A2000","pubmed-id":16622728,"citation":"Mori S, Imamura F, Kiyofuji C, Ito K, Koga Y, Honda I, Sugimoto M: Pneumocystis jiroveci pneumonia in a patient with rheumatoid arthritis as a complication of treatment with infliximab, anti-tumor necrosis factor alpha neutralizing antibody. Mod Rheumatol. 2006;16(1):58-62.","parent_key":"BE0000704"}
{"ref-id":"A2002","pubmed-id":12110154,"citation":"Maini RN, Feldmann M: How does infliximab work in rheumatoid arthritis? Arthritis Res. 2002;4 Suppl 2:S22-8. Epub 2002 Mar 27.","parent_key":"BE0000704"}
{"ref-id":"A2004","pubmed-id":15481318,"citation":"Sapienza MS, Cohen S, Dimarino AJ: Treatment of pyoderma gangrenosum with infliximab in Crohn's disease. Dig Dis Sci. 2004 Sep;49(9):1454-7.","parent_key":"BE0000704"}
{"ref-id":"A2005","pubmed-id":15691217,"citation":"Tobin AM, Kirby B: TNF alpha inhibitors in the treatment of psoriasis and psoriatic arthritis. BioDrugs. 2005;19(1):47-57.","parent_key":"BE0000704"}
{"ref-id":"A2007","pubmed-id":15691299,"citation":"Shen C, Assche GV, Colpaert S, Maerten P, Geboes K, Rutgeerts P, Ceuppens JL: Adalimumab induces apoptosis of human monocytes: a comparative study with infliximab and etanercept. Aliment Pharmacol Ther. 2005 Feb 1;21(3):251-8.","parent_key":"BE0000704"}
{"ref-id":"A2009","pubmed-id":15804598,"citation":"Popa C, Netea MG, Barrera P, Radstake TR, van Riel PL, Kullberg BJ, Van der Meer JW: Cytokine production of stimulated whole blood cultures in rheumatoid arthritis patients receiving short-term infliximab therapy. Cytokine. 2005 Apr 21;30(2):72-7.","parent_key":"BE0000704"}
{"ref-id":"A2033","pubmed-id":12528473,"citation":"Yasuda S, Miyata K: [Interferon alfacon-1 (Advaferon): a novel synthetic interferon for the treatment of hepatitis C, its pharmacological and clinical profile]. Nihon Yakurigaku Zasshi. 2002 Dec;120(6):421-6.","parent_key":"BE0000661"}
{"ref-id":"A6923","pubmed-id":17768100,"citation":"Glennie MJ, French RR, Cragg MS, Taylor RP: Mechanisms of killing by anti-CD20 monoclonal antibodies. Mol Immunol. 2007 Sep;44(16):3823-37.","parent_key":"BE0002099"}
{"ref-id":"A202865","pubmed-id":25568316,"citation":"Vaughan AT, Chan CH, Klein C, Glennie MJ, Beers SA, Cragg MS: Activatory and inhibitory Fcgamma receptors augment rituximab-mediated internalization of CD20 independent of signaling via the cytoplasmic domain. J Biol Chem. 2015 Feb 27;290(9):5424-37. doi: 10.1074/jbc.M114.593806. Epub 2015 Jan 7.","parent_key":"BE0002099"}
{"ref-id":"A13297","pubmed-id":15217834,"citation":"Lin TS, Flinn IW, Modali R, Lehman TA, Webb J, Waymer S, Moran ME, Lucas MS, Farag SS, Byrd JC: FCGR3A and FCGR2A polymorphisms may not correlate with response to alemtuzumab in chronic lymphocytic leukemia. Blood. 2005 Jan 1;105(1):289-91. Epub 2004 Jun 24.","parent_key":"BE0002097"}
{"ref-id":"A202025","pubmed-id":23543215,"citation":"White AL, Chan HT, French RR, Beers SA, Cragg MS, Johnson PW, Glennie MJ: FcgammaRIotaIotaB controls the potency of agonistic anti-TNFR mAbs. Cancer Immunol Immunother. 2013 May;62(5):941-8. doi: 10.1007/s00262-013-1398-6. Epub 2013 Mar 31.","parent_key":"BE0000710"}
{"ref-id":"A13297","pubmed-id":15217834,"citation":"Lin TS, Flinn IW, Modali R, Lehman TA, Webb J, Waymer S, Moran ME, Lucas MS, Farag SS, Byrd JC: FCGR3A and FCGR2A polymorphisms may not correlate with response to alemtuzumab in chronic lymphocytic leukemia. Blood. 2005 Jan 1;105(1):289-91. Epub 2004 Jun 24.","parent_key":"BE0002098"}
{"ref-id":"A202025","pubmed-id":23543215,"citation":"White AL, Chan HT, French RR, Beers SA, Cragg MS, Johnson PW, Glennie MJ: FcgammaRIotaIotaB controls the potency of agonistic anti-TNFR mAbs. Cancer Immunol Immunother. 2013 May;62(5):941-8. doi: 10.1007/s00262-013-1398-6. Epub 2013 Mar 31.","parent_key":"BE0002099"}
{"ref-id":"A202025","pubmed-id":23543215,"citation":"White AL, Chan HT, French RR, Beers SA, Cragg MS, Johnson PW, Glennie MJ: FcgammaRIotaIotaB controls the potency of agonistic anti-TNFR mAbs. Cancer Immunol Immunother. 2013 May;62(5):941-8. doi: 10.1007/s00262-013-1398-6. Epub 2013 Mar 31.","parent_key":"BE0002100"}
{"ref-id":"A2104","pubmed-id":11970990,"citation":"da Silva AJ, Brickelmaier M, Majeau GR, Li Z, Su L, Hsu YM, Hochman PS: Alefacept, an immunomodulatory recombinant LFA-3/IgG1 fusion protein, induces CD16 signaling and CD2/CD16-dependent apoptosis of CD2(+) cells. J Immunol. 2002 May 1;168(9):4462-71.","parent_key":"BE0002097"}
{"ref-id":"A13298","pubmed-id":12795239,"citation":"Vaishnaw AK, TenHoor CN: Pharmacokinetics, biologic activity, and tolerability of alefacept by intravenous and intramuscular administration. J Pharmacokinet Pharmacodyn. 2002 Dec;29(5-6):415-26.","parent_key":"BE0002097"}
{"ref-id":"A15362","pubmed-id":12586600,"citation":"Monti P, Allavena P, Di Carlo V, Piemonti L: Effects of anti-lymphocytes and anti-thymocytes globulin on human dendritic cells. Int Immunopharmacol. 2003 Feb;3(2):189-96.","parent_key":"BE0002099"}
{"ref-id":"A6726","pubmed-id":10567921,"citation":"Khine AA, Lingwood CA: Functional significance of globotriaosyl ceramide in interferon-alpha(2)/type 1 interferon receptor-mediated antiviral activity. J Cell Physiol. 2000 Jan;182(1):97-108.","parent_key":"BE0000661"}
{"ref-id":"A201869","pubmed-id":31002172,"citation":"Dudek S, Weissmuller S, Anzaghe M, Miller L, Sterr S, Hoffmann K, Hengel H, Waibler Z: Human Fcgamma receptors compete for TGN1412 binding that determines the antibody's effector function. Eur J Immunol. 2019 Jul;49(7):1117-1126. doi: 10.1002/eji.201847924. Epub 2019 Apr 29.","parent_key":"BE0000710"}
{"ref-id":"A201875","pubmed-id":24711420,"citation":"Hiatt A, Bohorova N, Bohorov O, Goodman C, Kim D, Pauly MH, Velasco J, Whaley KJ, Piedra PA, Gilbert BE, Zeitlin L: Glycan variants of a respiratory syncytial virus antibody with enhanced effector function and in vivo efficacy. Proc Natl Acad Sci U S A. 2014 Apr 22;111(16):5992-7. doi: 10.1073/pnas.1402458111. Epub 2014 Apr 7.","parent_key":"BE0002094"}
{"ref-id":"A201875","pubmed-id":24711420,"citation":"Hiatt A, Bohorova N, Bohorov O, Goodman C, Kim D, Pauly MH, Velasco J, Whaley KJ, Piedra PA, Gilbert BE, Zeitlin L: Glycan variants of a respiratory syncytial virus antibody with enhanced effector function and in vivo efficacy. Proc Natl Acad Sci U S A. 2014 Apr 22;111(16):5992-7. doi: 10.1073/pnas.1402458111. Epub 2014 Apr 7.","parent_key":"BE0002095"}
{"ref-id":"A201875","pubmed-id":24711420,"citation":"Hiatt A, Bohorova N, Bohorov O, Goodman C, Kim D, Pauly MH, Velasco J, Whaley KJ, Piedra PA, Gilbert BE, Zeitlin L: Glycan variants of a respiratory syncytial virus antibody with enhanced effector function and in vivo efficacy. Proc Natl Acad Sci U S A. 2014 Apr 22;111(16):5992-7. doi: 10.1073/pnas.1402458111. Epub 2014 Apr 7.","parent_key":"BE0002096"}
{"ref-id":"A201875","pubmed-id":24711420,"citation":"Hiatt A, Bohorova N, Bohorov O, Goodman C, Kim D, Pauly MH, Velasco J, Whaley KJ, Piedra PA, Gilbert BE, Zeitlin L: Glycan variants of a respiratory syncytial virus antibody with enhanced effector function and in vivo efficacy. Proc Natl Acad Sci U S A. 2014 Apr 22;111(16):5992-7. doi: 10.1073/pnas.1402458111. Epub 2014 Apr 7.","parent_key":"BE0002097"}
{"ref-id":"A201875","pubmed-id":24711420,"citation":"Hiatt A, Bohorova N, Bohorov O, Goodman C, Kim D, Pauly MH, Velasco J, Whaley KJ, Piedra PA, Gilbert BE, Zeitlin L: Glycan variants of a respiratory syncytial virus antibody with enhanced effector function and in vivo efficacy. Proc Natl Acad Sci U S A. 2014 Apr 22;111(16):5992-7. doi: 10.1073/pnas.1402458111. Epub 2014 Apr 7.","parent_key":"BE0000710"}
{"ref-id":"A201875","pubmed-id":24711420,"citation":"Hiatt A, Bohorova N, Bohorov O, Goodman C, Kim D, Pauly MH, Velasco J, Whaley KJ, Piedra PA, Gilbert BE, Zeitlin L: Glycan variants of a respiratory syncytial virus antibody with enhanced effector function and in vivo efficacy. Proc Natl Acad Sci U S A. 2014 Apr 22;111(16):5992-7. doi: 10.1073/pnas.1402458111. Epub 2014 Apr 7.","parent_key":"BE0002099"}
{"ref-id":"A1713","pubmed-id":17139284,"citation":"Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.","parent_key":"BE0002094"}
{"ref-id":"A1715","pubmed-id":17016423,"citation":"Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.","parent_key":"BE0002094"}
{"ref-id":"A1713","pubmed-id":17139284,"citation":"Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.","parent_key":"BE0002095"}
{"ref-id":"A1715","pubmed-id":17016423,"citation":"Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.","parent_key":"BE0002095"}
{"ref-id":"A1713","pubmed-id":17139284,"citation":"Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.","parent_key":"BE0002096"}
{"ref-id":"A1715","pubmed-id":17016423,"citation":"Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.","parent_key":"BE0002096"}
{"ref-id":"A13336","pubmed-id":1828823,"citation":"Simms HH, Gaither TA, Fries LF, Frank MM: Monokines released during short-term Fc gamma receptor phagocytosis up-regulate polymorphonuclear leukocytes and monocyte-phagocytic function. J Immunol. 1991 Jul 1;147(1):265-72.","parent_key":"BE0000710"}
{"ref-id":"A1713","pubmed-id":17139284,"citation":"Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.","parent_key":"BE0002099"}
{"ref-id":"A1715","pubmed-id":17016423,"citation":"Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.","parent_key":"BE0002099"}
{"ref-id":"A1713","pubmed-id":17139284,"citation":"Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.","parent_key":"BE0002100"}
{"ref-id":"A1715","pubmed-id":17016423,"citation":"Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.","parent_key":"BE0002100"}
{"ref-id":"A9","pubmed-id":11752352,"citation":"Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5.","parent_key":"BE0000163"}
{"ref-id":"A13437","pubmed-id":15705858,"citation":"Gerber HP, Ferrara N: Pharmacology and pharmacodynamics of bevacizumab as monotherapy or in combination with cytotoxic therapy in preclinical studies. Cancer Res. 2005 Feb 1;65(3):671-80.","parent_key":"BE0000163"}
{"ref-id":"A192828","pubmed-id":27329360,"citation":"Han K, Peyret T, Marchand M, Quartino A, Gosselin NH, Girish S, Allison DE, Jin J: Population pharmacokinetics of bevacizumab in cancer patients with external validation. Cancer Chemother Pharmacol. 2016 Aug;78(2):341-51. doi: 10.1007/s00280-016-3079-6. Epub 2016 Jun 21.","parent_key":"BE0000163"}
{"ref-id":"A202856","pubmed-id":15886877,"citation":"Wang Y, Fei D, Vanderlaan M, Song A: Biological activity of bevacizumab, a humanized anti-VEGF antibody in vitro. Angiogenesis. 2004;7(4):335-45. doi: 10.1007/s10456-004-8272-2. Epub 2005 May 9.","parent_key":"BE0002094"}
{"ref-id":"A202856","pubmed-id":15886877,"citation":"Wang Y, Fei D, Vanderlaan M, Song A: Biological activity of bevacizumab, a humanized anti-VEGF antibody in vitro. Angiogenesis. 2004;7(4):335-45. doi: 10.1007/s10456-004-8272-2. Epub 2005 May 9.","parent_key":"BE0002095"}
{"ref-id":"A202856","pubmed-id":15886877,"citation":"Wang Y, Fei D, Vanderlaan M, Song A: Biological activity of bevacizumab, a humanized anti-VEGF antibody in vitro. Angiogenesis. 2004;7(4):335-45. doi: 10.1007/s10456-004-8272-2. Epub 2005 May 9.","parent_key":"BE0002096"}
{"ref-id":"A202856","pubmed-id":15886877,"citation":"Wang Y, Fei D, Vanderlaan M, Song A: Biological activity of bevacizumab, a humanized anti-VEGF antibody in vitro. Angiogenesis. 2004;7(4):335-45. doi: 10.1007/s10456-004-8272-2. Epub 2005 May 9.","parent_key":"BE0002097"}
{"ref-id":"A202856","pubmed-id":15886877,"citation":"Wang Y, Fei D, Vanderlaan M, Song A: Biological activity of bevacizumab, a humanized anti-VEGF antibody in vitro. Angiogenesis. 2004;7(4):335-45. doi: 10.1007/s10456-004-8272-2. Epub 2005 May 9.","parent_key":"BE0000710"}
{"ref-id":"A202856","pubmed-id":15886877,"citation":"Wang Y, Fei D, Vanderlaan M, Song A: Biological activity of bevacizumab, a humanized anti-VEGF antibody in vitro. Angiogenesis. 2004;7(4):335-45. doi: 10.1007/s10456-004-8272-2. Epub 2005 May 9.","parent_key":"BE0002098"}
{"ref-id":"A202856","pubmed-id":15886877,"citation":"Wang Y, Fei D, Vanderlaan M, Song A: Biological activity of bevacizumab, a humanized anti-VEGF antibody in vitro. Angiogenesis. 2004;7(4):335-45. doi: 10.1007/s10456-004-8272-2. Epub 2005 May 9.","parent_key":"BE0002099"}
{"ref-id":"A202856","pubmed-id":15886877,"citation":"Wang Y, Fei D, Vanderlaan M, Song A: Biological activity of bevacizumab, a humanized anti-VEGF antibody in vitro. Angiogenesis. 2004;7(4):335-45. doi: 10.1007/s10456-004-8272-2. Epub 2005 May 9.","parent_key":"BE0002100"}
{"ref-id":"A9751","pubmed-id":16778961,"citation":"Cui YY, Tang CS, Geng B: [Restraint stress down-regulates L-Arg/NOS/NO pathway of platelet and aortic intima in rats]. Beijing Da Xue Xue Bao. 2006 Jun 18;38(3):231-5.","parent_key":"BE0000005"}
{"ref-id":"A9752","pubmed-id":17362916,"citation":"Devan BD, Pistell PJ, Daffin LW Jr, Nelson CM, Duffy KB, Bowker JL, Bharati IS, Sierra-Mercado D, Spangler EL, Ingram DK: Sildenafil citrate attenuates a complex maze impairment induced by intracerebroventricular infusion of the NOS inhibitor Nomega-nitro-L-arginine methyl ester. Eur J Pharmacol. 2007 Jun 1;563(1-3):134-40. Epub 2007 Feb 17.","parent_key":"BE0000005"}
{"ref-id":"A9753","pubmed-id":17363779,"citation":"Rotoli BM, Dall'asta V, Barilli A, D'Ippolito R, Tipa A, Olivieri D, Gazzola GC, Bussolati O: Alveolar macrophages from normal subjects lack the NOS-related system y+ for arginine transport. Am J Respir Cell Mol Biol. 2007 Jul;37(1):105-12. Epub 2007 Mar 15.","parent_key":"BE0000005"}
{"ref-id":"A9754","pubmed-id":17340133,"citation":"Kagemann G, Sies H, Schnorr O: Limited availability of L-arginine increases DNA-binding activity of NF-kappaB and contributes to regulation of iNOS expression. J Mol Med (Berl). 2007 Jul;85(7):723-32. Epub 2007 Mar 6.","parent_key":"BE0000005"}
{"ref-id":"A9755","pubmed-id":17513447,"citation":"Popovic PJ, Zeh HJ 3rd, Ochoa JB: Arginine and immunity. J Nutr. 2007 Jun;137(6 Suppl 2):1681S-1686S.","parent_key":"BE0000005"}
{"ref-id":"A19808","pubmed-id":10403814,"citation":"Murakami K, Ide T, Suzuki M, Mochizuki T, Kadowaki T: Evidence for direct binding of fatty acids and eicosanoids to human peroxisome proliferators-activated receptor alpha. Biochem Biophys Res Commun. 1999 Jul 14;260(3):609-13.","parent_key":"BE0000071"}
{"ref-id":"A19810","pubmed-id":16731579,"citation":"Vanden Heuvel JP, Thompson JT, Frame SR, Gillies PJ: Differential activation of nuclear receptors by perfluorinated fatty acid analogs and natural fatty acids: a comparison of human, mouse, and rat peroxisome proliferator-activated receptor-alpha, -beta, and -gamma, liver X receptor-beta, and retinoid X receptor-alpha. Toxicol Sci. 2006 Aug;92(2):476-89. Epub 2006 May 26.","parent_key":"BE0000071"}
{"ref-id":"A19810","pubmed-id":16731579,"citation":"Vanden Heuvel JP, Thompson JT, Frame SR, Gillies PJ: Differential activation of nuclear receptors by perfluorinated fatty acid analogs and natural fatty acids: a comparison of human, mouse, and rat peroxisome proliferator-activated receptor-alpha, -beta, and -gamma, liver X receptor-beta, and retinoid X receptor-alpha. Toxicol Sci. 2006 Aug;92(2):476-89. Epub 2006 May 26.","parent_key":"BE0000215"}
{"ref-id":"A13761","pubmed-id":17317527,"citation":"Sharma P, Ahmad Shah Z, Kumar A, Islam F, Mishra KP: Role of combined administration of Tiron and glutathione against aluminum-induced oxidative stress in rat brain. J Trace Elem Med Biol. 2007;21(1):63-70. Epub 2007 Feb 6.","parent_key":"BE0002189"}
{"ref-id":"A13762","pubmed-id":17321661,"citation":"Skamarauskas J, Carter W, Fowler M, Madjd A, Lister T, Mavroudis G, Ray DE: The selective neurotoxicity produced by 3-chloropropanediol in the rat is not a result of energy deprivation. Toxicology. 2007 Apr 11;232(3):268-76. Epub 2007 Jan 21.","parent_key":"BE0002189"}
{"ref-id":"A13763","pubmed-id":17338280,"citation":"Ozkilic AC, Cengiz M, Ozaydin A, Cobanoglu A, Kanigur G: The role of N-acetylcysteine treatment on anti-oxidative status in patients with type II diabetes mellitus. J Basic Clin Physiol Pharmacol. 2006;17(4):245-54.","parent_key":"BE0002189"}
{"ref-id":"A11266","pubmed-id":17338281,"citation":"Guruvayoorappan C, Afira AH, Kuttan G: Antioxidant potential of Biophytum sensitivum extract in vitro and in vivo. J Basic Clin Physiol Pharmacol. 2006;17(4):255-67.","parent_key":"BE0002189"}
{"ref-id":"A13764","pubmed-id":17401685,"citation":"Gupta S, Sarotra P, Aggarwal R, Dutta N, Agnihotri N: Role of oxidative stress in celecoxib-induced renal damage in wistar rats. Dig Dis Sci. 2007 Nov;52(11):3092-8. Epub 2007 Mar 31.","parent_key":"BE0002189"}
{"ref-id":"A11272","pubmed-id":17311259,"citation":"Moore LE, Malats N, Rothman N, Real FX, Kogevinas M, Karami S, Garcia-Closas R, Silverman D, Chanock S, Welch R, Tardon A, Serra C, Carrato A, Dosemeci M, Garcia-Closas M: Polymorphisms in one-carbon metabolism and trans-sulfuration pathway genes and susceptibility to bladder cancer. Int J Cancer. 2007 Jun 1;120(11):2452-8.","parent_key":"BE0000807"}
{"ref-id":"A11273","pubmed-id":17624589,"citation":"Sakoda LC, Blackston CR, Xue K, Doherty JA, Ray RM, Lin MG, Stalsberg H, Gao DL, Feng Z, Thomas DB, Chen C: Glutathione S-transferase M1 and P1 polymorphisms and risk of breast cancer and fibrocystic breast conditions in Chinese women. Breast Cancer Res Treat. 2008 May;109(1):143-55. Epub 2007 Jul 12.","parent_key":"BE0000807"}
{"ref-id":"A11274","pubmed-id":17381051,"citation":"Ouerhani S, Tebourski F, Slama MR, Marrakchi R, Rabeh M, Hassine LB, Ayed M, Elgaaied AB: The role of glutathione transferases M1 and T1 in individual susceptibility to bladder cancer in a Tunisian population. Ann Hum Biol. 2006 Sep-Dec;33(5-6):529-35.","parent_key":"BE0000807"}
{"ref-id":"A11275","pubmed-id":17427177,"citation":"Contreras-Vergara CA, Valenzuela-Soto E, Garcia-Orozco KD, Sotelo-Mundo RR, Yepiz-Plascencia G: A Mu-class glutathione S-transferase from gills of the marine shrimp Litopenaeus vannamei: purification and characterization. J Biochem Mol Toxicol. 2007;21(2):62-7.","parent_key":"BE0000807"}
{"ref-id":"A11276","pubmed-id":17372252,"citation":"Schwartzbaum JA, Ahlbom A, Lonn S, Warholm M, Rannug A, Auvinen A, Christensen HC, Henriksson R, Johansen C, Lindholm C, Malmer B, Salminen T, Schoemaker MJ, Swerdlow AJ, Feychting M: An international case-control study of glutathione transferase and functionally related polymorphisms and risk of primary adult brain tumors. Cancer Epidemiol Biomarkers Prev. 2007 Mar;16(3):559-65.","parent_key":"BE0000807"}
{"ref-id":"A4190","pubmed-id":11939906,"citation":"Levin G, Duffin KL, Obukowicz MG, Hummert SL, Fujiwara H, Needleman P, Raz A: Differential metabolism of dihomo-gamma-linolenic acid and arachidonic acid by cyclo-oxygenase-1 and cyclo-oxygenase-2: implications for cellular synthesis of prostaglandin E1 and prostaglandin E2. Biochem J. 2002 Jul 15;365(Pt 2):489-96.","parent_key":"BE0000017"}
{"ref-id":"A4189","pubmed-id":16190133,"citation":"Das UN: Can COX-2 inhibitor-induced increase in cardiovascular disease risk be modified by essential fatty acids? J Assoc Physicians India. 2005 Jul;53:623-7.","parent_key":"BE0000017"}
{"ref-id":"A4191","pubmed-id":15990700,"citation":"Das UN: COX-2 inhibitors and metabolism of essential fatty acids. Med Sci Monit. 2005 Jul;11(7):RA233-7. Epub 2005 Jun 29.","parent_key":"BE0000017"}
{"ref-id":"A4192","pubmed-id":11121413,"citation":"Thuresson ED, Malkowski MG, Lakkides KM, Rieke CJ, Mulichak AM, Ginell SL, Garavito RM, Smith WL: Mutational and X-ray crystallographic analysis of the interaction of dihomo-gamma -linolenic acid with prostaglandin endoperoxide H synthases. J Biol Chem. 2001 Mar 30;276(13):10358-65. Epub 2000 Dec 19.","parent_key":"BE0000017"}
{"ref-id":"A9966","pubmed-id":11477109,"citation":"Malkowski MG, Thuresson ED, Lakkides KM, Rieke CJ, Micielli R, Smith WL, Garavito RM: Structure of eicosapentaenoic and linoleic acids in the cyclooxygenase site of prostaglandin endoperoxide H synthase-1. J Biol Chem. 2001 Oct 5;276(40):37547-55. Epub 2001 Jul 27.","parent_key":"BE0000017"}
{"ref-id":"A9","pubmed-id":11752352,"citation":"Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5.","parent_key":"BE0000017"}
{"ref-id":"A4189","pubmed-id":16190133,"citation":"Das UN: Can COX-2 inhibitor-induced increase in cardiovascular disease risk be modified by essential fatty acids? J Assoc Physicians India. 2005 Jul;53:623-7.","parent_key":"BE0000262"}
{"ref-id":"A4190","pubmed-id":11939906,"citation":"Levin G, Duffin KL, Obukowicz MG, Hummert SL, Fujiwara H, Needleman P, Raz A: Differential metabolism of dihomo-gamma-linolenic acid and arachidonic acid by cyclo-oxygenase-1 and cyclo-oxygenase-2: implications for cellular synthesis of prostaglandin E1 and prostaglandin E2. Biochem J. 2002 Jul 15;365(Pt 2):489-96.","parent_key":"BE0000262"}
{"ref-id":"A4191","pubmed-id":15990700,"citation":"Das UN: COX-2 inhibitors and metabolism of essential fatty acids. Med Sci Monit. 2005 Jul;11(7):RA233-7. Epub 2005 Jun 29.","parent_key":"BE0000262"}
{"ref-id":"A4192","pubmed-id":11121413,"citation":"Thuresson ED, Malkowski MG, Lakkides KM, Rieke CJ, Mulichak AM, Ginell SL, Garavito RM, Smith WL: Mutational and X-ray crystallographic analysis of the interaction of dihomo-gamma -linolenic acid with prostaglandin endoperoxide H synthases. J Biol Chem. 2001 Mar 30;276(13):10358-65. Epub 2000 Dec 19.","parent_key":"BE0000262"}
{"ref-id":"A9987","pubmed-id":10906995,"citation":"Cunningham JM, Rayne RC: Radiochemical measurement of NOS activity by conversion of [14C]L-arginine to citrulline using HPLC separation. Methods Mol Biol. 1998;100:75-81.","parent_key":"BE0000005"}
{"ref-id":"A9969","pubmed-id":10944418,"citation":"Keilhoff G, Reiser M, Stanarius A, Aoki E, Wolf G: Citrulline immunohistochemistry for demonstration of NOS activity in vivo and in vitro. Nitric Oxide. 2000 Aug;4(4):343-53.","parent_key":"BE0000005"}
{"ref-id":"A9988","pubmed-id":11742852,"citation":"Conrad KP, Powers RW, Davis AK, Novak J: Citrulline is not the major product using the standard \"NOS activity\" assay on renal cortical homogenates. Am J Physiol Regul Integr Comp Physiol. 2002 Jan;282(1):R303-10.","parent_key":"BE0000005"}
{"ref-id":"A9989","pubmed-id":10906994,"citation":"Knowles RG, Salter M: Measurement of NOS activity by conversion of radiolabeled arginine to citrulline using ion-exchange separation. Methods Mol Biol. 1998;100:67-73.","parent_key":"BE0000005"}
{"ref-id":"A9990","pubmed-id":12745988,"citation":"Yi GB, McClendon D, Desaiah D, Goddard J, Lister A, Moffitt J, Meer RK, deShazo R, Lee KS, Rockhold RW: Fire ant venom alkaloid, isosolenopsin A, a potent and selective inhibitor of neuronal nitric oxide synthase. Int J Toxicol. 2003 Mar-Apr;22(2):81-6.","parent_key":"BE0000005"}
{"ref-id":"A11703","pubmed-id":15345777,"citation":"Wang Y, Wysocka J, Sayegh J, Lee YH, Perlin JR, Leonelli L, Sonbuchner LS, McDonald CH, Cook RG, Dou Y, Roeder RG, Clarke S, Stallcup MR, Allis CD, Coonrod SA: Human PAD4 regulates histone arginine methylation levels via demethylimination. Science. 2004 Oct 8;306(5694):279-83. Epub 2004 Sep 2.","parent_key":"BE0001092"}
{"ref-id":"A11704","pubmed-id":16146736,"citation":"Wysocka J, Allis CD, Coonrod S: Histone arginine methylation and its dynamic regulation. Front Biosci. 2006 Jan 1;11:344-55.","parent_key":"BE0001092"}
{"ref-id":"A11705","pubmed-id":16271291,"citation":"Yamamoto K, Yamada R: Genome-wide single nucleotide polymorphism analyses of rheumatoid arthritis. J Autoimmun. 2005;25 Suppl:12-5. Epub 2005 Nov 2.","parent_key":"BE0001092"}
{"ref-id":"A11706","pubmed-id":16355400,"citation":"Chang X, Han J: Expression of peptidylarginine deiminase type 4 (PAD4) in various tumors. Mol Carcinog. 2006 Mar;45(3):183-96.","parent_key":"BE0001092"}
{"ref-id":"A11707","pubmed-id":16412378,"citation":"Okazaki Y, Suzuki A, Sawada T, Ohtake-Yamanaka M, Inoue T, Hasebe T, Yamada R, Yamamoto K: Identification of citrullinated eukaryotic translation initiation factor 4G1 as novel autoantigen in rheumatoid arthritis. Biochem Biophys Res Commun. 2006 Mar 3;341(1):94-100. Epub 2006 Jan 6.","parent_key":"BE0001092"}
{"ref-id":"A4198","pubmed-id":12562875,"citation":"Lee JY, Plakidas A, Lee WH, Heikkinen A, Chanmugam P, Bray G, Hwang DH: Differential modulation of Toll-like receptors by fatty acids: preferential inhibition by n-3 polyunsaturated fatty acids. J Lipid Res. 2003 Mar;44(3):479-86. Epub 2002 Dec 1.","parent_key":"BE0000262"}
{"ref-id":"A4199","pubmed-id":12573452,"citation":"Ait-Said F, Elalamy I, Werts C, Gomard MT, Jacquemin C, Couetil JP, Hatmi M: Inhibition by eicosapentaenoic acid of IL-1beta-induced PGHS-2 expression in human microvascular endothelial cells: involvement of lipoxygenase-derived metabolites and p38 MAPK pathway. Biochim Biophys Acta. 2003 Feb 20;1631(1):77-84.","parent_key":"BE0000262"}
{"ref-id":"A4200","pubmed-id":16141635,"citation":"Machida T, Hiramatsu M, Hamaue N, Minami M, Hirafuji M: Docosahexaenoic acid enhances cyclooxygenase-2 induction by facilitating p44/42, but not p38, mitogen-activated protein kinase activation in rat vascular smooth muscle cells. J Pharmacol Sci. 2005 Sep;99(1):113-6. Epub 2005 Sep 1.","parent_key":"BE0000262"}
{"ref-id":"A4201","pubmed-id":17459764,"citation":"Chene G, Dubourdeau M, Balard P, Escoubet-Lozach L, Orfila C, Berry A, Bernad J, Aries MF, Charveron M, Pipy B: n-3 and n-6 polyunsaturated fatty acids induce the expression of COX-2 via PPARgamma activation in human keratinocyte HaCaT cells. Biochim Biophys Acta. 2007 May;1771(5):576-89. Epub 2007 Mar 16.","parent_key":"BE0000262"}
{"ref-id":"A4202","pubmed-id":20463020,"citation":"Vecchio AJ, Simmons DM, Malkowski MG: Structural basis of fatty acid substrate binding to cyclooxygenase-2. J Biol Chem. 2010 Jul 16;285(29):22152-63. doi: 10.1074/jbc.M110.119867. Epub 2010 May 12.","parent_key":"BE0000262"}
{"ref-id":"A4200","pubmed-id":16141635,"citation":"Machida T, Hiramatsu M, Hamaue N, Minami M, Hirafuji M: Docosahexaenoic acid enhances cyclooxygenase-2 induction by facilitating p44/42, but not p38, mitogen-activated protein kinase activation in rat vascular smooth muscle cells. J Pharmacol Sci. 2005 Sep;99(1):113-6. Epub 2005 Sep 1.","parent_key":"BE0000017"}
{"ref-id":"A10168","pubmed-id":14993240,"citation":"Yang P, Chan D, Felix E, Cartwright C, Menter DG, Madden T, Klein RD, Fischer SM, Newman RA: Formation and antiproliferative effect of prostaglandin E(3) from eicosapentaenoic acid in human lung cancer cells. J Lipid Res. 2004 Jun;45(6):1030-9. Epub 2004 Mar 1.","parent_key":"BE0000017"}
{"ref-id":"A4202","pubmed-id":20463020,"citation":"Vecchio AJ, Simmons DM, Malkowski MG: Structural basis of fatty acid substrate binding to cyclooxygenase-2. J Biol Chem. 2010 Jul 16;285(29):22152-63. doi: 10.1074/jbc.M110.119867. Epub 2010 May 12.","parent_key":"BE0000017"}
{"ref-id":"A4198","pubmed-id":12562875,"citation":"Lee JY, Plakidas A, Lee WH, Heikkinen A, Chanmugam P, Bray G, Hwang DH: Differential modulation of Toll-like receptors by fatty acids: preferential inhibition by n-3 polyunsaturated fatty acids. J Lipid Res. 2003 Mar;44(3):479-86. Epub 2002 Dec 1.","parent_key":"BE0000017"}
{"ref-id":"A13877","pubmed-id":12055328,"citation":"Chambrier C, Bastard JP, Rieusset J, Chevillotte E, Bonnefont-Rousselot D, Therond P, Hainque B, Riou JP, Laville M, Vidal H: Eicosapentaenoic acid induces mRNA expression of peroxisome proliferator-activated receptor gamma. Obes Res. 2002 Jun;10(6):518-25.","parent_key":"BE0000215"}
{"ref-id":"A13878","pubmed-id":16702329,"citation":"Selvaraj RK, Klasing KC: Lutein and eicosapentaenoic acid interact to modify iNOS mRNA levels through the PPARgamma/RXR pathway in chickens and HD11 cell lines. J Nutr. 2006 Jun;136(6):1610-6.","parent_key":"BE0000215"}
{"ref-id":"A13879","pubmed-id":11552681,"citation":"Iwata Y, Miyamoto S, Takamura M, Yanagisawa H, Kasuya A: Interaction between peroxisome proliferator-activated receptor gamma and its agonists: docking study of oximes having 5-benzyl-2,4-thiazolidinedione. J Mol Graph Model. 2001;19(6):536-42, 598-600.","parent_key":"BE0000215"}
{"ref-id":"A13880","pubmed-id":17052999,"citation":"Horia E, Watkins BA: Complementary actions of docosahexaenoic acid and genistein on COX-2, PGE2 and invasiveness in MDA-MB-231 breast cancer cells. Carcinogenesis. 2007 Apr;28(4):809-15. Epub 2006 Oct 19.","parent_key":"BE0000215"}
{"ref-id":"A13881","pubmed-id":17610002,"citation":"Ramakers JD, Mensink RP, Schaart G, Plat J: Arachidonic acid but not eicosapentaenoic acid (EPA) and oleic acid activates NF-kappaB and elevates ICAM-1 expression in Caco-2 cells. Lipids. 2007 Aug;42(8):687-98. Epub 2007 Jul 3.","parent_key":"BE0000215"}
{"ref-id":"A13901","pubmed-id":16603143,"citation":"Rabovsky A, Cuomo J, Eich N: Measurement of plasma antioxidant reserve after supplementation with various antioxidants in healthy subjects. Clin Chim Acta. 2006 Sep;371(1-2):55-60. Epub 2006 Mar 6.","parent_key":"BE0000956"}
{"ref-id":"A13902","pubmed-id":16880233,"citation":"Meijerman I, Beijnen JH, Schellens JH: Herb-drug interactions in oncology: focus on mechanisms of induction. Oncologist. 2006 Jul-Aug;11(7):742-52.","parent_key":"BE0000956"}
{"ref-id":"A19931","pubmed-id":15623556,"citation":"Berger AL, Ikuma M, Welsh MJ: Normal gating of CFTR requires ATP binding to both nucleotide-binding domains and hydrolysis at the second nucleotide-binding domain. Proc Natl Acad Sci U S A. 2005 Jan 11;102(2):455-60. Epub 2004 Dec 27.","parent_key":"BE0001195"}
{"ref-id":"A13941","pubmed-id":2386110,"citation":"Hochhaus G, Moellmann HW: Binding affinities of rimexolone (ORG 6216), flunisolide and their putative metabolites for the glucocorticoid receptor of human synovial tissue. Agents Actions. 1990 Jun;30(3-4):377-80.","parent_key":"BE0000794"}
{"ref-id":"A13942","pubmed-id":9563368,"citation":"Johnson M: Development of fluticasone propionate and comparison with other inhaled corticosteroids. J Allergy Clin Immunol. 1998 Apr;101(4 Pt 2):S434-9.","parent_key":"BE0000794"}
{"ref-id":"A13943","pubmed-id":15285788,"citation":"Valotis A, Hogger P: Significant receptor affinities of metabolites and a degradation product of mometasone furoate. Respir Res. 2004 Jul 22;5:7.","parent_key":"BE0000794"}
{"ref-id":"A13944","pubmed-id":9523318,"citation":"Hogger P, Erpenstein U, Rohdewald P, Sorg C: Biochemical characterization of a glucocorticoid-induced membrane protein (RM3/1) in human monocytes and its application as model system for ranking glucocorticoid potency. Pharm Res. 1998 Feb;15(2):296-302.","parent_key":"BE0000794"}
{"ref-id":"A13945","pubmed-id":11368283,"citation":"Badia L, Lund V: Topical corticosteroids in nasal polyposis. Drugs. 2001;61(5):573-8.","parent_key":"BE0000794"}
{"ref-id":"A13946","pubmed-id":8466638,"citation":"Philibert D, Bouchoux F, Cerede E, Corallo F, Allaire JM: [Pharmacologic study of the glucocorticoid activity of flunisolide compared with other steroids in the rat]. Allerg Immunol (Paris). 1993 Feb;25(2):77-81.","parent_key":"BE0000794"}
{"ref-id":"A9","pubmed-id":11752352,"citation":"Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5.","parent_key":"BE0000794"}
{"ref-id":"A4266","pubmed-id":10961373,"citation":"Gillen C, Haurand M, Kobelt DJ, Wnendt S: Affinity, potency and efficacy of tramadol and its metabolites at the cloned human mu-opioid receptor. Naunyn Schmiedebergs Arch Pharmacol. 2000 Aug;362(2):116-21.","parent_key":"BE0000770"}
{"ref-id":"A4267","pubmed-id":10991912,"citation":"Potschka H, Friderichs E, Loscher W: Anticonvulsant and proconvulsant effects of tramadol, its enantiomers and its M1 metabolite in the rat kindling model of epilepsy. Br J Pharmacol. 2000 Sep;131(2):203-12.","parent_key":"BE0000770"}
{"ref-id":"A4268","pubmed-id":1309873,"citation":"Raffa RB, Friderichs E, Reimann W, Shank RP, Codd EE, Vaught JL: Opioid and nonopioid components independently contribute to the mechanism of action of tramadol, an 'atypical' opioid analgesic. J Pharmacol Exp Ther. 1992 Jan;260(1):275-85.","parent_key":"BE0000770"}
{"ref-id":"A4269","pubmed-id":15509185,"citation":"Grond S, Sablotzki A: Clinical pharmacology of tramadol. Clin Pharmacokinet. 2004;43(13):879-923.","parent_key":"BE0000770"}
{"ref-id":"A4270","pubmed-id":16793069,"citation":"Ide S, Minami M, Ishihara K, Uhl GR, Sora I, Ikeda K: Mu opioid receptor-dependent and independent components in effects of tramadol. Neuropharmacology. 2006 Sep;51(3):651-8. Epub 2006 Jun 21.","parent_key":"BE0000770"}
{"ref-id":"A9","pubmed-id":11752352,"citation":"Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5.","parent_key":"BE0000770"}
{"ref-id":"A4271","pubmed-id":17380034,"citation":"Minami K, Uezono Y, Ueta Y: Pharmacological aspects of the effects of tramadol on G-protein coupled receptors. J Pharmacol Sci. 2007 Mar;103(3):253-60.","parent_key":"BE0000770"}
{"ref-id":"A4272","pubmed-id":8955860,"citation":"Frink MC, Hennies HH, Englberger W, Haurand M, Wilffert B: Influence of tramadol on neurotransmitter systems of the rat brain. Arzneimittelforschung. 1996 Nov;46(11):1029-36.","parent_key":"BE0000770"}
{"ref-id":"A182300","pubmed-id":31004280,"citation":"Barakat A: Revisiting Tramadol: A Multi-Modal Agent for Pain Management. CNS Drugs. 2019 May;33(5):481-501. doi: 10.1007/s40263-019-00623-5.","parent_key":"BE0000770"}
{"ref-id":"A15383","pubmed-id":19027293,"citation":"Wentland MP, Lou R, Lu Q, Bu Y, VanAlstine MA, Cohen DJ, Bidlack JM: Syntheses and opioid receptor binding properties of carboxamido-substituted opioids. Bioorg Med Chem Lett. 2009 Jan 1;19(1):203-8. doi: 10.1016/j.bmcl.2008.10.134. Epub 2008 Nov 7.","parent_key":"BE0000420"}
{"ref-id":"A182300","pubmed-id":31004280,"citation":"Barakat A: Revisiting Tramadol: A Multi-Modal Agent for Pain Management. CNS Drugs. 2019 May;33(5):481-501. doi: 10.1007/s40263-019-00623-5.","parent_key":"BE0000420"}
{"ref-id":"A4276","pubmed-id":10076568,"citation":"Kitamura S, Miyazaki Y, Shinomura Y, Kondo S, Kanayama S, Matsuzawa Y: Peroxisome proliferator-activated receptor gamma induces growth arrest and differentiation markers of human colon cancer cells. Jpn J Cancer Res. 1999 Jan;90(1):75-80.","parent_key":"BE0000215"}
{"ref-id":"A4277","pubmed-id":10097144,"citation":"Demetri GD, Fletcher CD, Mueller E, Sarraf P, Naujoks R, Campbell N, Spiegelman BM, Singer S: Induction of solid tumor differentiation by the peroxisome proliferator-activated receptor-gamma ligand troglitazone in patients with liposarcoma. Proc Natl Acad Sci U S A. 1999 Mar 30;96(7):3951-6.","parent_key":"BE0000215"}
{"ref-id":"A4278","pubmed-id":10200320,"citation":"Petrova TV, Akama KT, Van Eldik LJ: Cyclopentenone prostaglandins suppress activation of microglia: down-regulation of inducible nitric-oxide synthase by 15-deoxy-Delta12,14-prostaglandin J2. Proc Natl Acad Sci U S A. 1999 Apr 13;96(8):4668-73.","parent_key":"BE0000215"}
{"ref-id":"A4279","pubmed-id":10214942,"citation":"Camp HS, Whitton AL, Tafuri SR: PPARgamma activators down-regulate the expression of PPARgamma in 3T3-L1 adipocytes. FEBS Lett. 1999 Mar 26;447(2-3):186-90.","parent_key":"BE0000215"}
{"ref-id":"A4280","pubmed-id":10222233,"citation":"Satoh T, Furuta K, Suzuki M, Watanabe Y: Prostaglandin J2 and its metabolites promote neurite outgrowth induced by nerve growth factor in PC12 cells. Biochem Biophys Res Commun. 1999 Apr 29;258(1):50-3.","parent_key":"BE0000215"}
{"ref-id":"A9","pubmed-id":11752352,"citation":"Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5.","parent_key":"BE0000215"}
{"ref-id":"A4281","pubmed-id":12475986,"citation":"Baek SJ, Wilson LC, Hsi LC, Eling TE: Troglitazone, a peroxisome proliferator-activated receptor gamma (PPAR gamma ) ligand, selectively induces the early growth response-1 gene independently of PPAR gamma. A novel mechanism for its anti-tumorigenic activity. J Biol Chem. 2003 Feb 21;278(8):5845-53. Epub 2002 Dec 9.","parent_key":"BE0000215"}
{"ref-id":"A19851","pubmed-id":11779144,"citation":"Inoue I, Itoh F, Aoyagi S, Tazawa S, Kusama H, Akahane M, Mastunaga T, Hayashi K, Awata T, Komoda T, Katayama S: Fibrate and statin synergistically increase the transcriptional activities of PPARalpha/RXRalpha and decrease the transactivation of NFkappaB. Biochem Biophys Res Commun. 2002 Jan 11;290(1):131-9.","parent_key":"BE0000071"}
{"ref-id":"A14180","pubmed-id":3122849,"citation":"Moazed D, Noller HF: Chloramphenicol, erythromycin, carbomycin and vernamycin B protect overlapping sites in the peptidyl transferase region of 23S ribosomal RNA. Biochimie. 1987 Aug;69(8):879-84.","parent_key":"BE0004800"}
{"ref-id":"A6446","pubmed-id":11677599,"citation":"Schlunzen F, Zarivach R, Harms J, Bashan A, Tocilj A, Albrecht R, Yonath A, Franceschi F: Structural basis for the interaction of antibiotics with the peptidyl transferase centre in eubacteria. Nature. 2001 Oct 25;413(6858):814-21.","parent_key":"BE0004800"}
{"ref-id":"A14181","pubmed-id":11698379,"citation":"Garza-Ramos G, Xiong L, Zhong P, Mankin A: Binding site of macrolide antibiotics on the ribosome: new resistance mutation identifies a specific interaction of ketolides with rRNA. J Bacteriol. 2001 Dec;183(23):6898-907.","parent_key":"BE0004800"}
{"ref-id":"A18690","pubmed-id":7689111,"citation":"Douthwaite S, Aagaard C: Erythromycin binding is reduced in ribosomes with conformational alterations in the 23 S rRNA peptidyl transferase loop. J Mol Biol. 1993 Aug 5;232(3):725-31.","parent_key":"BE0004800"}
{"ref-id":"A18691","pubmed-id":18533733,"citation":"Wahab HA, Yam WK, Samian MR, Najimudin N: Refinement of a low-resolution crystal structure to better understand erythromycin interactions on large ribosomal subunit. J Biomol Struct Dyn. 2008 Aug;26(1):131-46.","parent_key":"BE0004800"}
{"ref-id":"A14172","pubmed-id":12183262,"citation":"Ng LK, Martin I, Liu G, Bryden L: Mutation in 23S rRNA associated with macrolide resistance in Neisseria gonorrhoeae. Antimicrob Agents Chemother. 2002 Sep;46(9):3020-5.","parent_key":"BE0004800"}
{"ref-id":"A14173","pubmed-id":15128458,"citation":"Jalava J, Vaara M, Huovinen P: Mutation at the position 2058 of the 23S rRNA as a cause of macrolide resistance in Streptococcus pyogenes. Ann Clin Microbiol Antimicrob. 2004 May 6;3:5.","parent_key":"BE0004800"}
{"ref-id":"A14174","pubmed-id":16464889,"citation":"Pereyre S, Renaudin H, Charron A, Bebear C, Bebear CM: Emergence of a 23S rRNA mutation in Mycoplasma hominis associated with a loss of the intrinsic resistance to erythromycin and azithromycin. J Antimicrob Chemother. 2006 Apr;57(4):753-6. Epub 2006 Feb 7.","parent_key":"BE0004800"}
{"ref-id":"A174190","pubmed-id":22644032,"citation":"Marvig RL, Sondergaard MS, Damkiaer S, Hoiby N, Johansen HK, Molin S, Jelsbak L: Mutations in 23S rRNA confer resistance against azithromycin in Pseudomonas aeruginosa. Antimicrob Agents Chemother. 2012 Aug;56(8):4519-21. doi: 10.1128/AAC.00630-12. Epub 2012 May 29.","parent_key":"BE0004800"}
{"ref-id":"A18346","pubmed-id":17964793,"citation":"Knuckley B, Luo Y, Thompson PR: Profiling Protein Arginine Deiminase 4 (PAD4): a novel screen to identify PAD4 inhibitors. Bioorg Med Chem. 2008 Jan 15;16(2):739-45. Epub 2007 Oct 13.","parent_key":"BE0001092"}
{"ref-id":"A1713","pubmed-id":17139284,"citation":"Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.","parent_key":"BE0000664"}
{"ref-id":"A1715","pubmed-id":17016423,"citation":"Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.","parent_key":"BE0000664"}
{"ref-id":"A4346","pubmed-id":17854027,"citation":"Garriga C, Perez-Elias MJ, Delgado R, Ruiz L, Najera R, Pumarola T, Alonso-Socas Mdel M, Garcia-Bujalance S, Menendez-Arias L: Mutational patterns and correlated amino acid substitutions in the HIV-1 protease after virological failure to nelfinavir- and lopinavir/ritonavir-based treatments. J Med Virol. 2007 Nov;79(11):1617-28.","parent_key":"BE0000664"}
{"ref-id":"A4347","pubmed-id":17849388,"citation":"Wittayanarakul K, Hannongbua S, Feig M: Accurate prediction of protonation state as a prerequisite for reliable MM-PB(GB)SA binding free energy calculations of HIV-1 protease inhibitors. J Comput Chem. 2008 Apr 15;29(5):673-85.","parent_key":"BE0000664"}
{"ref-id":"A4348","pubmed-id":17638694,"citation":"Dandache S, Sevigny G, Yelle J, Stranix BR, Parkin N, Schapiro JM, Wainberg MA, Wu JJ: In vitro antiviral activity and cross-resistance profile of PL-100, a novel protease inhibitor of human immunodeficiency virus type 1. Antimicrob Agents Chemother. 2007 Nov;51(11):4036-43. Epub 2007 Jul 16.","parent_key":"BE0000664"}
{"ref-id":"A4349","pubmed-id":17459746,"citation":"Perez MA, Fernandes PA, Ramos MJ: Drug design: new inhibitors for HIV-1 protease based on Nelfinavir as lead. J Mol Graph Model. 2007 Oct;26(3):634-42. Epub 2007 Mar 24.","parent_key":"BE0000664"}
{"ref-id":"A4350","pubmed-id":11396919,"citation":"Velazquez-Campoy A, Kiso Y, Freire E: The binding energetics of first- and second-generation HIV-1 protease inhibitors: implications for drug design. Arch Biochem Biophys. 2001 Jun 15;390(2):169-75.","parent_key":"BE0000664"}
{"ref-id":"A9","pubmed-id":11752352,"citation":"Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5.","parent_key":"BE0000664"}
{"ref-id":"A16818","pubmed-id":15764038,"citation":"Pearce DJ, Spencer L, Hu J, Balkrishnan R, Fleischer AB Jr, Feldman SR: Class I topical corticosteroid use by psoriasis patients in an academic practice. J Dermatolog Treat. 2004 Jul;15(4):235-8.","parent_key":"BE0000794"}
{"ref-id":"A4347","pubmed-id":17849388,"citation":"Wittayanarakul K, Hannongbua S, Feig M: Accurate prediction of protonation state as a prerequisite for reliable MM-PB(GB)SA binding free energy calculations of HIV-1 protease inhibitors. J Comput Chem. 2008 Apr 15;29(5):673-85.","parent_key":"BE0004854"}
{"ref-id":"A4348","pubmed-id":17638694,"citation":"Dandache S, Sevigny G, Yelle J, Stranix BR, Parkin N, Schapiro JM, Wainberg MA, Wu JJ: In vitro antiviral activity and cross-resistance profile of PL-100, a novel protease inhibitor of human immunodeficiency virus type 1. Antimicrob Agents Chemother. 2007 Nov;51(11):4036-43. Epub 2007 Jul 16.","parent_key":"BE0004854"}
{"ref-id":"A4358","pubmed-id":9297727,"citation":"Hoetelmans RM, Meenhorst PL, Mulder JW, Burger DM, Koks CH, Beijnen JH: Clinical pharmacology of HIV protease inhibitors: focus on saquinavir, indinavir, and ritonavir. Pharm World Sci. 1997 Aug;19(4):159-75.","parent_key":"BE0004854"}
{"ref-id":"A4359","pubmed-id":8724039,"citation":"Stein DS, Fish DG, Bilello JA, Preston SL, Martineau GL, Drusano GL: A 24-week open-label phase I/II evaluation of the HIV protease inhibitor MK-639 (indinavir). AIDS. 1996 May;10(5):485-92.","parent_key":"BE0004854"}
{"ref-id":"A10315","pubmed-id":14742690,"citation":"Mifflin RC, Saada JI, Di Mari JF, Valentich JD, Adegboyega PA, Powell DW: Aspirin-mediated COX-2 transcript stabilization via sustained p38 activation in human intestinal myofibroblasts. Mol Pharmacol. 2004 Feb;65(2):470-8.","parent_key":"BE0000262"}
{"ref-id":"A10316","pubmed-id":12463455,"citation":"Generini S, Fiori G, Matucci Cerinic M: Therapy of spondylarthropathy in inflammatory bowel disease. Clin Exp Rheumatol. 2002 Nov-Dec;20(6 Suppl 28):S88-94.","parent_key":"BE0000262"}
{"ref-id":"A10317","pubmed-id":16855178,"citation":"Distrutti E, Sediari L, Mencarelli A, Renga B, Orlandi S, Russo G, Caliendo G, Santagada V, Cirino G, Wallace JL, Fiorucci S: 5-Amino-2-hydroxybenzoic acid 4-(5-thioxo-5H-[1,2]dithiol-3yl)-phenyl ester (ATB-429), a hydrogen sulfide-releasing derivative of mesalamine, exerts antinociceptive effects in a model of postinflammatory hypersensitivity. J Pharmacol Exp Ther. 2006 Oct;319(1):447-58. Epub 2006 Jul 19.","parent_key":"BE0000262"}
{"ref-id":"A10318","pubmed-id":12208114,"citation":"Cipolla G, Crema F, Sacco S, Moro E, de Ponti F, Frigo G: Nonsteroidal anti-inflammatory drugs and inflammatory bowel disease: current perspectives. Pharmacol Res. 2002 Jul;46(1):1-6.","parent_key":"BE0000262"}
{"ref-id":"A10319","pubmed-id":9256165,"citation":"Pruzanski W, Stefanski E, Vadas P, Ramamurthy NS: Inhibition of extracellular release of proinflammatory secretory phospholipase A2 (sPLA2) by sulfasalazine: a novel mechanism of anti-inflammatory activity. Biochem Pharmacol. 1997 Jun 15;53(12):1901-7.","parent_key":"BE0000262"}
{"ref-id":"A17770","pubmed-id":17998298,"citation":"Svecova L, Vrzal R, Burysek L, Anzenbacherova E, Cerveny L, Grim J, Trejtnar F, Kunes J, Pour M, Staud F, Anzenbacher P, Dvorak Z, Pavek P: Azole antimycotics differentially affect rifampicin-induced pregnane X receptor-mediated CYP3A4 gene expression. Drug Metab Dispos. 2008 Feb;36(2):339-48. Epub 2007 Nov 12.","parent_key":"BE0000956"}
{"ref-id":"A13994","pubmed-id":20920967,"citation":"Labeur M, Holsboer F: Molecular mechanisms of glucocorticoid receptor signaling. Medicina (B Aires). 2010;70(5):457-62.","parent_key":"BE0000794"}
{"ref-id":"A16709","pubmed-id":9891987,"citation":"Hofmann TG, Hehner SP, Bacher S, Droge W, Schmitz ML: Various glucocorticoids differ in their ability to induce gene expression, apoptosis and to repress NF-kappaB-dependent transcription. FEBS Lett. 1998 Dec 28;441(3):441-6.","parent_key":"BE0000794"}
{"ref-id":"A4391","pubmed-id":12950415,"citation":"Allgayer H: Review article: mechanisms of action of mesalazine in preventing colorectal carcinoma in inflammatory bowel disease. Aliment Pharmacol Ther. 2003 Sep;18 Suppl 2:10-4.","parent_key":"BE0000017"}
{"ref-id":"A16797","pubmed-id":15824083,"citation":"Rousseaux C, Lefebvre B, Dubuquoy L, Lefebvre P, Romano O, Auwerx J, Metzger D, Wahli W, Desvergne B, Naccari GC, Chavatte P, Farce A, Bulois P, Cortot A, Colombel JF, Desreumaux P: Intestinal antiinflammatory effect of 5-aminosalicylic acid is dependent on peroxisome proliferator-activated receptor-gamma. J Exp Med. 2005 Apr 18;201(8):1205-15. Epub 2005 Apr 11.","parent_key":"BE0000215"}
{"ref-id":"A16798","pubmed-id":18544567,"citation":"Schwab M, Reynders V, Loitsch S, Shastri YM, Steinhilber D, Schroder O, Stein J: PPARgamma is involved in mesalazine-mediated induction of apoptosis and inhibition of cell growth in colon cancer cells. Carcinogenesis. 2008 Jul;29(7):1407-14. doi: 10.1093/carcin/bgn118. Epub 2008 Jun 9.","parent_key":"BE0000215"}
{"ref-id":"A16516","pubmed-id":18077625,"citation":"Linard C, Gremy O, Benderitter M: Reduction of peroxisome proliferation-activated receptor gamma expression by gamma-irradiation as a mechanism contributing to inflammatory response in rat colon: modulation by the 5-aminosalicylic acid agonist. J Pharmacol Exp Ther. 2008 Mar;324(3):911-20. Epub 2007 Dec 12.","parent_key":"BE0000215"}
{"ref-id":"A16515","pubmed-id":16939423,"citation":"Desreumaux P, Ghosh S: Review article: mode of action and delivery of 5-aminosalicylic acid - new evidence. Aliment Pharmacol Ther. 2006 Sep;24 Suppl 1:2-9.","parent_key":"BE0000215"}
{"ref-id":"A15669","pubmed-id":14977870,"citation":"Faucette SR, Wang H, Hamilton GA, Jolley SL, Gilbert D, Lindley C, Yan B, Negishi M, LeCluyse EL: Regulation of CYP2B6 in primary human hepatocytes by prototypical inducers. Drug Metab Dispos. 2004 Mar;32(3):348-58.","parent_key":"BE0000956"}
{"ref-id":"A19899","pubmed-id":15039302,"citation":"Kobayashi K, Yamagami S, Higuchi T, Hosokawa M, Chiba K: Key structural features of ligands for activation of human pregnane X receptor. Drug Metab Dispos. 2004 Apr;32(4):468-72.","parent_key":"BE0000956"}
{"ref-id":"A16728","pubmed-id":6336597,"citation":"Southren AL, Dominguez MO, Gordon GG, Wenk EJ, Hernandez MR, Dunn MW, Weinstein BI: Nuclear translocation of the cytoplasmic glucocorticoid receptor in the iris-ciliary body and adjacent corneoscleral tissue of the rabbit following topical administration of various glucocorticoids. A rapid screening method for glucocorticoid activity. Invest Ophthalmol Vis Sci. 1983 Feb;24(2):147-52.","parent_key":"BE0000794"}
{"ref-id":"A187436","pubmed-id":15634032,"citation":"Czock D, Keller F, Rasche FM, Haussler U: Pharmacokinetics and pharmacodynamics of systemically administered glucocorticoids. Clin Pharmacokinet. 2005;44(1):61-98. doi: 10.2165/00003088-200544010-00003.","parent_key":"BE0000794"}
{"ref-id":"A19965","pubmed-id":16054614,"citation":"Kretschmer XC, Baldwin WS: CAR and PXR: xenosensors of endocrine disrupters? Chem Biol Interact. 2005 Aug 15;155(3):111-28.","parent_key":"BE0000956"}
{"ref-id":"A19900","pubmed-id":15849716,"citation":"Smith CM, Faucette SR, Wang H, LeCluyse EL: Modulation of UDP-glucuronosyltransferase 1A1 in primary human hepatocytes by prototypical inducers. J Biochem Mol Toxicol. 2005;19(2):96-108.","parent_key":"BE0000956"}
{"ref-id":"A19901","pubmed-id":20869355,"citation":"Dring AM, Anderson LE, Qamar S, Stoner MA: Rational quantitative structure-activity relationship (RQSAR) screen for PXR and CAR isoform-specific nuclear receptor ligands. Chem Biol Interact. 2010 Dec 5;188(3):512-25. doi: 10.1016/j.cbi.2010.09.018. Epub 2010 Oct 20.","parent_key":"BE0000956"}
{"ref-id":"A1713","pubmed-id":17139284,"citation":"Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.","parent_key":"BE0000794"}
{"ref-id":"A1715","pubmed-id":17016423,"citation":"Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.","parent_key":"BE0000794"}
{"ref-id":"A4503","pubmed-id":16891588,"citation":"Grossman R, Yehuda R, Golier J, McEwen B, Harvey P, Maria NS: Cognitive effects of intravenous hydrocortisone in subjects with PTSD and healthy control subjects. Ann N Y Acad Sci. 2006 Jul;1071:410-21.","parent_key":"BE0000794"}
{"ref-id":"A4504","pubmed-id":16895953,"citation":"Rautanen A, Eriksson JG, Kere J, Andersson S, Osmond C, Tienari P, Sairanen H, Barker DJ, Phillips DI, Forsen T, Kajantie E: Associations of body size at birth with late-life cortisol concentrations and glucose tolerance are modified by haplotypes of the glucocorticoid receptor gene. J Clin Endocrinol Metab. 2006 Nov;91(11):4544-51. Epub 2006 Aug 8.","parent_key":"BE0000794"}
{"ref-id":"A4505","pubmed-id":16980198,"citation":"Hammer F, Stewart PM: Cortisol metabolism in hypertension. Best Pract Res Clin Endocrinol Metab. 2006 Sep;20(3):337-53.","parent_key":"BE0000794"}
{"ref-id":"A4506","pubmed-id":17038445,"citation":"Shaw JR, Gabor K, Hand E, Lankowski A, Durant L, Thibodeau R, Stanton CR, Barnaby R, Coutermarsh B, Karlson KH, Sato JD, Hamilton JW, Stanton BA: Role of glucocorticoid receptor in acclimation of killifish (Fundulus heteroclitus) to seawater and effects of arsenic. Am J Physiol Regul Integr Comp Physiol. 2007 Feb;292(2):R1052-60. Epub 2006 Oct 12.","parent_key":"BE0000794"}
{"ref-id":"A4507","pubmed-id":17086345,"citation":"Sher L: Combined dexamethasone suppression-corticotropin-releasing hormone stimulation test in studies of depression, alcoholism, and suicidal behavior. ScientificWorldJournal. 2006 Oct 31;6:1398-404.","parent_key":"BE0000794"}
{"ref-id":"A1713","pubmed-id":17139284,"citation":"Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.","parent_key":"BE0000422"}
{"ref-id":"A1715","pubmed-id":17016423,"citation":"Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.","parent_key":"BE0000422"}
{"ref-id":"A10366","pubmed-id":7981624,"citation":"Serres M, Comera C, Schmitt D: Annexin 1 regulation in human epidermal cells. Cell Mol Biol (Noisy-le-grand). 1994 Jul;40(5):701-6.","parent_key":"BE0000422"}
{"ref-id":"A4525","pubmed-id":16530171,"citation":"Yamada H, Shimoyama N, Sora I, Uhl GR, Fukuda Y, Moriya H, Shimoyama M: Morphine can produce analgesia via spinal kappa opioid receptors in the absence of mu opioid receptors. Brain Res. 2006 Apr 14;1083(1):61-9. Epub 2006 Mar 10.","parent_key":"BE0000770"}
{"ref-id":"A4526","pubmed-id":16580639,"citation":"Choi HS, Kim CS, Hwang CK, Song KY, Wang W, Qiu Y, Law PY, Wei LN, Loh HH: The opioid ligand binding of human mu-opioid receptor is modulated by novel splice variants of the receptor. Biochem Biophys Res Commun. 2006 May 19;343(4):1132-40. Epub 2006 Mar 23.","parent_key":"BE0000770"}
{"ref-id":"A4527","pubmed-id":16580848,"citation":"Castro RR, Cunha FQ, Silva FS Jr, Rocha FA: A quantitative approach to measure joint pain in experimental osteoarthritis--evidence of a role for nitric oxide. Osteoarthritis Cartilage. 2006 Aug;14(8):769-76. Epub 2006 Mar 31.","parent_key":"BE0000770"}
{"ref-id":"A4528","pubmed-id":16682505,"citation":"Johnson EA, Oldfield S, Braksator E, Gonzalez-Cuello A, Couch D, Hall KJ, Mundell SJ, Bailey CP, Kelly E, Henderson G: Agonist-selective mechanisms of mu-opioid receptor desensitization in human embryonic kidney 293 cells. Mol Pharmacol. 2006 Aug;70(2):676-85. Epub 2006 May 8.","parent_key":"BE0000770"}
{"ref-id":"A4525","pubmed-id":16530171,"citation":"Yamada H, Shimoyama N, Sora I, Uhl GR, Fukuda Y, Moriya H, Shimoyama M: Morphine can produce analgesia via spinal kappa opioid receptors in the absence of mu opioid receptors. Brain Res. 2006 Apr 14;1083(1):61-9. Epub 2006 Mar 10.","parent_key":"BE0000420"}
{"ref-id":"A11807","pubmed-id":16534251,"citation":"Dortch-Carnes J, Russell KR: Morphine-induced reduction of intraocular pressure and pupil diameter: role of nitric oxide. Pharmacology. 2006;77(1):17-24. Epub 2006 Mar 13.","parent_key":"BE0000420"}
{"ref-id":"A11808","pubmed-id":16539674,"citation":"Koch T, Wu DF, Yang LQ, Brandenburg LO, Hollt V: Role of phospholipase D2 in the agonist-induced and constitutive endocytosis of G-protein coupled receptors. J Neurochem. 2006 Apr;97(2):365-72. Epub 2006 Mar 15.","parent_key":"BE0000420"}
{"ref-id":"A11809","pubmed-id":16650582,"citation":"Galeotti N, Stefano GB, Guarna M, Bianchi E, Ghelardini C: Signaling pathway of morphine induced acute thermal hyperalgesia in mice. Pain. 2006 Aug;123(3):294-305. Epub 2006 May 2.","parent_key":"BE0000420"}
{"ref-id":"A11810","pubmed-id":16678156,"citation":"Asensio VJ, Miralles A, Garcia-Sevilla JA: Stimulation of mitogen-activated protein kinase kinases (MEK1/2) by mu-, delta- and kappa-opioid receptor agonists in the rat brain: regulation by chronic morphine and opioid withdrawal. Eur J Pharmacol. 2006 Jun 6;539(1-2):49-56. Epub 2006 Apr 6.","parent_key":"BE0000420"}
{"ref-id":"A9","pubmed-id":11752352,"citation":"Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5.","parent_key":"BE0000420"}
{"ref-id":"A11811","pubmed-id":12015197,"citation":"Kieffer BL, Gaveriaux-Ruff C: Exploring the opioid system by gene knockout. Prog Neurobiol. 2002 Apr;66(5):285-306.","parent_key":"BE0000420"}
{"ref-id":"A20227","pubmed-id":24489787,"citation":"Szalowska E, van der Burg B, Man HY, Hendriksen PJ, Peijnenburg AA: Model steatogenic compounds (amiodarone, valproic acid, and tetracycline) alter lipid metabolism by different mechanisms in mouse liver slices. PLoS One. 2014 Jan 29;9(1):e86795. doi: 10.1371/journal.pone.0086795. eCollection 2014.","parent_key":"BE0000071"}
{"ref-id":"A20227","pubmed-id":24489787,"citation":"Szalowska E, van der Burg B, Man HY, Hendriksen PJ, Peijnenburg AA: Model steatogenic compounds (amiodarone, valproic acid, and tetracycline) alter lipid metabolism by different mechanisms in mouse liver slices. PLoS One. 2014 Jan 29;9(1):e86795. doi: 10.1371/journal.pone.0086795. eCollection 2014.","parent_key":"BE0000215"}
{"ref-id":"A9","pubmed-id":11752352,"citation":"Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5.","parent_key":"BE0000262"}
{"ref-id":"A10381","pubmed-id":17175104,"citation":"Lee YS, Kim H, Brahim JS, Rowan J, Lee G, Dionne RA: Acetaminophen selectively suppresses peripheral prostaglandin E2 release and increases COX-2 gene expression in a clinical model of acute inflammation. Pain. 2007 Jun;129(3):279-86. Epub 2006 Dec 18.","parent_key":"BE0000262"}
{"ref-id":"A10382","pubmed-id":17884974,"citation":"Hinz B, Cheremina O, Brune K: Acetaminophen (paracetamol) is a selective cyclooxygenase-2 inhibitor in man. FASEB J. 2008 Feb;22(2):383-90. Epub 2007 Sep 20.","parent_key":"BE0000262"}
{"ref-id":"A10383","pubmed-id":17322116,"citation":"Weinheimer EM, Jemiolo B, Carroll CC, Harber MP, Haus JM, Burd NA, LeMoine JK, Trappe SW, Trappe TA: Resistance exercise and cyclooxygenase (COX) expression in human skeletal muscle: implications for COX-inhibiting drugs and protein synthesis. Am J Physiol Regul Integr Comp Physiol. 2007 Jun;292(6):R2241-8. Epub 2007 Feb 22.","parent_key":"BE0000262"}
{"ref-id":"A10382","pubmed-id":17884974,"citation":"Hinz B, Cheremina O, Brune K: Acetaminophen (paracetamol) is a selective cyclooxygenase-2 inhibitor in man. FASEB J. 2008 Feb;22(2):383-90. Epub 2007 Sep 20.","parent_key":"BE0000017"}
{"ref-id":"A4584","pubmed-id":17620111,"citation":"Takahama K, Shirasaki T: Central and peripheral mechanisms of narcotic antitussives: codeine-sensitive and -resistant coughs. Cough. 2007 Jul 9;3:8.","parent_key":"BE0000770"}
{"ref-id":"A10385","pubmed-id":7885194,"citation":"Mignat C, Wille U, Ziegler A: Affinity profiles of morphine, codeine, dihydrocodeine and their glucuronides at opioid receptor subtypes. Life Sci. 1995;56(10):793-9.","parent_key":"BE0000420"}
{"ref-id":"A39299","pubmed-id":12420793,"citation":"Schmidt H, Vormfelde Sv, Klinder K, Gundert-Remy U, Gleiter CH, Skopp G, Aderjan R, Fuhr U: Affinities of dihydrocodeine and its metabolites to opioid receptors. Pharmacol Toxicol. 2002 Aug;91(2):57-63.","parent_key":"BE0000420"}
{"ref-id":"A15566","pubmed-id":19828880,"citation":"Onali P, Dedoni S, Olianas MC: Direct agonist activity of tricyclic antidepressants at distinct opioid receptor subtypes. J Pharmacol Exp Ther. 2010 Jan;332(1):255-65. doi: 10.1124/jpet.109.159939. Epub 2009 Oct 14.","parent_key":"BE0000420"}
{"ref-id":"A174703","pubmed-id":17693391,"citation":"Benbouzid M, Gaveriaux-Ruff C, Yalcin I, Waltisperger E, Tessier LH, Muller A, Kieffer BL, Freund-Mercier MJ, Barrot M: Delta-opioid receptors are critical for tricyclic antidepressant treatment of neuropathic allodynia. Biol Psychiatry. 2008 Mar 15;63(6):633-6. doi: 10.1016/j.biopsych.2007.06.016. Epub 2007 Aug 13.","parent_key":"BE0000420"}
{"ref-id":"A18269","pubmed-id":3037421,"citation":"Hamon M, Gozlan H, Bourgoin S, Benoliel JJ, Mauborgne A, Taquet H, Cesselin F, Mico JA: Opioid receptors and neuropeptides in the CNS in rats treated chronically with amoxapine or amitriptyline. Neuropharmacology. 1987 Jun;26(6):531-9.","parent_key":"BE0000770"}
{"ref-id":"A10909","pubmed-id":15684812,"citation":"Samudre SS, Lattanzio FA Jr, Williams PB, Sheppard JD Jr: Comparison of topical steroids for acute anterior uveitis. J Ocul Pharmacol Ther. 2004 Dec;20(6):533-47.","parent_key":"BE0000794"}
{"ref-id":"A4604","pubmed-id":11869661,"citation":"Quigley C: Hydromorphone for acute and chronic pain. Cochrane Database Syst Rev. 2002;(1):CD003447.","parent_key":"BE0000770"}
{"ref-id":"A4605","pubmed-id":12479250,"citation":"Inturrisi CE: Clinical pharmacology of opioids for pain. Clin J Pain. 2002 Jul-Aug;18(4 Suppl):S3-13.","parent_key":"BE0000770"}
{"ref-id":"A4606","pubmed-id":11305075,"citation":"Sarhill N, Walsh D, Nelson KA: Hydromorphone: pharmacology and clinical applications in cancer patients. Support Care Cancer. 2001 Mar;9(2):84-96.","parent_key":"BE0000770"}
{"ref-id":"A4607","pubmed-id":18789923,"citation":"Kumar P, Sunkaraneni S, Sirohi S, Dighe SV, Walker EA, Yoburn BC: Hydromorphone efficacy and treatment protocol impact on tolerance and mu-opioid receptor regulation. Eur J Pharmacol. 2008 Nov 12;597(1-3):39-45. doi: 10.1016/j.ejphar.2008.08.025. Epub 2008 Aug 30.","parent_key":"BE0000770"}
{"ref-id":"A10389","pubmed-id":9301669,"citation":"Fang X, Larson DL, Portoghese PS: 7-spirobenzocyclohexyl derivatives of naltrexone, oxymorphone, and hydromorphone as selective opioid receptor ligands. J Med Chem. 1997 Sep 12;40(19):3064-70.","parent_key":"BE0000420"}
{"ref-id":"A5974","pubmed-id":2849950,"citation":"Hennies HH, Friderichs E, Schneider J: Receptor binding, analgesic and antitussive potency of tramadol and other selected opioids. Arzneimittelforschung. 1988 Jul;38(7):877-80.","parent_key":"BE0000420"}
{"ref-id":"A10390","pubmed-id":7511163,"citation":"Jiang Q, Sebastian A, Archer S, Bidlack JM: 5 beta-Methyl-14 beta-(p-nitrocinnamoylamino)-7,8-dihydromorphinone and its corresponding N-cyclopropylmethyl analog, N-cyclopropylmethylnor-5 beta-methyl-14 beta-(p-nitrocinnamoylamino)- 7,8-dihydromorphinone: mu-selective irreversible opioid antagonists. J Pharmacol Exp Ther. 1994 Mar;268(3):1107-13.","parent_key":"BE0000420"}
{"ref-id":"A10391","pubmed-id":17658959,"citation":"Guay DR: Use of oral oxymorphone in the elderly. Consult Pharm. 2007 May;22(5):417-30.","parent_key":"BE0000420"}
{"ref-id":"A10392","pubmed-id":2478994,"citation":"Hartvig P, Neil A, Terenius L, Antoni G, Rimland A, Ulin J, Langstrom B: Brain and plasma kinetics of the opioid 11C-hydromorphone in two macaque species. Pharmacol Toxicol. 1989 Sep;65(3):214-6.","parent_key":"BE0000420"}
{"ref-id":"A4608","pubmed-id":15743404,"citation":"Bobadilla L RA, Perez-Alvarez V, Bracho Valdes I, Lopez-Sanchez P: Effect of pregnancy on the roles of nitric oxide and prostaglandins in 5-hydroxytryptamine-induced contractions in rat isolated thoracic and abdominal aorta. Clin Exp Pharmacol Physiol. 2005 Mar;32(3):202-9.","parent_key":"BE0000017"}
{"ref-id":"A4609","pubmed-id":15831902,"citation":"Fornai M, Blandizzi C, Colucci R, Antonioli L, Bernardini N, Segnani C, Baragatti B, Barogi S, Berti P, Spisni R, Del Tacca M: Role of cyclooxygenases 1 and 2 in the modulation of neuromuscular functions in the distal colon of humans and mice. Gut. 2005 May;54(5):608-16.","parent_key":"BE0000017"}
{"ref-id":"A4610","pubmed-id":15700751,"citation":"Higuchi K, Tominaga K, Watanabe T, Uno H, Shiba M, Sasaki E, Tanigawa T, Takashima T, Hamaguchi M, Oshitani N, Matsumoto T, Iwanaga Y, Fukuda T, Fujiwara Y, Arakawa T: Indomethacin, but not Helicobacter pylori, inhibits adaptive relaxation in isolated guinea-pig stomach. Drugs Exp Clin Res. 2004;30(5-6):235-41.","parent_key":"BE0000017"}
{"ref-id":"A4611","pubmed-id":15891886,"citation":"Kundu N, Walser TC, Ma X, Fulton AM: Cyclooxygenase inhibitors modulate NK activities that control metastatic disease. Cancer Immunol Immunother. 2005 Oct;54(10):981-7. Epub 2005 May 13.","parent_key":"BE0000017"}
{"ref-id":"A4612","pubmed-id":15887968,"citation":"Moth CW, Prusakiewicz JJ, Marnett LJ, Lybrand TP: Stereoselective binding of indomethacin ethanolamide derivatives to cyclooxygenase-1. J Med Chem. 2005 May 19;48(10):3613-20.","parent_key":"BE0000017"}
{"ref-id":"A5120","pubmed-id":10381057,"citation":"Blanco FJ, Guitian R, Moreno J, de Toro FJ, Galdo F: Effect of antiinflammatory drugs on COX-1 and COX-2 activity in human articular chondrocytes. J Rheumatol. 1999 Jun;26(6):1366-73.","parent_key":"BE0000017"}
{"ref-id":"A10394","pubmed-id":15770365,"citation":"Armstrong PJ, Franklin DP, Carey DJ, Elmore JR: Suppression of experimental aortic aneurysms: comparison of inducible nitric oxide synthase and cyclooxygenase inhibitors. Ann Vasc Surg. 2005 Mar;19(2):248-57.","parent_key":"BE0000262"}
{"ref-id":"A10395","pubmed-id":15667901,"citation":"Jerde TJ, Calamon-Dixon JL, Bjorling DE, Nakada SY: Celecoxib inhibits ureteral contractility and prostanoid release. Urology. 2005 Jan;65(1):185-90.","parent_key":"BE0000262"}
{"ref-id":"A10396","pubmed-id":15668944,"citation":"Pilane CM, Labelle EF: Nitric oxide stimulated vascular smooth muscle cells undergo apoptosis induced in part by arachidonic acid derived eicosanoids. J Cell Physiol. 2005 Aug;204(2):423-7.","parent_key":"BE0000262"}
{"ref-id":"A10397","pubmed-id":15831440,"citation":"Yokota A, Taniguchi M, Takahira Y, Tanaka A, Takeuchi K: Rofecoxib produces intestinal but not gastric damage in the presence of a low dose of indomethacin in rats. J Pharmacol Exp Ther. 2005 Jul;314(1):302-9. Epub 2005 Apr 14.","parent_key":"BE0000262"}
{"ref-id":"A10398","pubmed-id":15730717,"citation":"Zhang GS, Fu YB, Xia M: [Proliferation inhibition effect of indomethacin on CML cells associated with down-regulation of phosphorylated STAT1/STAT5 and inhibition of COX-2 expression]. Zhonghua Xue Ye Xue Za Zhi. 2004 Dec;25(12):732-5.","parent_key":"BE0000262"}
{"ref-id":"A5120","pubmed-id":10381057,"citation":"Blanco FJ, Guitian R, Moreno J, de Toro FJ, Galdo F: Effect of antiinflammatory drugs on COX-1 and COX-2 activity in human articular chondrocytes. J Rheumatol. 1999 Jun;26(6):1366-73.","parent_key":"BE0000262"}
{"ref-id":"A15305","pubmed-id":12689521,"citation":"Cho MC, Lee HS, Kim JH, Choe YK, Hong JT, Paik SG, Yoon DY: A simple ELISA for screening ligands of peroxisome proliferator-activated receptor-gamma. J Biochem Mol Biol. 2003 Mar 31;36(2):207-13.","parent_key":"BE0000215"}
{"ref-id":"A15306","pubmed-id":9013583,"citation":"Lehmann JM, Lenhard JM, Oliver BB, Ringold GM, Kliewer SA: Peroxisome proliferator-activated receptors alpha and gamma are activated by indomethacin and other non-steroidal anti-inflammatory drugs. J Biol Chem. 1997 Feb 7;272(6):3406-10.","parent_key":"BE0000215"}
{"ref-id":"A15306","pubmed-id":9013583,"citation":"Lehmann JM, Lenhard JM, Oliver BB, Ringold GM, Kliewer SA: Peroxisome proliferator-activated receptors alpha and gamma are activated by indomethacin and other non-steroidal anti-inflammatory drugs. J Biol Chem. 1997 Feb 7;272(6):3406-10.","parent_key":"BE0000071"}
{"ref-id":"A1713","pubmed-id":17139284,"citation":"Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.","parent_key":"BE0000770"}
{"ref-id":"A1715","pubmed-id":17016423,"citation":"Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.","parent_key":"BE0000770"}
{"ref-id":"A10403","pubmed-id":11933204,"citation":"Shi J, Hui L, Xu Y, Wang F, Huang W, Hu G: Sequence variations in the mu-opioid receptor gene (OPRM1) associated with human addiction to heroin. Hum Mutat. 2002 Apr;19(4):459-60.","parent_key":"BE0000770"}
{"ref-id":"A10404","pubmed-id":17850768,"citation":"Kakko J, von Wachenfeldt J, Svanborg KD, Lidstrom J, Barr CS, Heilig M: Mood and neuroendocrine response to a chemical stressor, metyrapone, in buprenorphine-maintained heroin dependence. Biol Psychiatry. 2008 Jan 15;63(2):172-7. Epub 2007 Sep 11.","parent_key":"BE0000770"}
{"ref-id":"A10405","pubmed-id":14991152,"citation":"Kvam TM, Baar C, Rakvag TT, Kaasa S, Krokan HE, Skorpen F: Genetic analysis of the murine mu opioid receptor: increased complexity of Oprm gene splicing. J Mol Med (Berl). 2004 Apr;82(4):250-5. Epub 2004 Jan 9.","parent_key":"BE0000770"}
{"ref-id":"A497","pubmed-id":12405865,"citation":"Eap CB, Buclin T, Baumann P: Interindividual variability of the clinical pharmacokinetics of methadone: implications for the treatment of opioid dependence. Clin Pharmacokinet. 2002;41(14):1153-93. doi: 10.2165/00003088-200241140-00003.","parent_key":"BE0000770"}
{"ref-id":"A4626","pubmed-id":19717013,"citation":"Sotgiu ML, Valente M, Storchi R, Caramenti G, Biella GE: Cooperative N-methyl-D-aspartate (NMDA) receptor antagonism and mu-opioid receptor agonism mediate the methadone inhibition of the spinal neuron pain-related hyperactivity in a rat model of neuropathic pain. Pharmacol Res. 2009 Oct;60(4):284-90. doi: 10.1016/j.phrs.2009.04.002. Epub 2009  Apr 11.","parent_key":"BE0000770"}
{"ref-id":"A15392","pubmed-id":19843777,"citation":"Gross ER, Hsu AK, Gross GJ: Acute methadone treatment reduces myocardial infarct size via the delta-opioid receptor in rats during reperfusion. Anesth Analg. 2009 Nov;109(5):1395-402. doi: 10.1213/ANE.0b013e3181b92201.","parent_key":"BE0000420"}
{"ref-id":"A497","pubmed-id":12405865,"citation":"Eap CB, Buclin T, Baumann P: Interindividual variability of the clinical pharmacokinetics of methadone: implications for the treatment of opioid dependence. Clin Pharmacokinet. 2002;41(14):1153-93. doi: 10.2165/00003088-200241140-00003.","parent_key":"BE0000420"}
{"ref-id":"A11822","pubmed-id":10616041,"citation":"Kurbel S, Kurbel B, Zanic-Matanic D: Minoxidil and male-pattern alopecia: a potential role for a local regulator of sebum secretion with vasoconstrictive effects? Med Hypotheses. 1999 Nov;53(5):402-6.","parent_key":"BE0000017"}
{"ref-id":"A11823","pubmed-id":7560228,"citation":"Gaffar A, Scherl D, Afflitto J, Coleman EJ: The effect of triclosan on mediators of gingival inflammation. J Clin Periodontol. 1995 Jun;22(6):480-4.","parent_key":"BE0000017"}
{"ref-id":"A11824","pubmed-id":9008235,"citation":"Michelet JF, Commo S, Billoni N, Mahe YF, Bernard BA: Activation of cytoprotective prostaglandin synthase-1 by minoxidil as a possible explanation for its hair growth-stimulating effect. J Invest Dermatol. 1997 Feb;108(2):205-9.","parent_key":"BE0000017"}
{"ref-id":"A4669","pubmed-id":15595341,"citation":"Wermers RA, Hurley DL, Kearns AE: Osteoporosis associated with megestrol acetate. Mayo Clin Proc. 2004 Dec;79(12):1557-61.","parent_key":"BE0000794"}
{"ref-id":"A15724","pubmed-id":18411198,"citation":"Gonzalez Villarroel P, Fernandez Perez I, Paramo C, Gentil Gonzalez M, Carnero Lopez B, Vazquez Tunas ML, Carrasco Alvarez JA: Megestrol acetate-induced adrenal insufficiency. Clin Transl Oncol. 2008 Apr;10(4):235-7.","parent_key":"BE0000794"}
{"ref-id":"A4670","pubmed-id":9744490,"citation":"Wiedemann K, Hirschmann M, Knaudt K, Rupprecht R, Seier FE, Holsboer F: Sleep endocrine effects of megestrol acetate in healthy men. J Neuroendocrinol. 1998 Sep;10(9):719-27.","parent_key":"BE0000794"}
{"ref-id":"A15725","pubmed-id":9195366,"citation":"Chao Y, Chan WK, Wang SS, Lai KH, Chi CW, Lin CY, Chan A, Whang-Peng J, Lui WY, Lee SD: Phase II study of megestrol acetate in the treatment of hepatocellular carcinoma. J Gastroenterol Hepatol. 1997 Apr;12(4):277-81.","parent_key":"BE0000794"}
{"ref-id":"A4671","pubmed-id":2982481,"citation":"Lamberts SW, Uitterlinden P, Bons EG, Verleun T: Comparison of the actions of RU 38486 and megestrol acetate in the model of a transplantable adrenocorticotropin- and prolactin-secreting rat pituitary tumor. Cancer Res. 1985 Mar;45(3):1015-9.","parent_key":"BE0000794"}
{"ref-id":"A15726","pubmed-id":6222739,"citation":"Kontula K, Paavonen T, Luukkainen T, Andersson LC: Binding of progestins to the glucocorticoid receptor. Correlation to their glucocorticoid-like effects on in vitro functions of human mononuclear leukocytes. Biochem Pharmacol. 1983 May 1;32(9):1511-8.","parent_key":"BE0000794"}
{"ref-id":"A1713","pubmed-id":17139284,"citation":"Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.","parent_key":"BE0000143"}
{"ref-id":"A1715","pubmed-id":17016423,"citation":"Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.","parent_key":"BE0000143"}
{"ref-id":"A4684","pubmed-id":9515574,"citation":"Kruczynski A, Barret JM, Etievant C, Colpaert F, Fahy J, Hill BT: Antimitotic and tubulin-interacting properties of vinflunine, a novel fluorinated Vinca alkaloid. Biochem Pharmacol. 1998 Mar 1;55(5):635-48.","parent_key":"BE0000143"}
{"ref-id":"A4685","pubmed-id":7740336,"citation":"Chang AY, Garrow GC: Pilot study of vinorelbine (Navelbine) and paclitaxel (Taxol) in patients with refractory breast cancer and lung cancer. Semin Oncol. 1995 Apr;22(2 Suppl 5):66-70; discussion 70-1.","parent_key":"BE0000143"}
{"ref-id":"A4686","pubmed-id":20403547,"citation":"Seve P, Dumontet C: [Class III beta tubulin expression in nonsmall cell lung cancer]. Rev Mal Respir. 2010 Apr;27(4):383-6. doi: 10.1016/j.rmr.2010.03.006. Epub 2010 Mar 25.","parent_key":"BE0000143"}
{"ref-id":"A10375","pubmed-id":2175153,"citation":"Juchem M, Pollow K: Binding of oral contraceptive progestogens to serum proteins and cytoplasmic receptor. Am J Obstet Gynecol. 1990 Dec;163(6 Pt 2):2171-83. doi: 10.1016/0002-9378(90)90559-p.","parent_key":"BE0000794"}
{"ref-id":"A16694","pubmed-id":12010562,"citation":"Saklatvala J: Glucocorticoids: do we know how they work? Arthritis Res. 2002;4(3):146-50. Epub 2002 Jan 21.","parent_key":"BE0000794"}
{"ref-id":"A16608","pubmed-id":16507850,"citation":"Issar M, Sahasranaman S, Buchwald P, Hochhaus G: Differences in the glucocorticoid to progesterone receptor selectivity of inhaled glucocorticoids. Eur Respir J. 2006 Mar;27(3):511-6.","parent_key":"BE0000794"}
{"ref-id":"A16695","pubmed-id":15860753,"citation":"Usmani OS, Ito K, Maneechotesuwan K, Ito M, Johnson M, Barnes PJ, Adcock IM: Glucocorticoid receptor nuclear translocation in airway cells after inhaled combination therapy. Am J Respir Crit Care Med. 2005 Sep 15;172(6):704-12. Epub 2005 Apr 28.","parent_key":"BE0000794"}
{"ref-id":"A179890","pubmed-id":2207292,"citation":"Wurthwein G, Rohdewald P: Activation of beclomethasone dipropionate by hydrolysis to beclomethasone-17-monopropionate. Biopharm Drug Dispos. 1990 Jul;11(5):381-94.","parent_key":"BE0000794"}
{"ref-id":"A20075","pubmed-id":18060946,"citation":"Attardi BJ, Zeleznik A, Simhan H, Chiao JP, Mattison DR, Caritis SN: Comparison of progesterone and glucocorticoid receptor binding and stimulation of gene expression by progesterone, 17-alpha hydroxyprogesterone caproate, and related progestins. Am J Obstet Gynecol. 2007 Dec;197(6):599.e1-7.","parent_key":"BE0000794"}
{"ref-id":"A175714","pubmed-id":2214763,"citation":"Xu XF, Hoebeke J, Bjorntorp P: Progestin binds to the glucocorticoid receptor and mediates antiglucocorticoid effect in rat adipose precursor cells. J Steroid Biochem. 1990 Aug 14;36(5):465-71.","parent_key":"BE0000794"}
{"ref-id":"A175735","pubmed-id":14617569,"citation":"Leo JC, Guo C, Woon CT, Aw SE, Lin VC: Glucocorticoid and mineralocorticoid cross-talk with progesterone receptor to induce focal adhesion and growth inhibition in breast cancer cells. Endocrinology. 2004 Mar;145(3):1314-21. doi: 10.1210/en.2003-0732. Epub 2003 Nov 14.","parent_key":"BE0000794"}
{"ref-id":"A4814","pubmed-id":10475242,"citation":"Su JL, Winegar DA, Wisely GB, Sigel CS, Hull-Ryde EA: Use of a PPAR gamma-specific monoclonal antibody to demonstrate thiazolidinediones induce PPAR gamma receptor expression in vitro. Hybridoma. 1999 Jun;18(3):273-80.","parent_key":"BE0000215"}
{"ref-id":"A4815","pubmed-id":10548525,"citation":"Rieusset J, Auwerx J, Vidal H: Regulation of gene expression by activation of the peroxisome proliferator-activated receptor gamma with rosiglitazone (BRL 49653) in human adipocytes. Biochem Biophys Res Commun. 1999 Nov;265(1):265-71.","parent_key":"BE0000215"}
{"ref-id":"A4816","pubmed-id":10707565,"citation":"Kameda N, Okuya S, Oka Y: [Rosiglitazone (BRL-49653)]. Nihon Rinsho. 2000 Feb;58(2):401-4.","parent_key":"BE0000215"}
{"ref-id":"A4817","pubmed-id":10764590,"citation":"Johnson BA, Wilson EM, Li Y, Moller DE, Smith RG, Zhou G: Ligand-induced stabilization of PPARgamma monitored by NMR spectroscopy: implications for nuclear receptor activation. J Mol Biol. 2000 Apr 28;298(2):187-94.","parent_key":"BE0000215"}
{"ref-id":"A4818","pubmed-id":10871190,"citation":"Camp HS, Li O, Wise SC, Hong YH, Frankowski CL, Shen X, Vanbogelen R, Leff T: Differential activation of peroxisome proliferator-activated receptor-gamma by troglitazone and rosiglitazone. Diabetes. 2000 Apr;49(4):539-47.","parent_key":"BE0000215"}
{"ref-id":"A19957","pubmed-id":15949695,"citation":"Drevon CA: Fatty acids and expression of adipokines. Biochim Biophys Acta. 2005 May 30;1740(2):287-92. Epub 2004 Dec 8.","parent_key":"BE0000071"}
{"ref-id":"A18226","pubmed-id":20650892,"citation":"Fagart J, Hillisch A, Huyet J, Barfacker L, Fay M, Pleiss U, Pook E, Schafer S, Rafestin-Oblin ME, Kolkhof P: A new mode of mineralocorticoid receptor antagonism by a potent and selective nonsteroidal molecule. J Biol Chem. 2010 Sep 24;285(39):29932-40. doi: 10.1074/jbc.M110.131342. Epub 2010 Jul 22.","parent_key":"BE0000794"}
{"ref-id":"A4883","pubmed-id":12188035,"citation":"Tanigawa K, Nagase H, Ohmori K, Tanaka K, Miyake H, Kiniwa M, Ikizawa K: Species-specific differences in the glucocorticoid receptor transactivation function upon binding with betamethasone-esters. Int Immunopharmacol. 2002 Jun;2(7):941-50.","parent_key":"BE0000794"}
{"ref-id":"A4884","pubmed-id":15336699,"citation":"Aida K, Shi Q, Wang J, VandeBerg JL, McDonald T, Nathanielsz P, Wang XL: The effects of betamethasone (BM) on endothelial nitric oxide synthase (eNOS) expression in adult baboon femoral arterial endothelial cells. J Steroid Biochem Mol Biol. 2004 Aug;91(4-5):219-24.","parent_key":"BE0000794"}
{"ref-id":"A4885","pubmed-id":15866114,"citation":"Johnstone JF, Bocking AD, Unlugedik E, Challis JR: The effects of chorioamnionitis and betamethasone on 11beta hydroxysteroid dehydrogenase types 1 and 2 and the glucocorticoid receptor in preterm human placenta. J Soc Gynecol Investig. 2005 May;12(4):238-45.","parent_key":"BE0000794"}
{"ref-id":"A18240","pubmed-id":11585443,"citation":"Poulain R, Horvath D, Bonnet B, Eckhoff C, Chapelain B, Bodinier MC, Deprez B: From hit to lead. Combining two complementary methods for focused library design. Application to mu opiate ligands. J Med Chem. 2001 Oct 11;44(21):3378-90.","parent_key":"BE0000770"}
{"ref-id":"A5122","pubmed-id":11153163,"citation":"Fackovcova D, Kristova V, Kriska M: Renal damage induced by the treatment with non-opioid analgesics--theoretical assumption or clinical significance. Bratisl Lek Listy. 2000;101(8):417-22.","parent_key":"BE0000262"}
{"ref-id":"A10545","pubmed-id":11304699,"citation":"Roy HK, Karolski WJ, Ratashak A: Distal bowel selectivity in the chemoprevention of experimental colon carcinogenesis by the non-steroidal anti-inflammatory drug nabumetone. Int J Cancer. 2001 May 15;92(4):609-15.","parent_key":"BE0000262"}
{"ref-id":"A10546","pubmed-id":12047490,"citation":"van Kraaij DJ, Hovestad-Witterland AH, de Metz M, Vollaard EJ: A comparison of the effects of nabumetone vs meloxicam on serum thromboxane B2 and platelet function in healthy volunteers. Br J Clin Pharmacol. 2002 Jun;53(6):644-7.","parent_key":"BE0000262"}
{"ref-id":"A10547","pubmed-id":15456329,"citation":"Hedner T, Samulesson O, Wahrborg P, Wadenvik H, Ung KA, Ekbom A: Nabumetone: therapeutic use and safety profile in the management of osteoarthritis and rheumatoid arthritis. Drugs. 2004;64(20):2315-43; discussion 2344-5.","parent_key":"BE0000262"}
{"ref-id":"A10548","pubmed-id":7615202,"citation":"Elliott SN, McKnight W, Cirino G, Wallace JL: A nitric oxide-releasing nonsteroidal anti-inflammatory drug accelerates gastric ulcer healing in rats. Gastroenterology. 1995 Aug;109(2):524-30.","parent_key":"BE0000262"}
{"ref-id":"A4918","pubmed-id":11525777,"citation":"Giuliano F, Ferraz JG, Pereira R, de Nucci G, Warner TD: Cyclooxygenase selectivity of non-steroid anti-inflammatory drugs in humans: ex vivo evaluation. Eur J Pharmacol. 2001 Aug 24;426(1-2):95-103.","parent_key":"BE0000017"}
{"ref-id":"A4919","pubmed-id":16469680,"citation":"Takeuchi K, Smale S, Premchand P, Maiden L, Sherwood R, Thjodleifsson B, Bjornsson E, Bjarnason I: Prevalence and mechanism of nonsteroidal anti-inflammatory drug-induced clinical relapse in patients with inflammatory bowel disease. Clin Gastroenterol Hepatol. 2006 Feb;4(2):196-202.","parent_key":"BE0000017"}
{"ref-id":"A4920","pubmed-id":7554708,"citation":"Cipollone F, Ganci A, Panara MR, Greco A, Cuccurullo F, Patrono C, Patrignani P: Effects of nabumetone on prostanoid biosynthesis in humans. Clin Pharmacol Ther. 1995 Sep;58(3):335-41.","parent_key":"BE0000017"}
{"ref-id":"A4921","pubmed-id":9481468,"citation":"Bensen W, Zizzo A: Newer, safer nonsteroidal anti-inflammatory drugs. Rational NSAID selection for arthritis. Can Fam Physician. 1998 Jan;44:101-2, 105-7.","parent_key":"BE0000017"}
{"ref-id":"A10550","pubmed-id":12446609,"citation":"Blais V, Zhang J, Rivest S: In altering the release of glucocorticoids, ketorolac exacerbates the effects of systemic immune stimuli on expression of proinflammatory genes in the brain. Endocrinology. 2002 Dec;143(12):4820-7.","parent_key":"BE0000262"}
{"ref-id":"A10552","pubmed-id":14568029,"citation":"Ma W, Eisenach JC: Cyclooxygenase 2 in infiltrating inflammatory cells in injured nerve is universally up-regulated following various types of peripheral nerve injury. Neuroscience. 2003;121(3):691-704.","parent_key":"BE0000262"}
{"ref-id":"A10553","pubmed-id":15102535,"citation":"Padi SS, Jain NK, Singh S, Kulkarni SK: Pharmacological profile of parecoxib: a novel, potent injectable selective cyclooxygenase-2 inhibitor. Eur J Pharmacol. 2004 Apr 26;491(1):69-76.","parent_key":"BE0000262"}
{"ref-id":"A4927","pubmed-id":11695255,"citation":"Dionne RA, Khan AA, Gordon SM: Analgesia and COX-2 inhibition. Clin Exp Rheumatol. 2001 Nov-Dec;19(6 Suppl 25):S63-70.","parent_key":"BE0000262"}
{"ref-id":"A4927","pubmed-id":11695255,"citation":"Dionne RA, Khan AA, Gordon SM: Analgesia and COX-2 inhibition. Clin Exp Rheumatol. 2001 Nov-Dec;19(6 Suppl 25):S63-70.","parent_key":"BE0000017"}
{"ref-id":"A4928","pubmed-id":16262557,"citation":"Uzan A: The unexpected side effects of new nonsteroidal anti-inflammatory drugs. Expert Opin Emerg Drugs. 2005 Nov;10(4):687-8.","parent_key":"BE0000017"}
{"ref-id":"A4929","pubmed-id":16277613,"citation":"Blais V, Turrin NP, Rivest S: Cyclooxygenase 2 (COX-2) inhibition increases the inflammatory response in the brain during systemic immune stimuli. J Neurochem. 2005 Dec;95(6):1563-74. Epub 2005 Nov 8.","parent_key":"BE0000017"}
{"ref-id":"A4941","pubmed-id":11563332,"citation":"Kothekar V, Sahi S, Srinivasan M, Mohan A, Mishra J: Recognition of cyclooxygenase-2 (COX-2) active site by NSAIDs: a computer modelling study. Indian J Biochem Biophys. 2001 Feb-Apr;38(1-2):56-63.","parent_key":"BE0000262"}
{"ref-id":"A4937","pubmed-id":9152412,"citation":"Yamada M, Niki H, Yamashita M, Mue S, Ohuchi K: Prostaglandin E2 production dependent upon cyclooxygenase-1 and cyclooxygenase-2 and its contradictory modulation by auranofin in rat peritoneal macrophages. J Pharmacol Exp Ther. 1997 May;281(2):1005-12.","parent_key":"BE0000262"}
{"ref-id":"A4938","pubmed-id":15943176,"citation":"Ozgocmen S, Ardicoglu O, Erdogan H, Fadillioglu E, Gudul H: In vivo effect of celecoxib and tenoxicam on oxidant/ anti-oxidant status of patients with knee osteoarthritis. Ann Clin Lab Sci. 2005 Spring;35(2):137-43.","parent_key":"BE0000262"}
{"ref-id":"A10555","pubmed-id":16245223,"citation":"Yilmaz H, Gurel S, Ozdemir O: The use and safety profile of non-steroidal antiinflammatory drugs among Turkish patients with osteoarthritis. Turk J Gastroenterol. 2005 Sep;16(3):138-42.","parent_key":"BE0000262"}
{"ref-id":"A10556","pubmed-id":15756931,"citation":"Galvao RI, Diogenes JP, Maia GC, Filho EA, Vasconcelos SM, de Menezes DB, Cunha GM, Viana GS: Tenoxicam exerts a neuroprotective action after cerebral ischemia in rats. Neurochem Res. 2005 Jan;30(1):39-46.","parent_key":"BE0000262"}
{"ref-id":"A4937","pubmed-id":9152412,"citation":"Yamada M, Niki H, Yamashita M, Mue S, Ohuchi K: Prostaglandin E2 production dependent upon cyclooxygenase-1 and cyclooxygenase-2 and its contradictory modulation by auranofin in rat peritoneal macrophages. J Pharmacol Exp Ther. 1997 May;281(2):1005-12.","parent_key":"BE0000017"}
{"ref-id":"A4938","pubmed-id":15943176,"citation":"Ozgocmen S, Ardicoglu O, Erdogan H, Fadillioglu E, Gudul H: In vivo effect of celecoxib and tenoxicam on oxidant/ anti-oxidant status of patients with knee osteoarthritis. Ann Clin Lab Sci. 2005 Spring;35(2):137-43.","parent_key":"BE0000017"}
{"ref-id":"A4939","pubmed-id":17017983,"citation":"Lucio M, Ferreira H, Lima JL, Reis S: Interactions between oxicams and membrane bilayers: an explanation for their different COX selectivity. Med Chem. 2006 Sep;2(5):447-56.","parent_key":"BE0000017"}
{"ref-id":"A4940","pubmed-id":9175172,"citation":"Lora M, Morisset S, Menard HA, Leduc R, de Brum-Fernandes AJ: Expression of recombinant human cyclooxygenase isoenzymes in transfected COS-7 cells in vitro and inhibition by tenoxicam, indomethacin and aspirin. Prostaglandins Leukot Essent Fatty Acids. 1997 May;56(5):361-7.","parent_key":"BE0000017"}
{"ref-id":"A4941","pubmed-id":11563332,"citation":"Kothekar V, Sahi S, Srinivasan M, Mohan A, Mishra J: Recognition of cyclooxygenase-2 (COX-2) active site by NSAIDs: a computer modelling study. Indian J Biochem Biophys. 2001 Feb-Apr;38(1-2):56-63.","parent_key":"BE0000017"}
{"ref-id":"A4973","pubmed-id":15598423,"citation":"Payvandi F, Wu L, Haley M, Schafer PH, Zhang LH, Chen RS, Muller GW, Stirling DI: Immunomodulatory drugs inhibit expression of cyclooxygenase-2 from TNF-alpha, IL-1beta, and LPS-stimulated human PBMC in a partially IL-10-dependent manner. Cell Immunol. 2004 Aug;230(2):81-8.","parent_key":"BE0000262"}
{"ref-id":"A4974","pubmed-id":12720152,"citation":"Zeldis JB, Schafer PH, Bennett BL, Mercurio F, Stirling DI: Potential new therapeutics for Waldenstrom's macroglobulinemia. Semin Oncol. 2003 Apr;30(2):275-81.","parent_key":"BE0000262"}
{"ref-id":"A4980","pubmed-id":12055598,"citation":"Sigthorsson G, Simpson RJ, Walley M, Anthony A, Foster R, Hotz-Behoftsitz C, Palizban A, Pombo J, Watts J, Morham SG, Bjarnason I: COX-1 and 2, intestinal integrity, and pathogenesis of nonsteroidal anti-inflammatory drug enteropathy in mice. Gastroenterology. 2002 Jun;122(7):1913-23.","parent_key":"BE0000262"}
{"ref-id":"A4981","pubmed-id":12086292,"citation":"Scheiman JM: Outcomes studies of the gastrointestinal safety of cyclooxygenase-2 inhibitors. Cleve Clin J Med. 2002;69 Suppl 1:SI40-6.","parent_key":"BE0000262"}
{"ref-id":"A4982","pubmed-id":12086402,"citation":"Reddy BS, Rao CV: Novel approaches for colon cancer prevention by cyclooxygenase-2 inhibitors. J Environ Pathol Toxicol Oncol. 2002;21(2):155-64.","parent_key":"BE0000262"}
{"ref-id":"A4983","pubmed-id":12093311,"citation":"Ahmad SR, Kortepeter C, Brinker A, Chen M, Beitz J: Renal failure associated with the use of celecoxib and rofecoxib. Drug Saf. 2002;25(7):537-44. doi: 10.2165/00002018-200225070-00007.","parent_key":"BE0000262"}
{"ref-id":"A4984","pubmed-id":12104042,"citation":"Lu S, Zhang X, Badawi AF, El-Sohemy A, Archer MC: Cyclooxygenase-2 inhibitor celecoxib inhibits promotion of mammary tumorigenesis in rats fed a high fat diet rich in n-6 polyunsaturated fatty acids. Cancer Lett. 2002 Oct 8;184(1):7-12.","parent_key":"BE0000262"}
{"ref-id":"A752","pubmed-id":17525040,"citation":"Ordonez Gallego A, Gonzalez Baron M, Espinosa Arranz E: Oxycodone: a pharmacological and clinical review. Clin Transl Oncol. 2007 May;9(5):298-307.","parent_key":"BE0000770"}
{"ref-id":"A753","pubmed-id":18039433,"citation":"Riley J, Eisenberg E, Muller-Schwefe G, Drewes AM, Arendt-Nielsen L: Oxycodone: a review of its use in the management of pain. Curr Med Res Opin. 2008 Jan;24(1):175-92.","parent_key":"BE0000770"}
{"ref-id":"A14251","pubmed-id":19474215,"citation":"Dietis N, Guerrini R, Calo G, Salvadori S, Rowbotham DJ, Lambert DG: Simultaneous targeting of multiple opioid receptors: a strategy to improve side-effect profile. Br J Anaesth. 2009 Jul;103(1):38-49. doi: 10.1093/bja/aep129. Epub 2009 May 27.","parent_key":"BE0000770"}
{"ref-id":"A752","pubmed-id":17525040,"citation":"Ordonez Gallego A, Gonzalez Baron M, Espinosa Arranz E: Oxycodone: a pharmacological and clinical review. Clin Transl Oncol. 2007 May;9(5):298-307.","parent_key":"BE0000420"}
{"ref-id":"A17277","pubmed-id":18839173,"citation":"Harmsen S, Meijerman I, Beijnen JH, Schellens JH: Nuclear receptor mediated induction of cytochrome P450 3A4 by anticancer drugs: a key role for the pregnane X receptor. Cancer Chemother Pharmacol. 2009 Jun;64(1):35-43. doi: 10.1007/s00280-008-0842-3. Epub 2008 Oct 7.","parent_key":"BE0000956"}
{"ref-id":"A10584","pubmed-id":15458776,"citation":"Burdan F, Szumilo J, Klepacz R, Dudka J, Korobowicz A, Tokarska E, Cendrowska-Pinkosz M, Madej B, Klepacz L: Gastrointestinal and hepatic toxicity of selective and non-selective cyclooxygenase-2 inhibitors in pregnant and non-pregnant rats. Pharmacol Res. 2004 Nov;50(5):533-43.","parent_key":"BE0000262"}
{"ref-id":"A5017","pubmed-id":9253954,"citation":"Capasso A, Sorrentino L: Arachidonic acid and its metabolites are involved in the expression of morphine dependence in guinea-pig isolated ileum. Eur J Pharmacol. 1997 Jul 9;330(2-3):199-204.","parent_key":"BE0000262"}
{"ref-id":"A10585","pubmed-id":17391279,"citation":"Kirkova M, Alexandova A, Kesiova M, Todorov S: In vivo effects of amtolmetin guacyl on lipid peroxidation and antioxidant defence systems. Comparison with non-selective and COX-2 selective NSAIDs. Auton Autacoid Pharmacol. 2007 Apr;27(2):99-104.","parent_key":"BE0000262"}
{"ref-id":"A5018","pubmed-id":14613550,"citation":"Kennedy JH, Korn N, Thurston RJ: Prostaglandin levels in seminal plasma and sperm extracts of the domestic turkey, and the effects of cyclooxygenase inhibitors on sperm mobility. Reprod Biol Endocrinol. 2003 Oct 9;1:74.","parent_key":"BE0000262"}
{"ref-id":"A5019","pubmed-id":10465690,"citation":"Capasso A: Further studies on the involvement of the arachidonic acid cascade in the acute dependence produced by mu, kappa and delta opioid agonists in isolated tissues. Neuropharmacology. 1999 Jun;38(6):871-7.","parent_key":"BE0000262"}
{"ref-id":"A5017","pubmed-id":9253954,"citation":"Capasso A, Sorrentino L: Arachidonic acid and its metabolites are involved in the expression of morphine dependence in guinea-pig isolated ileum. Eur J Pharmacol. 1997 Jul 9;330(2-3):199-204.","parent_key":"BE0000017"}
{"ref-id":"A5018","pubmed-id":14613550,"citation":"Kennedy JH, Korn N, Thurston RJ: Prostaglandin levels in seminal plasma and sperm extracts of the domestic turkey, and the effects of cyclooxygenase inhibitors on sperm mobility. Reprod Biol Endocrinol. 2003 Oct 9;1:74.","parent_key":"BE0000017"}
{"ref-id":"A5019","pubmed-id":10465690,"citation":"Capasso A: Further studies on the involvement of the arachidonic acid cascade in the acute dependence produced by mu, kappa and delta opioid agonists in isolated tissues. Neuropharmacology. 1999 Jun;38(6):871-7.","parent_key":"BE0000017"}
{"ref-id":"A5020","pubmed-id":16182428,"citation":"Burdan F, Szumilo J, Marzec B, Klepacz R, Dudka J: Skeletal developmental effects of selective and nonselective cyclooxygenase-2 inhibitors administered through organogenesis and fetogenesis in Wistar CRL:(WI)WUBR rats. Toxicology. 2005 Dec 15;216(2-3):204-23. Epub 2005 Sep 22.","parent_key":"BE0000017"}
{"ref-id":"A4346","pubmed-id":17854027,"citation":"Garriga C, Perez-Elias MJ, Delgado R, Ruiz L, Najera R, Pumarola T, Alonso-Socas Mdel M, Garcia-Bujalance S, Menendez-Arias L: Mutational patterns and correlated amino acid substitutions in the HIV-1 protease after virological failure to nelfinavir- and lopinavir/ritonavir-based treatments. J Med Virol. 2007 Nov;79(11):1617-28.","parent_key":"BE0004854"}
{"ref-id":"A5030","pubmed-id":17627597,"citation":"Das A, Rao DR, Hosur MV: X-ray structure of HIV-1 protease tethered dimer complexed to ritonavir. Protein Pept Lett. 2007;14(6):565-8.","parent_key":"BE0004854"}
{"ref-id":"A5031","pubmed-id":7477168,"citation":"Markowitz M, Saag M, Powderly WG, Hurley AM, Hsu A, Valdes JM, Henry D, Sattler F, La Marca A, Leonard JM, et al.: A preliminary study of ritonavir, an inhibitor of HIV-1 protease, to treat HIV-1 infection. N Engl J Med. 1995 Dec 7;333(23):1534-9.","parent_key":"BE0004854"}
{"ref-id":"A5032","pubmed-id":8968334,"citation":"Picker MJ, Benyas S, Horwitz JA, Thompson K, Mathewson C, Smith MA: Discriminative stimulus effects of butorphanol: influence of training dose on the substitution patterns produced by Mu, Kappa and Delta opioid agonists. J Pharmacol Exp Ther. 1996 Dec;279(3):1130-41.","parent_key":"BE0000770"}
{"ref-id":"A5033","pubmed-id":7723747,"citation":"Traynor JR, Nahorski SR: Modulation by mu-opioid agonists of guanosine-5'-O-(3-[35S]thio)triphosphate binding to membranes from human neuroblastoma SH-SY5Y cells. Mol Pharmacol. 1995 Apr;47(4):848-54.","parent_key":"BE0000770"}
{"ref-id":"A5034","pubmed-id":9016350,"citation":"Selley DE, Sim LJ, Xiao R, Liu Q, Childers SR: mu-Opioid receptor-stimulated guanosine-5'-O-(gamma-thio)-triphosphate binding in rat thalamus and cultured cell lines: signal transduction mechanisms underlying agonist efficacy. Mol Pharmacol. 1997 Jan;51(1):87-96.","parent_key":"BE0000770"}
{"ref-id":"A5035","pubmed-id":8819494,"citation":"Emmerson PJ, Clark MJ, Mansour A, Akil H, Woods JH, Medzihradsky F: Characterization of opioid agonist efficacy in a C6 glioma cell line expressing the mu opioid receptor. J Pharmacol Exp Ther. 1996 Sep;278(3):1121-7.","parent_key":"BE0000770"}
{"ref-id":"A5036","pubmed-id":9862398,"citation":"Morgan D, Picker MJ: The mu opioid irreversible antagonist beta-funaltrexamine differentiates the discriminative stimulus effects of opioids with high and low efficacy at the mu opioid receptor. Psychopharmacology (Berl). 1998 Nov;140(1):20-8.","parent_key":"BE0000770"}
{"ref-id":"A5344","pubmed-id":7562497,"citation":"Codd EE, Shank RP, Schupsky JJ, Raffa RB: Serotonin and norepinephrine uptake inhibiting activity of centrally acting analgesics: structural determinants and role in antinociception. J Pharmacol Exp Ther. 1995 Sep;274(3):1263-70.","parent_key":"BE0000770"}
{"ref-id":"A5344","pubmed-id":7562497,"citation":"Codd EE, Shank RP, Schupsky JJ, Raffa RB: Serotonin and norepinephrine uptake inhibiting activity of centrally acting analgesics: structural determinants and role in antinociception. J Pharmacol Exp Ther. 1995 Sep;274(3):1263-70.","parent_key":"BE0000420"}
{"ref-id":"A14792","pubmed-id":19733976,"citation":"van Erp NP, Gelderblom H, Guchelaar HJ: Clinical pharmacokinetics of tyrosine kinase inhibitors. Cancer Treat Rev. 2009 Dec;35(8):692-706. doi: 10.1016/j.ctrv.2009.08.004. Epub 2009 Sep 5.","parent_key":"BE0000956"}
{"ref-id":"A5071","pubmed-id":10555907,"citation":"Ehrich EW, Schnitzer TJ, McIlwain H, Levy R, Wolfe F, Weisman M, Zeng Q, Morrison B, Bolognese J, Seidenberg B, Gertz BJ: Effect of specific COX-2 inhibition in osteoarthritis of the knee: a 6 week double blind, placebo controlled pilot study of rofecoxib. Rofecoxib Osteoarthritis Pilot Study Group. J Rheumatol. 1999 Nov;26(11):2438-47.","parent_key":"BE0000262"}
{"ref-id":"A5072","pubmed-id":10566562,"citation":"Malmstrom K, Daniels S, Kotey P, Seidenberg BC, Desjardins PJ: Comparison of rofecoxib and celecoxib, two cyclooxygenase-2 inhibitors, in postoperative dental pain: a randomized, placebo- and active-comparator-controlled clinical trial. Clin Ther. 1999 Oct;21(10):1653-63.","parent_key":"BE0000262"}
{"ref-id":"A5073","pubmed-id":10580458,"citation":"Langman MJ, Jensen DM, Watson DJ, Harper SE, Zhao PL, Quan H, Bolognese JA, Simon TJ: Adverse upper gastrointestinal effects of rofecoxib compared with NSAIDs. JAMA. 1999 Nov 24;282(20):1929-33.","parent_key":"BE0000262"}
{"ref-id":"A5074","pubmed-id":10643177,"citation":"Pascucci RA: COX-2-specific inhibition: implications for clinical practice. J Am Osteopath Assoc. 1999 Nov;99(11 Suppl):S18-22.","parent_key":"BE0000262"}
{"ref-id":"A5075","pubmed-id":10693877,"citation":"Hawkey C, Laine L, Simon T, Beaulieu A, Maldonado-Cocco J, Acevedo E, Shahane A, Quan H, Bolognese J, Mortensen E: Comparison of the effect of rofecoxib (a cyclooxygenase 2 inhibitor), ibuprofen, and placebo on the gastroduodenal mucosa of patients with osteoarthritis: a randomized, double-blind, placebo-controlled trial. The Rofecoxib Osteoarthritis Endoscopy Multinational Study Group. Arthritis Rheum. 2000 Feb;43(2):370-7.","parent_key":"BE0000262"}
{"ref-id":"A5076","pubmed-id":20724158,"citation":"Ashok V, Dash C, Rohan TE, Sprafka JM, Terry PD: Selective cyclooxygenase-2 (COX-2) inhibitors and breast cancer risk. Breast. 2011 Feb;20(1):66-70. doi: 10.1016/j.breast.2010.07.004. Epub 2010 Aug 17.","parent_key":"BE0000262"}
{"ref-id":"A816","pubmed-id":18922570,"citation":"Baron JA, Sandler RS, Bresalier RS, Lanas A, Morton DG, Riddell R, Iverson ER, Demets DL: Cardiovascular events associated with rofecoxib: final analysis of the APPROVe trial. Lancet. 2008 Nov 15;372(9651):1756-64. doi: 10.1016/S0140-6736(08)61490-7. Epub 2008 Oct 14.","parent_key":"BE0000262"}
{"ref-id":"A5077","pubmed-id":20166930,"citation":"Chakraborti AK, Garg SK, Kumar R, Motiwala HF, Jadhavar PS: Progress in COX-2 inhibitors: a journey so far. Curr Med Chem. 2010;17(15):1563-93.","parent_key":"BE0000262"}
{"ref-id":"A817","pubmed-id":11398914,"citation":"Matheson AJ, Figgitt DP: Rofecoxib: a review of its use in the management of osteoarthritis, acute pain and rheumatoid arthritis. Drugs. 2001;61(6):833-65.","parent_key":"BE0000262"}
{"ref-id":"A5094","pubmed-id":19277662,"citation":"Kurtzberg LS, Roth SD, Bagley RG, Rouleau C, Yao M, Crawford JL, Krumbholz RD, Schmid SM, Teicher BA: Bone marrow CFU-GM and human tumor xenograft efficacy of three tubulin binding agents. Cancer Chemother Pharmacol. 2009 Oct;64(5):1029-38. doi: 10.1007/s00280-009-0959-z. Epub 2009 Mar 10.","parent_key":"BE0000143"}
{"ref-id":"A5095","pubmed-id":20442307,"citation":"Gan PP, McCarroll JA, Po'uha ST, Kamath K, Jordan MA, Kavallaris M: Microtubule dynamics, mitotic arrest, and apoptosis: drug-induced differential effects of betaIII-tubulin. Mol Cancer Ther. 2010 May;9(5):1339-48. doi: 10.1158/1535-7163.MCT-09-0679. Epub  2010 May 4.","parent_key":"BE0000143"}
{"ref-id":"A16716","pubmed-id":10754457,"citation":"Lange K, Kleuser B, Gysler A, Bader M, Maia C, Scheidereit C, Korting HC, Schafer-Korting M: Cutaneous inflammation and proliferation in vitro: differential effects and mode of action of topical glucocorticoids. Skin Pharmacol Appl Skin Physiol. 2000 Mar-Apr;13(2):93-103.","parent_key":"BE0000794"}
{"ref-id":"A5121","pubmed-id":11785774,"citation":"Bugajski J, Glod R, Gadek-Michalska A, Bugajski AJ: Involvement of constitutive (COX-1) and inducible cyclooxygenase (COX-2) in the adrenergic-induced ACTH and corticosterone secretion. J Physiol Pharmacol. 2001 Dec;52(4 Pt 2):795-809.","parent_key":"BE0000262"}
{"ref-id":"A5123","pubmed-id":11952155,"citation":"Raju J, Bird RP: Differential modulation of transforming growth factor-betas and cyclooxygenases in the platelet lysates of male F344 rats by dietary lipids and piroxicam. Mol Cell Biochem. 2002 Feb;231(1-2):139-46.","parent_key":"BE0000262"}
{"ref-id":"A5124","pubmed-id":15464832,"citation":"Veiga AP, Duarte ID, Avila MN, da Motta PG, Tatsuo MA, Francischi JN: Prevention by celecoxib of secondary hyperalgesia induced by formalin in rats. Life Sci. 2004 Oct 22;75(23):2807-17.","parent_key":"BE0000262"}
{"ref-id":"A5121","pubmed-id":11785774,"citation":"Bugajski J, Glod R, Gadek-Michalska A, Bugajski AJ: Involvement of constitutive (COX-1) and inducible cyclooxygenase (COX-2) in the adrenergic-induced ACTH and corticosterone secretion. J Physiol Pharmacol. 2001 Dec;52(4 Pt 2):795-809.","parent_key":"BE0000017"}
{"ref-id":"A5122","pubmed-id":11153163,"citation":"Fackovcova D, Kristova V, Kriska M: Renal damage induced by the treatment with non-opioid analgesics--theoretical assumption or clinical significance. Bratisl Lek Listy. 2000;101(8):417-22.","parent_key":"BE0000017"}
{"ref-id":"A5123","pubmed-id":11952155,"citation":"Raju J, Bird RP: Differential modulation of transforming growth factor-betas and cyclooxygenases in the platelet lysates of male F344 rats by dietary lipids and piroxicam. Mol Cell Biochem. 2002 Feb;231(1-2):139-46.","parent_key":"BE0000017"}
{"ref-id":"A5124","pubmed-id":15464832,"citation":"Veiga AP, Duarte ID, Avila MN, da Motta PG, Tatsuo MA, Francischi JN: Prevention by celecoxib of secondary hyperalgesia induced by formalin in rats. Life Sci. 2004 Oct 22;75(23):2807-17.","parent_key":"BE0000017"}
{"ref-id":"A5150","pubmed-id":18220533,"citation":"Jordan MA, Kamath K: How do microtubule-targeted drugs work? An overview. Curr Cancer Drug Targets. 2007 Dec;7(8):730-42.","parent_key":"BE0000143"}
{"ref-id":"A5151","pubmed-id":1818332,"citation":"Correia JJ: Effects of antimitotic agents on tubulin-nucleotide interactions. Pharmacol Ther. 1991 Nov;52(2):127-47.","parent_key":"BE0000143"}
{"ref-id":"A5152","pubmed-id":9664292,"citation":"Jordan A, Hadfield JA, Lawrence NJ, McGown AT: Tubulin as a target for anticancer drugs: agents which interact with the mitotic spindle. Med Res Rev. 1998 Jul;18(4):259-96.","parent_key":"BE0000143"}
{"ref-id":"A5153","pubmed-id":15579115,"citation":"Islam MN, Iskander MN: Microtubulin binding sites as target for developing anticancer agents. Mini Rev Med Chem. 2004 Dec;4(10):1077-104.","parent_key":"BE0000143"}
{"ref-id":"A5154","pubmed-id":14619954,"citation":"Gupta S, Bhattacharyya B: Antimicrotubular drugs binding to vinca domain of tubulin. Mol Cell Biochem. 2003 Nov;253(1-2):41-7.","parent_key":"BE0000143"}
{"ref-id":"A5164","pubmed-id":17050798,"citation":"Poggi JC, Barissa GR, Donadi EA, Foss MC, Cunha FQ, Lanchote VL, dos Reis ML: Pharmacodynamics, chiral pharmacokinetics, and pharmacokinetic-pharmacodynamic modeling of fenoprofen in patients with diabetes mellitus. J Clin Pharmacol. 2006 Nov;46(11):1328-36.","parent_key":"BE0000262"}
{"ref-id":"A5164","pubmed-id":17050798,"citation":"Poggi JC, Barissa GR, Donadi EA, Foss MC, Cunha FQ, Lanchote VL, dos Reis ML: Pharmacodynamics, chiral pharmacokinetics, and pharmacokinetic-pharmacodynamic modeling of fenoprofen in patients with diabetes mellitus. J Clin Pharmacol. 2006 Nov;46(11):1328-36.","parent_key":"BE0000017"}
{"ref-id":"A5183","pubmed-id":10715145,"citation":"Talley JJ, Brown DL, Carter JS, Graneto MJ, Koboldt CM, Masferrer JL, Perkins WE, Rogers RS, Shaffer AF, Zhang YY, Zweifel BS, Seibert K: 4-[5-Methyl-3-phenylisoxazol-4-yl]- benzenesulfonamide, valdecoxib: a potent and selective inhibitor of COX-2. J Med Chem. 2000 Mar 9;43(5):775-7.","parent_key":"BE0000262"}
{"ref-id":"A5184","pubmed-id":11060833,"citation":"Jain KK: Evaluation of intravenous parecoxib for the relief of acute post-surgical pain. Expert Opin Investig Drugs. 2000 Nov;9(11):2717-23.","parent_key":"BE0000262"}
{"ref-id":"A5185","pubmed-id":12167567,"citation":"Yuan JJ, Yang DC, Zhang JY, Bible R Jr, Karim A, Findlay JW: Disposition of a specific cyclooxygenase-2 inhibitor, valdecoxib, in human. Drug Metab Dispos. 2002 Sep;30(9):1013-21.","parent_key":"BE0000262"}
{"ref-id":"A5186","pubmed-id":12564662,"citation":"Tacconelli S, Capone ML, Sciulli MG, Ricciotti E, Patrignani P: The biochemical selectivity of novel COX-2 inhibitors in whole blood assays of COX-isozyme activity. Curr Med Res Opin. 2002;18(8):503-11.","parent_key":"BE0000262"}
{"ref-id":"A5187","pubmed-id":12644588,"citation":"Hood WF, Gierse JK, Isakson PC, Kiefer JR, Kurumbail RG, Seibert K, Monahan JB: Characterization of celecoxib and valdecoxib binding to cyclooxygenase. Mol Pharmacol. 2003 Apr;63(4):870-7.","parent_key":"BE0000262"}
{"ref-id":"A5188","pubmed-id":15494548,"citation":"Gierse JK, Zhang Y, Hood WF, Walker MC, Trigg JS, Maziasz TJ, Koboldt CM, Muhammad JL, Zweifel BS, Masferrer JL, Isakson PC, Seibert K: Valdecoxib: assessment of cyclooxygenase-2 potency and selectivity. J Pharmacol Exp Ther. 2005 Mar;312(3):1206-12. Epub 2004 Oct 19.","parent_key":"BE0000262"}
{"ref-id":"A5204","pubmed-id":12534640,"citation":"Kirchheiner J, Meineke I, Steinbach N, Meisel C, Roots I, Brockmoller J: Pharmacokinetics of diclofenac and inhibition of cyclooxygenases 1 and 2: no relationship to the CYP2C9 genetic polymorphism in humans. Br J Clin Pharmacol. 2003 Jan;55(1):51-61.","parent_key":"BE0000262"}
{"ref-id":"A10667","pubmed-id":12588370,"citation":"Blomme EA, Chinn KS, Hardy MM, Casler JJ, Kim SH, Opsahl AC, Hall WA, Trajkovic D, Khan KN, Tripp CS: Selective cyclooxygenase-2 inhibition does not affect the healing of cutaneous full-thickness incisional wounds in SKH-1 mice. Br J Dermatol. 2003 Feb;148(2):211-23.","parent_key":"BE0000262"}
{"ref-id":"A10668","pubmed-id":12705061,"citation":"Beubler E: [Pharmacology of cyclooxygenase 2 inhibition]. Wien Med Wochenschr. 2003;153(5-6):95-9.","parent_key":"BE0000262"}
{"ref-id":"A5206","pubmed-id":12852704,"citation":"Chavez ML, DeKorte CJ: Valdecoxib: a review. Clin Ther. 2003 Mar;25(3):817-51.","parent_key":"BE0000262"}
{"ref-id":"A10669","pubmed-id":12925531,"citation":"Rowlinson SW, Kiefer JR, Prusakiewicz JJ, Pawlitz JL, Kozak KR, Kalgutkar AS, Stallings WC, Kurumbail RG, Marnett LJ: A novel mechanism of cyclooxygenase-2 inhibition involving interactions with Ser-530 and Tyr-385. J Biol Chem. 2003 Nov 14;278(46):45763-9. Epub 2003 Aug 18.","parent_key":"BE0000262"}
{"ref-id":"A5203","pubmed-id":12414874,"citation":"Calkin AC, Sudhir K, Honisett S, Williams MR, Dawood T, Komesaroff PA: Rapid potentiation of endothelium-dependent vasodilation by estradiol in postmenopausal women is mediated via cyclooxygenase 2. J Clin Endocrinol Metab. 2002 Nov;87(11):5072-5.","parent_key":"BE0000017"}
{"ref-id":"A5204","pubmed-id":12534640,"citation":"Kirchheiner J, Meineke I, Steinbach N, Meisel C, Roots I, Brockmoller J: Pharmacokinetics of diclofenac and inhibition of cyclooxygenases 1 and 2: no relationship to the CYP2C9 genetic polymorphism in humans. Br J Clin Pharmacol. 2003 Jan;55(1):51-61.","parent_key":"BE0000017"}
{"ref-id":"A5205","pubmed-id":12713596,"citation":"Kampfer H, Brautigam L, Geisslinger G, Pfeilschifter J, Frank S: Cyclooxygenase-1-coupled prostaglandin biosynthesis constitutes an essential prerequisite for skin repair. J Invest Dermatol. 2003 May;120(5):880-90.","parent_key":"BE0000017"}
{"ref-id":"A5206","pubmed-id":12852704,"citation":"Chavez ML, DeKorte CJ: Valdecoxib: a review. Clin Ther. 2003 Mar;25(3):817-51.","parent_key":"BE0000017"}
{"ref-id":"A5207","pubmed-id":12966366,"citation":"Hinz B, Rau T, Auge D, Werner U, Ramer R, Rietbrock S, Brune K: Aceclofenac spares cyclooxygenase 1 as a result of limited but sustained biotransformation to diclofenac. Clin Pharmacol Ther. 2003 Sep;74(3):222-35.","parent_key":"BE0000017"}
{"ref-id":"A11916","pubmed-id":10200007,"citation":"Andersson O, Cassel TN, Gronneberg R, Bronnegard M, Stierna P, Nord M: In vivo modulation of glucocorticoid receptor mRNA by inhaled fluticasone propionate in bronchial mucosa and blood lymphocytes in subjects with mild asthma. J Allergy Clin Immunol. 1999 Apr;103(4):595-600.","parent_key":"BE0000794"}
{"ref-id":"A5589","pubmed-id":10518812,"citation":"Lumry WR: A review of the preclinical and clinical data of newer intranasal steroids used in the treatment of allergic rhinitis. J Allergy Clin Immunol. 1999 Oct;104(4 Pt 1):S150-8.","parent_key":"BE0000794"}
{"ref-id":"A6530","pubmed-id":11730731,"citation":"Zhang X, Moilanen E, Kankaanranta H: Beclomethasone, budesonide and fluticasone propionate inhibit human neutrophil apoptosis. Eur J Pharmacol. 2001 Nov 23;431(3):365-71.","parent_key":"BE0000794"}
{"ref-id":"A11917","pubmed-id":7878687,"citation":"Hogger P, Rohdewald P: Binding kinetics of fluticasone propionate to the human glucocorticoid receptor. Steroids. 1994 Oct;59(10):597-602.","parent_key":"BE0000794"}
{"ref-id":"A11918","pubmed-id":8646863,"citation":"Johnson M: Fluticasone propionate: safety profile. Cutis. 1996 Feb;57(2 Suppl):10-2.","parent_key":"BE0000794"}
{"ref-id":"A16592","pubmed-id":19744340,"citation":"Nehme A, Lobenhofer EK, Stamer WD, Edelman JL: Glucocorticoids with different chemical structures but similar glucocorticoid receptor potency regulate subsets of common and unique genes in human trabecular meshwork cells. BMC Med Genomics. 2009 Sep 10;2:58. doi: 10.1186/1755-8794-2-58.","parent_key":"BE0000794"}
{"ref-id":"A16727","pubmed-id":19293512,"citation":"Mohandas S, Rai R, Srinivas CR: Halobetasol versus clobetasol: a study of potency. Indian J Dermatol Venereol Leprol. 2009 Mar-Apr;75(2):186-7.","parent_key":"BE0000794"}
{"ref-id":"A1713","pubmed-id":17139284,"citation":"Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.","parent_key":"BE0004800"}
{"ref-id":"A1715","pubmed-id":17016423,"citation":"Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.","parent_key":"BE0004800"}
{"ref-id":"A11224","pubmed-id":14576130,"citation":"Sinclair A, Arnold C, Woodford N: Rapid detection and estimation by pyrosequencing of 23S rRNA genes with a single nucleotide polymorphism conferring linezolid resistance in Enterococci. Antimicrob Agents Chemother. 2003 Nov;47(11):3620-2.","parent_key":"BE0004800"}
{"ref-id":"A11225","pubmed-id":15216466,"citation":"Meka VG, Pillai SK, Sakoulas G, Wennersten C, Venkataraman L, DeGirolami PC, Eliopoulos GM, Moellering RC Jr, Gold HS: Linezolid resistance in sequential Staphylococcus aureus isolates associated with a T2500A mutation in the 23S rRNA gene and loss of a single copy of rRNA. J Infect Dis. 2004 Jul 15;190(2):311-7. Epub 2004 Jun 9.","parent_key":"BE0004800"}
{"ref-id":"A11226","pubmed-id":17393201,"citation":"Zhu W, Tenover FC, Limor J, Lonsway D, Prince D, Dunne WM Jr, Patel JB: Use of pyrosequencing to identify point mutations in domain V of 23S rRNA genes of linezolid-resistant Staphylococcus aureus and Staphylococcus epidermidis. Eur J Clin Microbiol Infect Dis. 2007 Mar;26(3):161-5.","parent_key":"BE0004800"}
{"ref-id":"A11227","pubmed-id":12690106,"citation":"Colca JR, McDonald WG, Waldon DJ, Thomasco LM, Gadwood RC, Lund ET, Cavey GS, Mathews WR, Adams LD, Cecil ET, Pearson JD, Bock JH, Mott JE, Shinabarger DL, Xiong L, Mankin AS: Cross-linking in the living cell locates the site of action of oxazolidinone antibiotics. J Biol Chem. 2003 Jun 13;278(24):21972-9. Epub 2003 Apr 10.","parent_key":"BE0004800"}
{"ref-id":"A11228","pubmed-id":19351617,"citation":"Feng J, Lupien A, Gingras H, Wasserscheid J, Dewar K, Legare D, Ouellette M: Genome sequencing of linezolid-resistant Streptococcus pneumoniae mutants reveals novel mechanisms of resistance. Genome Res. 2009 Jul;19(7):1214-23. doi: 10.1101/gr.089342.108. Epub 2009 Apr 6.","parent_key":"BE0004800"}
{"ref-id":"A5237","pubmed-id":10372826,"citation":"Giuliano F, Warner TD: Ex vivo assay to determine the cyclooxygenase selectivity of non-steroidal anti-inflammatory drugs. Br J Pharmacol. 1999 Apr;126(8):1824-30.","parent_key":"BE0000262"}
{"ref-id":"A5238","pubmed-id":10485483,"citation":"Molina MA, Sitja-Arnau M, Lemoine MG, Frazier ML, Sinicrope FA: Increased cyclooxygenase-2 expression in human pancreatic carcinomas and cell lines: growth inhibition by nonsteroidal anti-inflammatory drugs. Cancer Res. 1999 Sep 1;59(17):4356-62.","parent_key":"BE0000262"}
{"ref-id":"A5239","pubmed-id":10657949,"citation":"Yip-Schneider MT, Barnard DS, Billings SD, Cheng L, Heilman DK, Lin A, Marshall SJ, Crowell PL, Marshall MS, Sweeney CJ: Cyclooxygenase-2 expression in human pancreatic adenocarcinomas. Carcinogenesis. 2000 Feb;21(2):139-46.","parent_key":"BE0000262"}
{"ref-id":"A5240","pubmed-id":11078056,"citation":"Fosslien E: Biochemistry of cyclooxygenase (COX)-2 inhibitors and molecular pathology of COX-2 in neoplasia. Crit Rev Clin Lab Sci. 2000 Oct;37(5):431-502.","parent_key":"BE0000262"}
{"ref-id":"A5241","pubmed-id":11118042,"citation":"Taylor MT, Lawson KR, Ignatenko NA, Marek SE, Stringer DE, Skovan BA, Gerner EW: Sulindac sulfone inhibits K-ras-dependent cyclooxygenase-2 expression in human colon cancer cells. Cancer Res. 2000 Dec 1;60(23):6607-10.","parent_key":"BE0000262"}
{"ref-id":"A5237","pubmed-id":10372826,"citation":"Giuliano F, Warner TD: Ex vivo assay to determine the cyclooxygenase selectivity of non-steroidal anti-inflammatory drugs. Br J Pharmacol. 1999 Apr;126(8):1824-30.","parent_key":"BE0000017"}
{"ref-id":"A11942","pubmed-id":10484067,"citation":"Lim JT, Piazza GA, Han EK, Delohery TM, Li H, Finn TS, Buttyan R, Yamamoto H, Sperl GJ, Brendel K, Gross PH, Pamukcu R, Weinstein IB: Sulindac derivatives inhibit growth and induce apoptosis in human prostate cancer cell lines. Biochem Pharmacol. 1999 Oct 1;58(7):1097-107.","parent_key":"BE0000017"}
{"ref-id":"A11943","pubmed-id":10626810,"citation":"Soriano AF, Helfrich B, Chan DC, Heasley LE, Bunn PA Jr, Chou TC: Synergistic effects of new chemopreventive agents and conventional cytotoxic agents against human lung cancer cell lines. Cancer Res. 1999 Dec 15;59(24):6178-84.","parent_key":"BE0000017"}
{"ref-id":"A11944","pubmed-id":12512695,"citation":"Cheng ZJ, Tikkanen I, Vapaatalo H, Mervaala EM: Vascular effects of COX inhibition and AT1 receptor blockade in transgenic rats harboring mouse renin-2 gene. J Physiol Pharmacol. 2002 Dec;53(4 Pt 1):597-613.","parent_key":"BE0000017"}
{"ref-id":"A11945","pubmed-id":12586211,"citation":"Cheng ZJ, Finckenberg P, Louhelainen M, Merasto S, Tikkanen I, Vapaatalo H, Mervaala EM: Cardiovascular and renal effects of cyclooxygenase inhibition in transgenic rats harboring mouse renin-2 gene (TGR[mREN2]27). Eur J Pharmacol. 2003 Feb 14;461(2-3):159-69.","parent_key":"BE0000017"}
{"ref-id":"A9","pubmed-id":11752352,"citation":"Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5.","parent_key":"BE0002189"}
{"ref-id":"A191763","pubmed-id":9385457,"citation":"Mukanganyama S, Masimirembwa CM, Naik YS, Hasler JA: Phenotyping of the glutathione S-transferase M1 polymorphism in Zimbabweans and the effects of chloroquine on blood glutathione S-transferases M1 and A. Clin Chim Acta. 1997 Sep 30;265(2):145-55. doi: 10.1016/s0009-8981(97)00104-6.","parent_key":"BE0002189"}
{"ref-id":"A11956","pubmed-id":16418198,"citation":"Jang CH, Choi JH, Byun MS, Jue DM: Chloroquine inhibits production of TNF-alpha, IL-1beta and IL-6 from lipopolysaccharide-stimulated human monocytes/macrophages by different modes. Rheumatology (Oxford). 2006 Jun;45(6):703-10. Epub 2006 Jan 17.","parent_key":"BE0000704"}
{"ref-id":"A11957","pubmed-id":16670522,"citation":"Rachmilewitz D, Karmeli F, Shteingart S, Lee J, Takabayashi K, Raz E: Immunostimulatory oligonucleotides inhibit colonic proinflammatory cytokine production in ulcerative colitis. Inflamm Bowel Dis. 2006 May;12(5):339-45.","parent_key":"BE0000704"}
{"ref-id":"A11958","pubmed-id":16761500,"citation":"Wozniacka A, Lesiak A, Narbutt J, McCauliffe DP, Sysa-Jedrzejowska A: Chloroquine treatment influences proinflammatory cytokine levels in systemic lupus erythematosus patients. Lupus. 2006;15(5):268-75.","parent_key":"BE0000704"}
{"ref-id":"A11959","pubmed-id":16870179,"citation":"Lim EJ, Lee SH, Lee JG, Chin BR, Bae YS, Kim JR, Lee CH, Baek SH: Activation of toll-like receptor-9 induces matrix metalloproteinase-9 expression through Akt and tumor necrosis factor-alpha signaling. FEBS Lett. 2006 Aug 7;580(18):4533-8. Epub 2006 Jul 17.","parent_key":"BE0000704"}
{"ref-id":"A11960","pubmed-id":17456179,"citation":"Dias-Melicio LA, Calvi SA, Bordon AP, Golim MA, Peracoli MT, Soares AM: Chloroquine is therapeutic in murine experimental model of paracoccidioidomycosis. FEMS Immunol Med Microbiol. 2007 Jun;50(1):133-43. Epub 2007 Apr 23.","parent_key":"BE0000704"}
{"ref-id":"A11961","pubmed-id":14579285,"citation":"Trevani AS, Chorny A, Salamone G, Vermeulen M, Gamberale R, Schettini J, Raiden S, Geffner J: Bacterial DNA activates human neutrophils by a CpG-independent pathway. Eur J Immunol. 2003 Nov;33(11):3164-74.","parent_key":"BE0001171"}
{"ref-id":"A11962","pubmed-id":15307186,"citation":"Rutz M, Metzger J, Gellert T, Luppa P, Lipford GB, Wagner H, Bauer S: Toll-like receptor 9 binds single-stranded CpG-DNA in a sequence- and pH-dependent manner. Eur J Immunol. 2004 Sep;34(9):2541-50.","parent_key":"BE0001171"}
{"ref-id":"A11963","pubmed-id":15762869,"citation":"Lenert P: Inhibitory oligodeoxynucleotides - therapeutic promise for systemic autoimmune diseases? Clin Exp Immunol. 2005 Apr;140(1):1-10.","parent_key":"BE0001171"}
{"ref-id":"A11964","pubmed-id":16148144,"citation":"Huang LY, Ishii KJ, Akira S, Aliberti J, Golding B: Th1-like cytokine induction by heat-killed Brucella abortus is dependent on triggering of TLR9. J Immunol. 2005 Sep 15;175(6):3964-70.","parent_key":"BE0001171"}
{"ref-id":"A11965","pubmed-id":16849519,"citation":"Merrell MA, Ilvesaro JM, Lehtonen N, Sorsa T, Gehrs B, Rosenthal E, Chen D, Shackley B, Harris KW, Selander KS: Toll-like receptor 9 agonists promote cellular invasion by increasing matrix metalloproteinase activity. Mol Cancer Res. 2006 Jul;4(7):437-47.","parent_key":"BE0001171"}
{"ref-id":"A18276","pubmed-id":16385005,"citation":"Hiller N, Fritz-Wolf K, Deponte M, Wende W, Zimmermann H, Becker K: Plasmodium falciparum glutathione S-transferase--structural and mechanistic studies on ligand binding and enzyme inhibition. Protein Sci. 2006 Feb;15(2):281-9. Epub 2005 Dec 29.","parent_key":"BE0002659"}
{"ref-id":"A191760","pubmed-id":23707973,"citation":"Yang M, Cao L, Xie M, Yu Y, Kang R, Yang L, Zhao M, Tang D: Chloroquine inhibits HMGB1 inflammatory signaling and protects mice from lethal sepsis. Biochem Pharmacol. 2013 Aug 1;86(3):410-8. doi: 10.1016/j.bcp.2013.05.013. Epub 2013 May 22.","parent_key":"BE0003428"}
{"ref-id":"A191763","pubmed-id":9385457,"citation":"Mukanganyama S, Masimirembwa CM, Naik YS, Hasler JA: Phenotyping of the glutathione S-transferase M1 polymorphism in Zimbabweans and the effects of chloroquine on blood glutathione S-transferases M1 and A. Clin Chim Acta. 1997 Sep 30;265(2):145-55. doi: 10.1016/s0009-8981(97)00104-6.","parent_key":"BE0000807"}
{"ref-id":"A191625","pubmed-id":16115318,"citation":"Vincent MJ, Bergeron E, Benjannet S, Erickson BR, Rollin PE, Ksiazek TG, Seidah NG, Nichol ST: Chloroquine is a potent inhibitor of SARS coronavirus infection and spread. Virol J. 2005 Aug 22;2:69. doi: 10.1186/1743-422X-2-69.","parent_key":"BE0000982"}
{"ref-id":"A937","pubmed-id":12127012,"citation":"Fan LW, Tanaka S, Tien LT, Ma T, Rockhold RW, Ho IK: Withdrawal from dependence upon butorphanol uniquely increases kappa(1)-opioid receptor binding in the rat brain. Brain Res Bull. 2002 Jun;58(2):149-60.","parent_key":"BE0000420"}
{"ref-id":"A5249","pubmed-id":12470863,"citation":"Fan LW, Tanaka S, Park Y, Sasaki K, Ma T, Tien LT, Rockhold RW, Ho IK: Butorphanol dependence and withdrawal decrease hippocampal kappa 2-opioid receptor binding. Brain Res. 2002 Dec 27;958(2):277-90.","parent_key":"BE0000420"}
{"ref-id":"A5250","pubmed-id":15942128,"citation":"Commiskey S, Fan LW, Ho IK, Rockhold RW: Butorphanol: effects of a prototypical agonist-antagonist analgesic on kappa-opioid receptors. J Pharmacol Sci. 2005 Jun;98(2):109-16. Epub 2005 Jun 8.","parent_key":"BE0000420"}
{"ref-id":"A5032","pubmed-id":8968334,"citation":"Picker MJ, Benyas S, Horwitz JA, Thompson K, Mathewson C, Smith MA: Discriminative stimulus effects of butorphanol: influence of training dose on the substitution patterns produced by Mu, Kappa and Delta opioid agonists. J Pharmacol Exp Ther. 1996 Dec;279(3):1130-41.","parent_key":"BE0000420"}
{"ref-id":"A5251","pubmed-id":8746803,"citation":"Wakabayashi H, Tokuyama S, Ho IK: Simultaneous measurement of biogenic amines and their metabolites in rat brain regions after acute administration of and abrupt withdrawal from butorphanol or morphine. Neurochem Res. 1995 Oct;20(10):1179-85.","parent_key":"BE0000420"}
{"ref-id":"A5252","pubmed-id":7705457,"citation":"Narita M, Feng Y, Makimura M, Hoskins B, Ho IK: Repeated administration of opioids alters characteristics of membrane-bound phorbol ester binding in rat brain. Eur J Pharmacol. 1994 Dec 27;271(2-3):547-50.","parent_key":"BE0000420"}
{"ref-id":"A5254","pubmed-id":17909753,"citation":"Walsh SL, Chausmer AE, Strain EC, Bigelow GE: Evaluation of the mu and kappa opioid actions of butorphanol in humans through differential naltrexone blockade. Psychopharmacology (Berl). 2008 Jan;196(1):143-55. Epub 2007 Oct 2.","parent_key":"BE0000420"}
{"ref-id":"A5247","pubmed-id":10381785,"citation":"Vivian JA, DeYoung MB, Sumpter TL, Traynor JR, Lewis JW, Woods JH: kappa-Opioid receptor effects of butorphanol in rhesus monkeys. J Pharmacol Exp Ther. 1999 Jul;290(1):259-65.","parent_key":"BE0000770"}
{"ref-id":"A937","pubmed-id":12127012,"citation":"Fan LW, Tanaka S, Tien LT, Ma T, Rockhold RW, Ho IK: Withdrawal from dependence upon butorphanol uniquely increases kappa(1)-opioid receptor binding in the rat brain. Brain Res Bull. 2002 Jun;58(2):149-60.","parent_key":"BE0000770"}
{"ref-id":"A5249","pubmed-id":12470863,"citation":"Fan LW, Tanaka S, Park Y, Sasaki K, Ma T, Tien LT, Rockhold RW, Ho IK: Butorphanol dependence and withdrawal decrease hippocampal kappa 2-opioid receptor binding. Brain Res. 2002 Dec 27;958(2):277-90.","parent_key":"BE0000770"}
{"ref-id":"A5250","pubmed-id":15942128,"citation":"Commiskey S, Fan LW, Ho IK, Rockhold RW: Butorphanol: effects of a prototypical agonist-antagonist analgesic on kappa-opioid receptors. J Pharmacol Sci. 2005 Jun;98(2):109-16. Epub 2005 Jun 8.","parent_key":"BE0000770"}
{"ref-id":"A5251","pubmed-id":8746803,"citation":"Wakabayashi H, Tokuyama S, Ho IK: Simultaneous measurement of biogenic amines and their metabolites in rat brain regions after acute administration of and abrupt withdrawal from butorphanol or morphine. Neurochem Res. 1995 Oct;20(10):1179-85.","parent_key":"BE0000770"}
{"ref-id":"A5343","pubmed-id":9399970,"citation":"Picker MJ: Discriminative stimulus effects of the mixed-opioid agonist/antagonist dezocine: cross-substitution by mu and delta opioid agonists. J Pharmacol Exp Ther. 1997 Dec;283(3):1009-17.","parent_key":"BE0000770"}
{"ref-id":"A5252","pubmed-id":7705457,"citation":"Narita M, Feng Y, Makimura M, Hoskins B, Ho IK: Repeated administration of opioids alters characteristics of membrane-bound phorbol ester binding in rat brain. Eur J Pharmacol. 1994 Dec 27;271(2-3):547-50.","parent_key":"BE0000770"}
{"ref-id":"A5254","pubmed-id":17909753,"citation":"Walsh SL, Chausmer AE, Strain EC, Bigelow GE: Evaluation of the mu and kappa opioid actions of butorphanol in humans through differential naltrexone blockade. Psychopharmacology (Berl). 2008 Jan;196(1):143-55. Epub 2007 Oct 2.","parent_key":"BE0000770"}
{"ref-id":"A16697","pubmed-id":15976447,"citation":"Shahin V, Ludwig Y, Schafer C, Nikova D, Oberleithner H: Glucocorticoids remodel nuclear envelope structure and permeability. J Cell Sci. 2005 Jul 1;118(Pt 13):2881-9.","parent_key":"BE0000794"}
{"ref-id":"A5304","pubmed-id":17121036,"citation":"Liu BG, Li ZY, Du M: [Effects of jingui shenqi pill combined prednisone on expression of glucocorticoid receptor and its clinical effect in treating bullous pemphigoid patients]. Zhongguo Zhong Xi Yi Jie He Za Zhi. 2006 Oct;26(10):881-4.","parent_key":"BE0000794"}
{"ref-id":"A5305","pubmed-id":16597193,"citation":"Friel PN, Alexander T, Wright JV: Suppression of adrenal function by low-dose prednisone: assessment with 24-hour urinary steroid hormone profiles--a review of five cases. Altern Med Rev. 2006 Mar;11(1):40-6.","parent_key":"BE0000794"}
{"ref-id":"A5306","pubmed-id":17504182,"citation":"Diez JJ, Iglesias P: Pharmacological therapy of Cushing's syndrome: drugs and indications. Mini Rev Med Chem. 2007 May;7(5):467-80.","parent_key":"BE0000794"}
{"ref-id":"A5307","pubmed-id":17062674,"citation":"Yano A, Fujii Y, Iwai A, Kawakami S, Kageyama Y, Kihara K: Glucocorticoids suppress tumor lymphangiogenesis of prostate cancer cells. Clin Cancer Res. 2006 Oct 15;12(20 Pt 1):6012-7.","parent_key":"BE0000794"}
{"ref-id":"A5308","pubmed-id":16707595,"citation":"Yano A, Fujii Y, Iwai A, Kageyama Y, Kihara K: Glucocorticoids suppress tumor angiogenesis and in vivo growth of prostate cancer cells. Clin Cancer Res. 2006 May 15;12(10):3003-9.","parent_key":"BE0000794"}
{"ref-id":"A12004","pubmed-id":10454501,"citation":"Barclay TB, Peters JM, Sewer MB, Ferrari L, Gonzalez FJ, Morgan ET: Modulation of cytochrome P-450 gene expression in endotoxemic mice is tissue specific and peroxisome proliferator-activated receptor-alpha dependent. J Pharmacol Exp Ther. 1999 Sep;290(3):1250-7.","parent_key":"BE0000071"}
{"ref-id":"A12005","pubmed-id":10753628,"citation":"Murata M, Kaji H, Takahashi Y, Iida K, Mizuno I, Okimura Y, Abe H, Chihara K: Stimulation by eicosapentaenoic acids of leptin mRNA expression and its secretion in mouse 3T3-L1 adipocytes in vitro. Biochem Biophys Res Commun. 2000 Apr 13;270(2):343-8.","parent_key":"BE0000071"}
{"ref-id":"A12006","pubmed-id":10787442,"citation":"Hunt MC, Lindquist PJ, Peters JM, Gonzalez FJ, Diczfalusy U, Alexson SE: Involvement of the peroxisome proliferator-activated receptor alpha in regulating long-chain acyl-CoA thioesterases. J Lipid Res. 2000 May;41(5):814-23.","parent_key":"BE0000071"}
{"ref-id":"A12007","pubmed-id":10922459,"citation":"Casas F, Domenjoud L, Rochard P, Hatier R, Rodier A, Daury L, Bianchi A, Kremarik-Bouillaud P, Becuwe P, Keller J, Schohn H, Wrutniak-Cabello C, Cabello G, Dauca M: A 45 kDa protein related to PPARgamma2, induced by peroxisome proliferators, is located in the mitochondrial matrix. FEBS Lett. 2000 Jul 28;478(1-2):4-8.","parent_key":"BE0000071"}
{"ref-id":"A12008","pubmed-id":10951268,"citation":"Komuves LG, Hanley K, Lefebvre AM, Man MQ, Ng DC, Bikle DD, Williams ML, Elias PM, Auwerx J, Feingold KR: Stimulation of PPARalpha promotes epidermal keratinocyte differentiation in vivo. J Invest Dermatol. 2000 Sep;115(3):353-60.","parent_key":"BE0000071"}
{"ref-id":"A12009","pubmed-id":20671072,"citation":"Gelosa P, Banfi C, Gianella A, Brioschi M, Pignieri A, Nobili E, Castiglioni L, Cimino M, Tremoli E, Sironi L: Peroxisome proliferator-activated receptor {alpha} agonism prevents renal damage and the oxidative stress and inflammatory processes affecting the brains of stroke-prone rats. J Pharmacol Exp Ther. 2010 Nov;335(2):324-31. doi: 10.1124/jpet.110.171090. Epub  2010 Jul 29.","parent_key":"BE0000071"}
{"ref-id":"A12010","pubmed-id":20637823,"citation":"Palkar PS, Anderson CR, Ferry CH, Gonzalez FJ, Peters JM: Effect of prenatal peroxisome proliferator-activated receptor alpha (PPARalpha) agonism on postnatal development. Toxicology. 2010 Sep 30;276(1):79-84. doi: 10.1016/j.tox.2010.07.008. Epub 2010 Jul 15.","parent_key":"BE0000071"}
{"ref-id":"A5341","pubmed-id":10690289,"citation":"Ulens C, Daenens P, Tytgat J: Norpropoxyphene-induced cardiotoxicity is associated with changes in ion-selectivity and gating of HERG currents. Cardiovasc Res. 1999 Dec;44(3):568-78.","parent_key":"BE0000770"}
{"ref-id":"A5342","pubmed-id":6249436,"citation":"Tyers MB: A classification of opiate receptors that mediate antinociception in animals. Br J Pharmacol. 1980 Jul;69(3):503-12.","parent_key":"BE0000770"}
{"ref-id":"A5345","pubmed-id":19604717,"citation":"Bannwarth B, Richez C: The dextropropoxyphene controversy. Joint Bone Spine. 2009 Oct;76(5):449-51. doi: 10.1016/j.jbspin.2009.04.004. Epub  2009 Jul 14.","parent_key":"BE0000770"}
{"ref-id":"A5346","pubmed-id":10379623,"citation":"Walker EA, Tiano MJ, Benyas SI, Dykstra LA, Picker MJ: Naltrexone and beta-funaltrexamine antagonism of the antinociceptive and response rate-decreasing effects of morphine, dezocine, and d-propoxyphene. Psychopharmacology (Berl). 1999 May;144(1):45-53.","parent_key":"BE0000770"}
{"ref-id":"A10748","pubmed-id":6151117,"citation":"Neil A: Affinities of some common opioid analgesics towards four binding sites in mouse brain. Naunyn Schmiedebergs Arch Pharmacol. 1984 Nov;328(1):24-9.","parent_key":"BE0000420"}
{"ref-id":"A5353","pubmed-id":3419842,"citation":"Levine JD, Gordon NC: Synergism between the analgesic actions of morphine and pentazocine. Pain. 1988 Jun;33(3):369-72.","parent_key":"BE0000770"}
{"ref-id":"A5354","pubmed-id":6094791,"citation":"Martin BR, Katzen JS, Woods JA, Tripathi HL, Harris LS, May EL: Stereoisomers of [3H]-N-allylnormetazocine bind to different sites in mouse brain. J Pharmacol Exp Ther. 1984 Dec;231(3):539-44.","parent_key":"BE0000770"}
{"ref-id":"A5355","pubmed-id":8042002,"citation":"Kamei J, Iwamoto Y, Misawa M, Nagase H, Kasuya Y: Effects of diabetes on the antinociceptive effect of (+/-)pentazocine in mice. Res Commun Chem Pathol Pharmacol. 1994 Apr;84(1):105-10.","parent_key":"BE0000770"}
{"ref-id":"A5356","pubmed-id":2286420,"citation":"Saha N, Datta H, Sharma PL: Effects of morphine, buprenorphine, pentazocine and nalorphine on acquisition and extinction of active avoidance responses in rats. Indian J Physiol Pharmacol. 1990 Jul;34(3):179-82.","parent_key":"BE0000770"}
{"ref-id":"A13993","pubmed-id":16079279,"citation":"Maier C, Runzler D, Schindelar J, Grabner G, Waldhausl W, Kohler G, Luger A: G-protein-coupled glucocorticoid receptors on the pituitary cell membrane. J Cell Sci. 2005 Aug 1;118(Pt 15):3353-61.","parent_key":"BE0000794"}
{"ref-id":"A18192","pubmed-id":8609227,"citation":"van der Poll T, Coyle SM, Barbosa K, Braxton CC, Lowry SF: Epinephrine inhibits tumor necrosis factor-alpha and potentiates interleukin 10 production during human endotoxemia. J Clin Invest. 1996 Feb 1;97(3):713-9.","parent_key":"BE0000704"}
{"ref-id":"A37726","pubmed-id":7733399,"citation":"Liao J, Keiser JA, Scales WE, Kunkel SL, Kluger MJ: Role of epinephrine in TNF and IL-6 production from isolated perfused rat liver. Am J Physiol. 1995 Apr;268(4 Pt 2):R896-901. doi: 10.1152/ajpregu.1995.268.4.R896.","parent_key":"BE0000704"}
{"ref-id":"A20147","pubmed-id":20735727,"citation":"Rulcova A, Prokopova I, Krausova L, Bitman M, Vrzal R, Dvorak Z, Blahos J, Pavek P: Stereoselective interactions of warfarin enantiomers with the pregnane X nuclear receptor in gene regulation of major drug-metabolizing cytochrome P450 enzymes. J Thromb Haemost. 2010 Dec;8(12):2708-17. doi: 10.1111/j.1538-7836.2010.04036.x.","parent_key":"BE0000956"}
{"ref-id":"A187048","pubmed-id":907708,"citation":"Agarwal MK, Coupry F, Philippe M: Physiological activity and receptor binding of 9 alpha fluorohydrocortisone. Biochem Biophys Res Commun. 1977 Sep 23;78(2):747-53. doi: 10.1016/0006-291x(77)90242-x.","parent_key":"BE0000794"}
{"ref-id":"A187051","pubmed-id":6274900,"citation":"Lan NC, Graham B, Bartter FC, Baxter JD: Binding of steroids to mineralocorticoid receptors: implications for in vivo occupancy by glucocorticoids. J Clin Endocrinol Metab. 1982 Feb;54(2):332-42. doi: 10.1210/jcem-54-2-332.","parent_key":"BE0000794"}
{"ref-id":"A5445","pubmed-id":10390223,"citation":"Sadler BM, Hanson CD, Chittick GE, Symonds WT, Roskell NS: Safety and pharmacokinetics of amprenavir (141W94), a human immunodeficiency virus (HIV) type 1 protease inhibitor, following oral administration of single doses to HIV-infected adults. Antimicrob Agents Chemother. 1999 Jul;43(7):1686-92.","parent_key":"BE0004854"}
{"ref-id":"A5446","pubmed-id":10436772,"citation":"Authors unspecified: Amprenavir: a new HIV protease inhibitor. Med Lett Drugs Ther. 1999 Jul 16;41(1057):64-6.","parent_key":"BE0004854"}
{"ref-id":"A13503","pubmed-id":15788780,"citation":"Roy S, Guo X, Kelschenbach J, Liu Y, Loh HH: In vivo activation of a mutant mu-opioid receptor by naltrexone produces a potent analgesic effect but no tolerance: role of mu-receptor activation and delta-receptor blockade in morphine tolerance. J Neurosci. 2005 Mar 23;25(12):3229-33.","parent_key":"BE0000420"}
{"ref-id":"A5453","pubmed-id":17661275,"citation":"Barrios de Tomasi E, Juarez-Gonzalez J: [Opioid antagonists and alcohol consumption]. Rev Neurol. 2007 Aug 1-15;45(3):155-62.","parent_key":"BE0000420"}
{"ref-id":"A5454","pubmed-id":17487229,"citation":"Weerts EM, Kim YK, Wand GS, Dannals RF, Lee JS, Frost JJ, McCaul ME: Differences in delta- and mu-opioid receptor blockade measured by positron emission tomography in naltrexone-treated recently abstinent alcohol-dependent subjects. Neuropsychopharmacology. 2008 Feb;33(3):653-65. Epub 2007 May 9.","parent_key":"BE0000420"}
{"ref-id":"A5455","pubmed-id":9673788,"citation":"Herz A: Opioid reward mechanisms: a key role in drug abuse? Can J Physiol Pharmacol. 1998 Mar;76(3):252-8.","parent_key":"BE0000420"}
{"ref-id":"A13435","pubmed-id":9040115,"citation":"Herz A: Endogenous opioid systems and alcohol addiction. Psychopharmacology (Berl). 1997 Jan;129(2):99-111.","parent_key":"BE0000420"}
{"ref-id":"A5450","pubmed-id":19068776,"citation":"Kato H: [Pharmacological effects of a mu-opioid receptor antagonist naltrexone on alcohol dependence]. Nihon Arukoru Yakubutsu Igakkai Zasshi. 2008 Oct;43(5):697-704.","parent_key":"BE0000770"}
{"ref-id":"A5451","pubmed-id":18354714,"citation":"Helm S, Trescot AM, Colson J, Sehgal N, Silverman S: Opioid antagonists, partial agonists, and agonists/antagonists: the role of office-based detoxification. Pain Physician. 2008 Mar-Apr;11(2):225-35.","parent_key":"BE0000770"}
{"ref-id":"A5452","pubmed-id":17918759,"citation":"Goodman AJ, Le Bourdonnec B, Dolle RE: Mu opioid receptor antagonists: recent developments. ChemMedChem. 2007 Nov;2(11):1552-70.","parent_key":"BE0000770"}
{"ref-id":"A5453","pubmed-id":17661275,"citation":"Barrios de Tomasi E, Juarez-Gonzalez J: [Opioid antagonists and alcohol consumption]. Rev Neurol. 2007 Aug 1-15;45(3):155-62.","parent_key":"BE0000770"}
{"ref-id":"A5454","pubmed-id":17487229,"citation":"Weerts EM, Kim YK, Wand GS, Dannals RF, Lee JS, Frost JJ, McCaul ME: Differences in delta- and mu-opioid receptor blockade measured by positron emission tomography in naltrexone-treated recently abstinent alcohol-dependent subjects. Neuropsychopharmacology. 2008 Feb;33(3):653-65. Epub 2007 May 9.","parent_key":"BE0000770"}
{"ref-id":"A5455","pubmed-id":9673788,"citation":"Herz A: Opioid reward mechanisms: a key role in drug abuse? Can J Physiol Pharmacol. 1998 Mar;76(3):252-8.","parent_key":"BE0000770"}
{"ref-id":"A10785","pubmed-id":2544592,"citation":"Krutmann J, Athar M, Mendel DB, Khan IU, Guyre PM, Mukhtar H, Elmets CA: Inhibition of the high affinity Fc receptor (Fc gamma RI) on human monocytes by porphyrin photosensitization is highly specific and mediated by the generation of superoxide radicals. J Biol Chem. 1989 Jul 5;264(19):11407-13.","parent_key":"BE0000710"}
{"ref-id":"A5468","pubmed-id":11299311,"citation":"Hurle MA: Changes in the expression of G protein-coupled receptor kinases and beta-arrestin 2 in rat brain during opioid tolerance and supersensitivity. J Neurochem. 2001 Apr;77(2):486-92.","parent_key":"BE0000770"}
{"ref-id":"A5469","pubmed-id":1688220,"citation":"Levron JC: [Pharmacokinetics and pharmacodynamics of morphinomimetics in the central nervous system]. Agressologie. 1991;32(6-7):318-20.","parent_key":"BE0000770"}
{"ref-id":"A5470","pubmed-id":2847746,"citation":"Ilien B, Galzi JL, Mejean A, Goeldner M, Hirth C: A mu-opioid receptor-filter assay. Rapid estimation of binding affinity of ligands and reversibility of long-lasting ligand-receptor complexes. Biochem Pharmacol. 1988 Oct 15;37(20):3843-51.","parent_key":"BE0000770"}
{"ref-id":"A5471","pubmed-id":3014923,"citation":"Colpaert FC, Leysen JE, Michiels M, van den Hoogen RH: Epidural and intravenous sufentanil in the rat: analgesia, opiate receptor binding, and drug concentrations in plasma and brain. Anesthesiology. 1986 Jul;65(1):41-9.","parent_key":"BE0000770"}
{"ref-id":"A5472","pubmed-id":6131653,"citation":"Leysen JE, Gommeren W: In vitro binding properties of 3H-sufentanil, a superior ligand for the mu-opiate receptor. Arch Int Pharmacodyn Ther. 1982 Dec;260(2):287-9.","parent_key":"BE0000770"}
{"ref-id":"A15401","pubmed-id":1330549,"citation":"Freye E, Latasch L, Portoghese PS: The delta receptor is involved in sufentanil-induced respiratory depression--opioid subreceptors mediate different effects. Eur J Anaesthesiol. 1992 Nov;9(6):457-62.","parent_key":"BE0000420"}
{"ref-id":"A15402","pubmed-id":8612823,"citation":"Zhu J, Xue JC, Law PY, Claude PA, Luo LY, Yin J, Chen C, Liu-Chen LY: The region in the mu opioid receptor conferring selectivity for sufentanil over the delta receptor is different from that over the kappa receptor. FEBS Lett. 1996 Apr 15;384(2):198-202.","parent_key":"BE0000420"}
{"ref-id":"A15607","pubmed-id":15932636,"citation":"McGarry HF, Plant LD, Taylor MJ: Diethylcarbamazine activity against Brugia malayi microfilariae is dependent on inducible nitric-oxide synthase and the cyclooxygenase pathway. Filaria J. 2005 Jun 2;4:4.","parent_key":"BE0000017"}
{"ref-id":"A10787","pubmed-id":10358065,"citation":"Rieke CJ, Mulichak AM, Garavito RM, Smith WL: The role of arginine 120 of human prostaglandin endoperoxide H synthase-2 in the interaction with fatty acid substrates and inhibitors. J Biol Chem. 1999 Jun 11;274(24):17109-14.","parent_key":"BE0000017"}
{"ref-id":"A5484","pubmed-id":10773011,"citation":"Hewett SJ, Uliasz TF, Vidwans AS, Hewett JA: Cyclooxygenase-2 contributes to N-methyl-D-aspartate-mediated neuronal cell death in primary cortical cell culture. J Pharmacol Exp Ther. 2000 May;293(2):417-25.","parent_key":"BE0000017"}
{"ref-id":"A6096","pubmed-id":11811354,"citation":"Kurahashi K, Shirahase H, Nakamura S, Tarumi T, Koshino Y, Wang AM, Nishihashi T, Shimizu Y: Nicotine-induced contraction in the rat coronary artery: possible involvement of the endothelium, reactive oxygen species and COX-1 metabolites. J Cardiovasc Pharmacol. 2001 Oct;38 Suppl 1:S21-5.","parent_key":"BE0000017"}
{"ref-id":"A10788","pubmed-id":12392782,"citation":"Klegeris A, McGeer PL: Cyclooxygenase and 5-lipoxygenase inhibitors protect against mononuclear phagocyte neurotoxicity. Neurobiol Aging. 2002 Sep-Oct;23(5):787-94.","parent_key":"BE0000017"}
{"ref-id":"A10789","pubmed-id":12711844,"citation":"Droge MJ, van Sorge AA, van Haeringen NJ, Quax WJ, Zaagsma J: Alternative splicing of cyclooxygenase-1 mRNA in the human iris. Ophthalmic Res. 2003 May-Jun;35(3):160-3.","parent_key":"BE0000017"}
{"ref-id":"A5485","pubmed-id":17562170,"citation":"Basselin M, Villacreses NE, Lee HJ, Bell JM, Rapoport SI: Flurbiprofen, a cyclooxygenase inhibitor, reduces the brain arachidonic acid signal in response to the cholinergic muscarinic agonist, arecoline, in awake rats. Neurochem Res. 2007 Nov;32(11):1857-67. Epub 2007 Jun 12.","parent_key":"BE0000017"}
{"ref-id":"A5486","pubmed-id":19066416,"citation":"Nivsarkar M, Banerjee A, Padh H: Cyclooxygenase inhibitors: a novel direction for Alzheimer's management. Pharmacol Rep. 2008 Sep-Oct;60(5):692-8.","parent_key":"BE0000017"}
{"ref-id":"A5480","pubmed-id":10091674,"citation":"Bayly CI, Black WC, Leger S, Ouimet N, Ouellet M, Percival MD: Structure-based design of COX-2 selectivity into flurbiprofen. Bioorg Med Chem Lett. 1999 Feb 8;9(3):307-12.","parent_key":"BE0000262"}
{"ref-id":"A5481","pubmed-id":10977131,"citation":"van Haeringen NJ, van Sorge AA, Carballosa Core-Bodelier VM: Constitutive cyclooxygenase-1 and induced cyclooxygenase-2 in isolated human iris inhibited by S(+) flurbiprofen. J Ocul Pharmacol Ther. 2000 Aug;16(4):353-61.","parent_key":"BE0000262"}
{"ref-id":"A5482","pubmed-id":11006278,"citation":"Smith T, McCracken J, Shin YK, DeWitt D: Arachidonic acid and nonsteroidal anti-inflammatory drugs induce conformational changes in the human prostaglandin endoperoxide H2 synthase-2 (cyclooxygenase-2). J Biol Chem. 2000 Dec 22;275(51):40407-15.","parent_key":"BE0000262"}
{"ref-id":"A5483","pubmed-id":11405284,"citation":"Hinz B, Brune K, Rau T, Pahl A: Flurbiprofen enantiomers inhibit inducible nitric oxide synthase expression in RAW 264.7 macrophages. Pharm Res. 2001 Feb;18(2):151-6.","parent_key":"BE0000262"}
{"ref-id":"A5484","pubmed-id":10773011,"citation":"Hewett SJ, Uliasz TF, Vidwans AS, Hewett JA: Cyclooxygenase-2 contributes to N-methyl-D-aspartate-mediated neuronal cell death in primary cortical cell culture. J Pharmacol Exp Ther. 2000 May;293(2):417-25.","parent_key":"BE0000262"}
{"ref-id":"A5485","pubmed-id":17562170,"citation":"Basselin M, Villacreses NE, Lee HJ, Bell JM, Rapoport SI: Flurbiprofen, a cyclooxygenase inhibitor, reduces the brain arachidonic acid signal in response to the cholinergic muscarinic agonist, arecoline, in awake rats. Neurochem Res. 2007 Nov;32(11):1857-67. Epub 2007 Jun 12.","parent_key":"BE0000262"}
{"ref-id":"A5486","pubmed-id":19066416,"citation":"Nivsarkar M, Banerjee A, Padh H: Cyclooxygenase inhibitors: a novel direction for Alzheimer's management. Pharmacol Rep. 2008 Sep-Oct;60(5):692-8.","parent_key":"BE0000262"}
{"ref-id":"A10367","pubmed-id":15063480,"citation":"Sitruk-Ware R: Pharmacological profile of progestins. Maturitas. 2004 Apr 15;47(4):277-83.","parent_key":"BE0000794"}
{"ref-id":"A15372","pubmed-id":17082235,"citation":"Scarsi M, Podvinec M, Roth A, Hug H, Kersten S, Albrecht H, Schwede T, Meyer UA, Rucker C: Sulfonylureas and glinides exhibit peroxisome proliferator-activated receptor gamma activity: a combined virtual screening and biological assay approach. Mol Pharmacol. 2007 Feb;71(2):398-406. Epub 2006 Nov 2.","parent_key":"BE0000215"}
{"ref-id":"A5546","pubmed-id":11142771,"citation":"Sato-Matsumura KC, Matsumura T, Nakamura H, Sawa H, Nagashima K, Koizumi H: Membrane expression of annexin I is enhanced by calcium and TPA in cultured human keratinocytes. Arch Dermatol Res. 2000 Oct;292(10):496-9.","parent_key":"BE0000422"}
{"ref-id":"A5547","pubmed-id":1712816,"citation":"White MV, Igarashi Y, Lundgren JD, Shelhamer J, Kaliner M: Hydrocortisone inhibits rat basophilic leukemia cell mediator release induced by neutrophil-derived histamine releasing activity as well as by anti-IgE. J Immunol. 1991 Jul 15;147(2):667-73.","parent_key":"BE0000422"}
{"ref-id":"A5548","pubmed-id":8060156,"citation":"Serres M, Viac J, Comera C, Schmitt D: Expression of annexin I in freshly isolated human epidermal cells and in cultured keratinocytes. Arch Dermatol Res. 1994;286(5):268-72.","parent_key":"BE0000422"}
{"ref-id":"A10811","pubmed-id":12824918,"citation":"Chen WS, Liu JH, Wei SJ, Liu JM, Hong CY, Yang WK: Colon cancer cells with high invasive potential are susceptible to induction of apoptosis by a selective COX-2 inhibitor. Cancer Sci. 2003 Mar;94(3):253-8.","parent_key":"BE0000262"}
{"ref-id":"A10812","pubmed-id":11275997,"citation":"Chen WS, Wei SJ, Liu JM, Hsiao M, Kou-Lin J, Yang WK: Tumor invasiveness and liver metastasis of colon cancer cells correlated with cyclooxygenase-2 (COX-2) expression and inhibited by a COX-2-selective inhibitor, etodolac. Int J Cancer. 2001 Mar 15;91(6):894-9.","parent_key":"BE0000262"}
{"ref-id":"A10813","pubmed-id":10594327,"citation":"Kusuhara H, Komatsu H, Sumichika H, Sugahara K: Reactive oxygen species are involved in the apoptosis induced by nonsteroidal anti-inflammatory drugs in cultured gastric cells. Eur J Pharmacol. 1999 Nov 3;383(3):331-7.","parent_key":"BE0000262"}
{"ref-id":"A10814","pubmed-id":11009046,"citation":"Svendsen KB, Bech JN, Sorensen TB, Pedersen EB: A comparison of the effects of etodolac and ibuprofen on renal haemodynamics, tubular function, renin, vasopressin and urinary excretion of albumin and alpha-glutathione-S-transferase in healthy subjects: a placebo-controlled cross-over study. Eur J Clin Pharmacol. 2000 Aug;56(5):383-8.","parent_key":"BE0000262"}
{"ref-id":"A5563","pubmed-id":15198222,"citation":"Wilson JE, Chandrasekharan NV, Westover KD, Eager KB, Simmons DL: Determination of expression of cyclooxygenase-1 and -2 isozymes in canine tissues and their differential sensitivity to nonsteroidal anti-inflammatory drugs. Am J Vet Res. 2004 Jun;65(6):810-8.","parent_key":"BE0000262"}
{"ref-id":"A5559","pubmed-id":12358053,"citation":"Campbell NB, Jones SL, Blikslager AT: The effects of cyclo-oxygenase inhibitors on bile-injured and normal equine colon. Equine Vet J. 2002 Jul;34(5):493-8.","parent_key":"BE0000017"}
{"ref-id":"A5560","pubmed-id":8566109,"citation":"Glaser K, Sung ML, O'Neill K, Belfast M, Hartman D, Carlson R, Kreft A, Kubrak D, Hsiao CL, Weichman B: Etodolac selectively inhibits human prostaglandin G/H synthase 2 (PGHS-2) versus human PGHS-1. Eur J Pharmacol. 1995 Jul 25;281(1):107-11.","parent_key":"BE0000017"}
{"ref-id":"A5561","pubmed-id":16473424,"citation":"Hirate K, Uchida A, Ogawa Y, Arai T, Yoda K: Zaltoprofen, a non-steroidal anti-inflammatory drug, inhibits bradykinin-induced pain responses without blocking bradykinin receptors. Neurosci Res. 2006 Apr;54(4):288-94. Epub 2006 Feb 13.","parent_key":"BE0000017"}
{"ref-id":"A5562","pubmed-id":9146894,"citation":"Riendeau D, Percival MD, Boyce S, Brideau C, Charleson S, Cromlish W, Ethier D, Evans J, Falgueyret JP, Ford-Hutchinson AW, Gordon R, Greig G, Gresser M, Guay J, Kargman S, Leger S, Mancini JA, O'Neill G, Ouellet M, Rodger IW, Therien M, Wang Z, Webb JK, Wong E, Chan CC, et al.: Biochemical and pharmacological profile of a tetrasubstituted furanone as a highly selective COX-2 inhibitor. Br J Pharmacol. 1997 May;121(1):105-17.","parent_key":"BE0000017"}
{"ref-id":"A5563","pubmed-id":15198222,"citation":"Wilson JE, Chandrasekharan NV, Westover KD, Eager KB, Simmons DL: Determination of expression of cyclooxygenase-1 and -2 isozymes in canine tissues and their differential sensitivity to nonsteroidal anti-inflammatory drugs. Am J Vet Res. 2004 Jun;65(6):810-8.","parent_key":"BE0000017"}
{"ref-id":"A5588","pubmed-id":8439518,"citation":"Isogai M, Shimizu H, Esumi Y, Terasawa T, Okada T, Sugeno K: Binding affinities of mometasone furoate and related compounds including its metabolites for the glucocorticoid receptor of rat skin tissue. J Steroid Biochem Mol Biol. 1993 Feb;44(2):141-5.","parent_key":"BE0000794"}
{"ref-id":"A5590","pubmed-id":9793625,"citation":"Smith CL, Kreutner W: In vitro glucocorticoid receptor binding and transcriptional activation by topically active glucocorticoids. Arzneimittelforschung. 1998 Sep;48(9):956-60.","parent_key":"BE0000794"}
{"ref-id":"A5591","pubmed-id":12127907,"citation":"Zhang X, Moilanen E, Adcock IM, Lindsay MA, Kankaanranta H: Divergent effect of mometasone on human eosinophil and neutrophil apoptosis. Life Sci. 2002 Aug 16;71(13):1523-34.","parent_key":"BE0000794"}
{"ref-id":"A202193","pubmed-id":14046902,"citation":"CHADFIELD HW: CORTICOSTEROID THERAPY IN CURRENT DERMATOLOGICAL PRACTICE. Postgrad Med J. 1963 Sep;39:526-33. doi: 10.1136/pgmj.39.455.526.","parent_key":"BE0000794"}
{"ref-id":"A12096","pubmed-id":17327420,"citation":"Xue Y, Moore LB, Orans J, Peng L, Bencharit S, Kliewer SA, Redinbo MR: Crystal structure of the pregnane X receptor-estradiol complex provides insights into endobiotic recognition. Mol Endocrinol. 2007 May;21(5):1028-38. Epub 2007 Feb 27.","parent_key":"BE0000956"}
{"ref-id":"A190510","pubmed-id":23884115,"citation":"Banerjee M, Robbins D, Chen T: Modulation of xenobiotic receptors by steroids. Molecules. 2013 Jun 24;18(7):7389-406. doi: 10.3390/molecules18077389.","parent_key":"BE0000956"}
{"ref-id":"A190513","pubmed-id":26417296,"citation":"Wang J, Dai S, Guo Y, Xie W, Zhai Y: Biology of PXR: role in drug-hormone interactions. EXCLI J. 2014 Jul 7;13:728-39. eCollection 2014.","parent_key":"BE0000956"}
{"ref-id":"A5626","pubmed-id":7832763,"citation":"Gierse JK, Hauser SD, Creely DP, Koboldt C, Rangwala SH, Isakson PC, Seibert K: Expression and selective inhibition of the constitutive and inducible forms of human cyclo-oxygenase. Biochem J. 1995 Jan 15;305 ( Pt 2):479-84.","parent_key":"BE0000262"}
{"ref-id":"A5627","pubmed-id":17150210,"citation":"Bhat AS, Tandan SK, Kumar D, Krishna V, Prakash VR: Interaction between inhibitors of inducible nitric oxide synthase and cyclooxygenase in adjuvant-induced arthritis in female albino rats: an isobolographic study. Eur J Pharmacol. 2007 Feb 5;556(1-3):190-9. Epub 2006 Oct 27.","parent_key":"BE0000262"}
{"ref-id":"A5628","pubmed-id":15792781,"citation":"Bhat AS, Tandan SK, Kumar D, Krishna V, Prakash VR: Interaction between inhibitors of inducible nitric oxide synthase and cyclooxygenase in Brewer's yeast induced pyrexia in mice: an isobolographic study. Eur J Pharmacol. 2005 Mar 28;511(2-3):137-42.","parent_key":"BE0000262"}
{"ref-id":"A5629","pubmed-id":9626023,"citation":"Cryer B, Feldman M: Cyclooxygenase-1 and cyclooxygenase-2 selectivity of widely used nonsteroidal anti-inflammatory drugs. Am J Med. 1998 May;104(5):413-21.","parent_key":"BE0000262"}
{"ref-id":"A5630","pubmed-id":10393680,"citation":"Walton LJ, Franklin IJ, Bayston T, Brown LC, Greenhalgh RM, Taylor GW, Powell JT: Inhibition of prostaglandin E2 synthesis in abdominal aortic aneurysms: implications for smooth muscle cell viability, inflammatory processes, and the expansion of abdominal aortic aneurysms. Circulation. 1999 Jul 6;100(1):48-54.","parent_key":"BE0000262"}
{"ref-id":"A10838","pubmed-id":11316248,"citation":"Sinniah R, Lye WC: Acute renal failure from hemoglobinuric and interstitial nephritis secondary to iodine and mefenamic acid. Clin Nephrol. 2001 Mar;55(3):254-8.","parent_key":"BE0000017"}
{"ref-id":"A10839","pubmed-id":16223958,"citation":"Joo Y, Kim HS, Woo RS, Park CH, Shin KY, Lee JP, Chang KA, Kim S, Suh YH: Mefenamic acid shows neuroprotective effects and improves cognitive impairment in in vitro and in vivo Alzheimer's disease models. Mol Pharmacol. 2006 Jan;69(1):76-84. Epub 2005 Oct 13.","parent_key":"BE0000017"}
{"ref-id":"A5629","pubmed-id":9626023,"citation":"Cryer B, Feldman M: Cyclooxygenase-1 and cyclooxygenase-2 selectivity of widely used nonsteroidal anti-inflammatory drugs. Am J Med. 1998 May;104(5):413-21.","parent_key":"BE0000017"}
{"ref-id":"A5626","pubmed-id":7832763,"citation":"Gierse JK, Hauser SD, Creely DP, Koboldt C, Rangwala SH, Isakson PC, Seibert K: Expression and selective inhibition of the constitutive and inducible forms of human cyclo-oxygenase. Biochem J. 1995 Jan 15;305 ( Pt 2):479-84.","parent_key":"BE0000017"}
{"ref-id":"A10840","pubmed-id":9773153,"citation":"Laudanno OM, Cesolari JA, Esnarriaga J, Flaherty P, Vada J, Guastalli G, San Miguel P, Bedini OA: [In vivo selectivity of nonsteroidal anti-inflammatory drugs on COX-1-COX-2 and gastrointestinal ulcers, in rats]. Acta Gastroenterol Latinoam. 1998;28(3):249-55.","parent_key":"BE0000017"}
{"ref-id":"A5640","pubmed-id":17541796,"citation":"James MJ, Cook-Johnson RJ, Cleland LG: Selective COX-2 inhibitors, eicosanoid synthesis and clinical outcomes: a case study of system failure. Lipids. 2007 Sep;42(9):779-85. Epub 2007 Jun 2.","parent_key":"BE0000017"}
{"ref-id":"A178975","pubmed-id":30247840,"citation":"Brutzkus JC, Varacallo M: Naproxen .","parent_key":"BE0000017"}
{"ref-id":"A10844","pubmed-id":17604186,"citation":"Dhir A, Naidu PS, Kulkarni SK: Neuroprotective effect of nimesulide, a preferential COX-2 inhibitor, against pentylenetetrazol (PTZ)-induced chemical kindling and associated biochemical parameters in mice. Seizure. 2007 Dec;16(8):691-7. Epub 2007 Jul 2.","parent_key":"BE0000262"}
{"ref-id":"A10847","pubmed-id":17532719,"citation":"Hassan-Alin M, Naesdal J, Nilsson-Pieschl C, Langstrom G, Andersson T: Lack of Pharmacokinetic Interaction between Esomeprazole and the Nonsteroidal Anti-Inflammatory Drugs Naproxen and Rofecoxib in Healthy Subjects. Clin Drug Investig. 2005;25(11):731-40.","parent_key":"BE0000262"}
{"ref-id":"A178975","pubmed-id":30247840,"citation":"Brutzkus JC, Varacallo M: Naproxen .","parent_key":"BE0000262"}
{"ref-id":"A5670","pubmed-id":10955836,"citation":"Garrido M, Gubbens-Stibbe J, Tukker E, Cox E, von Frijtag J, Kunzel D, IJzerman A, Danhof M, van der Graaf PH: Pharmacokinetic-pharmacodynamic analysis of the EEG effect of alfentanil in rats following beta-funaltrexamine-induced mu-opioid receptor \"knockdown\" in vivo. Pharm Res. 2000 Jun;17(6):653-9.","parent_key":"BE0000770"}
{"ref-id":"A5671","pubmed-id":15694871,"citation":"Lotsch J, Geisslinger G: Are mu-opioid receptor polymorphisms important for clinical opioid therapy? Trends Mol Med. 2005 Feb;11(2):82-9.","parent_key":"BE0000770"}
{"ref-id":"A5672","pubmed-id":16906017,"citation":"Oertel BG, Schmidt R, Schneider A, Geisslinger G, Lotsch J: The mu-opioid receptor gene polymorphism 118A>G depletes alfentanil-induced analgesia and protects against respiratory depression in homozygous carriers. Pharmacogenet Genomics. 2006 Sep;16(9):625-36.","parent_key":"BE0000770"}
{"ref-id":"A5673","pubmed-id":11240090,"citation":"Leung A, Wallace MS, Ridgeway B, Yaksh T: Concentration-effect relationship of intravenous alfentanil and ketamine on peripheral neurosensory thresholds, allodynia and hyperalgesia of neuropathic pain. Pain. 2001 Mar;91(1-2):177-87.","parent_key":"BE0000770"}
{"ref-id":"A5678","pubmed-id":12213119,"citation":"Arifah AK, Lees P: Pharmacodynamics and pharmacokinetics of phenylbutazone in calves. J Vet Pharmacol Ther. 2002 Aug;25(4):299-309.","parent_key":"BE0000262"}
{"ref-id":"A5679","pubmed-id":15489888,"citation":"Takada Y, Bhardwaj A, Potdar P, Aggarwal BB: Nonsteroidal anti-inflammatory agents differ in their ability to suppress NF-kappaB activation, inhibition of expression of cyclooxygenase-2 and cyclin D1, and abrogation of tumor cell proliferation. Oncogene. 2004 Dec 9;23(57):9247-58.","parent_key":"BE0000262"}
{"ref-id":"A5680","pubmed-id":15939622,"citation":"Beretta C, Garavaglia G, Cavalli M: COX-1 and COX-2 inhibition in horse blood by phenylbutazone, flunixin, carprofen and meloxicam: an in vitro analysis. Pharmacol Res. 2005 Oct;52(4):302-6.","parent_key":"BE0000262"}
{"ref-id":"A16534","pubmed-id":19849999,"citation":"Zitova A, Hynes J, Kollar J, Borisov SM, Klimant I, Papkovsky DB: Analysis of activity and inhibition of oxygen-dependent enzymes by optical respirometry on the LightCycler system. Anal Biochem. 2010 Feb 15;397(2):144-51. doi: 10.1016/j.ab.2009.10.029. Epub 2009 Oct 20.","parent_key":"BE0000017"}
{"ref-id":"A5680","pubmed-id":15939622,"citation":"Beretta C, Garavaglia G, Cavalli M: COX-1 and COX-2 inhibition in horse blood by phenylbutazone, flunixin, carprofen and meloxicam: an in vitro analysis. Pharmacol Res. 2005 Oct;52(4):302-6.","parent_key":"BE0000017"}
{"ref-id":"A16535","pubmed-id":15563928,"citation":"Morton AJ, Campbell NB, Gayle JM, Redding WR, Blikslager AT: Preferential and non-selective cyclooxygenase inhibitors reduce inflammation during lipopolysaccharide-induced synovitis. Res Vet Sci. 2005 Apr;78(2):189-92.","parent_key":"BE0000017"}
{"ref-id":"A5681","pubmed-id":15589524,"citation":"You HJ, Colpaert FC, Arendt-Nielsen L: The novel analgesic and high-efficacy 5-HT1A receptor agonist F 13640 inhibits nociceptive responses, wind-up, and after-discharges in spinal neurons and withdrawal reflexes. Exp Neurol. 2005 Jan;191(1):174-83.","parent_key":"BE0000770"}
{"ref-id":"A5682","pubmed-id":16114980,"citation":"Scott LJ, Perry CM: Remifentanil: a review of its use during the induction and maintenance of general anaesthesia. Drugs. 2005;65(13):1793-823.","parent_key":"BE0000770"}
{"ref-id":"A5683","pubmed-id":16332149,"citation":"Scott LJ, Perry CM: Spotlight on remifentanil for general anaesthesia. CNS Drugs. 2005;19(12):1069-74.","parent_key":"BE0000770"}
{"ref-id":"A5684","pubmed-id":16376082,"citation":"Dosen-Micovic L, Ivanovic M, Micovic V: Steric interactions and the activity of fentanyl analogs at the mu-opioid receptor. Bioorg Med Chem. 2006 May 1;14(9):2887-95. Epub 2006 Jan 11.","parent_key":"BE0000770"}
{"ref-id":"A5685","pubmed-id":16797997,"citation":"Dardonville C, Fernandez-Fernandez C, Gibbons SL, Ryan GJ, Jagerovic N, Gabilondo AM, Meana JJ, Callado LF: Synthesis and pharmacological studies of new hybrid derivatives of fentanyl active at the mu-opioid receptor and I2-imidazoline binding sites. Bioorg Med Chem. 2006 Oct 1;14(19):6570-80. Epub 2006 Jun 23.","parent_key":"BE0000770"}
{"ref-id":"A5686","pubmed-id":19403616,"citation":"Hajiha M, DuBord MA, Liu H, Horner RL: Opioid receptor mechanisms at the hypoglossal motor pool and effects on tongue muscle activity in vivo. J Physiol. 2009 Jun 1;587(Pt 11):2677-92. doi: 10.1113/jphysiol.2009.171678. Epub 2009 Apr 29.","parent_key":"BE0000770"}
{"ref-id":"A12108","pubmed-id":15665994,"citation":"Rodrigues AR, Castro MS, Francischi JN, Perez AC, Duarte ID: Participation of ATP-sensitive K+ channels in the peripheral antinociceptive effect of fentanyl in rats. Braz J Med Biol Res. 2005 Jan;38(1):91-7. Epub 2005 Jan 18.","parent_key":"BE0000420"}
{"ref-id":"A12109","pubmed-id":15828941,"citation":"Poonawala T, Levay-Young BK, Hebbel RP, Gupta K: Opioids heal ischemic wounds in the rat. Wound Repair Regen. 2005 Mar-Apr;13(2):165-74.","parent_key":"BE0000420"}
{"ref-id":"A12110","pubmed-id":15868528,"citation":"Sahin AS, Duman A, Atalik EK, Ogun CO, Sahin TK, Erol A, Ozergin U: The mechanisms of the direct vascular effects of fentanyl on isolated human saphenous veins in vitro. J Cardiothorac Vasc Anesth. 2005 Apr;19(2):197-200.","parent_key":"BE0000420"}
{"ref-id":"A4077","pubmed-id":16372825,"citation":"Darwish M, Tempero K, Kirby M, Thompson J: Pharmacokinetics and dose proportionality of fentanyl effervescent buccal tablets in healthy volunteers. Clin Pharmacokinet. 2005;44(12):1279-86.","parent_key":"BE0000420"}
{"ref-id":"A4076","pubmed-id":16861092,"citation":"Darwish M, Kirby M, Robertson P Jr, Tracewell W, Jiang JG: Pharmacokinetic properties of fentanyl effervescent buccal tablets: a phase I, open-label, crossover study of single-dose 100, 200, 400, and 800 microg in healthy adult volunteers. Clin Ther. 2006 May;28(5):707-14.","parent_key":"BE0000420"}
{"ref-id":"A5686","pubmed-id":19403616,"citation":"Hajiha M, DuBord MA, Liu H, Horner RL: Opioid receptor mechanisms at the hypoglossal motor pool and effects on tongue muscle activity in vivo. J Physiol. 2009 Jun 1;587(Pt 11):2677-92. doi: 10.1113/jphysiol.2009.171678. Epub 2009 Apr 29.","parent_key":"BE0000420"}
{"ref-id":"A10870","pubmed-id":10220944,"citation":"Poulsen Nautrup B, Horstermann D: [Pharmacodynamic and pharmacokinetic aspects of the non-inflammatory non-steroidal agent meloxicam in dogs]. Dtsch Tierarztl Wochenschr. 1999 Mar;106(3):94-100.","parent_key":"BE0000262"}
{"ref-id":"A10871","pubmed-id":10340919,"citation":"Tegeder I, Lotsch J, Krebs S, Muth-Selbach U, Brune K, Geisslinger G: Comparison of inhibitory effects of meloxicam and diclofenac on human thromboxane biosynthesis after single doses and at steady state. Clin Pharmacol Ther. 1999 May;65(5):533-44.","parent_key":"BE0000262"}
{"ref-id":"A10872","pubmed-id":10381787,"citation":"Panara MR, Renda G, Sciulli MG, Santini G, Di Giamberardino M, Rotondo MT, Tacconelli S, Seta F, Patrono C, Patrignani P: Dose-dependent inhibition of platelet cyclooxygenase-1 and monocyte cyclooxygenase-2 by meloxicam in healthy subjects. J Pharmacol Exp Ther. 1999 Jul;290(1):276-80.","parent_key":"BE0000262"}
{"ref-id":"A10873","pubmed-id":10567199,"citation":"Gross JM, Dwyer JE, Knox FG: Natriuretic response to increased pressure is preserved with COX-2 inhibitors. Hypertension. 1999 Nov;34(5):1163-7.","parent_key":"BE0000262"}
{"ref-id":"A190189","pubmed-id":30774225,"citation":"Bekker A, Kloepping C, Collingwood S: Meloxicam in the management of post-operative pain: Narrative review. J Anaesthesiol Clin Pharmacol. 2018 Oct-Dec;34(4):450-457. doi: 10.4103/joacp.JOACP_133_18.","parent_key":"BE0000262"}
{"ref-id":"A190231","pubmed-id":16197363,"citation":"Gates BJ, Nguyen TT, Setter SM, Davies NM: Meloxicam: a reappraisal of pharmacokinetics, efficacy and safety. Expert Opin Pharmacother. 2005 Oct;6(12):2117-40. doi: 10.1517/14656566.6.12.2117.","parent_key":"BE0000262"}
{"ref-id":"A10872","pubmed-id":10381787,"citation":"Panara MR, Renda G, Sciulli MG, Santini G, Di Giamberardino M, Rotondo MT, Tacconelli S, Seta F, Patrono C, Patrignani P: Dose-dependent inhibition of platelet cyclooxygenase-1 and monocyte cyclooxygenase-2 by meloxicam in healthy subjects. J Pharmacol Exp Ther. 1999 Jul;290(1):276-80.","parent_key":"BE0000017"}
{"ref-id":"A190189","pubmed-id":30774225,"citation":"Bekker A, Kloepping C, Collingwood S: Meloxicam in the management of post-operative pain: Narrative review. J Anaesthesiol Clin Pharmacol. 2018 Oct-Dec;34(4):450-457. doi: 10.4103/joacp.JOACP_133_18.","parent_key":"BE0000017"}
{"ref-id":"A190231","pubmed-id":16197363,"citation":"Gates BJ, Nguyen TT, Setter SM, Davies NM: Meloxicam: a reappraisal of pharmacokinetics, efficacy and safety. Expert Opin Pharmacother. 2005 Oct;6(12):2117-40. doi: 10.1517/14656566.6.12.2117.","parent_key":"BE0000017"}
{"ref-id":"A5697","pubmed-id":10895904,"citation":"Kay-Mugford P, Benn SJ, LaMarre J, Conlon P: In vitro effects of nonsteroidal anti-inflammatory drugs on cyclooxygenase activity in dogs. Am J Vet Res. 2000 Jul;61(7):802-10.","parent_key":"BE0000262"}
{"ref-id":"A5698","pubmed-id":11703020,"citation":"Brideau C, Van Staden C, Chan CC: In vitro effects of cyclooxygenase inhibitors in whole blood of horses, dogs, and cats. Am J Vet Res. 2001 Nov;62(11):1755-60.","parent_key":"BE0000262"}
{"ref-id":"A5699","pubmed-id":17181139,"citation":"Narlawar R, Perez Revuelta BI, Haass C, Steiner H, Schmidt B, Baumann K: Scaffold of the cyclooxygenase-2 (COX-2) inhibitor carprofen provides Alzheimer gamma-secretase modulators. J Med Chem. 2006 Dec 28;49(26):7588-91.","parent_key":"BE0000262"}
{"ref-id":"A12134","pubmed-id":10796070,"citation":"LeVan TD, Babin EA, Yamamura HI, Bloom JW: Pharmacological characterization of glucocorticoid receptors in primary human bronchial epithelial cells. Biochem Pharmacol. 1999 May 1;57(9):1003-9.","parent_key":"BE0000794"}
{"ref-id":"A12135","pubmed-id":15120421,"citation":"Attardi BJ, Burgenson J, Hild SA, Reel JR: In vitro antiprogestational/antiglucocorticoid activity and progestin and glucocorticoid receptor binding of the putative metabolites and synthetic derivatives of CDB-2914, CDB-4124, and mifepristone. J Steroid Biochem Mol Biol. 2004 Mar;88(3):277-88.","parent_key":"BE0000794"}
{"ref-id":"A12136","pubmed-id":15909120,"citation":"Gu G, Hentunen TA, Nars M, Harkonen PL, Vaananen HK: Estrogen protects primary osteocytes against glucocorticoid-induced apoptosis. Apoptosis. 2005 May;10(3):583-95.","parent_key":"BE0000794"}
{"ref-id":"A12137","pubmed-id":16723527,"citation":"de Pablos RM, Villaran RF, Arguelles S, Herrera AJ, Venero JL, Ayala A, Cano J, Machado A: Stress increases vulnerability to inflammation in the rat prefrontal cortex. J Neurosci. 2006 May 24;26(21):5709-19.","parent_key":"BE0000794"}
{"ref-id":"A10879","pubmed-id":10087042,"citation":"DeHaven-Hudkins DL, Burgos LC, Cassel JA, Daubert JD, DeHaven RN, Mansson E, Nagasaka H, Yu G, Yaksh T: Loperamide (ADL 2-1294), an opioid antihyperalgesic agent with peripheral selectivity. J Pharmacol Exp Ther. 1999 Apr;289(1):494-502.","parent_key":"BE0000770"}
{"ref-id":"A10880","pubmed-id":14592702,"citation":"Tan-No K, Niijima F, Nakagawasai O, Sato T, Satoh S, Tadano T: Development of tolerance to the inhibitory effect of loperamide on gastrointestinal transit in mice. Eur J Pharm Sci. 2003 Nov;20(3):357-63.","parent_key":"BE0000770"}
{"ref-id":"A10881","pubmed-id":8488368,"citation":"Roge J, Baumer P, Berard H, Schwartz JC, Lecomte JM: The enkephalinase inhibitor, acetorphan, in acute diarrhoea. A double-blind, controlled clinical trial versus loperamide. Scand J Gastroenterol. 1993 Apr;28(4):352-4.","parent_key":"BE0000770"}
{"ref-id":"A10882","pubmed-id":6319884,"citation":"Giagnoni G, Casiraghi L, Senini R, Revel L, Parolaro D, Sala M, Gori E: Loperamide: evidence of interaction with mu and delta opioid receptors. Life Sci. 1983;33 Suppl 1:315-8.","parent_key":"BE0000770"}
{"ref-id":"A10883","pubmed-id":18284554,"citation":"di Bosco AM, Grieco P, Diurno MV, Campiglia P, Novellino E, Mazzoni O: Binding site of loperamide: automated docking of loperamide in human mu- and delta-opioid receptors. Chem Biol Drug Des. 2008 Apr;71(4):328-35. doi: 10.1111/j.1747-0285.2008.00637.x. Epub 2008 Feb 12.","parent_key":"BE0000770"}
{"ref-id":"A10882","pubmed-id":6319884,"citation":"Giagnoni G, Casiraghi L, Senini R, Revel L, Parolaro D, Sala M, Gori E: Loperamide: evidence of interaction with mu and delta opioid receptors. Life Sci. 1983;33 Suppl 1:315-8.","parent_key":"BE0000420"}
{"ref-id":"A10883","pubmed-id":18284554,"citation":"di Bosco AM, Grieco P, Diurno MV, Campiglia P, Novellino E, Mazzoni O: Binding site of loperamide: automated docking of loperamide in human mu- and delta-opioid receptors. Chem Biol Drug Des. 2008 Apr;71(4):328-35. doi: 10.1111/j.1747-0285.2008.00637.x. Epub 2008 Feb 12.","parent_key":"BE0000420"}
{"ref-id":"A16714","pubmed-id":18691892,"citation":"Ali A, Balkovec JM, Greenlee M, Hammond ML, Rouen G, Taylor G, Einstein M, Ge L, Harris G, Kelly TM, Mazur P, Pandit S, Santoro J, Sitlani A, Wang C, Williamson J, Forrest MJ, Carballo-Jane E, Luell S, Lowitz K, Visco D: Discovery of betamethasone 17alpha-carbamates as dissociated glucocorticoid receptor modulators in the rat. Bioorg Med Chem. 2008 Aug 15;16(16):7535-42. doi: 10.1016/j.bmc.2008.07.037. Epub 2008 Jul 20.","parent_key":"BE0000794"}
{"ref-id":"A16715","pubmed-id":18022656,"citation":"Buchwald P: Glucocorticoid receptor binding: a biphasic dependence on molecular size as revealed by the bilinear LinBiExp model. Steroids. 2008 Feb;73(2):193-208. Epub 2007 Oct 11.","parent_key":"BE0000794"}
{"ref-id":"A10889","pubmed-id":10844102,"citation":"Kishioka S, Ko MC, Woods JH: Diltiazem enhances the analgesic but not the respiratory depressant effects of morphine in rhesus monkeys. Eur J Pharmacol. 2000 May 26;397(1):85-92.","parent_key":"BE0000770"}
{"ref-id":"A5736","pubmed-id":8388112,"citation":"Hoehe M, Duka T: Opiates increase plasma catecholamines in humans. Psychoneuroendocrinology. 1993;18(2):141-8.","parent_key":"BE0000770"}
{"ref-id":"A10890","pubmed-id":9084061,"citation":"Zernig G, Lewis JW, Woods JH: Clocinnamox inhibits the intravenous self-administration of opioid agonists in rhesus monkeys: comparison with effects on opioid agonist-mediated antinociception. Psychopharmacology (Berl). 1997 Feb;129(3):233-42.","parent_key":"BE0000770"}
{"ref-id":"A10891","pubmed-id":18425947,"citation":"McNicol ED, Boyce D, Schumann R, Carr DB: Mu-opioid antagonists for opioid-induced bowel dysfunction. Cochrane Database Syst Rev. 2008 Apr 16;(2):CD006332. doi: 10.1002/14651858.CD006332.pub2.","parent_key":"BE0000770"}
{"ref-id":"A5738","pubmed-id":16517095,"citation":"Tao PL, Liang KW, Sung WY, Wu YT, Huang EY: Nalbuphine is effective in decreasing the rewarding effect induced by morphine in rats. Drug Alcohol Depend. 2006 Sep 15;84(2):175-81. Epub 2006 Mar 6.","parent_key":"BE0000770"}
{"ref-id":"A5739","pubmed-id":19403853,"citation":"Smith MA, Greene-Naples JL, Lyle MA, Iordanou JC, Felder JN: The effects of repeated opioid administration on locomotor activity: I. Opposing actions of mu and kappa receptors. J Pharmacol Exp Ther. 2009 Aug;330(2):468-75. doi: 10.1124/jpet.108.150011. Epub  2009 Apr 29.","parent_key":"BE0000770"}
{"ref-id":"A5740","pubmed-id":15602503,"citation":"Mello NK, Mendelson JH, Sholar MB, Jaszyna-Gasior M, Goletiani N, Siegel AJ: Effects of the mixed mu/kappa opioid nalbuphine on cocaine-induced changes in subjective and cardiovascular responses in men. Neuropsychopharmacology. 2005 Mar;30(3):618-32.","parent_key":"BE0000770"}
{"ref-id":"A10892","pubmed-id":18810678,"citation":"Meerpohl JJ, Timmer A: [News from the cochrane library: mu opioid antagonists for opioid-induced bowel dysfunction]. Z Gastroenterol. 2008 Sep;46(9):917-21. doi: 10.1055/s-2008-1027720. Epub 2008 Sep 22.","parent_key":"BE0000770"}
{"ref-id":"A5741","pubmed-id":17407276,"citation":"Peng X, Knapp BI, Bidlack JM, Neumeyer JL: Pharmacological properties of bivalent ligands containing butorphan linked to nalbuphine, naltrexone, and naloxone at mu, delta, and kappa opioid receptors. J Med Chem. 2007 May 3;50(9):2254-8. Epub 2007 Apr 4.","parent_key":"BE0000770"}
{"ref-id":"A10893","pubmed-id":8093631,"citation":"Chen JC, Smith ER, Cahill M, Cohen R, Fishman JB: The opioid receptor binding of dezocine, morphine, fentanyl, butorphanol and nalbuphine. Life Sci. 1993;52(4):389-96.","parent_key":"BE0000420"}
{"ref-id":"A10894","pubmed-id":2826773,"citation":"De Souza EB, Schmidt WK, Kuhar MJ: Nalbuphine: an autoradiographic opioid receptor binding profile in the central nervous system of an agonist/antagonist analgesic. J Pharmacol Exp Ther. 1988 Jan;244(1):391-402.","parent_key":"BE0000420"}
{"ref-id":"A203141","pubmed-id":31371410,"citation":"Kumar H, Chattopadhyay S, Das N, Shree S, Patel D, Mohapatra J, Gurjar A, Kushwaha S, Singh AK, Dubey S, Lata K, Kushwaha R, Mohammed R, Dastidar KG, Yadav N, Vishwakarma AL, Gayen JR, Bandyopadhyay S, Chatterjee A, Jain MR, Tripathi AK, Trivedi AK, Chattopadhyay N, Ramachandran R, Sanyal S: Leprosy drug clofazimine activates peroxisome proliferator-activated receptor-gamma and synergizes with imatinib to inhibit chronic myeloid leukemia cells. Haematologica. 2020 Apr;105(4):971-986. doi: 10.3324/haematol.2018.194910. Epub 2019 Aug 1.","parent_key":"BE0000215"}
{"ref-id":"A16606","pubmed-id":20346397,"citation":"Baschant U, Tuckermann J: The role of the glucocorticoid receptor in inflammation and immunity. J Steroid Biochem Mol Biol. 2010 May 31;120(2-3):69-75. doi: 10.1016/j.jsbmb.2010.03.058. Epub 2010 Mar 24.","parent_key":"BE0000794"}
{"ref-id":"A16607","pubmed-id":16255837,"citation":"Fitzgerald P, O'Brien SM, Scully P, Rijkers K, Scott LV, Dinan TG: Cutaneous glucocorticoid receptor sensitivity and pro-inflammatory cytokine levels in antidepressant-resistant depression. Psychol Med. 2006 Jan;36(1):37-43. Epub 2005 Oct 28.","parent_key":"BE0000794"}
{"ref-id":"A18245","pubmed-id":24365491,"citation":"Wu Z, Kong X, Zhang T, Ye J, Fang Z, Yang X: Pseudoephedrine/ephedrine shows potent anti-inflammatory activity against TNF-alpha-mediated acute liver failure induced by lipopolysaccharide/D-galactosamine. Eur J Pharmacol. 2014 Feb 5;724:112-21. doi: 10.1016/j.ejphar.2013.11.032. Epub 2013 Dec 21.","parent_key":"BE0000704"}
{"ref-id":"A18244","pubmed-id":21631396,"citation":"Fiebich BL, Collado JA, Stratz C, Valina C, Hochholzer W, Munoz E, Bellido LM: Pseudoephedrine inhibits T-cell activation by targeting NF-kappaB, NFAT and AP-1 signaling pathways. Immunopharmacol Immunotoxicol. 2012 Feb;34(1):98-106. doi: 10.3109/08923973.2011.582118. Epub 2011 Jun 2.","parent_key":"BE0000704"}
{"ref-id":"A5755","pubmed-id":12975489,"citation":"Allen RM, Granger AL, Dykstra LA: The competitive N-methyl-D-aspartate receptor antagonist (-)-6-phosphonomethyl-deca-hydroisoquinoline-3-carboxylic acid (LY235959) potentiates the antinociceptive effects of opioids that vary in efficacy at the mu-opioid receptor. J Pharmacol Exp Ther. 2003 Nov;307(2):785-92. Epub 2003 Sep 15.","parent_key":"BE0000770"}
{"ref-id":"A5756","pubmed-id":17039381,"citation":"Prommer E: Levorphanol: the forgotten opioid. Support Care Cancer. 2007 Mar;15(3):259-64. Epub 2006 Oct 13.","parent_key":"BE0000770"}
{"ref-id":"A5756","pubmed-id":17039381,"citation":"Prommer E: Levorphanol: the forgotten opioid. Support Care Cancer. 2007 Mar;15(3):259-64. Epub 2006 Oct 13.","parent_key":"BE0000420"}
{"ref-id":"A15765","pubmed-id":19482847,"citation":"Ikonomidis I, Tzortzis S, Lekakis J, Paraskevaidis I, Andreadou I, Nikolaou M, Kaplanoglou T, Katsimbri P, Skarantavos G, Soucacos P, Kremastinos DT: Lowering interleukin-1 activity with anakinra improves myocardial deformation in rheumatoid arthritis. Heart. 2009 Sep;95(18):1502-7. doi: 10.1136/hrt.2009.168971. Epub 2009 May 28.","parent_key":"BE0000794"}
{"ref-id":"A15764","pubmed-id":2879901,"citation":"Boudinot FD, D'Ambrosio R, Jusko WJ: Receptor-mediated pharmacodynamics of prednisolone in the rat. J Pharmacokinet Biopharm. 1986 Oct;14(5):469-93.","parent_key":"BE0000794"}
{"ref-id":"A5769","pubmed-id":12852483,"citation":"Cappon GD, Cook JC, Hurtt ME: Relationship between cyclooxygenase 1 and 2 selective inhibitors and fetal development when administered to rats and rabbits during the sensitive periods for heart development and midline closure. Birth Defects Res B Dev Reprod Toxicol. 2003 Feb;68(1):47-56.","parent_key":"BE0000262"}
{"ref-id":"A10899","pubmed-id":10825891,"citation":"Jeske AH: COX-2 inhibitors and dental pain control. J Gt Houst Dent Soc. 1999 Nov;71(4):39-40.","parent_key":"BE0000262"}
{"ref-id":"A10900","pubmed-id":11673972,"citation":"Mao H, Hajduk PJ, Craig R, Bell R, Borre T, Fesik SW: Rational design of diflunisal analogues with reduced affinity for human serum albumin. J Am Chem Soc. 2001 Oct 31;123(43):10429-35.","parent_key":"BE0000262"}
{"ref-id":"A10901","pubmed-id":11315375,"citation":"Moore PA, Hersh EV: Celecoxib and rofecoxib. The role of COX-2 inhibitors in dental practice. J Am Dent Assoc. 2001 Apr;132(4):451-6.","parent_key":"BE0000262"}
{"ref-id":"A5771","pubmed-id":8737748,"citation":"Young JM, Panah S, Satchawatcharaphong C, Cheung PS: Human whole blood assays for inhibition of prostaglandin G/H synthases-1 and -2 using A23187 and lipopolysaccharide stimulation of thromboxane B2 production. Inflamm Res. 1996 May;45(5):246-53.","parent_key":"BE0000262"}
{"ref-id":"A5769","pubmed-id":12852483,"citation":"Cappon GD, Cook JC, Hurtt ME: Relationship between cyclooxygenase 1 and 2 selective inhibitors and fetal development when administered to rats and rabbits during the sensitive periods for heart development and midline closure. Birth Defects Res B Dev Reprod Toxicol. 2003 Feb;68(1):47-56.","parent_key":"BE0000017"}
{"ref-id":"A5770","pubmed-id":15755648,"citation":"Chen QH, Rao PN, Knaus EE: Design, synthesis, and biological evaluation of N-acetyl-2-carboxybenzenesulfonamides: a novel class of cyclooxygenase-2 (COX-2) inhibitors. Bioorg Med Chem. 2005 Apr 1;13(7):2459-68.","parent_key":"BE0000017"}
{"ref-id":"A5771","pubmed-id":8737748,"citation":"Young JM, Panah S, Satchawatcharaphong C, Cheung PS: Human whole blood assays for inhibition of prostaglandin G/H synthases-1 and -2 using A23187 and lipopolysaccharide stimulation of thromboxane B2 production. Inflamm Res. 1996 May;45(5):246-53.","parent_key":"BE0000017"}
{"ref-id":"A5799","pubmed-id":8652509,"citation":"Loll PJ, Picot D, Ekabo O, Garavito RM: Synthesis and use of iodinated nonsteroidal antiinflammatory drug analogs as crystallographic probes of the prostaglandin H2 synthase cyclooxygenase active site. Biochemistry. 1996 Jun 11;35(23):7330-40.","parent_key":"BE0000017"}
{"ref-id":"A5800","pubmed-id":17477341,"citation":"Bender A, Scheiber J, Glick M, Davies JW, Azzaoui K, Hamon J, Urban L, Whitebread S, Jenkins JL: Analysis of pharmacology data and the prediction of adverse drug reactions and off-target effects from chemical structure. ChemMedChem. 2007 Jun;2(6):861-73.","parent_key":"BE0000017"}
{"ref-id":"A5801","pubmed-id":11885959,"citation":"Llorens O, Perez JJ, Palomer A, Mauleon D: Differential binding mode of diverse cyclooxygenase inhibitors. J Mol Graph Model. 2002 Mar;20(5):359-71.","parent_key":"BE0000017"}
{"ref-id":"A27471","pubmed-id":10377455,"citation":"Warner TD, Giuliano F, Vojnovic I, Bukasa A, Mitchell JA, Vane JR: Nonsteroid drug selectivities for cyclo-oxygenase-1 rather than cyclo-oxygenase-2 are associated with human gastrointestinal toxicity: a full in vitro analysis. Proc Natl Acad Sci U S A. 1999 Jun 22;96(13):7563-8.","parent_key":"BE0000017"}
{"ref-id":"A1713","pubmed-id":17139284,"citation":"Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.","parent_key":"BE0000262"}
{"ref-id":"A1715","pubmed-id":17016423,"citation":"Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.","parent_key":"BE0000262"}
{"ref-id":"A5801","pubmed-id":11885959,"citation":"Llorens O, Perez JJ, Palomer A, Mauleon D: Differential binding mode of diverse cyclooxygenase inhibitors. J Mol Graph Model. 2002 Mar;20(5):359-71.","parent_key":"BE0000262"}
{"ref-id":"A27471","pubmed-id":10377455,"citation":"Warner TD, Giuliano F, Vojnovic I, Bukasa A, Mitchell JA, Vane JR: Nonsteroid drug selectivities for cyclo-oxygenase-1 rather than cyclo-oxygenase-2 are associated with human gastrointestinal toxicity: a full in vitro analysis. Proc Natl Acad Sci U S A. 1999 Jun 22;96(13):7563-8.","parent_key":"BE0000262"}
{"ref-id":"A10906","pubmed-id":2004037,"citation":"Druzgala P, Hochhaus G, Bodor N: Soft drugs--10. Blanching activity and receptor binding affinity of a new type of glucocorticoid: loteprednol etabonate. J Steroid Biochem Mol Biol. 1991 Feb;38(2):149-54.","parent_key":"BE0000794"}
{"ref-id":"A10907","pubmed-id":17020532,"citation":"Bodor N, Buchwald P: Corticosteroid design for the treatment of asthma: structural insights and the therapeutic potential of soft corticosteroids. Curr Pharm Des. 2006;12(25):3241-60.","parent_key":"BE0000794"}
{"ref-id":"A10908","pubmed-id":12861354,"citation":"Szelenyi I, Hochhaus G, Heer S, Kusters S, Marx D, Poppe H, Engel J: Loteprednol etabonate: a soft steroid for the treatment of allergic diseases of the airways. Drugs Today (Barc). 2000 May;36(5):313-20.","parent_key":"BE0000794"}
{"ref-id":"A12163","pubmed-id":9886939,"citation":"Reddy MM, Quinton PM: Bumetanide blocks CFTR GCl in the native sweat duct. Am J Physiol. 1999 Jan;276(1 Pt 1):C231-7.","parent_key":"BE0001195"}
{"ref-id":"A5856","pubmed-id":8694317,"citation":"Warner DS, Hindman BJ, Todd MM, Sawin PD, Kirchner J, Roland CL, Jamerson BD: Intracranial pressure and hemodynamic effects of remifentanil versus alfentanil in patients undergoing supratentorial craniotomy. Anesth Analg. 1996 Aug;83(2):348-53.","parent_key":"BE0000770"}
{"ref-id":"A5857","pubmed-id":9066316,"citation":"Guy J, Hindman BJ, Baker KZ, Borel CO, Maktabi M, Ostapkovich N, Kirchner J, Todd MM, Fogarty-Mack P, Yancy V, Sokoll MD, McAllister A, Roland C, Young WL, Warner DS: Comparison of remifentanil and fentanyl in patients undergoing craniotomy for supratentorial space-occupying lesions. Anesthesiology. 1997 Mar;86(3):514-24.","parent_key":"BE0000770"}
{"ref-id":"A5858","pubmed-id":9103501,"citation":"Hoke JF, Cunningham F, James MK, Muir KT, Hoffman WE: Comparative pharmacokinetics and pharmacodynamics of remifentanil, its principle metabolite (GR90291) and alfentanil in dogs. J Pharmacol Exp Ther. 1997 Apr;281(1):226-32.","parent_key":"BE0000770"}
{"ref-id":"A5859","pubmed-id":8875131,"citation":"Patel SS, Spencer CM: Remifentanil. Drugs. 1996 Sep;52(3):417-27; discussion 428.","parent_key":"BE0000770"}
{"ref-id":"A17145","pubmed-id":18815346,"citation":"Stucke AG, Zuperku EJ, Sanchez A, Tonkovic-Capin M, Tonkovic-Capin V, Mustapic S, Stuth EA: Opioid receptors on bulbospinal respiratory neurons are not activated during neuronal depression by clinically relevant opioid concentrations. J Neurophysiol. 2008 Nov;100(5):2878-88. doi: 10.1152/jn.90620.2008. Epub 2008 Sep 24.","parent_key":"BE0000420"}
{"ref-id":"A16823","pubmed-id":2164935,"citation":"van Wijngaarden I, Tulp MT, Soudijn W: The concept of selectivity in 5-HT receptor research. Eur J Pharmacol. 1990 Jun 12;188(6):301-12.","parent_key":"BE0000770"}
{"ref-id":"A10965","pubmed-id":10729371,"citation":"Kishioka S, Paronis CA, Lewis JW, Woods JH: Buprenorphine and methoclocinnamox: agonist and antagonist effects on respiratory function in rhesus monkeys. Eur J Pharmacol. 2000 Mar 17;391(3):289-97.","parent_key":"BE0000770"}
{"ref-id":"A10966","pubmed-id":10942856,"citation":"Zubieta J, Greenwald MK, Lombardi U, Woods JH, Kilbourn MR, Jewett DM, Koeppe RA, Schuster CR, Johanson CE: Buprenorphine-induced changes in mu-opioid receptor availability in male heroin-dependent volunteers: a preliminary study. Neuropsychopharmacology. 2000 Sep;23(3):326-34.","parent_key":"BE0000770"}
{"ref-id":"A10967","pubmed-id":11275413,"citation":"Sanchez-Blazquez P, Gomez-Serranillos P, Garzon J: Agonists determine the pattern of G-protein activation in mu-opioid receptor-mediated supraspinal analgesia. Brain Res Bull. 2001 Jan 15;54(2):229-35.","parent_key":"BE0000770"}
{"ref-id":"A10968","pubmed-id":12435410,"citation":"Mizoguchi H, Wu HE, Narita M, Hall FS, Sora I, Uhl GR, Nagase H, Tseng LF: Antagonistic property of buprenorphine for putative epsilon-opioid receptor-mediated G-protein activation by beta-endorphin in pons/medulla of the mu-opioid receptor knockout mouse. Neuroscience. 2002;115(3):715-21.","parent_key":"BE0000770"}
{"ref-id":"A10969","pubmed-id":15100703,"citation":"Ide S, Minami M, Satoh M, Uhl GR, Sora I, Ikeda K: Buprenorphine antinociception is abolished, but naloxone-sensitive reward is retained, in mu-opioid receptor knockout mice. Neuropsychopharmacology. 2004 Sep;29(9):1656-63.","parent_key":"BE0000770"}
{"ref-id":"A16496","pubmed-id":19666890,"citation":"Induru RR, Davis MP: Buprenorphine for neuropathic pain--targeting hyperalgesia. Am J Hosp Palliat Care. 2009 Dec-2010 Jan;26(6):470-3. doi: 10.1177/1049909109341868. Epub 2009 Aug 7.","parent_key":"BE0000420"}
{"ref-id":"A16497","pubmed-id":16443205,"citation":"Lester PA, Traynor JR: Comparison of the in vitro efficacy of mu, delta, kappa and ORL1 receptor agonists and non-selective opioid agonists in dog brain membranes. Brain Res. 2006 Feb 16;1073-1074:290-6. Epub 2006 Jan 27.","parent_key":"BE0000420"}
{"ref-id":"A16498","pubmed-id":16169027,"citation":"Megarbane B, Marie N, Pirnay S, Borron SW, Gueye PN, Risede P, Monier C, Noble F, Baud FJ: Buprenorphine is protective against the depressive effects of norbuprenorphine on ventilation. Toxicol Appl Pharmacol. 2006 May 1;212(3):256-67. Epub 2005 Sep 16.","parent_key":"BE0000420"}
{"ref-id":"A2279","pubmed-id":17635930,"citation":"Koh Y, Matsumi S, Das D, Amano M, Davis DA, Li J, Leschenko S, Baldridge A, Shioda T, Yarchoan R, Ghosh AK, Mitsuya H: Potent inhibition of HIV-1 replication by novel non-peptidyl small molecule inhibitors of protease dimerization. J Biol Chem. 2007 Sep 28;282(39):28709-20. Epub 2007 Jul 17.","parent_key":"BE0004854"}
{"ref-id":"A5913","pubmed-id":20428639,"citation":"Tenore SB, Ferreira PR: The Place of protease inhibitors in antiretroviral treatment. Braz J Infect Dis. 2009 Oct;13(5):371-4. doi: 10.1590/S1413-86702009000500012.","parent_key":"BE0004854"}
{"ref-id":"A5914","pubmed-id":17360759,"citation":"Muzammil S, Armstrong AA, Kang LW, Jakalian A, Bonneau PR, Schmelmer V, Amzel LM, Freire E: Unique thermodynamic response of tipranavir to human immunodeficiency virus type 1 protease drug resistance mutations. J Virol. 2007 May;81(10):5144-54. Epub 2007 Mar 14.","parent_key":"BE0004854"}
{"ref-id":"A5915","pubmed-id":19751502,"citation":"Hsieh SM, Chang SY, Hung CC, Sheng WH, Chen MY, Chang SC: Impact of first-line protease inhibitors on predicted resistance to tipranavir in HIV-1-infected patients with virological failure. BMC Infect Dis. 2009 Sep 14;9:154. doi: 10.1186/1471-2334-9-154.","parent_key":"BE0004854"}
{"ref-id":"A1428","pubmed-id":17712762,"citation":"Temesgen Z, Feinberg J: Tipranavir: a new option for the treatment of drug-resistant HIV infection. Clin Infect Dis. 2007 Sep 15;45(6):761-9. Epub 2007 Aug 7.","parent_key":"BE0004854"}
{"ref-id":"A1429","pubmed-id":18158073,"citation":"Luna B, Townsend MU: Tipranavir: the first nonpeptidic protease inhibitor for the treatment of protease resistance. Clin Ther. 2007 Nov;29(11):2309-18.","parent_key":"BE0004854"}
{"ref-id":"A5916","pubmed-id":16060700,"citation":"Croom KF, Keam SJ: Tipranavir: a ritonavir-boosted protease inhibitor. Drugs. 2005;65(12):1669-77; discussion 1678-9.","parent_key":"BE0004854"}
{"ref-id":"A9","pubmed-id":11752352,"citation":"Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5.","parent_key":"BE0004854"}
{"ref-id":"A12199","pubmed-id":14746879,"citation":"Moon C, Ahn M, Jee Y, Heo S, Kim S, Kim H, Sim KB, Koh CS, Shin YG, Shin T: Sodium salicylate-induced amelioration of experimental autoimmune encephalomyelitis in Lewis rats is associated with the suppression of inducible nitric oxide synthase and cyclooxygenases. Neurosci Lett. 2004 Feb 12;356(2):123-6.","parent_key":"BE0000017"}
{"ref-id":"A12200","pubmed-id":15035793,"citation":"Graham GG, Scott KF: Mechanisms of action of paracetamol and related analgesics. Inflammopharmacology. 2003;11(4):401-13.","parent_key":"BE0000017"}
{"ref-id":"A12201","pubmed-id":15840771,"citation":"Sun R, Carlson NG, Hemmert AC, Kishore BK: P2Y2 receptor-mediated release of prostaglandin E2 by IMCD is altered in hydrated and dehydrated rats: relevance to AVP-independent regulation of IMCD function. Am J Physiol Renal Physiol. 2005 Sep;289(3):F585-92. Epub 2005 Apr 19.","parent_key":"BE0000017"}
{"ref-id":"A12202","pubmed-id":15871445,"citation":"Celik G, Pasaoglu G, Bavbek S, Abadoglu O, Dursun B, Mungan D, Misirligil Z: Tolerability of selective cyclooxygenase inhibitor, celecoxib, in patients with analgesic intolerance. J Asthma. 2005 Mar;42(2):127-31.","parent_key":"BE0000017"}
{"ref-id":"A12203","pubmed-id":16368818,"citation":"Liu X, Lee TL, Wong PT: Cyclooxygenase-1 inhibition shortens the duration of diazepam-induced loss of righting reflex in mice. Anesth Analg. 2006 Jan;102(1):135-40.","parent_key":"BE0000017"}
{"ref-id":"A1430","pubmed-id":5284360,"citation":"Vane JR: Inhibition of prostaglandin synthesis as a mechanism of action for aspirin-like drugs. Nat New Biol. 1971 Jun 23;231(25):232-5.","parent_key":"BE0000017"}
{"ref-id":"A12200","pubmed-id":15035793,"citation":"Graham GG, Scott KF: Mechanisms of action of paracetamol and related analgesics. Inflammopharmacology. 2003;11(4):401-13.","parent_key":"BE0000262"}
{"ref-id":"A12204","pubmed-id":15070163,"citation":"Fiebich BL, Chrubasik S: Effects of an ethanolic salix extract on the release of selected inflammatory mediators in vitro. Phytomedicine. 2004 Feb;11(2-3):135-8.","parent_key":"BE0000262"}
{"ref-id":"A12205","pubmed-id":15106733,"citation":"Chae HJ, Chae SW, Reed JC, Kim HR: Salicylate regulates COX-2 expression through ERK and subsequent NF-kappaB activation in osteoblasts. Immunopharmacol Immunotoxicol. 2004 Feb;26(1):75-91.","parent_key":"BE0000262"}
{"ref-id":"A12206","pubmed-id":15199473,"citation":"Wu KK: Aspirin and other cyclooxygenase inhibitors: new therapeutic insights. Semin Vasc Med. 2003 May;3(2):107-12.","parent_key":"BE0000262"}
{"ref-id":"A12207","pubmed-id":15348270,"citation":"Elvira C, Gallardo A, Lacroix N, Schacht E, San Roman J: Incorporation of salicylic acid derivatives to hydrophilic copolymer systems with biomedical applications. J Mater Sci Mater Med. 2001 Jun;12(6):535-42.","parent_key":"BE0000262"}
{"ref-id":"A1430","pubmed-id":5284360,"citation":"Vane JR: Inhibition of prostaglandin synthesis as a mechanism of action for aspirin-like drugs. Nat New Biol. 1971 Jun 23;231(25):232-5.","parent_key":"BE0000262"}
{"ref-id":"A12208","pubmed-id":17259377,"citation":"Zheng L, Howell SJ, Hatala DA, Huang K, Kern TS: Salicylate-based anti-inflammatory drugs inhibit the early lesion of diabetic retinopathy. Diabetes. 2007 Feb;56(2):337-45.","parent_key":"BE0000262"}
{"ref-id":"A5932","pubmed-id":12225961,"citation":"Perez-Vizcaino F, Lopez-Lopez JG, Santiago R, Cogolludo A, Zaragoza-Arnaez F, Moreno L, Alonso MJ, Salaices M, Tamargo J: Postnatal maturation in nitric oxide-induced pulmonary artery relaxation involving cyclooxygenase-1 activity. Am J Physiol Lung Cell Mol Physiol. 2002 Oct;283(4):L839-48.","parent_key":"BE0000017"}
{"ref-id":"A5933","pubmed-id":11094641,"citation":"Shiels IA, Whitehouse MW: Lyprinol: anti-inflammatory and uterine-relaxant activities in rats, with special reference to a model for dysmenorrhoea. Allerg Immunol (Paris). 2000 Sep;32(7):279-83.","parent_key":"BE0000017"}
{"ref-id":"A5934","pubmed-id":10639181,"citation":"Kalgutkar AS, Crews BC, Rowlinson SW, Marnett AB, Kozak KR, Remmel RP, Marnett LJ: Biochemically based design of cyclooxygenase-2 (COX-2) inhibitors: facile conversion of nonsteroidal antiinflammatory drugs to potent and highly selective COX-2 inhibitors. Proc Natl Acad Sci U S A. 2000 Jan 18;97(2):925-30.","parent_key":"BE0000017"}
{"ref-id":"A5935","pubmed-id":8454631,"citation":"Meade EA, Smith WL, DeWitt DL: Differential inhibition of prostaglandin endoperoxide synthase (cyclooxygenase) isozymes by aspirin and other non-steroidal anti-inflammatory drugs. J Biol Chem. 1993 Mar 25;268(9):6610-4.","parent_key":"BE0000017"}
{"ref-id":"A5934","pubmed-id":10639181,"citation":"Kalgutkar AS, Crews BC, Rowlinson SW, Marnett AB, Kozak KR, Remmel RP, Marnett LJ: Biochemically based design of cyclooxygenase-2 (COX-2) inhibitors: facile conversion of nonsteroidal antiinflammatory drugs to potent and highly selective COX-2 inhibitors. Proc Natl Acad Sci U S A. 2000 Jan 18;97(2):925-30.","parent_key":"BE0000262"}
{"ref-id":"A10982","pubmed-id":12409963,"citation":"Traupe T, Lang M, Goettsch W, Munter K, Morawietz H, Vetter W, Barton M: Obesity increases prostanoid-mediated vasoconstriction and vascular thromboxane receptor gene expression. J Hypertens. 2002 Nov;20(11):2239-45.","parent_key":"BE0000262"}
{"ref-id":"A10983","pubmed-id":16290292,"citation":"Narsinghani T, Chaturvedi SC: QSAR analysis of meclofenamic acid analogues as selective COX-2 inhibitors. Bioorg Med Chem Lett. 2006 Jan 15;16(2):461-8. Epub 2005 Nov 14.","parent_key":"BE0000262"}
{"ref-id":"A10984","pubmed-id":7825862,"citation":"Smith WL, Meade EA, DeWitt DL: Interactions of PGH synthase isozymes-1 and -2 with NSAIDs. Ann N Y Acad Sci. 1994 Nov 15;744:50-7.","parent_key":"BE0000262"}
{"ref-id":"A5937","pubmed-id":17078596,"citation":"Flipo RM: [Are the NSAIDs able to compromising the cardio-preventive efficacy of aspirin?]. Presse Med. 2006 Sep;35(9 Spec No 1):1S53-60.","parent_key":"BE0000017"}
{"ref-id":"A5938","pubmed-id":17131625,"citation":"Schwartz KA: Aspirin resistance: a review of diagnostic methodology, mechanisms, and clinical utility. Adv Clin Chem. 2006;42:81-110.","parent_key":"BE0000017"}
{"ref-id":"A5939","pubmed-id":17259075,"citation":"Birnbaum Y, Ye Y, Lin Y, Freeberg SY, Huang MH, Perez-Polo JR, Uretsky BF: Aspirin augments 15-epi-lipoxin A4 production by lipopolysaccharide, but blocks the pioglitazone and atorvastatin induction of 15-epi-lipoxin A4 in the rat heart. Prostaglandins Other Lipid Mediat. 2007 Feb;83(1-2):89-98. Epub 2006 Nov 7.","parent_key":"BE0000017"}
{"ref-id":"A5940","pubmed-id":17319904,"citation":"Guthikonda S, Lev EI, Patel R, DeLao T, Bergeron AL, Dong JF, Kleiman NS: Reticulated platelets and uninhibited COX-1 and COX-2 decrease the antiplatelet effects of aspirin. J Thromb Haemost. 2007 Mar;5(3):490-6.","parent_key":"BE0000017"}
{"ref-id":"A10989","pubmed-id":17301265,"citation":"Hall MN, Campos H, Li H, Sesso HD, Stampfer MJ, Willett WC, Ma J: Blood levels of long-chain polyunsaturated fatty acids, aspirin, and the risk of colorectal cancer. Cancer Epidemiol Biomarkers Prev. 2007 Feb;16(2):314-21.","parent_key":"BE0000262"}
{"ref-id":"A32682","pubmed-id":14592543,"citation":"Vane JR, Botting RM: The mechanism of action of aspirin. Thromb Res. 2003 Jun 15;110(5-6):255-8.","parent_key":"BE0000262"}
{"ref-id":"A11229","pubmed-id":11324679,"citation":"Zhanel GG, Dueck M, Hoban DJ, Vercaigne LM, Embil JM, Gin AS, Karlowsky JA: Review of macrolides and ketolides: focus on respiratory tract infections. Drugs. 2001;61(4):443-98.","parent_key":"BE0004800"}
{"ref-id":"A11230","pubmed-id":12762831,"citation":"Parsad D, Pandhi R, Dogra S: A guide to selection and appropriate use of macrolides in skin infections. Am J Clin Dermatol. 2003;4(6):389-97.","parent_key":"BE0004800"}
{"ref-id":"A11231","pubmed-id":8478301,"citation":"Williams JD, Sefton AM: Comparison of macrolide antibiotics. J Antimicrob Chemother. 1993 Mar;31 Suppl C:11-26.","parent_key":"BE0004800"}
{"ref-id":"A5972","pubmed-id":10640321,"citation":"Kotzer CJ, Hay DW, Dondio G, Giardina G, Petrillo P, Underwood DC: The antitussive activity of delta-opioid receptor stimulation in guinea pigs. J Pharmacol Exp Ther. 2000 Feb;292(2):803-9.","parent_key":"BE0000770"}
{"ref-id":"A5973","pubmed-id":16291875,"citation":"Peckham EM, Traynor JR: Comparison of the antinociceptive response to morphine and morphine-like compounds in male and female Sprague-Dawley rats. J Pharmacol Exp Ther. 2006 Mar;316(3):1195-201. Epub 2005 Nov 16.","parent_key":"BE0000770"}
{"ref-id":"A5974","pubmed-id":2849950,"citation":"Hennies HH, Friderichs E, Schneider J: Receptor binding, analgesic and antitussive potency of tramadol and other selected opioids. Arzneimittelforschung. 1988 Jul;38(7):877-80.","parent_key":"BE0000770"}
{"ref-id":"A5975","pubmed-id":14600248,"citation":"Thompson CM, Wojno H, Greiner E, May EL, Rice KC, Selley DE: Activation of G-proteins by morphine and codeine congeners: insights to the relevance of O- and N-demethylated metabolites at mu- and delta-opioid receptors. J Pharmacol Exp Ther. 2004 Feb;308(2):547-54. Epub 2003 Nov 4.","parent_key":"BE0000770"}
{"ref-id":"A5976","pubmed-id":20665209,"citation":"Stoops WW, Hatton KW, Lofwall MR, Nuzzo PA, Walsh SL: Intravenous oxycodone, hydrocodone, and morphine in recreational opioid users: abuse potential and relative potencies. Psychopharmacology (Berl). 2010 Oct;212(2):193-203. doi: 10.1007/s00213-010-1942-4. Epub 2010 Jul 28.","parent_key":"BE0000770"}
{"ref-id":"A5977","pubmed-id":18606504,"citation":"Walsh SL, Nuzzo PA, Lofwall MR, Holtman JR Jr: The relative abuse liability of oral oxycodone, hydrocodone and hydromorphone assessed in prescription opioid abusers. Drug Alcohol Depend. 2008 Dec 1;98(3):191-202. doi: 10.1016/j.drugalcdep.2008.05.007. Epub 2008 Jul 7.","parent_key":"BE0000770"}
{"ref-id":"A182165","pubmed-id":31170174,"citation":"Olson KM, Duron DI, Womer D, Fell R, Streicher JM: Comprehensive molecular pharmacology screening reveals potential new receptor interactions for clinically relevant opioids. PLoS One. 2019 Jun 6;14(6):e0217371. doi: 10.1371/journal.pone.0217371. eCollection 2019.","parent_key":"BE0000770"}
{"ref-id":"A5975","pubmed-id":14600248,"citation":"Thompson CM, Wojno H, Greiner E, May EL, Rice KC, Selley DE: Activation of G-proteins by morphine and codeine congeners: insights to the relevance of O- and N-demethylated metabolites at mu- and delta-opioid receptors. J Pharmacol Exp Ther. 2004 Feb;308(2):547-54. Epub 2003 Nov 4.","parent_key":"BE0000420"}
{"ref-id":"A182165","pubmed-id":31170174,"citation":"Olson KM, Duron DI, Womer D, Fell R, Streicher JM: Comprehensive molecular pharmacology screening reveals potential new receptor interactions for clinically relevant opioids. PLoS One. 2019 Jun 6;14(6):e0217371. doi: 10.1371/journal.pone.0217371. eCollection 2019.","parent_key":"BE0000420"}
{"ref-id":"A5982","pubmed-id":17182172,"citation":"Owen HC, Miner JN, Ahmed SF, Farquharson C: The growth plate sparing effects of the selective glucocorticoid receptor modulator, AL-438. Mol Cell Endocrinol. 2007 Jan 29;264(1-2):164-70. Epub 2006 Dec 19.","parent_key":"BE0000794"}
{"ref-id":"A5983","pubmed-id":17016711,"citation":"Juruena MF, Cleare AJ, Papadopoulos AS, Poon L, Lightman S, Pariante CM: Different responses to dexamethasone and prednisolone in the same depressed patients. Psychopharmacology (Berl). 2006 Dec;189(2):225-35. Epub 2006 Oct 3.","parent_key":"BE0000794"}
{"ref-id":"A5984","pubmed-id":17068119,"citation":"Boivin MA, Ye D, Kennedy JC, Al-Sadi R, Shepela C, Ma TY: Mechanism of glucocorticoid regulation of the intestinal tight junction barrier. Am J Physiol Gastrointest Liver Physiol. 2007 Feb;292(2):G590-8. Epub 2006 Oct 26.","parent_key":"BE0000794"}
{"ref-id":"A5985","pubmed-id":17251323,"citation":"Quesnell RR, Han X, Schultz BD: Glucocorticoids stimulate ENaC upregulation in bovine mammary epithelium. Am J Physiol Cell Physiol. 2007 May;292(5):C1739-45. Epub 2007 Jan 24.","parent_key":"BE0000794"}
{"ref-id":"A5992","pubmed-id":16846546,"citation":"Waterbury LD, Silliman D, Jolas T: Comparison of cyclooxygenase inhibitory activity and ocular anti-inflammatory effects of ketorolac tromethamine and bromfenac sodium. Curr Med Res Opin. 2006 Jun;22(6):1133-40.","parent_key":"BE0000262"}
{"ref-id":"A11000","pubmed-id":16982289,"citation":"Sanchez-Matienzo D, Arana A, Castellsague J, Perez-Gutthann S: Hepatic disorders in patients treated with COX-2 selective inhibitors or nonselective NSAIDs: a case/noncase analysis of spontaneous reports. Clin Ther. 2006 Aug;28(8):1123-32.","parent_key":"BE0000262"}
{"ref-id":"A11001","pubmed-id":12016548,"citation":"Chitturi S, George J: Hepatotoxicity of commonly used drugs: nonsteroidal anti-inflammatory drugs, antihypertensives, antidiabetic agents, anticonvulsants, lipid-lowering agents, psychotropic drugs. Semin Liver Dis. 2002;22(2):169-83.","parent_key":"BE0000262"}
{"ref-id":"A5992","pubmed-id":16846546,"citation":"Waterbury LD, Silliman D, Jolas T: Comparison of cyclooxygenase inhibitory activity and ocular anti-inflammatory effects of ketorolac tromethamine and bromfenac sodium. Curr Med Res Opin. 2006 Jun;22(6):1133-40.","parent_key":"BE0000017"}
{"ref-id":"A6006","pubmed-id":19147680,"citation":"Tagami T, Yamamoto H, Moriyama K, Sawai K, Usui T, Shimatsu A, Naruse M: A selective peroxisome proliferator-activated receptor-gamma modulator, telmisartan, binds to the receptor in a different fashion from thiazolidinediones. Endocrinology. 2009 Feb;150(2):862-70. doi: 10.1210/en.2008-0502. Epub 2009 Jan 15.","parent_key":"BE0000215"}
{"ref-id":"A6007","pubmed-id":16938288,"citation":"Imayama I, Ichiki T, Inanaga K, Ohtsubo H, Fukuyama K, Ono H, Hashiguchi Y, Sunagawa K: Telmisartan downregulates angiotensin II type 1 receptor through activation of peroxisome proliferator-activated receptor gamma. Cardiovasc Res. 2006 Oct 1;72(1):184-90. Epub 2006 Jul 21.","parent_key":"BE0000215"}
{"ref-id":"A6008","pubmed-id":18580862,"citation":"Kurtz TW: Beyond the classic angiotensin-receptor-blocker profile. Nat Clin Pract Cardiovasc Med. 2008 Jul;5 Suppl 1:S19-26. doi: 10.1038/ncpcardio0805.","parent_key":"BE0000215"}
{"ref-id":"A6009","pubmed-id":15617852,"citation":"Yamagishi S, Takeuchi M: Telmisartan is a promising cardiometabolic sartan due to its unique PPAR-gamma-inducing property. Med Hypotheses. 2005;64(3):476-8.","parent_key":"BE0000215"}
{"ref-id":"A15408","pubmed-id":15868121,"citation":"Kurtz TW: Treating the metabolic syndrome: telmisartan as a peroxisome proliferator-activated receptor-gamma activator. Acta Diabetol. 2005 Apr;42 Suppl 1:S9-16.","parent_key":"BE0000215"}
{"ref-id":"A6010","pubmed-id":17691961,"citation":"Yamagishi S, Nakamura K, Matsui T: Potential utility of telmisartan, an angiotensin II type 1 receptor blocker with peroxisome proliferator-activated receptor-gamma (PPAR-gamma)-modulating activity for the treatment of cardiometabolic disorders. Curr Mol Med. 2007 Aug;7(5):463-9.","parent_key":"BE0000215"}
{"ref-id":"A15409","pubmed-id":16154710,"citation":"Yamagishi S, Takenaka K, Inoue H: Role of insulin-sensitizing property of telmisartan, a commercially available angiotensin II type 1 receptor blocker in preventing the development of atrial fibrillation. Med Hypotheses. 2006;66(1):118-20. Epub 2005 Sep 12.","parent_key":"BE0000215"}
{"ref-id":"A11232","pubmed-id":15980387,"citation":"Reinert RR, Al-Lahham A: Time-kill study of the activity of telithromycin against macrolide-resistant Streptococcus pneumoniae Isolates with 23S rRNA mutations and changes in ribosomal proteins L4 and L22. Antimicrob Agents Chemother. 2005 Jul;49(7):3011-3.","parent_key":"BE0004800"}
{"ref-id":"A11233","pubmed-id":16436755,"citation":"Farrell DJ, Shackcloth J, Barbadora KA, Green MD: Streptococcus pyogenes isolates with high-level macrolide resistance and reduced susceptibility to telithromycin associated with 23S rRNA mutations. Antimicrob Agents Chemother. 2006 Feb;50(2):817-8.","parent_key":"BE0004800"}
{"ref-id":"A11234","pubmed-id":17314426,"citation":"Hirakata Y, Mizuta Y, Wada A, Kondoh A, Kurihara S, Izumikawa K, Seki M, Yanagihara K, Miyazaki Y, Tomono K, Kohno S: The first telithromycin-resistant Streptococcus pneumoniae isolate in Japan associated with erm(B) and mutations in 23S rRNA and riboprotein L4. Jpn J Infect Dis. 2007 Feb;60(1):48-50.","parent_key":"BE0004800"}
{"ref-id":"A11235","pubmed-id":15386111,"citation":"Champney WS, Mentens N, Zurawick K: An examination of the differential sensitivity to ketolide antibiotics in ermB strains of Streptococcus pyogenes and Streptococcus pneumoniae. Curr Microbiol. 2004 Oct;49(4):239-47.","parent_key":"BE0004800"}
{"ref-id":"A6063","pubmed-id":9831331,"citation":"Kawai S: Cyclooxygenase selectivity and the risk of gastro-intestinal complications of various non-steroidal anti-inflammatory drugs: a clinical consideration. Inflamm Res. 1998 Oct;47 Suppl 2:S102-6.","parent_key":"BE0000017"}
{"ref-id":"A15395","pubmed-id":15324530,"citation":"Kean WF: Oxaprozin: kinetic and dynamic profile in the treatment of pain. Curr Med Res Opin. 2004 Aug;20(8):1275-7.","parent_key":"BE0000017"}
{"ref-id":"A6065","pubmed-id":19952416,"citation":"Zhou XP, Zhang MX, Sun W, Yang XH, Wang GS, Sui DY, Yu XF, Qu SC: Design, synthesis, and in-vivo evaluation of 4,5-diaryloxazole as novel nonsteroidal anti-inflammatory drug. Biol Pharm Bull. 2009 Dec;32(12):1986-90.","parent_key":"BE0000017"}
{"ref-id":"A6066","pubmed-id":19338579,"citation":"Ottonello L, Bertolotto M, Montecucco F, Bianchi G, Dallegri F: Delayed apoptosis of human monocytes exposed to immune complexes is reversed by oxaprozin: role of the Akt/IkappaB kinase/nuclear factor kappaB pathway. Br J Pharmacol. 2009 May;157(2):294-306. doi: 10.1111/j.1476-5381.2009.00162.x. Epub 2009 Mar 26.","parent_key":"BE0000017"}
{"ref-id":"A6061","pubmed-id":17024689,"citation":"Yood MU, Watkins E, Wells K, Kucera G, Johnson CC: The impact of NSAID or COX-2 inhibitor use on the initiation of antihypertensive therapy. Pharmacoepidemiol Drug Saf. 2006 Dec;15(12):852-60.","parent_key":"BE0000017"}
{"ref-id":"A6061","pubmed-id":17024689,"citation":"Yood MU, Watkins E, Wells K, Kucera G, Johnson CC: The impact of NSAID or COX-2 inhibitor use on the initiation of antihypertensive therapy. Pharmacoepidemiol Drug Saf. 2006 Dec;15(12):852-60.","parent_key":"BE0000262"}
{"ref-id":"A6062","pubmed-id":9650852,"citation":"Kawai S, Nishida S, Kato M, Furumaya Y, Okamoto R, Koshino T, Mizushima Y: Comparison of cyclooxygenase-1 and -2 inhibitory activities of various nonsteroidal anti-inflammatory drugs using human platelets and synovial cells. Eur J Pharmacol. 1998 Apr 17;347(1):87-94.","parent_key":"BE0000262"}
{"ref-id":"A6063","pubmed-id":9831331,"citation":"Kawai S: Cyclooxygenase selectivity and the risk of gastro-intestinal complications of various non-steroidal anti-inflammatory drugs: a clinical consideration. Inflamm Res. 1998 Oct;47 Suppl 2:S102-6.","parent_key":"BE0000262"}
{"ref-id":"A6064","pubmed-id":12065695,"citation":"Yamazaki R, Kusunoki N, Matsuzaki T, Hashimoto S, Kawai S: Nonsteroidal anti-inflammatory drugs induce apoptosis in association with activation of peroxisome proliferator-activated receptor gamma in rheumatoid synovial cells. J Pharmacol Exp Ther. 2002 Jul;302(1):18-25.","parent_key":"BE0000262"}
{"ref-id":"A6065","pubmed-id":19952416,"citation":"Zhou XP, Zhang MX, Sun W, Yang XH, Wang GS, Sui DY, Yu XF, Qu SC: Design, synthesis, and in-vivo evaluation of 4,5-diaryloxazole as novel nonsteroidal anti-inflammatory drug. Biol Pharm Bull. 2009 Dec;32(12):1986-90.","parent_key":"BE0000262"}
{"ref-id":"A6066","pubmed-id":19338579,"citation":"Ottonello L, Bertolotto M, Montecucco F, Bianchi G, Dallegri F: Delayed apoptosis of human monocytes exposed to immune complexes is reversed by oxaprozin: role of the Akt/IkappaB kinase/nuclear factor kappaB pathway. Br J Pharmacol. 2009 May;157(2):294-306. doi: 10.1111/j.1476-5381.2009.00162.x. Epub 2009 Mar 26.","parent_key":"BE0000262"}
{"ref-id":"A6095","pubmed-id":10929089,"citation":"Parsadaniantz SM, Lebeau A, Duval P, Grimaldi B, Terlain B, Kerdelhue B: Effects of the inhibition of cyclo-oxygenase 1 or 2 or 5-lipoxygenase on the activation of the hypothalamic-pituitary-adrenal axis induced by interleukin-1beta in the male Rat. J Neuroendocrinol. 2000 Aug;12(8):766-73.","parent_key":"BE0000017"}
{"ref-id":"A6097","pubmed-id":14513718,"citation":"Zuniga J, Fuenzalida M, Guerrero A, Illanes J, Dabancens A, Diaz E, Lemus D: Effects of steroidal and non steroidal drugs on the neovascularization response induced by tumoral TA3 supernatant on CAM from chick embryo. Biol Res. 2003;36(2):233-40.","parent_key":"BE0000017"}
{"ref-id":"A6098","pubmed-id":14987823,"citation":"Martic M, Tatic I, Markovic S, Kujundzic N, Kostrun S: Synthesis, biological activity and molecular modeling studies of novel COX-1 inhibitors. Eur J Med Chem. 2004 Feb;39(2):141-51.","parent_key":"BE0000017"}
{"ref-id":"A6099","pubmed-id":15476667,"citation":"Levoin N, Blondeau C, Guillaume C, Grandcolas L, Chretien F, Jouzeau JY, Benoit E, Chapleur Y, Netter P, Lapicque F: Elucidation of the mechanism of inhibition of cyclooxygenases by acyl-coenzyme A and acylglucuronic conjugates of ketoprofen. Biochem Pharmacol. 2004 Nov 15;68(10):1957-69.","parent_key":"BE0000017"}
{"ref-id":"A11011","pubmed-id":11729362,"citation":"Sommerauer M, Ates M, Guhring H, Brune K, Amann R, Peskar BA: Ketoprofen-induced cyclooxygenase inhibition in renal medulla and platelets of rats treated with caffeine. Pharmacology. 2001;63(4):234-9.","parent_key":"BE0000262"}
{"ref-id":"A11012","pubmed-id":11814865,"citation":"Levoin N, Chretien F, Lapicque F, Chapleur Y: Synthesis and biological testing of Acyl-CoA-ketoprofen conjugates as selective irreversible inhibitors of COX-2. Bioorg Med Chem. 2002 Mar;10(3):753-7.","parent_key":"BE0000262"}
{"ref-id":"A6097","pubmed-id":14513718,"citation":"Zuniga J, Fuenzalida M, Guerrero A, Illanes J, Dabancens A, Diaz E, Lemus D: Effects of steroidal and non steroidal drugs on the neovascularization response induced by tumoral TA3 supernatant on CAM from chick embryo. Biol Res. 2003;36(2):233-40.","parent_key":"BE0000262"}
{"ref-id":"A16513","pubmed-id":19708827,"citation":"Tursi A: Balsalazide in treating colonic diseases. Expert Opin Drug Metab Toxicol. 2009 Dec;5(12):1555-63. doi: 10.1517/17425250903228842.","parent_key":"BE0000215"}
{"ref-id":"A16514","pubmed-id":20151072,"citation":"Iacucci M, de Silva S, Ghosh S: Mesalazine in inflammatory bowel disease: a trendy topic once again? Can J Gastroenterol. 2010 Feb;24(2):127-33.","parent_key":"BE0000215"}
{"ref-id":"A1601","pubmed-id":19743890,"citation":"Wiggins JB, Rajapakse R: Balsalazide: a novel 5-aminosalicylate prodrug for the treatment of active ulcerative colitis. Expert Opin Drug Metab Toxicol. 2009 Oct;5(10):1279-84. doi: 10.1517/17425250903206996.","parent_key":"BE0000262"}
{"ref-id":"A11013","pubmed-id":17981262,"citation":"Stolfi C, Fina D, Caruso R, Caprioli F, Sarra M, Fantini MC, Rizzo A, Pallone F, Monteleone G: Cyclooxygenase-2-dependent and -independent inhibition of proliferation of colon cancer cells by 5-aminosalicylic acid. Biochem Pharmacol. 2008 Feb 1;75(3):668-76. Epub 2007 Sep 29.","parent_key":"BE0000262"}
{"ref-id":"A4391","pubmed-id":12950415,"citation":"Allgayer H: Review article: mechanisms of action of mesalazine in preventing colorectal carcinoma in inflammatory bowel disease. Aliment Pharmacol Ther. 2003 Sep;18 Suppl 2:10-4.","parent_key":"BE0000262"}
{"ref-id":"A1713","pubmed-id":17139284,"citation":"Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.","parent_key":"BE0000017"}
{"ref-id":"A1715","pubmed-id":17016423,"citation":"Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.","parent_key":"BE0000017"}
{"ref-id":"A1601","pubmed-id":19743890,"citation":"Wiggins JB, Rajapakse R: Balsalazide: a novel 5-aminosalicylate prodrug for the treatment of active ulcerative colitis. Expert Opin Drug Metab Toxicol. 2009 Oct;5(10):1279-84. doi: 10.1517/17425250903206996.","parent_key":"BE0000017"}
{"ref-id":"A12270","pubmed-id":12202948,"citation":"Reddy MM, Quinton PM: Effect of anion transport blockers on CFTR in the human sweat duct. J Membr Biol. 2002 Sep 1;189(1):15-25.","parent_key":"BE0001195"}
{"ref-id":"A12271","pubmed-id":12391048,"citation":"Jiang J, Song Y, Bai C, Koller BH, Matthay MA, Verkman AS: Pleural surface fluorescence measurement of Na+ and Cl- transport across the air space-capillary barrier. J Appl Physiol (1985). 2003 Jan;94(1):343-52. Epub 2002 Aug 30.","parent_key":"BE0001195"}
{"ref-id":"A12272","pubmed-id":12407077,"citation":"Zhou Z, Hu S, Hwang TC: Probing an open CFTR pore with organic anion blockers. J Gen Physiol. 2002 Nov;120(5):647-62.","parent_key":"BE0001195"}
{"ref-id":"A12273","pubmed-id":14729151,"citation":"Larsen EH, Amstrup J, Willumsen NJ: Beta-adrenergic receptors couple to CFTR chloride channels of intercalated mitochondria-rich cells in the heterocellular toad skin epithelium. Biochim Biophys Acta. 2003 Dec 30;1618(2):140-52.","parent_key":"BE0001195"}
{"ref-id":"A12274","pubmed-id":15365090,"citation":"Lee SY, Lee CO: Inhibition of Na+-K+ pump and L-type Ca2+ channel by glibenclamide in Guinea pig ventricular myocytes. J Pharmacol Exp Ther. 2005 Jan;312(1):61-8. Epub 2004 Sep 13.","parent_key":"BE0001195"}
{"ref-id":"A12294","pubmed-id":11875741,"citation":"Sasamura H, Takahashi A, Miyao N, Yanase M, Masumori N, Kitamura H, Itoh N, Tsukamoto T: Inhibitory effect on expression of angiogenic factors by antiangiogenic agents in renal cell carcinoma. Br J Cancer. 2002 Mar 4;86(5):768-73.","parent_key":"BE0000163"}
{"ref-id":"A12295","pubmed-id":15256478,"citation":"Yao JS, Chen Y, Zhai W, Xu K, Young WL, Yang GY: Minocycline exerts multiple inhibitory effects on vascular endothelial growth factor-induced smooth muscle cell migration: the role of ERK1/2, PI3K, and matrix metalloproteinases. Circ Res. 2004 Aug 20;95(4):364-71. Epub 2004 Jul 15.","parent_key":"BE0000163"}
{"ref-id":"A12296","pubmed-id":16224178,"citation":"Rocchetti R, Talevi S, Margiotta C, Calza R, Corallini A, Possati L: Antiangiogenic drugs for chemotherapy of bladder tumours. Chemotherapy. 2005 Oct;51(6):291-9. Epub 2005 Oct 13.","parent_key":"BE0000163"}
{"ref-id":"A12304","pubmed-id":11986668,"citation":"Zhu S, Stavrovskaya IG, Drozda M, Kim BY, Ona V, Li M, Sarang S, Liu AS, Hartley DM, Wu DC, Gullans S, Ferrante RJ, Przedborski S, Kristal BS, Friedlander RM: Minocycline inhibits cytochrome c release and delays progression of amyotrophic lateral sclerosis in mice. Nature. 2002 May 2;417(6884):74-8.","parent_key":"BE0000005"}
{"ref-id":"A20073","pubmed-id":23525103,"citation":"Li H, Redinbo MR, Venkatesh M, Ekins S, Chaudhry A, Bloch N, Negassa A, Mukherjee P, Kalpana G, Mani S: Novel yeast-based strategy unveils antagonist binding regions on the nuclear xenobiotic receptor PXR. J Biol Chem. 2013 May 10;288(19):13655-68. doi: 10.1074/jbc.M113.455485. Epub 2013 Mar 22.","parent_key":"BE0000956"}
{"ref-id":"A6170","pubmed-id":10494028,"citation":"Clavey V, Copin C, Mariotte MC, Bauge E, Chinetti G, Fruchart J, Fruchart JC, Dallongeville J, Staels B: Cell culture conditions determine apolipoprotein CIII secretion and regulation by fibrates in human hepatoma HepG2 cells. Cell Physiol Biochem. 1999;9(3):139-49.","parent_key":"BE0000071"}
{"ref-id":"A6171","pubmed-id":10799317,"citation":"Chaput E, Saladin R, Silvestre M, Edgar AD: Fenofibrate and rosiglitazone lower serum triglycerides with opposing effects on body weight. Biochem Biophys Res Commun. 2000 May 10;271(2):445-50.","parent_key":"BE0000071"}
{"ref-id":"A6172","pubmed-id":11018525,"citation":"Casas F, Pineau T, Rochard P, Rodier A, Daury L, Dauca M, Cabello G, Wrutniak-Cabello C: New molecular aspects of regulation of mitochondrial activity by fenofibrate and fasting. FEBS Lett. 2000 Sep 29;482(1-2):71-4.","parent_key":"BE0000071"}
{"ref-id":"A6173","pubmed-id":11342537,"citation":"Bouly M, Masson D, Gross B, Jiang XC, Fievet C, Castro G, Tall AR, Fruchart JC, Staels B, Lagrost L, Luc G: Induction of the phospholipid transfer protein gene accounts for the high density lipoprotein enlargement in mice treated with fenofibrate. J Biol Chem. 2001 Jul 13;276(28):25841-7. Epub 2001 May 7.","parent_key":"BE0000071"}
{"ref-id":"A6174","pubmed-id":11474486,"citation":"Dana SL, Hoener PA, Bilakovics JM, Crombie DL, Ogilvie KM, Kauffman RF, Mukherjee R, Paterniti JR Jr: Peroxisome proliferator-activated receptor subtype-specific regulation of hepatic and peripheral gene expression in the Zucker diabetic fatty rat. Metabolism. 2001 Aug;50(8):963-71.","parent_key":"BE0000071"}
{"ref-id":"A9","pubmed-id":11752352,"citation":"Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5.","parent_key":"BE0000071"}
{"ref-id":"A6175","pubmed-id":10828060,"citation":"Guerre-Millo M, Gervois P, Raspe E, Madsen L, Poulain P, Derudas B, Herbert JM, Winegar DA, Willson TM, Fruchart JC, Berge RK, Staels B: Peroxisome proliferator-activated receptor alpha activators improve insulin sensitivity and reduce adiposity. J Biol Chem. 2000 Jun 2;275(22):16638-42.","parent_key":"BE0000071"}
{"ref-id":"A20117","pubmed-id":20024649,"citation":"Creusot N, Kinani S, Balaguer P, Tapie N, LeMenach K, Maillot-Marechal E, Porcher JM, Budzinski H, Ait-Aissa S: Evaluation of an hPXR reporter gene assay for the detection of aquatic emerging pollutants: screening of chemicals and application to water samples. Anal Bioanal Chem. 2010 Jan;396(2):569-83. doi: 10.1007/s00216-009-3310-y. Epub 2009 Nov 29.","parent_key":"BE0000956"}
{"ref-id":"A6176","pubmed-id":12046682,"citation":"Richardson P, Hideshima T, Anderson K: Thalidomide in multiple myeloma. Biomed Pharmacother. 2002 May;56(3):115-28.","parent_key":"BE0000704"}
{"ref-id":"A6177","pubmed-id":12102294,"citation":"Fu LM, Fu-Liu CS: Thalidomide and tuberculosis. Int J Tuberc Lung Dis. 2002 Jul;6(7):569-72.","parent_key":"BE0000704"}
{"ref-id":"A6178","pubmed-id":12105857,"citation":"Enomoto N, Takei Y, Hirose M, Ikejima K, Miwa H, Kitamura T, Sato N: Thalidomide prevents alcoholic liver injury in rats through suppression of Kupffer cell sensitization and TNF-alpha production. Gastroenterology. 2002 Jul;123(1):291-300.","parent_key":"BE0000704"}
{"ref-id":"A6179","pubmed-id":12113124,"citation":"Rajkumar SV: Thalidomide in the treatment of multiple myeloma. Expert Rev Anticancer Ther. 2001 Jun;1(1):20-8.","parent_key":"BE0000704"}
{"ref-id":"A6180","pubmed-id":12167383,"citation":"Vescovo G, Ravara B, Angelini A, Sandri M, Carraro U, Ceconi C, Dalla Libera L: Effect of thalidomide on the skeletal muscle in experimental heart failure. Eur J Heart Fail. 2002 Aug;4(4):455-60.","parent_key":"BE0000704"}
{"ref-id":"A6181","pubmed-id":8755512,"citation":"Turk BE, Jiang H, Liu JO: Binding of thalidomide to alpha1-acid glycoprotein may be involved in its inhibition of tumor necrosis factor alpha production. Proc Natl Acad Sci U S A. 1996 Jul 23;93(15):7552-6.","parent_key":"BE0000704"}
{"ref-id":"A12348","pubmed-id":12710892,"citation":"Horrobin DF: A low toxicity maintenance regime, using eicosapentaenoic acid and readily available drugs, for mantle cell lymphoma and other malignancies with excess cyclin D1 levels. Med Hypotheses. 2003 May;60(5):615-23.","parent_key":"BE0000262"}
{"ref-id":"A12349","pubmed-id":15446566,"citation":"Hada M, Mizutari K: [A case report of metastatic pancreatic cancer that responded remarkably to the combination of thalidomide, celecoxib and irinotecan]. Gan To Kagaku Ryoho. 2004 Sep;31(9):1407-10.","parent_key":"BE0000262"}
{"ref-id":"A12350","pubmed-id":15892618,"citation":"Wiedmann MW, Caca K: Molecularly targeted therapy for gastrointestinal cancer. Curr Cancer Drug Targets. 2005 May;5(3):171-93.","parent_key":"BE0000262"}
{"ref-id":"A12351","pubmed-id":15982930,"citation":"Du GJ, Lin HH, Xu QT, Wang MW: Thalidomide inhibits growth of tumors through COX-2 degradation independent of antiangiogenesis. Vascul Pharmacol. 2005 Aug;43(2):112-9.","parent_key":"BE0000262"}
{"ref-id":"A12352","pubmed-id":21507989,"citation":"Kim JH, Scialli AR: Thalidomide: the tragedy of birth defects and the effective treatment of disease. Toxicol Sci. 2011 Jul;122(1):1-6. doi: 10.1093/toxsci/kfr088. Epub 2011 Apr 19.","parent_key":"BE0000262"}
{"ref-id":"A14231","pubmed-id":16480505,"citation":"Chen J, Raymond K: Roles of rifampicin in drug-drug interactions: underlying molecular mechanisms involving the nuclear pregnane X receptor. Ann Clin Microbiol Antimicrob. 2006 Feb 15;5:3.","parent_key":"BE0000956"}
{"ref-id":"A14232","pubmed-id":19460945,"citation":"Cheng J, Ma X, Krausz KW, Idle JR, Gonzalez FJ: Rifampicin-activated human pregnane X receptor and CYP3A4 induction enhance acetaminophen-induced toxicity. Drug Metab Dispos. 2009 Aug;37(8):1611-21. doi: 10.1124/dmd.109.027565. Epub 2009 May 21.","parent_key":"BE0000956"}
{"ref-id":"A16819","pubmed-id":11279785,"citation":"Jessop S, Whitelaw D, Jordaan F: Drugs for discoid lupus erythematosus. Cochrane Database Syst Rev. 2001;(1):CD002954.","parent_key":"BE0000794"}
{"ref-id":"A11024","pubmed-id":14510637,"citation":"Ouellet M, Falgueyret JP, Percival MD: Detergents profoundly affect inhibitor potencies against both cyclo-oxygenase isoforms. Biochem J. 2004 Feb 1;377(Pt 3):675-84.","parent_key":"BE0000262"}
{"ref-id":"A11025","pubmed-id":15481334,"citation":"Gallego-Sandin S, Novalbos J, Rosado A, Gisbert JP, Galvez-Mugica MA, Garcia AG, Pajares JM, Abad-Santos F: Effect of ibuprofen on cyclooxygenase and nitric oxide synthase of gastric mucosa: correlation with endoscopic lesions and adverse reactions. Dig Dis Sci. 2004 Sep;49(9):1538-44.","parent_key":"BE0000262"}
{"ref-id":"A11026","pubmed-id":15494133,"citation":"Murphey LJ, Williams MK, Sanchez SC, Byrne LM, Csiki I, Oates JA, Johnson DH, Morrow JD: Quantification of the major urinary metabolite of PGE2 by a liquid chromatographic/mass spectrometric assay: determination of cyclooxygenase-specific PGE2 synthesis in healthy humans and those with lung cancer. Anal Biochem. 2004 Nov 15;334(2):266-75.","parent_key":"BE0000262"}
{"ref-id":"A11027","pubmed-id":15556152,"citation":"Sanchez-Fidalgo S, Martin-Lacave I, Illanes M, Motilva V: Angiogenesis, cell proliferation and apoptosis in gastric ulcer healing. Effect of a selective cox-2 inhibitor. Eur J Pharmacol. 2004 Nov 28;505(1-3):187-94.","parent_key":"BE0000262"}
{"ref-id":"A6196","pubmed-id":14592549,"citation":"Patrignani P: Aspirin insensitive eicosanoid biosynthesis in cardiovascular disease. Thromb Res. 2003 Jun 15;110(5-6):281-6.","parent_key":"BE0000017"}
{"ref-id":"A6197","pubmed-id":14741265,"citation":"Gupta K, Kaub CJ, Carey KN, Casillas EG, Selinsky BS, Loll PJ: Manipulation of kinetic profiles in 2-aryl propionic acid cyclooxygenase inhibitors. Bioorg Med Chem Lett. 2004 Feb 9;14(3):667-71.","parent_key":"BE0000017"}
{"ref-id":"A6198","pubmed-id":15575422,"citation":"Hillarp A: [Acetylsalicylic acid resistance--clinical diagnosis with unclear mechanism]. Lakartidningen. 2004 Nov 4;101(45):3504-6, 3508-9.","parent_key":"BE0000017"}
{"ref-id":"A6199","pubmed-id":23536207,"citation":"Yu L, Shi D, Ma L, Zhou Q, Zeng S: Influence of CYP2C8 polymorphisms on the hydroxylation metabolism of paclitaxel, repaglinide and ibuprofen enantiomers in vitro. Biopharm Drug Dispos. 2013 Jul;34(5):278-87. doi: 10.1002/bdd.1842. Epub 2013 Jun 3.","parent_key":"BE0000017"}
{"ref-id":"A17953","pubmed-id":22668799,"citation":"Palayoor ST, J-Aryankalayil M, Makinde AY, Cerna D, Falduto MT, Magnuson SR, Coleman CN: Gene expression profile of coronary artery cells treated with nonsteroidal anti-inflammatory drugs reveals off-target effects. J Cardiovasc Pharmacol. 2012 Jun;59(6):487-99. doi: 10.1097/FJC.0b013e31824ba6b5.","parent_key":"BE0000246"}
{"ref-id":"A17953","pubmed-id":22668799,"citation":"Palayoor ST, J-Aryankalayil M, Makinde AY, Cerna D, Falduto MT, Magnuson SR, Coleman CN: Gene expression profile of coronary artery cells treated with nonsteroidal anti-inflammatory drugs reveals off-target effects. J Cardiovasc Pharmacol. 2012 Jun;59(6):487-99. doi: 10.1097/FJC.0b013e31824ba6b5.","parent_key":"BE0001151"}
{"ref-id":"A17954","pubmed-id":15722357,"citation":"Velkov T, Chuang S, Wielens J, Sakellaris H, Charman WN, Porter CJ, Scanlon MJ: The interaction of lipophilic drugs with intestinal fatty acid-binding protein. J Biol Chem. 2005 May 6;280(18):17769-76. Epub 2005 Feb 18.","parent_key":"BE0003591"}
{"ref-id":"A1656","pubmed-id":20089905,"citation":"Dill J, Patel AR, Yang XL, Bachoo R, Powell CM, Li S: A molecular mechanism for ibuprofen-mediated RhoA inhibition in neurons. J Neurosci. 2010 Jan 20;30(3):963-72. doi: 10.1523/JNEUROSCI.5045-09.2010.","parent_key":"BE0000215"}
{"ref-id":"A17985","pubmed-id":9710435,"citation":"Devor DC, Schultz BD: Ibuprofen inhibits cystic fibrosis transmembrane conductance regulator-mediated Cl- secretion. J Clin Invest. 1998 Aug 15;102(4):679-87.","parent_key":"BE0001195"}
{"ref-id":"A17953","pubmed-id":22668799,"citation":"Palayoor ST, J-Aryankalayil M, Makinde AY, Cerna D, Falduto MT, Magnuson SR, Coleman CN: Gene expression profile of coronary artery cells treated with nonsteroidal anti-inflammatory drugs reveals off-target effects. J Cardiovasc Pharmacol. 2012 Jun;59(6):487-99. doi: 10.1097/FJC.0b013e31824ba6b5.","parent_key":"BE0001025"}
{"ref-id":"A39196","pubmed-id":24918694,"citation":"Fujiwara R, Takenaka S, Hashimoto M, Narawa T, Itoh T: Expression of human solute carrier family transporters in skin: possible contributor to drug-induced skin disorders. Sci Rep. 2014 Jun 11;4:5251. doi: 10.1038/srep05251.","parent_key":"BE0003756"}
{"ref-id":"A6223","pubmed-id":17928344,"citation":"Dierynck I, De Wit M, Gustin E, Keuleers I, Vandersmissen J, Hallenberger S, Hertogs K: Binding kinetics of darunavir to human immunodeficiency virus type 1 protease explain the potent antiviral activity and high genetic barrier. J Virol. 2007 Dec;81(24):13845-51. Epub 2007 Oct 10.","parent_key":"BE0004854"}
{"ref-id":"A6224","pubmed-id":19053892,"citation":"Wood R: Atazanavir: its role in HIV treatment. Expert Rev Anti Infect Ther. 2008 Dec;6(6):785-96. doi: 10.1586/14787210.6.6.785.","parent_key":"BE0004854"}
{"ref-id":"A1695","pubmed-id":16176117,"citation":"Le Tiec C, Barrail A, Goujard C, Taburet AM: Clinical pharmacokinetics and summary of efficacy and tolerability of atazanavir. Clin Pharmacokinet. 2005;44(10):1035-50.","parent_key":"BE0004854"}
{"ref-id":"A6225","pubmed-id":18006837,"citation":"Pyrko P, Kardosh A, Wang W, Xiong W, Schonthal AH, Chen TC: HIV-1 protease inhibitors nelfinavir and atazanavir induce malignant glioma death by triggering endoplasmic reticulum stress. Cancer Res. 2007 Nov 15;67(22):10920-8.","parent_key":"BE0004854"}
{"ref-id":"A6226","pubmed-id":18054799,"citation":"Menendez-Arias L, Tozser J: HIV-1 protease inhibitors: effects on HIV-2 replication and resistance. Trends Pharmacol Sci. 2008 Jan;29(1):42-9. Epub 2007 Dec 4.","parent_key":"BE0004854"}
{"ref-id":"A1696","pubmed-id":20116610,"citation":"Lopez-Cortes LF: [Pharmacology, pharmacokinetic features and interactions of atazanavir]. Enferm Infecc Microbiol Clin. 2008 Dec;26 Suppl 17:2-8. doi: 10.1016/S0213-005X(08)76613-8.","parent_key":"BE0004854"}
{"ref-id":"A1697","pubmed-id":15585441,"citation":"Busti AJ, Hall RG, Margolis DM: Atazanavir for the treatment of human immunodeficiency virus infection. Pharmacotherapy. 2004 Dec;24(12):1732-47.","parent_key":"BE0004854"}
{"ref-id":"A6249","pubmed-id":18192961,"citation":"Baker DE: Loperamide: a pharmacological review. Rev Gastroenterol Disord. 2007;7 Suppl 3:S11-8.","parent_key":"BE0000770"}
{"ref-id":"A6250","pubmed-id":10202212,"citation":"Corazziari E: Role of opioid ligands in the irritable bowel syndrome. Can J Gastroenterol. 1999 Mar;13 Suppl A:71A-75A.","parent_key":"BE0000770"}
{"ref-id":"A6251","pubmed-id":8583364,"citation":"Coupar IM: The peristaltic reflex in the rat ileum: evidence for functional mu- and delta-opiate receptors. J Pharm Pharmacol. 1995 Aug;47(8):643-6.","parent_key":"BE0000770"}
{"ref-id":"A6252","pubmed-id":8386327,"citation":"De Luca A, Coupar IM: Difenoxin and loperamide: studies on possible mechanisms of intestinal antisecretory action. Naunyn Schmiedebergs Arch Pharmacol. 1993 Feb;347(2):231-7.","parent_key":"BE0000770"}
{"ref-id":"A6251","pubmed-id":8583364,"citation":"Coupar IM: The peristaltic reflex in the rat ileum: evidence for functional mu- and delta-opiate receptors. J Pharm Pharmacol. 1995 Aug;47(8):643-6.","parent_key":"BE0000420"}
{"ref-id":"A16634","pubmed-id":7683652,"citation":"Wolff DJ, Datto GA, Samatovicz RA: The dual mode of inhibition of calmodulin-dependent nitric-oxide synthase by antifungal imidazole agents. J Biol Chem. 1993 May 5;268(13):9430-6.","parent_key":"BE0000005"}
{"ref-id":"A16635","pubmed-id":7518297,"citation":"Bogle RG, Whitley GS, Soo SC, Johnstone AP, Vallance P: Effect of anti-fungal imidazoles on mRNA levels and enzyme activity of inducible nitric oxide synthase. Br J Pharmacol. 1994 Apr;111(4):1257-61.","parent_key":"BE0000005"}
{"ref-id":"A16636","pubmed-id":9873034,"citation":"Sennequier N, Wolan D, Stuehr DJ: Antifungal imidazoles block assembly of inducible NO synthase into an active dimer. J Biol Chem. 1999 Jan 8;274(2):930-8.","parent_key":"BE0000005"}
{"ref-id":"A16637","pubmed-id":7536941,"citation":"Dudek RR, Conforto A, Pinto V, Wildhirt S, Suzuki H: Inhibition of endothelial nitric oxide synthase by cytochrome P-450 reductase inhibitors. Proc Soc Exp Biol Med. 1995 May;209(1):60-4.","parent_key":"BE0000005"}
{"ref-id":"A20162","pubmed-id":21291553,"citation":"Krasowski MD, Ai N, Hagey LR, Kollitz EM, Kullman SW, Reschly EJ, Ekins S: The evolution of farnesoid X, vitamin D, and pregnane X receptors: insights from the green-spotted pufferfish (Tetraodon nigriviridis) and other non-mammalian species. BMC Biochem. 2011 Feb 3;12:5. doi: 10.1186/1471-2091-12-5.","parent_key":"BE0000956"}
{"ref-id":"A20650","pubmed-id":21123845,"citation":"Song M, Kim YJ, Ryu JC: Phospholipidosis induced by PPARgamma signaling in human bronchial epithelial (BEAS-2B) cells exposed to amiodarone. Toxicol Sci. 2011 Mar;120(1):98-108. doi: 10.1093/toxsci/kfq361. Epub 2010 Dec 1.","parent_key":"BE0000215"}
{"ref-id":"A189790","pubmed-id":15265979,"citation":"McCarthy TC, Pollak PT, Hanniman EA, Sinal CJ: Disruption of hepatic lipid homeostasis in mice after amiodarone treatment is associated with peroxisome proliferator-activated receptor-alpha target gene activation. J Pharmacol Exp Ther. 2004 Dec;311(3):864-73. doi: 10.1124/jpet.104.072785. Epub 2004 Jul 20.","parent_key":"BE0000071"}
{"ref-id":"A12439","pubmed-id":12126787,"citation":"Mamputu JC, Renier G: Advanced glycation end products increase, through a protein kinase C-dependent pathway, vascular endothelial growth factor expression in retinal endothelial cells. Inhibitory effect of gliclazide. J Diabetes Complications. 2002 Jul-Aug;16(4):284-93.","parent_key":"BE0000163"}
{"ref-id":"A12440","pubmed-id":14746574,"citation":"Mamputu JC, Renier G: Signalling pathways involved in retinal endothelial cell proliferation induced by advanced glycation end products: inhibitory effect of gliclazide. Diabetes Obes Metab. 2004 Mar;6(2):95-103.","parent_key":"BE0000163"}
{"ref-id":"A12441","pubmed-id":17046555,"citation":"Li L, Renier G: Activation of nicotinamide adenine dinucleotide phosphate (reduced form) oxidase by advanced glycation end products links oxidative stress to altered retinal vascular endothelial growth factor expression. Metabolism. 2006 Nov;55(11):1516-23.","parent_key":"BE0000163"}
{"ref-id":"A12442","pubmed-id":17602961,"citation":"Kimura T, Takagi H, Suzuma K, Kita M, Watanabe D, Yoshimura N: Comparisons between the beneficial effects of different sulphonylurea treatments on ischemia-induced retinal neovascularization. Free Radic Biol Med. 2007 Aug 1;43(3):454-61. Epub 2007 May 3.","parent_key":"BE0000163"}
{"ref-id":"A13489","pubmed-id":20018750,"citation":"Sugii S, Olson P, Sears DD, Saberi M, Atkins AR, Barish GD, Hong SH, Castro GL, Yin YQ, Nelson MC, Hsiao G, Greaves DR, Downes M, Yu RT, Olefsky JM, Evans RM: PPARgamma activation in adipocytes is sufficient for systemic insulin sensitization. Proc Natl Acad Sci U S A. 2009 Dec 29;106(52):22504-9. doi: 10.1073/pnas.0912487106. Epub 2009 Dec 16.","parent_key":"BE0000215"}
{"ref-id":"A13490","pubmed-id":15356026,"citation":"Miyazaki Y, Mahankali A, Wajcberg E, Bajaj M, Mandarino LJ, DeFronzo RA: Effect of pioglitazone on circulating adipocytokine levels and insulin sensitivity in type 2 diabetic patients. J Clin Endocrinol Metab. 2004 Sep;89(9):4312-9.","parent_key":"BE0000215"}
{"ref-id":"A13492","pubmed-id":9568680,"citation":"Spiegelman BM: PPAR-gamma: adipogenic regulator and thiazolidinedione receptor. Diabetes. 1998 Apr;47(4):507-14.","parent_key":"BE0000215"}
{"ref-id":"A13493","pubmed-id":8576907,"citation":"Willson TM, Cobb JE, Cowan DJ, Wiethe RW, Correa ID, Prakash SR, Beck KD, Moore LB, Kliewer SA, Lehmann JM: The structure-activity relationship between peroxisome proliferator-activated receptor gamma agonism and the antihyperglycemic activity of thiazolidinediones. J Med Chem. 1996 Feb 2;39(3):665-8.","parent_key":"BE0000215"}
{"ref-id":"A12457","pubmed-id":11378004,"citation":"de Boer RA, Siebelink HJ, Tio RA, Boomsma F, van Veldhuisen DJ: Carvedilol increases plasma vascular endothelial growth factor (VEGF) in patients with chronic heart failure. Eur J Heart Fail. 2001 Jun;3(3):331-3.","parent_key":"BE0000163"}
{"ref-id":"A12458","pubmed-id":15071347,"citation":"Saijonmaa O, Nyman T, Fyhrquist F: Carvedilol inhibits basal and stimulated ACE production in human endothelial cells. J Cardiovasc Pharmacol. 2004 May;43(5):616-21.","parent_key":"BE0000163"}
{"ref-id":"A12459","pubmed-id":15732037,"citation":"Shyu KG, Lu MJ, Chang H, Sun HY, Wang BW, Kuan P: Carvedilol modulates the expression of hypoxia-inducible factor-1alpha and vascular endothelial growth factor in a rat model of volume-overload heart failure. J Card Fail. 2005 Mar;11(2):152-9.","parent_key":"BE0000163"}
{"ref-id":"A12460","pubmed-id":15942707,"citation":"Shyu KG, Liou JY, Wang BW, Fang WJ, Chang H: Carvedilol prevents cardiac hypertrophy and overexpression of hypoxia-inducible factor-1alpha and vascular endothelial growth factor in pressure-overloaded rat heart. J Biomed Sci. 2005;12(2):409-20.","parent_key":"BE0000163"}
{"ref-id":"A20121","pubmed-id":20074581,"citation":"Huang HS, Liu ZM, Hong DY: Blockage of JNK pathway enhances arsenic trioxide-induced apoptosis in human keratinocytes. Toxicol Appl Pharmacol. 2010 Apr 15;244(2):234-41. doi: 10.1016/j.taap.2009.12.037. Epub 2010 Jan 11.","parent_key":"BE0002365"}
{"ref-id":"A17215","pubmed-id":2011590,"citation":"Wolff J, Knipling L, Cahnmann HJ, Palumbo G: Direct photoaffinity labeling of tubulin with colchicine. Proc Natl Acad Sci U S A. 1991 Apr 1;88(7):2820-4.","parent_key":"BE0000143"}
{"ref-id":"A6431","pubmed-id":12566163,"citation":"Narita M, Suzuki M, Mizoguchi H, Narita M, Yajima Y, Sakurada S, Tseng LF, Suzuki T: Up-regulation of mu-opioid receptor-mediated G-protein activation in protein kinase Cgamma knockout mice following repeated naloxone treatment. Neurosci Lett. 2003 Feb 27;338(2):103-6.","parent_key":"BE0000770"}
{"ref-id":"A6432","pubmed-id":12799988,"citation":"Freye E, Latasch L, Von Bredow G, Neruda B: [The opioid tramadol demonstrates excitatory properties of non-opioid character--a preclinical study using alfentanil as a comparison]. Schmerz. 1998 Feb 28;12(1):19-24.","parent_key":"BE0000770"}
{"ref-id":"A6433","pubmed-id":12842269,"citation":"Neal CR Jr, Owens CE, Taylor LP, Hoversten MT, Akil H, Watson SJ Jr: Binding and GTPgammaS autoradiographic analysis of preproorphanin precursor peptide products at the ORL1 and opioid receptors. J Chem Neuroanat. 2003 Jul;25(4):233-47.","parent_key":"BE0000770"}
{"ref-id":"A6434","pubmed-id":12887410,"citation":"Spetea M, Toth F, Schutz J, Otvos F, Toth G, Benyhe S, Borsodi A, Schmidhammer H: Binding characteristics of [3H]14-methoxymetopon, a high affinity mu-opioid receptor agonist. Eur J Neurosci. 2003 Jul;18(2):290-5.","parent_key":"BE0000770"}
{"ref-id":"A6435","pubmed-id":12909198,"citation":"Marek GJ: Behavioral evidence for mu-opioid and 5-HT2A receptor interactions. Eur J Pharmacol. 2003 Aug 1;474(1):77-83.","parent_key":"BE0000770"}
{"ref-id":"A6436","pubmed-id":17367258,"citation":"van Dorp E, Yassen A, Dahan A: Naloxone treatment in opioid addiction: the risks and benefits. Expert Opin Drug Saf. 2007 Mar;6(2):125-32.","parent_key":"BE0000770"}
{"ref-id":"A12523","pubmed-id":12650833,"citation":"Moncada A, Cendan CM, Baeyens JM, Del Pozo E: Effects of serine/threonine protein phosphatase inhibitors on morphine-induced antinociception in the tail flick test in mice. Eur J Pharmacol. 2003 Mar 28;465(1-2):53-60.","parent_key":"BE0000420"}
{"ref-id":"A12524","pubmed-id":12657847,"citation":"Kakinohana M, Marsala M, Carter C, Davison JK, Yaksh TL: Neuraxial morphine may trigger transient motor dysfunction after a noninjurious interval of spinal cord ischemia: a clinical and experimental study. Anesthesiology. 2003 Apr;98(4):862-70.","parent_key":"BE0000420"}
{"ref-id":"A12525","pubmed-id":12749773,"citation":"Breljak D, Boranic M, Horvat S: Oligopeptide fragments of the enkephalin molecule interfere with hematopoietic cell colony formation. Int J Immunopathol Pharmacol. 2000 Jan-Apr;13(1):13-19.","parent_key":"BE0000420"}
{"ref-id":"A12526","pubmed-id":14646257,"citation":"Chudapongse N, Kim SY, Kramer RE, Ho IK: Nonspecific effects of the selective kappa-opioid receptor agonist U-50,488H on dopamine uptake and release in PC12 cells. J Pharmacol Sci. 2003 Nov;93(3):372-5.","parent_key":"BE0000420"}
{"ref-id":"A12527","pubmed-id":14708857,"citation":"Osman AM, Gomma M, Saad AH: A possible role for an enkephalinergic system in the internal defense mechanism of Biomphalaria alexandrina exposed to Schistosoma mansoni. J Egypt Soc Parasitol. 2003 Dec;33(3):841-61.","parent_key":"BE0000420"}
{"ref-id":"A5451","pubmed-id":18354714,"citation":"Helm S, Trescot AM, Colson J, Sehgal N, Silverman S: Opioid antagonists, partial agonists, and agonists/antagonists: the role of office-based detoxification. Pain Physician. 2008 Mar-Apr;11(2):225-35.","parent_key":"BE0000420"}
{"ref-id":"A6436","pubmed-id":17367258,"citation":"van Dorp E, Yassen A, Dahan A: Naloxone treatment in opioid addiction: the risks and benefits. Expert Opin Drug Saf. 2007 Mar;6(2):125-32.","parent_key":"BE0000420"}
{"ref-id":"A16560","pubmed-id":173192,"citation":"Mayer M, Rosen F: Interaction of anabolic steroids with glucocorticoid receptor sites in rat muscle cytosol. Am J Physiol. 1975 Nov;229(5):1381-6.","parent_key":"BE0000794"}
{"ref-id":"A6452","pubmed-id":9712193,"citation":"Spetea M, Nevin ST, Hosztafi S, Ronai AZ, Toth G, Borsodi A: Affinity profiles of novel delta-receptor selective benzofuran derivatives of non-peptide opioids. Neurochem Res. 1998 Sep;23(9):1211-6.","parent_key":"BE0000770"}
{"ref-id":"A6453","pubmed-id":17006080,"citation":"Lemberg KK, Kontinen VK, Siiskonen AO, Viljakka KM, Yli-Kauhaluoma JT, Korpi ER, Kalso EA: Antinociception by spinal and systemic oxycodone: why does the route make a difference? In vitro and in vivo studies in rats. Anesthesiology. 2006 Oct;105(4):801-12.","parent_key":"BE0000770"}
{"ref-id":"A6454","pubmed-id":17595308,"citation":"Chamberlin KW, Cottle M, Neville R, Tan J: Oral oxymorphone for pain management. Ann Pharmacother. 2007 Jul;41(7):1144-52. Epub 2007 Jun 26.","parent_key":"BE0000770"}
{"ref-id":"A6455","pubmed-id":10854833,"citation":"Halimi G, Devaux C, Clot-Faybesse O, Sampol J, Legof L, Rochat H, Guieu R: Modulation of adenosine concentration by opioid receptor agonists in rat striatum. Eur J Pharmacol. 2000 Jun 16;398(2):217-24.","parent_key":"BE0000770"}
{"ref-id":"A6456","pubmed-id":16343768,"citation":"Gardell LR, King T, Ossipov MH, Rice KC, Lai J, Vanderah TW, Porreca F: Opioid receptor-mediated hyperalgesia and antinociceptive tolerance induced by sustained opiate delivery. Neurosci Lett. 2006 Mar 20;396(1):44-9. Epub 2005 Dec 15.","parent_key":"BE0000770"}
{"ref-id":"A6454","pubmed-id":17595308,"citation":"Chamberlin KW, Cottle M, Neville R, Tan J: Oral oxymorphone for pain management. Ann Pharmacother. 2007 Jul;41(7):1144-52. Epub 2007 Jun 26.","parent_key":"BE0000420"}
{"ref-id":"A15549","pubmed-id":14998329,"citation":"Ananthan S, Khare NK, Saini SK, Seitz LE, Bartlett JL, Davis P, Dersch CM, Porreca F, Rothman RB, Bilsky EJ: Identification of opioid ligands possessing mixed micro agonist/delta antagonist activity among pyridomorphinans derived from naloxone, oxymorphone, and hydromorphone [correction of hydropmorphone]. J Med Chem. 2004 Mar 11;47(6):1400-12.","parent_key":"BE0000420"}
{"ref-id":"A6494","pubmed-id":11702089,"citation":"Barrett AC, Cook CD, Terner JM, Craft RM, Picker MJ: Importance of sex and relative efficacy at the mu opioid receptor in the development of tolerance and cross-tolerance to the antinociceptive effects of opioids. Psychopharmacology (Berl). 2001 Nov;158(2):154-64.","parent_key":"BE0000770"}
{"ref-id":"A6495","pubmed-id":10958085,"citation":"Cook CD, Barrett AC, Roach EL, Bowman JR, Picker MJ: Sex-related differences in the antinociceptive effects of opioids: importance of rat genotype, nociceptive stimulus intensity, and efficacy at the mu opioid receptor. Psychopharmacology (Berl). 2000 Jul;150(4):430-42.","parent_key":"BE0000770"}
{"ref-id":"A6496","pubmed-id":12513698,"citation":"Gharagozlou P, Demirci H, David Clark J, Lameh J: Activity of opioid ligands in cells expressing cloned mu opioid receptors. BMC Pharmacol. 2003 Jan 4;3:1. Epub 2003 Jan 4.","parent_key":"BE0000770"}
{"ref-id":"A6497","pubmed-id":9972766,"citation":"Morgan D, Cook CD, Smith MA, Picker MJ: An examination of the interactions between the antinociceptive effects of morphine and various mu-opioids: the role of intrinsic efficacy and stimulus intensity. Anesth Analg. 1999 Feb;88(2):407-13.","parent_key":"BE0000770"}
{"ref-id":"A6498","pubmed-id":1361946,"citation":"Jacobs AM, Youngblood F: Opioid receptor affinity for agonist-antagonist analgesics. J Am Podiatr Med Assoc. 1992 Oct;82(10):520-4.","parent_key":"BE0000770"}
{"ref-id":"A15584","pubmed-id":20627999,"citation":"Cheng J, Shah YM, Ma X, Pang X, Tanaka T, Kodama T, Krausz KW, Gonzalez FJ: Therapeutic role of rifaximin in inflammatory bowel disease: clinical implication of human pregnane X receptor activation. J Pharmacol Exp Ther. 2010 Oct;335(1):32-41. doi: 10.1124/jpet.110.170225. Epub 2010 Jul 13.","parent_key":"BE0000956"}
{"ref-id":"A15585","pubmed-id":17442842,"citation":"Ma X, Shah YM, Guo GL, Wang T, Krausz KW, Idle JR, Gonzalez FJ: Rifaximin is a gut-specific human pregnane X receptor activator. J Pharmacol Exp Ther. 2007 Jul;322(1):391-8. Epub 2007 Apr 18.","parent_key":"BE0000956"}
{"ref-id":"A18290","pubmed-id":6246318,"citation":"Smith DJ, Pekoe GM, Martin LL, Coalgate B: The interaction of ketamine with the opiate receptor. Life Sci. 1980 Mar 10;26(10):789-95.","parent_key":"BE0000420"}
{"ref-id":"A18291","pubmed-id":8835358,"citation":"Hustveit O, Maurset A, Oye I: Interaction of the chiral forms of ketamine with opioid, phencyclidine, sigma and muscarinic receptors. Pharmacol Toxicol. 1995 Dec;77(6):355-9.","parent_key":"BE0000420"}
{"ref-id":"A18290","pubmed-id":6246318,"citation":"Smith DJ, Pekoe GM, Martin LL, Coalgate B: The interaction of ketamine with the opiate receptor. Life Sci. 1980 Mar 10;26(10):789-95.","parent_key":"BE0000770"}
{"ref-id":"A18291","pubmed-id":8835358,"citation":"Hustveit O, Maurset A, Oye I: Interaction of the chiral forms of ketamine with opioid, phencyclidine, sigma and muscarinic receptors. Pharmacol Toxicol. 1995 Dec;77(6):355-9.","parent_key":"BE0000770"}
{"ref-id":"A6528","pubmed-id":11040338,"citation":"Zhang X, Moilanen E, Kankaanranta H: Enhancement of human eosinophil apoptosis by fluticasone propionate, budesonide, and beclomethasone. Eur J Pharmacol. 2000 Oct 20;406(3):325-32.","parent_key":"BE0000794"}
{"ref-id":"A6529","pubmed-id":11258648,"citation":"Henriksson G, Norlander T, Forsgren J, Stierna P: Effects of topical budesonide treatment on glucocorticoid receptor mRNA down-regulation and cytokine patterns in nasal polyps. Am J Rhinol. 2001 Jan-Feb;15(1):1-8.","parent_key":"BE0000794"}
{"ref-id":"A6531","pubmed-id":12601049,"citation":"Kompella UB, Bandi N, Ayalasomayajula SP: Subconjunctival nano- and microparticles sustain retinal delivery of budesonide, a corticosteroid capable of inhibiting VEGF expression. Invest Ophthalmol Vis Sci. 2003 Mar;44(3):1192-201.","parent_key":"BE0000794"}
{"ref-id":"A6532","pubmed-id":12920235,"citation":"Kunz S, Sandoval R, Carlsson P, Carlstedt-Duke J, Bloom JW, Miesfeld RL: Identification of a novel glucocorticoid receptor mutation in budesonide-resistant human bronchial epithelial cells. Mol Endocrinol. 2003 Dec;17(12):2566-82. Epub 2003 Aug 14.","parent_key":"BE0000794"}
{"ref-id":"A6541","pubmed-id":9360954,"citation":"Yu Y, Zhang L, Yin X, Sun H, Uhl GR, Wang JB: Mu opioid receptor phosphorylation, desensitization, and ligand efficacy. J Biol Chem. 1997 Nov 14;272(46):28869-74.","parent_key":"BE0000770"}
{"ref-id":"A6542","pubmed-id":2471291,"citation":"Skoulis NP, James RC, Harbison RD, Roberts SM: Depression of hepatic glutathione by opioid analgesic drugs in mice. Toxicol Appl Pharmacol. 1989 Jun 1;99(1):139-47.","parent_key":"BE0000770"}
{"ref-id":"A6543","pubmed-id":10911931,"citation":"Kreek MJ: Methadone-related opioid agonist pharmacotherapy for heroin addiction. History, recent molecular and neurochemical research and future in mainstream medicine. Ann N Y Acad Sci. 2000;909:186-216.","parent_key":"BE0000770"}
{"ref-id":"A6544","pubmed-id":11561100,"citation":"Xiao Y, Smith RD, Caruso FS, Kellar KJ: Blockade of rat alpha3beta4 nicotinic receptor function by methadone, its metabolites, and structural analogs. J Pharmacol Exp Ther. 2001 Oct;299(1):366-71.","parent_key":"BE0000770"}
{"ref-id":"A6548","pubmed-id":16741658,"citation":"Gan Y, Wientjes MG, Au JL: Expression of basic fibroblast growth factor correlates with resistance to paclitaxel in human patient tumors. Pharm Res. 2006 Jun;23(6):1324-31. Epub 2006 Jun 8.","parent_key":"BE0000246"}
{"ref-id":"A6549","pubmed-id":16895478,"citation":"Thomadaki H, Talieri M, Scorilas A: Treatment of MCF-7 cells with taxol and etoposide induces distinct alterations in the expression of apoptosis-related genes BCL2, BCL2L12, BAX, CASPASE-9 and FAS. Biol Chem. 2006 Aug;387(8):1081-6.","parent_key":"BE0000246"}
{"ref-id":"A6550","pubmed-id":17062688,"citation":"Yoshino T, Shiina H, Urakami S, Kikuno N, Yoneda T, Shigeno K, Igawa M: Bcl-2 expression as a predictive marker of hormone-refractory prostate cancer treated with taxane-based chemotherapy. Clin Cancer Res. 2006 Oct 15;12(20 Pt 1):6116-24.","parent_key":"BE0000246"}
{"ref-id":"A6551","pubmed-id":17119350,"citation":"Matsuyoshi S, Shimada K, Nakamura M, Ishida E, Konishi N: Bcl-2 phosphorylation has pathological significance in human breast cancer. Pathobiology. 2006;73(4):205-12.","parent_key":"BE0000246"}
{"ref-id":"A6552","pubmed-id":17230521,"citation":"Zhang X, Wang Q, Ling MT, Wong YC, Leung SC, Wang X: Anti-apoptotic role of TWIST and its association with Akt pathway in mediating taxol resistance in nasopharyngeal carcinoma cells. Int J Cancer. 2007 May 1;120(9):1891-8.","parent_key":"BE0000246"}
{"ref-id":"A6561","pubmed-id":19040279,"citation":"Dandache S, Coburn CA, Oliveira M, Allison TJ, Holloway MK, Wu JJ, Stranix BR, Panchal C, Wainberg MA, Vacca JP: PL-100, a novel HIV-1 protease inhibitor displaying a high genetic barrier to resistance: an in vitro selection study. J Med Virol. 2008 Dec;80(12):2053-63. doi: 10.1002/jmv.21329.","parent_key":"BE0004854"}
{"ref-id":"A6562","pubmed-id":20660676,"citation":"Rhee SY, Taylor J, Fessel WJ, Kaufman D, Towner W, Troia P, Ruane P, Hellinger J, Shirvani V, Zolopa A, Shafer RW: HIV-1 protease mutations and protease inhibitor cross-resistance. Antimicrob Agents Chemother. 2010 Oct;54(10):4253-61. doi: 10.1128/AAC.00574-10.  Epub 2010 Jul 26.","parent_key":"BE0004854"}
{"ref-id":"A6563","pubmed-id":19537723,"citation":"Alcaro S, Artese A, Ceccherini-Silberstein F, Ortuso F, Perno CF, Sing T, Svicher V: Molecular dynamics and free energy studies on the wild-type and mutated HIV-1 protease complexed with four approved drugs: mechanism of binding and drug resistance. J Chem Inf Model. 2009 Jul;49(7):1751-61. doi: 10.1021/ci900012k.","parent_key":"BE0004854"}
{"ref-id":"A6564","pubmed-id":11322246,"citation":"Vella S, Lazzarin A, Carosi G, Sinicco A, Armignacco O, Angarano G, Andreoni M, Tambussi G, Chiodera A, Floridia M, Scaccabarozzi S, Facey K, Duncan I, Boudes P, Bragman K: A randomized controlled trial of a protease inhibitor (saquinavir) in combination with zidovudine in previously untreated patients with advanced HIV infection. Antivir Ther. 1996 Aug;1(3):129-40.","parent_key":"BE0004854"}
{"ref-id":"A6567","pubmed-id":16835395,"citation":"Warne JP, John CD, Christian HC, Morris JF, Flower RJ, Sugden D, Solito E, Gillies GE, Buckingham JC: Gene deletion reveals roles for annexin A1 in the regulation of lipolysis and IL-6 release in epididymal adipose tissue. Am J Physiol Endocrinol Metab. 2006 Dec;291(6):E1264-73. Epub 2006 Jul 11.","parent_key":"BE0000794"}
{"ref-id":"A6568","pubmed-id":16956592,"citation":"Funato H, Kobayashi A, Watanabe Y: Differential effects of antidepressants on dexamethasone-induced nuclear translocation and expression of glucocorticoid receptor. Brain Res. 2006 Oct 30;1117(1):125-34. Epub 2006 Sep 7.","parent_key":"BE0000794"}
{"ref-id":"A6569","pubmed-id":16963802,"citation":"Vaitkuviene A, Ulinskaite A, Meskys R, Duburs G, Klusa V, Liutkevicius E: Study of the interaction of 1,4-dihydropyridine derivatives with glucocorticoid hormone receptors from the rat liver. Pharmacol Rep. 2006 Jul-Aug;58(4):551-8.","parent_key":"BE0000794"}
{"ref-id":"A6570","pubmed-id":16971495,"citation":"Wang D, Zhang H, Lang F, Yun CC: Acute activation of NHE3 by dexamethasone correlates with activation of SGK1 and requires a functional glucocorticoid receptor. Am J Physiol Cell Physiol. 2007 Jan;292(1):C396-404. Epub 2006 Sep 13.","parent_key":"BE0000794"}
{"ref-id":"A12562","pubmed-id":16857744,"citation":"Gummow BM, Scheys JO, Cancelli VR, Hammer GD: Reciprocal regulation of a glucocorticoid receptor-steroidogenic factor-1 transcription complex on the Dax-1 promoter by glucocorticoids and adrenocorticotropic hormone in the adrenal cortex. Mol Endocrinol. 2006 Nov;20(11):2711-23. Epub 2006 Jul 20.","parent_key":"BE0000074"}
{"ref-id":"A12563","pubmed-id":17526944,"citation":"Yu CC, Li PH: In vivo inhibition of steroidogenic acute regulatory protein expression by dexamethasone parallels induction of the negative transcription factor DAX-1. Endocrine. 2006 Dec;30(3):313-23.","parent_key":"BE0000074"}
{"ref-id":"A11173","pubmed-id":16883066,"citation":"Morand EF, Hall P, Hutchinson P, Yang YH: Regulation of annexin I in rheumatoid synovial cells by glucocorticoids and interleukin-1. Mediators Inflamm. 2006;2006(2):73835.","parent_key":"BE0000422"}
{"ref-id":"A11174","pubmed-id":17076770,"citation":"John CD, Theogaraj E, Christian HC, Morris JF, Smith SF, Buckingham JC: Time-specific effects of perinatal glucocorticoid treatment on anterior pituitary morphology, annexin 1 expression and adrenocorticotrophic hormone secretion in the adult female rat. J Neuroendocrinol. 2006 Dec;18(12):949-59.","parent_key":"BE0000422"}
{"ref-id":"A11175","pubmed-id":17158208,"citation":"Davies E, Omer S, Buckingham JC, Morris JF, Christian HC: Expression and externalization of annexin 1 in the adrenal gland: structure and function of the adrenal gland in annexin 1-null mutant mice. Endocrinology. 2007 Mar;148(3):1030-8. Epub 2006 Dec 7.","parent_key":"BE0000422"}
{"ref-id":"A11176","pubmed-id":17644190,"citation":"Wang C, Wang J, Guo HF, Liu RY: Involvement of annexin I in the dexamethasone-mediated upregulation of A549 cells phagocytosis of apoptotic eosinophils. Immunol Lett. 2007 Aug 15;111(2):103-10. Epub 2007 Jul 2.","parent_key":"BE0000422"}
{"ref-id":"A12559","pubmed-id":17379310,"citation":"Soderberg M, Raffalli-Mathieu F, Lang MA: Regulation of the murine inducible nitric oxide synthase gene by dexamethasone involves a heterogeneous nuclear ribonucleoprotein I (hnRNPI) dependent pathway. Mol Immunol. 2007 May;44(12):3204-10. Epub 2007 Mar 26.","parent_key":"BE0000005"}
{"ref-id":"A12560","pubmed-id":17494951,"citation":"Huang H, Lavoie-Lamoureux A, Moran K, Lavoie JP: IL-4 stimulates the expression of CXCL-8, E-selectin, VEGF, and inducible nitric oxide synthase mRNA by equine pulmonary artery endothelial cells. Am J Physiol Lung Cell Mol Physiol. 2007 May;292(5):L1147-54.","parent_key":"BE0000005"}
{"ref-id":"A12561","pubmed-id":17503181,"citation":"Nandi J, Saud B, Zinkievich JM, Palma DT, Levine RA: 5-aminosalicylic acid improves indomethacin-induced enteropathy by inhibiting iNOS transcription in rats. Dig Dis Sci. 2008 Jan;53(1):123-32. Epub 2007 May 15.","parent_key":"BE0000005"}
{"ref-id":"A9","pubmed-id":11752352,"citation":"Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5.","parent_key":"BE0000005"}
{"ref-id":"A187310","pubmed-id":26346901,"citation":"de Bartolomeis A, Tomasetti C, Iasevoli F: Update on the Mechanism of Action of Aripiprazole: Translational Insights into Antipsychotic Strategies Beyond Dopamine Receptor Antagonism. CNS Drugs. 2015 Sep;29(9):773-99. doi: 10.1007/s40263-015-0278-3.","parent_key":"BE0000770"}
{"ref-id":"A187310","pubmed-id":26346901,"citation":"de Bartolomeis A, Tomasetti C, Iasevoli F: Update on the Mechanism of Action of Aripiprazole: Translational Insights into Antipsychotic Strategies Beyond Dopamine Receptor Antagonism. CNS Drugs. 2015 Sep;29(9):773-99. doi: 10.1007/s40263-015-0278-3.","parent_key":"BE0000420"}
{"ref-id":"A12564","pubmed-id":12172398,"citation":"Bosse Y, Pascot A, Dumont M, Brochu M, Prud'homme D, Bergeron J, Despres JP, Vohl MC: Influences of the PPAR alpha-L162V polymorphism on plasma HDL(2)-cholesterol response of abdominally obese men treated with gemfibrozil. Genet Med. 2002 Jul-Aug;4(4):311-5.","parent_key":"BE0000071"}
{"ref-id":"A12565","pubmed-id":12244038,"citation":"Pahan K, Jana M, Liu X, Taylor BS, Wood C, Fischer SM: Gemfibrozil, a lipid-lowering drug, inhibits the induction of nitric-oxide synthase in human astrocytes. J Biol Chem. 2002 Nov 29;277(48):45984-91. Epub 2002 Sep 18.","parent_key":"BE0000071"}
{"ref-id":"A12566","pubmed-id":12834305,"citation":"Shoji Y, Sanekata A, Sato M, Imaizumi K: Preparation of antiserum against rat delta6-desaturase and its use to evaluate the desaturase protein levels in rats treated with gemfibrozil, a ligand for peroxisome proliferator-activated receptor alpha. Biosci Biotechnol Biochem. 2003 May;67(5):1177-8.","parent_key":"BE0000071"}
{"ref-id":"A12567","pubmed-id":12935323,"citation":"Rizvi F, Iftikhar M, George JP: Beneficial effects of fish liver preparations of sea bass (Lates calcarifer) versus gemfibrozil in high fat diet-induced lipid-intolerant rats. J Med Food. 2003 Summer;6(2):123-8.","parent_key":"BE0000071"}
{"ref-id":"A6589","pubmed-id":15161985,"citation":"Gligorov J, Lotz JP: Preclinical pharmacology of the taxanes: implications of the differences. Oncologist. 2004;9 Suppl 2:3-8.","parent_key":"BE0000246"}
{"ref-id":"A6590","pubmed-id":15277270,"citation":"Marshall J, Chen H, Yang D, Figueira M, Bouker KB, Ling Y, Lippman M, Frankel SR, Hayes DF: A phase I trial of a Bcl-2 antisense (G3139) and weekly docetaxel in patients with advanced breast cancer and other solid tumors. Ann Oncol. 2004 Aug;15(8):1274-83.","parent_key":"BE0000246"}
{"ref-id":"A6591","pubmed-id":15643508,"citation":"Inoue Y, Gika M, Abiko T, Oyama T, Saitoh Y, Yamazaki H, Nakamura M, Abe Y, Kawamura M, Kobayashi K: Bcl-2 overexpression enhances in vitro sensitivity against docetaxel in non-small cell lung cancer. Oncol Rep. 2005 Feb;13(2):259-64.","parent_key":"BE0000246"}
{"ref-id":"A6592","pubmed-id":15685445,"citation":"Petrylak DP: Chemotherapy for androgen-independent prostate cancer. World J Urol. 2005 Feb;23(1):10-3. Epub 2005 Feb 1.","parent_key":"BE0000246"}
{"ref-id":"A6593","pubmed-id":15714982,"citation":"Miyoshi Y, Uemura H, Kubota Y: [Treatment of androgen-independent hormone refractory prostate cancer using docetaxel]. Nihon Rinsho. 2005 Feb;63(2):298-302.","parent_key":"BE0000246"}
{"ref-id":"A6594","pubmed-id":17674353,"citation":"Magi-Galluzzi C, Zhou M, Reuther AM, Dreicer R, Klein EA: Neoadjuvant docetaxel treatment for locally advanced prostate cancer: a clinicopathologic study. Cancer. 2007 Sep 15;110(6):1248-54.","parent_key":"BE0000246"}
{"ref-id":"A18211","pubmed-id":15492266,"citation":"Ikezoe T, Hisatake Y, Takeuchi T, Ohtsuki Y, Yang Y, Said JW, Taguchi H, Koeffler HP: HIV-1 protease inhibitor, ritonavir: a potent inhibitor of CYP3A4, enhanced the anticancer effects of docetaxel in androgen-independent prostate cancer cells in vitro and in vivo. Cancer Res. 2004 Oct 15;64(20):7426-31.","parent_key":"BE0000956"}
{"ref-id":"A16777","pubmed-id":20427668,"citation":"Russell GM, Henley DE, Leendertz J, Douthwaite JA, Wood SA, Stevens A, Woltersdorf WW, Peeters BW, Ruigt GS, White A, Veldhuis JD, Lightman SL: Rapid glucocorticoid receptor-mediated inhibition of hypothalamic-pituitary-adrenal ultradian activity in healthy males. J Neurosci. 2010 Apr 28;30(17):6106-15. doi: 10.1523/JNEUROSCI.5332-09.2010.","parent_key":"BE0000794"}
{"ref-id":"A16778","pubmed-id":20371666,"citation":"Otte C, Wust S, Zhao S, Pawlikowska L, Kwok PY, Whooley MA: Glucocorticoid receptor gene, low-grade inflammation, and heart failure: the Heart and Soul study. J Clin Endocrinol Metab. 2010 Jun;95(6):2885-91. doi: 10.1210/jc.2009-2251. Epub  2010 Apr 6.","parent_key":"BE0000794"}
{"ref-id":"A11428","pubmed-id":17900913,"citation":"Ghosh AK, Dawson ZL, Mitsuya H: Darunavir, a conceptually new HIV-1 protease inhibitor for the treatment of drug-resistant HIV. Bioorg Med Chem. 2007 Dec 15;15(24):7576-80. Epub 2007 Sep 14.","parent_key":"BE0004854"}
{"ref-id":"A11429","pubmed-id":17696515,"citation":"Wang YF, Tie Y, Boross PI, Tozser J, Ghosh AK, Harrison RW, Weber IT: Potent new antiviral compound shows similar inhibition and structural interactions with drug resistant mutants and wild type HIV-1 protease. J Med Chem. 2007 Sep 6;50(18):4509-15. Epub 2007 Aug 16.","parent_key":"BE0004854"}
{"ref-id":"A11430","pubmed-id":19323590,"citation":"McKeage K, Perry CM, Keam SJ: Darunavir: a review of its use in the management of HIV infection in adults. Drugs. 2009;69(4):477-503. doi: 10.2165/00003495-200969040-00007.","parent_key":"BE0004854"}
{"ref-id":"A2278","pubmed-id":19209258,"citation":"Tremblay CL: Combating HIV resistance - focus on darunavir. Ther Clin Risk Manag. 2008 Aug;4(4):759-66.","parent_key":"BE0004854"}
{"ref-id":"A2280","pubmed-id":16480273,"citation":"Kovalevsky AY, Tie Y, Liu F, Boross PI, Wang YF, Leshchenko S, Ghosh AK, Harrison RW, Weber IT: Effectiveness of nonpeptide clinical inhibitor TMC-114 on HIV-1 protease with highly drug resistant mutations D30N, I50V, and L90M. J Med Chem. 2006 Feb 23;49(4):1379-87.","parent_key":"BE0004854"}
{"ref-id":"A2281","pubmed-id":15917527,"citation":"De Meyer S, Azijn H, Surleraux D, Jochmans D, Tahri A, Pauwels R, Wigerinck P, de Bethune MP: TMC114, a novel human immunodeficiency virus type 1 protease inhibitor active against protease inhibitor-resistant viruses, including a broad range of clinical isolates. Antimicrob Agents Chemother. 2005 Jun;49(6):2314-21.","parent_key":"BE0004854"}
{"ref-id":"A2299","pubmed-id":15671306,"citation":"Gaudreault J, Fei D, Rusit J, Suboc P, Shiu V: Preclinical pharmacokinetics of Ranibizumab (rhuFabV2) after a single intravitreal administration. Invest Ophthalmol Vis Sci. 2005 Feb;46(2):726-33.","parent_key":"BE0000163"}
{"ref-id":"A11470","pubmed-id":15973626,"citation":"Michels S, Rosenfeld PJ: [Treatment of neovascular age-related macular degeneration with Ranibizumab/Lucentis]. Klin Monbl Augenheilkd. 2005 Jun;222(6):480-4.","parent_key":"BE0000163"}
{"ref-id":"A11471","pubmed-id":16935211,"citation":"Rosenfeld PJ, Rich RM, Lalwani GA: Ranibizumab: Phase III clinical trial results. Ophthalmol Clin North Am. 2006 Sep;19(3):361-72.","parent_key":"BE0000163"}
{"ref-id":"A11472","pubmed-id":17046701,"citation":"Nguyen QD, Tatlipinar S, Shah SM, Haller JA, Quinlan E, Sung J, Zimmer-Galler I, Do DV, Campochiaro PA: Vascular endothelial growth factor is a critical stimulus for diabetic macular edema. Am J Ophthalmol. 2006 Dec;142(6):961-9. Epub 2006 Aug 2.","parent_key":"BE0000163"}
{"ref-id":"A11473","pubmed-id":17049020,"citation":"Pieramici DJ, Avery RL: Ranibizumab: treatment in patients with neovascular age-related macular degeneration. Expert Opin Biol Ther. 2006 Nov;6(11):1237-45.","parent_key":"BE0000163"}
{"ref-id":"A2298","pubmed-id":18046235,"citation":"Gaudreault J, Fei D, Beyer JC, Ryan A, Rangell L, Shiu V, Damico LA: Pharmacokinetics and retinal distribution of ranibizumab, a humanized antibody fragment directed against VEGF-A, following intravitreal administration in rabbits. Retina. 2007 Nov-Dec;27(9):1260-6.","parent_key":"BE0000163"}
{"ref-id":"A11474","pubmed-id":17031284,"citation":"Ferrara N, Damico L, Shams N, Lowman H, Kim R: Development of ranibizumab, an anti-vascular endothelial growth factor antigen binding fragment, as therapy for neovascular age-related macular degeneration. Retina. 2006 Oct;26(8):859-70.","parent_key":"BE0000163"}
{"ref-id":"A2300","pubmed-id":18054637,"citation":"Bakri SJ, Snyder MR, Reid JM, Pulido JS, Ezzat MK, Singh RJ: Pharmacokinetics of intravitreal ranibizumab (Lucentis). Ophthalmology. 2007 Dec;114(12):2179-82.","parent_key":"BE0000163"}
{"ref-id":"A2301","pubmed-id":18035187,"citation":"Kourlas H, Abrams P: Ranibizumab for the treatment of neovascular age-related macular degeneration: a review. Clin Ther. 2007 Sep;29(9):1850-61.","parent_key":"BE0000163"}
{"ref-id":"A11475","pubmed-id":19668384,"citation":"Spitzer MS, Ziemssen F, Bartz-Schmidt KU, Gelisken F, Szurman P: Treatment of age-related macular degeneration: focus on ranibizumab. Clin Ophthalmol. 2008 Mar;2(1):1-14.","parent_key":"BE0000163"}
{"ref-id":"A11397","pubmed-id":14552704,"citation":"Capone ML, Tacconelli S, Sciulli MG, Patrignani P: Clinical pharmacology of selective COX-2 inhibitors. Int J Immunopathol Pharmacol. 2003 May-Aug;16(2 Suppl):49-58.","parent_key":"BE0000262"}
{"ref-id":"A11398","pubmed-id":14965322,"citation":"Tacconelli S, Capone ML, Patrignani P: Clinical pharmacology of novel selective COX-2 inhibitors. Curr Pharm Des. 2004;10(6):589-601.","parent_key":"BE0000262"}
{"ref-id":"A11399","pubmed-id":15017615,"citation":"Atherton C, Jones J, McKaig B, Bebb J, Cunliffe R, Burdsall J, Brough J, Stevenson D, Bonner J, Rordorf C, Scott G, Branson J, Hawkey CJ: Pharmacology and gastrointestinal safety of lumiracoxib, a novel cyclooxygenase-2 selective inhibitor: An integrated study. Clin Gastroenterol Hepatol. 2004 Feb;2(2):113-20.","parent_key":"BE0000262"}
{"ref-id":"A11400","pubmed-id":15177307,"citation":"Kalbag J, Yeh CM, Milosavljev S, Lasseter K, Oberstein S, Rordorf C: No influence of moderate hepatic impairment on the pharmacokinetics of lumiracoxib, an oral COX-2 selective inhibitor. Pharmacol Res. 2004 Aug;50(2):181-6.","parent_key":"BE0000262"}
{"ref-id":"A11401","pubmed-id":15655513,"citation":"Esser R, Berry C, Du Z, Dawson J, Fox A, Fujimoto RA, Haston W, Kimble EF, Koehler J, Peppard J, Quadros E, Quintavalla J, Toscano K, Urban L, van Duzer J, Zhang X, Zhou S, Marshall PJ: Preclinical pharmacology of lumiracoxib: a novel selective inhibitor of cyclooxygenase-2. Br J Pharmacol. 2005 Feb;144(4):538-50.","parent_key":"BE0000262"}
{"ref-id":"A11397","pubmed-id":14552704,"citation":"Capone ML, Tacconelli S, Sciulli MG, Patrignani P: Clinical pharmacology of selective COX-2 inhibitors. Int J Immunopathol Pharmacol. 2003 May-Aug;16(2 Suppl):49-58.","parent_key":"BE0000017"}
{"ref-id":"A11401","pubmed-id":15655513,"citation":"Esser R, Berry C, Du Z, Dawson J, Fox A, Fujimoto RA, Haston W, Kimble EF, Koehler J, Peppard J, Quadros E, Quintavalla J, Toscano K, Urban L, van Duzer J, Zhang X, Zhou S, Marshall PJ: Preclinical pharmacology of lumiracoxib: a novel selective inhibitor of cyclooxygenase-2. Br J Pharmacol. 2005 Feb;144(4):538-50.","parent_key":"BE0000017"}
{"ref-id":"A12606","pubmed-id":16172182,"citation":"Jermany J, Branson J, Schmouder R, Guillaume M, Rordorf C: Lumiracoxib does not affect the ex vivo antiplatelet aggregation activity of low-dose aspirin in healthy subjects. J Clin Pharmacol. 2005 Oct;45(10):1172-8.","parent_key":"BE0000017"}
{"ref-id":"A12607","pubmed-id":16403783,"citation":"Warner TD, Vojnovic I, Bishop-Bailey D, Mitchell JA: Influence of plasma protein on the potencies of inhibitors of cyclooxygenase-1 and -2. FASEB J. 2006 Mar;20(3):542-4. Epub 2006 Jan 10.","parent_key":"BE0000017"}
{"ref-id":"A12608","pubmed-id":17434872,"citation":"Blobaum AL, Marnett LJ: Molecular determinants for the selective inhibition of cyclooxygenase-2 by lumiracoxib. J Biol Chem. 2007 Jun 1;282(22):16379-90. Epub 2007 Apr 12.","parent_key":"BE0000017"}
{"ref-id":"A12614","pubmed-id":12244074,"citation":"Delcommenne M, Kannagi R, Johnson P: TNF-alpha increases the carbohydrate sulfation of CD44: induction of 6-sulfo N-acetyl lactosamine on N- and O-linked glycans. Glycobiology. 2002 Oct;12(10):613-22.","parent_key":"BE0000704"}
{"ref-id":"A12615","pubmed-id":15930455,"citation":"Bitler CM, Viale TM, Damaj B, Crea R: Hydrolyzed olive vegetation water in mice has anti-inflammatory activity. J Nutr. 2005 Jun;135(6):1475-9.","parent_key":"BE0000704"}
{"ref-id":"A12616","pubmed-id":16431966,"citation":"Chen JT, Liang JB, Chou CL, Chien MW, Shyu RC, Chou PI, Lu DW: Glucosamine sulfate inhibits TNF-alpha and IFN-gamma-induced production of ICAM-1 in human retinal pigment epithelial cells in vitro. Invest Ophthalmol Vis Sci. 2006 Feb;47(2):664-72.","parent_key":"BE0000704"}
{"ref-id":"A12617","pubmed-id":16445576,"citation":"Yi HA, Yi SD, Jang BC, Song DK, Shin DH, Mun KC, Kim SP, Suh SI, Bae JH: Inhibitory effects of glucosamine on lipopolysaccharide-induced activation in microglial cells. Clin Exp Pharmacol Physiol. 2005 Dec;32(12):1097-103.","parent_key":"BE0000704"}
{"ref-id":"A12618","pubmed-id":16469053,"citation":"Lapaque N, Takeuchi O, Corrales F, Akira S, Moriyon I, Howard JC, Gorvel JP: Differential inductions of TNF-alpha and IGTP, IIGP by structurally diverse classic and non-classic lipopolysaccharides. Cell Microbiol. 2006 Mar;8(3):401-13.","parent_key":"BE0000704"}
{"ref-id":"A2371","pubmed-id":18042502,"citation":"Hoffman RM, Umeh OC, Garris C, Givens N, Currier JS: Evaluation of sex differences of fosamprenavir (with and without ritonavir) in HIV-infected men and women. HIV Clin Trials. 2007 Nov-Dec;8(6):371-80.","parent_key":"BE0004854"}
{"ref-id":"A2373","pubmed-id":14982766,"citation":"Furfine ES, Baker CT, Hale MR, Reynolds DJ, Salisbury JA, Searle AD, Studenberg SD, Todd D, Tung RD, Spaltenstein A: Preclinical pharmacology and pharmacokinetics of GW433908, a water-soluble prodrug of the human immunodeficiency virus protease inhibitor amprenavir. Antimicrob Agents Chemother. 2004 Mar;48(3):791-8.","parent_key":"BE0004854"}
{"ref-id":"A2374","pubmed-id":15116286,"citation":"Sension M: Initial therapy for human immunodeficiency virus: broadening the options. HIV Clin Trials. 2004 Mar-Apr;5(2):99-111.","parent_key":"BE0004854"}
{"ref-id":"A2375","pubmed-id":14693528,"citation":"Wood R, Arasteh K, Stellbrink HJ, Teofilo E, Raffi F, Pollard RB, Eron J, Yeo J, Millard J, Wire MB, Naderer OJ: Six-week randomized controlled trial to compare the tolerabilities, pharmacokinetics, and antiviral activities of GW433908 and amprenavir in human immunodeficiency virus type 1-infected patients. Antimicrob Agents Chemother. 2004 Jan;48(1):116-23.","parent_key":"BE0004854"}
{"ref-id":"A2377","pubmed-id":16485915,"citation":"Wire MB, Shelton MJ, Studenberg S: Fosamprenavir : clinical pharmacokinetics and drug interactions of the amprenavir prodrug. Clin Pharmacokinet. 2006;45(2):137-68. doi: 10.2165/00003088-200645020-00002.","parent_key":"BE0004854"}
{"ref-id":"A12653","pubmed-id":12043833,"citation":"Youdim MB, Weinstock M: Molecular basis of neuroprotective activities of rasagiline and the anti-Alzheimer drug TV3326 [(N-propargyl-(3R)aminoindan-5-YL)-ethyl methyl carbamate]. Cell Mol Neurobiol. 2001 Dec;21(6):555-73.","parent_key":"BE0000246"}
{"ref-id":"A12654","pubmed-id":12057839,"citation":"Akao Y, Maruyama W, Yi H, Shamoto-Nagai M, Youdim MB, Naoi M: An anti-Parkinson's disease drug, N-propargyl-1(R)-aminoindan (rasagiline), enhances expression of anti-apoptotic bcl-2 in human dopaminergic SH-SY5Y cells. Neurosci Lett. 2002 Jun 28;326(2):105-8.","parent_key":"BE0000246"}
{"ref-id":"A12655","pubmed-id":12200198,"citation":"Maruyama W, Akao Y, Carrillo MC, Kitani K, Youdium MB, Naoi M: Neuroprotection by propargylamines in Parkinson's disease: suppression of apoptosis and induction of prosurvival genes. Neurotoxicol Teratol. 2002 Sep-Oct;24(5):675-82.","parent_key":"BE0000246"}
{"ref-id":"A12656","pubmed-id":14555244,"citation":"Youdim MB, Amit T, Falach-Yogev M, Bar Am O, Maruyama W, Naoi M: The essentiality of Bcl-2, PKC and proteasome-ubiquitin complex activations in the neuroprotective-antiapoptotic action of the anti-Parkinson drug, rasagiline. Biochem Pharmacol. 2003 Oct 15;66(8):1635-41.","parent_key":"BE0000246"}
{"ref-id":"A12657","pubmed-id":16148027,"citation":"Bar-Am O, Weinreb O, Amit T, Youdim MB: Regulation of Bcl-2 family proteins, neurotrophic factors, and APP processing in the neurorescue activity of propargylamine. FASEB J. 2005 Nov;19(13):1899-901. Epub 2005 Sep 7.","parent_key":"BE0000246"}
{"ref-id":"A16973","pubmed-id":18056275,"citation":"Barthel D, Schlitzer M, Pradel G: Telithromycin and quinupristin-dalfopristin induce delayed death in Plasmodium falciparum. Antimicrob Agents Chemother. 2008 Feb;52(2):774-7. Epub 2007 Dec 3.","parent_key":"BE0004800"}
{"ref-id":"A16974","pubmed-id":15991995,"citation":"Beyer D, Pepper K: The streptogramin antibiotics: update on their mechanism of action. Expert Opin Investig Drugs. 1998 Apr;7(4):591-9.","parent_key":"BE0004800"}
{"ref-id":"A16975","pubmed-id":15059283,"citation":"Harms JM, Schlunzen F, Fucini P, Bartels H, Yonath A: Alterations at the peptidyl transferase centre of the ribosome induced by the synergistic action of the streptogramins dalfopristin and quinupristin. BMC Biol. 2004 Apr 1;2:4.","parent_key":"BE0004800"}
{"ref-id":"A16976","pubmed-id":17432033,"citation":"Dang V, Nanda N, Cooper TW, Greenfield RA, Bronze MS: Part VII. Macrolides, azalides, ketolides, lincosamides, and streptogramins. J Okla State Med Assoc. 2007 Mar;100(3):75-81.","parent_key":"BE0004800"}
{"ref-id":"A16977","pubmed-id":7062741,"citation":"Schlechte JA, Ginsberg BH, Sherman BM: Regulation of the glucocorticoid receptor in human lymphocytes. J Steroid Biochem. 1982 Jan;16(1):69-74.","parent_key":"BE0000794"}
{"ref-id":"A16978","pubmed-id":7054210,"citation":"Schlechte JA, Sherman BM: Decreased glucocorticoid receptor binding in adrenal insufficiency. J Clin Endocrinol Metab. 1982 Jan;54(1):145-9.","parent_key":"BE0000794"}
{"ref-id":"A11513","pubmed-id":10909982,"citation":"Pedraza N, Solanes G, Carmona MC, Iglesias R, Vinas O, Mampel T, Vazquez M, Giralt M, Villarroya F: Impaired expression of the uncoupling protein-3 gene in skeletal muscle during lactation: fibrates and troglitazone reverse lactation-induced downregulation of the uncoupling protein-3 gene. Diabetes. 2000 Jul;49(7):1224-30.","parent_key":"BE0000071"}
{"ref-id":"A11514","pubmed-id":10933891,"citation":"Cabrero A, Alegret M, Sanchez R, Adzet T, Laguna JC, Vazquez M: Peroxisome proliferator-activated receptor alpha (PPARalpha) activators, bezafibrate and Wy-14,643, increase uncoupling protein-3 mRNA levels without modifying the mitochondrial membrane potential in primary culture of rat preadipocytes. Arch Biochem Biophys. 2000 Aug 15;380(2):353-9.","parent_key":"BE0000071"}
{"ref-id":"A11515","pubmed-id":11172467,"citation":"Inoue I, Goto S, Matsunaga T, Nakajima T, Awata T, Hokari S, Komoda T, Katayama S: The ligands/activators for peroxisome proliferator-activated receptor alpha (PPARalpha) and PPARgamma increase Cu2+,Zn2+-superoxide dismutase and decrease p22phox message expressions in primary endothelial cells. Metabolism. 2001 Jan;50(1):3-11.","parent_key":"BE0000071"}
{"ref-id":"A11516","pubmed-id":11422732,"citation":"Guan Y, Breyer MD: Peroxisome proliferator-activated receptors (PPARs): novel therapeutic targets in renal disease. Kidney Int. 2001 Jul;60(1):14-30.","parent_key":"BE0000071"}
{"ref-id":"A11517","pubmed-id":11519881,"citation":"Bonilla S, Redonnet A, Noel-Suberville C, Groubet R, Pallet V, Higueret P: Effect of a pharmacological activation of PPAR on the expression of RAR and TR in rat liver. J Physiol Biochem. 2001 Mar;57(1):1-8.","parent_key":"BE0000071"}
{"ref-id":"A11518","pubmed-id":18629356,"citation":"Goldenberg I, Benderly M, Goldbourt U: Update on the use of fibrates: focus on bezafibrate. Vasc Health Risk Manag. 2008;4(1):131-41.","parent_key":"BE0000071"}
{"ref-id":"A11519","pubmed-id":16511610,"citation":"Fruchart JC, Duriez P: Mode of action of fibrates in the regulation of triglyceride and HDL-cholesterol metabolism. Drugs Today (Barc). 2006 Jan;42(1):39-64.","parent_key":"BE0000071"}
{"ref-id":"A14656","pubmed-id":16168052,"citation":"Tenenbaum A, Motro M, Fisman EZ: Dual and pan-peroxisome proliferator-activated receptors (PPAR) co-agonism: the bezafibrate lessons. Cardiovasc Diabetol. 2005 Sep 16;4:14.","parent_key":"BE0000215"}
{"ref-id":"A11506","pubmed-id":16166440,"citation":"Yee KW, Hagey A, Verstovsek S, Cortes J, Garcia-Manero G, O'Brien SM, Faderl S, Thomas D, Wierda W, Kornblau S, Ferrajoli A, Albitar M, McKeegan E, Grimm DR, Mueller T, Holley-Shanks RR, Sahelijo L, Gordon GB, Kantarjian HM, Giles FJ: Phase 1 study of ABT-751, a novel microtubule inhibitor, in patients with refractory hematologic malignancies. Clin Cancer Res. 2005 Sep 15;11(18):6615-24.","parent_key":"BE0000143"}
{"ref-id":"A11502","pubmed-id":19527023,"citation":"Acharya BR, Choudhury D, Das A, Chakrabarti G: Vitamin K3 disrupts the microtubule networks by binding to tubulin: a novel mechanism of its antiproliferative activity. Biochemistry. 2009 Jul 28;48(29):6963-74. doi: 10.1021/bi900152k.","parent_key":"BE0000143"}
{"ref-id":"A11503","pubmed-id":20814887,"citation":"Li CM, Lu Y, Ahn S, Narayanan R, Miller DD, Dalton JT: Competitive mass spectrometry binding assay for characterization of three binding sites of tubulin. J Mass Spectrom. 2010 Oct;45(10):1160-6. doi: 10.1002/jms.1804.","parent_key":"BE0000143"}
{"ref-id":"A11505","pubmed-id":15720245,"citation":"Cerquaglia C, Diaco M, Nucera G, La Regina M, Montalto M, Manna R: Pharmacological and clinical basis of treatment of Familial Mediterranean Fever (FMF) with colchicine or analogues: an update. Curr Drug Targets Inflamm Allergy. 2005 Feb;4(1):117-24.","parent_key":"BE0000143"}
{"ref-id":"A183605","pubmed-id":25151572,"citation":"Dalbeth N, Lauterio TJ, Wolfe HR: Mechanism of action of colchicine in the treatment of gout. Clin Ther. 2014 Oct 1;36(10):1465-79. doi: 10.1016/j.clinthera.2014.07.017. Epub 2014 Aug 21.","parent_key":"BE0000143"}
{"ref-id":"A183941","pubmed-id":22814904,"citation":"Lu Y, Chen J, Xiao M, Li W, Miller DD: An overview of tubulin inhibitors that interact with the colchicine binding site. Pharm Res. 2012 Nov;29(11):2943-71. doi: 10.1007/s11095-012-0828-z. Epub 2012 Jul 20.","parent_key":"BE0000143"}
{"ref-id":"A11504","pubmed-id":20586571,"citation":"Finkelstein Y, Aks SE, Hutson JR, Juurlink DN, Nguyen P, Dubnov-Raz G, Pollak U, Koren G, Bentur Y: Colchicine poisoning: the dark side of an ancient drug. Clin Toxicol (Phila). 2010 Jun;48(5):407-14. doi: 10.3109/15563650.2010.495348.","parent_key":"BE0000143"}
{"ref-id":"A2439","pubmed-id":11024226,"citation":"Krattenmacher R: Drospirenone: pharmacology and pharmacokinetics of a unique progestogen. Contraception. 2000 Jul;62(1):29-38.","parent_key":"BE0000794"}
{"ref-id":"A16545","pubmed-id":7625729,"citation":"Muhn P, Fuhrmann U, Fritzemeier KH, Krattenmacher R, Schillinger E: Drospirenone: a novel progestogen with antimineralocorticoid and antiandrogenic activity. Ann N Y Acad Sci. 1995 Jun 12;761:311-35. doi: 10.1111/j.1749-6632.1995.tb31386.x.","parent_key":"BE0000794"}
{"ref-id":"A11510","pubmed-id":9711054,"citation":"Stichtenoth DO, Zeidler H, Frolich JC: [New non-steroidal anti-rheumatic drugs: selective inhibitors of inducible cyclooxygenase]. Med Klin (Munich). 1998 Jul 15;93(7):407-15.","parent_key":"BE0000262"}
{"ref-id":"A11511","pubmed-id":12901032,"citation":"Schaefer MG, Plowman BK, Morreale AP, Egan M: Interaction of rofecoxib and celecoxib with warfarin. Am J Health Syst Pharm. 2003 Jul 1;60(13):1319-23.","parent_key":"BE0000262"}
{"ref-id":"A11512","pubmed-id":16808554,"citation":"Motsko SP, Rascati KL, Busti AJ, Wilson JP, Barner JC, Lawson KA, Worchel J: Temporal relationship between use of NSAIDs, including selective COX-2 inhibitors, and cardiovascular risk. Drug Saf. 2006;29(7):621-32.","parent_key":"BE0000262"}
{"ref-id":"A11509","pubmed-id":10452868,"citation":"Josephs MD, Cheng G, Ksontini R, Moldawer LL, Hocking MP: Products of cyclooxygenase-2 catalysis regulate postoperative bowel motility. J Surg Res. 1999 Sep;86(1):50-4.","parent_key":"BE0000262"}
{"ref-id":"A11507","pubmed-id":15242723,"citation":"Stevenson DD: Aspirin and NSAID sensitivity. Immunol Allergy Clin North Am. 2004 Aug;24(3):491-505, vii.","parent_key":"BE0000017"}
{"ref-id":"A11508","pubmed-id":1680855,"citation":"Schmidt A, Hescheler J, Offermanns S, Spicher K, Hinsch KD, Klinz FJ, Codina J, Birnbaumer L, Gausepohl H, Frank R, et al.: Involvement of pertussis toxin-sensitive G-proteins in the hormonal inhibition of dihydropyridine-sensitive Ca2+ currents in an insulin-secreting cell line (RINm5F). J Biol Chem. 1991 Sep 25;266(27):18025-33.","parent_key":"BE0000017"}
{"ref-id":"A11509","pubmed-id":10452868,"citation":"Josephs MD, Cheng G, Ksontini R, Moldawer LL, Hocking MP: Products of cyclooxygenase-2 catalysis regulate postoperative bowel motility. J Surg Res. 1999 Sep;86(1):50-4.","parent_key":"BE0000017"}
{"ref-id":"A17122","pubmed-id":2083404,"citation":"Nizankowska E, Dworski R, Soja J, Szczeklik A: Salicylate pre-treatment attenuates intensity of bronchial and nasal symptoms precipitated by aspirin in aspirin-intolerant patients. Clin Exp Allergy. 1990 Nov;20(6):647-52.","parent_key":"BE0000017"}
{"ref-id":"A17123","pubmed-id":14680616,"citation":"Simon RA: Adverse respiratory reactions to aspirin and nonsteroidal anti-inflammatory drugs. Curr Allergy Asthma Rep. 2004 Jan;4(1):17-24.","parent_key":"BE0000017"}
{"ref-id":"A17123","pubmed-id":14680616,"citation":"Simon RA: Adverse respiratory reactions to aspirin and nonsteroidal anti-inflammatory drugs. Curr Allergy Asthma Rep. 2004 Jan;4(1):17-24.","parent_key":"BE0000262"}
{"ref-id":"A10985","pubmed-id":17033106,"citation":"Brzozowski T, Konturek PC, Sliwowski Z, Kwiecien S, Drozdowicz D, Pawlik M, Mach K, Konturek SJ, Pawlik WW: Interaction of nonsteroidal anti-inflammatory drugs (NSAID) with Helicobacter pylori in the stomach of humans and experimental animals. J Physiol Pharmacol. 2006 Sep;57 Suppl 3:67-79.","parent_key":"BE0000262"}
{"ref-id":"A10986","pubmed-id":17037745,"citation":"Wang HJ, Liu XJ, Yang KX, Luo FM, Lou JY, Peng ZL: [Effects of nonsteroidal anti-inflammatory drug celecoxib on expression of cyclooxygenase-2 (COX-2) in ovarian carcinoma cell]. Sichuan Da Xue Xue Bao Yi Xue Ban. 2006 Sep;37(5):757-60.","parent_key":"BE0000262"}
{"ref-id":"A10987","pubmed-id":17181859,"citation":"Shen J, Gammon MD, Terry MB, Teitelbaum SL, Neugut AI, Santella RM: Genetic polymorphisms in the cyclooxygenase-2 gene, use of nonsteroidal anti-inflammatory drugs, and breast cancer risk. Breast Cancer Res. 2006;8(6):R71.","parent_key":"BE0000262"}
{"ref-id":"A10988","pubmed-id":17258197,"citation":"Nakano M, Denda N, Matsumoto M, Kawamura M, Kawakubo Y, Hatanaka K, Hiramoto Y, Sato Y, Noshiro M, Harada Y: Interaction between cyclooxygenase (COX)-1- and COX-2-products modulates COX-2 expression in the late phase of acute inflammation. Eur J Pharmacol. 2007 Mar 22;559(2-3):210-8. Epub 2006 Dec 16.","parent_key":"BE0000262"}
{"ref-id":"A12695","pubmed-id":15753395,"citation":"Yim HW, Jong HS, Kim TY, Choi HH, Kim SG, Song SH, Kim J, Ko SG, Lee JW, Kim TY, Bang YJ: Cyclooxygenase-2 inhibits novel ginseng metabolite-mediated apoptosis. Cancer Res. 2005 Mar 1;65(5):1952-60.","parent_key":"BE0000262"}
{"ref-id":"A12696","pubmed-id":15778128,"citation":"Seo JY, Lee JH, Kim NW, Her E, Chang SH, Ko NY, Yoo YH, Kim JW, Seo DW, Han JW, Kim YM, Choi WS: Effect of a fermented ginseng extract, BST204, on the expression of cyclooxygenase-2 in murine macrophages. Int Immunopharmacol. 2005 May;5(5):929-36.","parent_key":"BE0000262"}
{"ref-id":"A12694","pubmed-id":17436372,"citation":"Kim SJ, Jeong HJ, Yi BJ, Kang TH, An NH, Lee EH, Yang DC, Kim HM, Hong SH, Um JY: Transgenic Panax ginseng inhibits the production of TNF-alpha, IL-6, and IL-8 as well as COX-2 expression in human mast cells. Am J Chin Med. 2007;35(2):329-39.","parent_key":"BE0000262"}
{"ref-id":"A12708","pubmed-id":10071758,"citation":"Izeboud CA, Mocking JA, Monshouwer M, van Miert AS, Witkamp RF: Participation of beta-adrenergic receptors on macrophages in modulation of LPS-induced cytokine release. J Recept Signal Transduct Res. 1999 Jan-Jul;19(1-4):191-202.","parent_key":"BE0000704"}
{"ref-id":"A12709","pubmed-id":11193379,"citation":"Yoshimura T: [Modulation of cytokine production from human mononuclear cells by several agents]. Yakugaku Zasshi. 2000 Dec;120(12):1277-90.","parent_key":"BE0000704"}
{"ref-id":"A12710","pubmed-id":15021963,"citation":"Izeboud CA, Hoebe KH, Grootendorst AF, Nijmeijer SM, van Miert AS, Witkamp RR, Rodenburg RJ: Endotoxin-induced liver damage in rats is minimized by beta 2-adrenoceptor stimulation. Inflamm Res. 2004 Mar;53(3):93-9. Epub 2004 Feb 16.","parent_key":"BE0000704"}
{"ref-id":"A12711","pubmed-id":16261833,"citation":"Laan TT, Bull S, Pirie RS, Fink-Gremmels J: Evaluation of cytokine production by equine alveolar macrophages exposed to lipopolysaccharide, Aspergillus fumigatus, and a suspension of hay dust. Am J Vet Res. 2005 Sep;66(9):1584-9.","parent_key":"BE0000704"}
{"ref-id":"A12712","pubmed-id":17139543,"citation":"van den Hoven R, Duvigneau JC, Hartl RT, Gemeiner M: Clenbuterol affects the expression of messenger RNA for interleukin 10 in peripheral leukocytes from horses challenged intrabronchially with lipopolysaccharides. Vet Res Commun. 2006 Nov;30(8):921-8.","parent_key":"BE0000704"}
{"ref-id":"A15515","pubmed-id":17530144,"citation":"Barnes NC: The properties of inhaled corticosteroids: similarities and differences. Prim Care Respir J. 2007 Jun;16(3):149-54.","parent_key":"BE0000794"}
{"ref-id":"A12713","pubmed-id":12801315,"citation":"Tomari S, Matsuse H, Machida I, Kondo Y, Kawano T, Obase Y, Fukushima C, Shimoda T, Kohno S: Pranlukast, a cysteinyl leukotriene receptor 1 antagonist, attenuates allergen-specific tumour necrosis factor alpha production and nuclear factor kappa B nuclear translocation in peripheral blood monocytes from atopic asthmatics. Clin Exp Allergy. 2003 Jun;33(6):795-801.","parent_key":"BE0000704"}
{"ref-id":"A12714","pubmed-id":12801316,"citation":"Ichiyama T, Hasegawa S, Umeda M, Terai K, Matsubara T, Furukawa S: Pranlukast inhibits NF-kappa B activation in human monocytes/macrophages and T cells. Clin Exp Allergy. 2003 Jun;33(6):802-7.","parent_key":"BE0000704"}
{"ref-id":"A12715","pubmed-id":17430359,"citation":"Ichiyama T, Kajimoto M, Hasegawa M, Hashimoto K, Matsubara T, Furukawa S: Cysteinyl leukotrienes enhance tumour necrosis factor-alpha-induced matrix metalloproteinase-9 in human monocytes/macrophages. Clin Exp Allergy. 2007 Apr;37(4):608-14.","parent_key":"BE0000704"}
{"ref-id":"A17120","pubmed-id":7088753,"citation":"Hassan SM, Olivesi A, Fish A, Turner P: A comparison of antrafenine and aspirin on platelet aggregation and frusemide-induced diuresis. Postgrad Med J. 1982 Jan;58(675):17-9.","parent_key":"BE0000017"}
{"ref-id":"A17121","pubmed-id":6342700,"citation":"Berry H, Coquelin JP, Gordon A, Seymour D: Antrafenine, naproxen and placebo in osteoarthritis: a comparative study. Br J Rheumatol. 1983 May;22(2):89-94.","parent_key":"BE0000017"}
{"ref-id":"A10843","pubmed-id":17607546,"citation":"Albertini R, Aimbire F, Villaverde AB, Silva JA Jr, Costa MS: COX-2 mRNA expression decreases in the subplantar muscle of rat paw subjected to carrageenan-induced inflammation after low level laser therapy. Inflamm Res. 2007 Jun;56(6):228-9.","parent_key":"BE0000262"}
{"ref-id":"A10845","pubmed-id":17521299,"citation":"Kumar P, Padi SS, Naidu PS, Kumar A: Cyclooxygenase inhibition attenuates 3-nitropropionic acid-induced neurotoxicity in rats: possible antioxidant mechanisms. Fundam Clin Pharmacol. 2007 Jun;21(3):297-306.","parent_key":"BE0000262"}
{"ref-id":"A10846","pubmed-id":17612049,"citation":"White WB: Cardiovascular effects of the selective cyclooxygenase-2 inhibitors. Subcell Biochem. 2007;42:145-58.","parent_key":"BE0000262"}
{"ref-id":"A12727","pubmed-id":10075051,"citation":"Kumar A, Kosuri R, Kandula P, Dimou C, Allen J, Parrillo JE: Effects of epinephrine and amrinone on contractility and cyclic adenosine monophosphate generation of tumor necrosis factor alpha-exposed cardiac myocytes. Crit Care Med. 1999 Feb;27(2):286-92.","parent_key":"BE0000704"}
{"ref-id":"A12728","pubmed-id":10444479,"citation":"Bergman MR, Kao RH, McCune SA, Holycross BJ: Myocardial tumor necrosis factor-alpha secretion in hypertensive and heart failure-prone rats. Am J Physiol. 1999 Aug;277(2 Pt 2):H543-50.","parent_key":"BE0000704"}
{"ref-id":"A12729","pubmed-id":11805217,"citation":"Haddad JJ, Land SC, Tarnow-Mordi WO, Zembala M, Kowalczyk D, Lauterbach R: Immunopharmacological potential of selective phosphodiesterase inhibition. I. Differential regulation of lipopolysaccharide-mediated proinflammatory cytokine (interleukin-6 and tumor necrosis factor-alpha) biosynthesis in alveolar epithelial cells. J Pharmacol Exp Ther. 2002 Feb;300(2):559-66.","parent_key":"BE0000704"}
{"ref-id":"A12730","pubmed-id":11969359,"citation":"Marx D, Tassabehji M, Heer S, Huttenbrink KB, Szelenyi I: Modulation of TNF and GM-CSF release from dispersed human nasal polyp cells and human whole blood by inhibitors of different PDE isoenzymes and glucocorticoids. Pulm Pharmacol Ther. 2002;15(1):7-15.","parent_key":"BE0000704"}
{"ref-id":"A12731","pubmed-id":1611705,"citation":"Giroir BP, Beutler B: Effect of amrinone on tumor necrosis factor production in endotoxic shock. Circ Shock. 1992 Mar;36(3):200-7.","parent_key":"BE0000704"}
{"ref-id":"A14213","pubmed-id":20163389,"citation":"Mancino MJ, McGaugh J, Feldman Z, Poling J, Oliveto A: Effect of PTSD diagnosis and contingency management procedures on cocaine use in dually cocaine- and opioid-dependent individuals maintained on LAAM: a retrospective analysis. Am J Addict. 2010 Mar-Apr;19(2):169-77. doi: 10.1111/j.1521-0391.2009.00025.x.","parent_key":"BE0000770"}
{"ref-id":"A14214","pubmed-id":6268422,"citation":"Walczak SA, Makman MH, Gardner EL: Acetylmethadol metabolites influence opiate receptors and adenylate cyclase in amygdala. Eur J Pharmacol. 1981 Jul 10;72(4):343-9.","parent_key":"BE0000770"}
{"ref-id":"A14215","pubmed-id":19153939,"citation":"Wolstein J, Gastpar M, Finkbeiner T, Heinrich C, Heitkamp R, Poehlke T, Scherbaum N: A randomized, open-label trial comparing methadone and Levo-Alpha-Acetylmethadol (LAAM) in maintenance treatment of opioid addiction. Pharmacopsychiatry. 2009 Jan;42(1):1-8. doi: 10.1055/s-0028-1083818. Epub 2009 Jan 19.","parent_key":"BE0000770"}
{"ref-id":"A17013","pubmed-id":11695253,"citation":"Brune K, Neubert A: Pharmacokinetic and pharmacodynamic aspects of the ideal COX-2 inhibitor: a pharmacologist's perspective. Clin Exp Rheumatol. 2001 Nov-Dec;19(6 Suppl 25):S51-7.","parent_key":"BE0000262"}
{"ref-id":"A17013","pubmed-id":11695253,"citation":"Brune K, Neubert A: Pharmacokinetic and pharmacodynamic aspects of the ideal COX-2 inhibitor: a pharmacologist's perspective. Clin Exp Rheumatol. 2001 Nov-Dec;19(6 Suppl 25):S51-7.","parent_key":"BE0000017"}
{"ref-id":"A12806","pubmed-id":13651575,"citation":"GREEN AF: Comparative effects of analgesics on pain threshold, respiratory frequency and gastrointestinal propulsion. Br J Pharmacol Chemother. 1959 Mar;14(1):26-34.","parent_key":"BE0000770"}
{"ref-id":"A1713","pubmed-id":17139284,"citation":"Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.","parent_key":"BE0000420"}
{"ref-id":"A1715","pubmed-id":17016423,"citation":"Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.","parent_key":"BE0000420"}
{"ref-id":"A13009","pubmed-id":12902992,"citation":"Greenwald MK, Johanson CE, Moody DE, Woods JH, Kilbourn MR, Koeppe RA, Schuster CR, Zubieta JK: Effects of buprenorphine maintenance dose on mu-opioid receptor availability, plasma concentrations, and antagonist blockade in heroin-dependent volunteers. Neuropsychopharmacology. 2003 Nov;28(11):2000-9.","parent_key":"BE0000770"}
{"ref-id":"A13010","pubmed-id":15013161,"citation":"Becker J, Schmidt P, Musshoff F, Fitzenreiter M, Madea B: MOR1 receptor mRNA expression in human brains of drug-related fatalities-a real-time PCR quantification. Forensic Sci Int. 2004 Feb 10;140(1):13-20.","parent_key":"BE0000770"}
{"ref-id":"A13011","pubmed-id":15937104,"citation":"Yao L, McFarland K, Fan P, Jiang Z, Inoue Y, Diamond I: Activator of G protein signaling 3 regulates opiate activation of protein kinase A signaling and relapse of heroin-seeking behavior. Proc Natl Acad Sci U S A. 2005 Jun 14;102(24):8746-51. Epub 2005 Jun 3.","parent_key":"BE0000770"}
{"ref-id":"A13012","pubmed-id":15986196,"citation":"Antonilli L, Petecchia E, Caprioli D, Badiani A, Nencini P: Effect of repeated administrations of heroin, naltrexone, methadone, and alcohol on morphine glucuronidation in the rat. Psychopharmacology (Berl). 2005 Oct;182(1):58-64. Epub 2005 Sep 29.","parent_key":"BE0000770"}
{"ref-id":"A15367","pubmed-id":18343363,"citation":"Klein G, Juni A, Arout CA, Waxman AR, Inturrisi CE, Kest B: Acute and chronic heroin dependence in mice: contribution of opioid and excitatory amino acid receptors. Eur J Pharmacol. 2008 May 31;586(1-3):179-88. doi: 10.1016/j.ejphar.2008.02.035.  Epub 2008 Feb 19.","parent_key":"BE0000420"}
{"ref-id":"A12758","pubmed-id":10881033,"citation":"Duttaroy A, Yoburn BC: In vivo regulation of mu-opioid receptor density and gene expression in CXBK and outbred Swiss Webster mice. Synapse. 2000 Aug;37(2):118-24.","parent_key":"BE0000770"}
{"ref-id":"A12759","pubmed-id":11098106,"citation":"Melone M, Brecha NC, Sternini C, Evans C, Conti F: Etorphine increases the number of mu-opioid receptor-positive cells in the cerebral cortex. Neuroscience. 2000;100(3):439-43.","parent_key":"BE0000770"}
{"ref-id":"A12760","pubmed-id":11420091,"citation":"Stafford K, Gomes AB, Shen J, Yoburn BC: mu-Opioid receptor downregulation contributes to opioid tolerance in vivo. Pharmacol Biochem Behav. 2001 May-Jun;69(1-2):233-7.","parent_key":"BE0000770"}
{"ref-id":"A12761","pubmed-id":11900797,"citation":"Gomes BA, Shen J, Stafford K, Patel M, Yoburn BC: Mu-opioid receptor down-regulation and tolerance are not equally dependent upon G-protein signaling. Pharmacol Biochem Behav. 2002 May;72(1-2):273-8.","parent_key":"BE0000770"}
{"ref-id":"A12762","pubmed-id":12435815,"citation":"Patel MB, Patel CN, Rajashekara V, Yoburn BC: Opioid agonists differentially regulate mu-opioid receptors and trafficking proteins in vivo. Mol Pharmacol. 2002 Dec;62(6):1464-70.","parent_key":"BE0000770"}
{"ref-id":"A12763","pubmed-id":10999950,"citation":"Li JG, Benovic JL, Liu-Chen LY: Mechanisms of agonist-induced down-regulation of the human kappa-opioid receptor: internalization is required for down-regulation. Mol Pharmacol. 2000 Oct;58(4):795-801.","parent_key":"BE0000420"}
{"ref-id":"A12764","pubmed-id":12606694,"citation":"Li JG, Zhang F, Jin XL, Liu-Chen LY: Differential regulation of the human kappa opioid receptor by agonists: etorphine and levorphanol reduced dynorphin A- and U50,488H-induced internalization and phosphorylation. J Pharmacol Exp Ther. 2003 May;305(2):531-40. Epub 2003 Jan 24.","parent_key":"BE0000420"}
{"ref-id":"A12765","pubmed-id":12672796,"citation":"Marie N, Lecoq I, Jauzac P, Allouche S: Differential sorting of human delta-opioid receptors after internalization by peptide and alkaloid agonists. J Biol Chem. 2003 Jun 20;278(25):22795-804. Epub 2003 Apr 2.","parent_key":"BE0000420"}
{"ref-id":"A12766","pubmed-id":1316589,"citation":"Sumner BE, Douglas AJ, Russell JA: Pregnancy alters the density of opioid binding sites in the supraoptic nucleus and posterior pituitary gland of rats. Neurosci Lett. 1992 Mar 30;137(2):216-20.","parent_key":"BE0000420"}
{"ref-id":"A12767","pubmed-id":1665782,"citation":"Tao PL, Tsai CL, Chang LR, Loh HH: Chronic effect of [D-Pen2,D-Pen5]enkephalin on rat brain opioid receptors. Eur J Pharmacol. 1991 Aug 29;201(2-3):209-14.","parent_key":"BE0000420"}
{"ref-id":"A12768","pubmed-id":7739347,"citation":"Niwa M, al-Essa LY, Ohta S, Kohno K, Nozaki M, Tsurumi K, Iwamura T, Kataoka T: Opioid receptor interaction and adenylyl cyclase inhibition of dihydroetorphine: direct comparison with etorphine. Life Sci. 1995;56(21):PL395-400.","parent_key":"BE0000420"}
{"ref-id":"A12769","pubmed-id":14744466,"citation":"Bencherif B, Wand GS, McCaul ME, Kim YK, Ilgin N, Dannals RF, Frost JJ: Mu-opioid receptor binding measured by [11C]carfentanil positron emission tomography is related to craving and mood in alcohol dependence. Biol Psychiatry. 2004 Feb 1;55(3):255-62.","parent_key":"BE0000770"}
{"ref-id":"A12770","pubmed-id":15001679,"citation":"Bencherif B, Stumpf MJ, Links JM, Frost JJ: Application of MRI-based partial-volume correction to the analysis of PET images of mu-opioid receptors using statistical parametric mapping. J Nucl Med. 2004 Mar;45(3):402-8.","parent_key":"BE0000770"}
{"ref-id":"A12771","pubmed-id":15028244,"citation":"Jewett DM, Kilbourn MR: In vivo evaluation of new carfentanil-based radioligands for the mu opiate receptor. Nucl Med Biol. 2004 Apr;31(3):321-5.","parent_key":"BE0000770"}
{"ref-id":"A12772","pubmed-id":1656846,"citation":"Mayberg HS, Sadzot B, Meltzer CC, Fisher RS, Lesser RP, Dannals RF, Lever JR, Wilson AA, Ravert HT, Wagner HN Jr, et al.: Quantification of mu and non-mu opiate receptors in temporal lobe epilepsy using positron emission tomography. Ann Neurol. 1991 Jul;30(1):3-11.","parent_key":"BE0000770"}
{"ref-id":"A12773","pubmed-id":7957034,"citation":"Bartenstein PA, Prevett MC, Duncan JS, Hajek M, Wieser HG: Quantification of opiate receptors in two patients with mesiobasal temporal lobe epilepsy, before and after selective amygdalohippocampectomy, using positron emission tomography. Epilepsy Res. 1994 Jun;18(2):119-25.","parent_key":"BE0000770"}
{"ref-id":"A12772","pubmed-id":1656846,"citation":"Mayberg HS, Sadzot B, Meltzer CC, Fisher RS, Lesser RP, Dannals RF, Lever JR, Wilson AA, Ravert HT, Wagner HN Jr, et al.: Quantification of mu and non-mu opiate receptors in temporal lobe epilepsy using positron emission tomography. Ann Neurol. 1991 Jul;30(1):3-11.","parent_key":"BE0000420"}
{"ref-id":"A15512","pubmed-id":15853689,"citation":"Barry U, Zuo Z: Opioids: old drugs for potential new applications. Curr Pharm Des. 2005;11(10):1343-50.","parent_key":"BE0000420"}
{"ref-id":"A12782","pubmed-id":20641600,"citation":"Leung K: [6-O-methyl-11C]Diprenorphine .","parent_key":"BE0000770"}
{"ref-id":"A12778","pubmed-id":10319982,"citation":"Willoch F, Tolle TR, Wester HJ, Munz F, Petzold A, Schwaiger M, Conrad B, Bartenstein P: Central pain after pontine infarction is associated with changes in opioid receptor binding: a PET study with 11C-diprenorphine. AJNR Am J Neuroradiol. 1999 Apr;20(4):686-90.","parent_key":"BE0000420"}
{"ref-id":"A12779","pubmed-id":10413036,"citation":"Jones AK, Kitchen ND, Watabe H, Cunningham VJ, Jones T, Luthra SK, Thomas DG: Measurement of changes in opioid receptor binding in vivo during trigeminal neuralgic pain using [11C] diprenorphine and positron emission tomography. J Cereb Blood Flow Metab. 1999 Jul;19(7):803-8.","parent_key":"BE0000420"}
{"ref-id":"A12780","pubmed-id":11526449,"citation":"Kampa M, Hatzoglou A, Notas G, Niniraki M, Kouroumalis E, Castanas E: Opioids are non-competitive inhibitors of nitric oxide synthase in T47D human breast cancer cells. Cell Death Differ. 2001 Sep;8(9):943-52.","parent_key":"BE0000420"}
{"ref-id":"A12781","pubmed-id":12909189,"citation":"Webster JM, Bentley MT, Wojcikiewicz RJ: N,N,N',N'-tetrakis(2-pyridylmethyl)ethylenediamine inhibits ligand binding to certain G protein-coupled receptors. Eur J Pharmacol. 2003 Aug 1;474(1):1-5.","parent_key":"BE0000420"}
{"ref-id":"A12782","pubmed-id":20641600,"citation":"Leung K: [6-O-methyl-11C]Diprenorphine .","parent_key":"BE0000420"}
{"ref-id":"A15766","pubmed-id":16777416,"citation":"Crooks PA, Kottayil SG, Al-Ghananeem AM, Byrn SR, Butterfield DA: Opiate receptor binding properties of morphine-, dihydromorphine-, and codeine 6-O-sulfate ester congeners. Bioorg Med Chem Lett. 2006 Aug 15;16(16):4291-5. Epub 2006 Jun 13.","parent_key":"BE0000770"}
{"ref-id":"A15767","pubmed-id":15178355,"citation":"Gilbert AK, Hosztafi S, Mahurter L, Pasternak GW: Pharmacological characterization of dihydromorphine, 6-acetyldihydromorphine and dihydroheroin analgesia and their differentiation from morphine. Eur J Pharmacol. 2004 May 25;492(2-3):123-30.","parent_key":"BE0000770"}
{"ref-id":"A15766","pubmed-id":16777416,"citation":"Crooks PA, Kottayil SG, Al-Ghananeem AM, Byrn SR, Butterfield DA: Opiate receptor binding properties of morphine-, dihydromorphine-, and codeine 6-O-sulfate ester congeners. Bioorg Med Chem Lett. 2006 Aug 15;16(16):4291-5. Epub 2006 Jun 13.","parent_key":"BE0000420"}
{"ref-id":"A14251","pubmed-id":19474215,"citation":"Dietis N, Guerrini R, Calo G, Salvadori S, Rowbotham DJ, Lambert DG: Simultaneous targeting of multiple opioid receptors: a strategy to improve side-effect profile. Br J Anaesth. 2009 Jul;103(1):38-49. doi: 10.1093/bja/aep129. Epub 2009 May 27.","parent_key":"BE0000420"}
{"ref-id":"A15767","pubmed-id":15178355,"citation":"Gilbert AK, Hosztafi S, Mahurter L, Pasternak GW: Pharmacological characterization of dihydromorphine, 6-acetyldihydromorphine and dihydroheroin analgesia and their differentiation from morphine. Eur J Pharmacol. 2004 May 25;492(2-3):123-30.","parent_key":"BE0000420"}
{"ref-id":"A14012","pubmed-id":10669565,"citation":"Subramanian G, Paterlini MG, Portoghese PS, Ferguson DM: Molecular docking reveals a novel binding site model for fentanyl at the mu-opioid receptor. J Med Chem. 2000 Feb 10;43(3):381-91.","parent_key":"BE0000770"}
{"ref-id":"A14013","pubmed-id":6264594,"citation":"Jin WQ, Xu H, Zhu YC, Fang SN, Xia XL, Huang ZM, Ge BL, Chi ZQ: Studies on synthesis and relationship between analgesic activity and receptor affinity for 3-methyl fentanyl derivatives. Sci Sin. 1981 May;24(5):710-20.","parent_key":"BE0000770"}
{"ref-id":"A14014","pubmed-id":8030414,"citation":"Wang ZX, Zhu YC, Chen XJ, Ji RY: [Stereoisomers of 3-methylfentanyl: synthesis, absolute configuration and analgesic activity]. Yao Xue Xue Bao. 1993;28(12):905-10.","parent_key":"BE0000770"}
{"ref-id":"A14015","pubmed-id":8576134,"citation":"Zhu J, Yin J, Law PY, Claude PA, Rice KC, Evans CJ, Chen C, Yu L, Liu-Chen LY: Irreversible binding of cis-(+)-3-methylfentanyl isothiocyanate to the delta opioid receptor and determination of its binding domain. J Biol Chem. 1996 Jan 19;271(3):1430-4.","parent_key":"BE0000770"}
{"ref-id":"A14013","pubmed-id":6264594,"citation":"Jin WQ, Xu H, Zhu YC, Fang SN, Xia XL, Huang ZM, Ge BL, Chi ZQ: Studies on synthesis and relationship between analgesic activity and receptor affinity for 3-methyl fentanyl derivatives. Sci Sin. 1981 May;24(5):710-20.","parent_key":"BE0000420"}
{"ref-id":"A14014","pubmed-id":8030414,"citation":"Wang ZX, Zhu YC, Chen XJ, Ji RY: [Stereoisomers of 3-methylfentanyl: synthesis, absolute configuration and analgesic activity]. Yao Xue Xue Bao. 1993;28(12):905-10.","parent_key":"BE0000420"}
{"ref-id":"A14015","pubmed-id":8576134,"citation":"Zhu J, Yin J, Law PY, Claude PA, Rice KC, Evans CJ, Chen C, Yu L, Liu-Chen LY: Irreversible binding of cis-(+)-3-methylfentanyl isothiocyanate to the delta opioid receptor and determination of its binding domain. J Biol Chem. 1996 Jan 19;271(3):1430-4.","parent_key":"BE0000420"}
{"ref-id":"A19981","pubmed-id":16439135,"citation":"Bhuiyan MP, Kato T, Okauchi T, Nishino N, Maeda S, Nishino TG, Yoshida M: Chlamydocin analogs bearing carbonyl group as possible ligand toward zinc atom in histone deacetylases. Bioorg Med Chem. 2006 May 15;14(10):3438-46. Epub 2006 Jan 24.","parent_key":"BE0002365"}
{"ref-id":"A20203","pubmed-id":23896426,"citation":"Wang F, Chmil C, Pierce F, Ganapathy K, Gump BB, MacKenzie JA, Metchref Y, Bendinskas K: Immobilized metal affinity chromatography and human serum proteomics. J Chromatogr B Analyt Technol Biomed Life Sci. 2013 Sep 1;934:26-33. doi: 10.1016/j.jchromb.2013.06.032. Epub 2013 Jul 5.","parent_key":"BE0002095"}
{"ref-id":"A20203","pubmed-id":23896426,"citation":"Wang F, Chmil C, Pierce F, Ganapathy K, Gump BB, MacKenzie JA, Metchref Y, Bendinskas K: Immobilized metal affinity chromatography and human serum proteomics. J Chromatogr B Analyt Technol Biomed Life Sci. 2013 Sep 1;934:26-33. doi: 10.1016/j.jchromb.2013.06.032. Epub 2013 Jul 5.","parent_key":"BE0002096"}
{"ref-id":"A20218","pubmed-id":10026247,"citation":"Brodersen DE, Nyborg J, Kjeldgaard M: Zinc-binding site of an S100 protein revealed. Two crystal structures of Ca2+-bound human psoriasin (S100A7) in the Zn2+-loaded and Zn2+-free states. Biochemistry. 1999 Feb 9;38(6):1695-704.","parent_key":"BE0003756"}
{"ref-id":"A12845","pubmed-id":2277128,"citation":"Brandt KD, Albrecht ME, Kalasinski LA: Effects of tiaprofenic acid on the concentration and metabolism of proteoglycans in normal and degenerating canine articular cartilage. J Clin Pharmacol. 1990 Sep;30(9):808-14.","parent_key":"BE0000262"}
{"ref-id":"A12846","pubmed-id":17696512,"citation":"Reddy GS, Ali A, Nalam MN, Anjum SG, Cao H, Nathans RS, Schiffer CA, Rana TM: Design and synthesis of HIV-1 protease inhibitors incorporating oxazolidinones as P2/P2' ligands in pseudosymmetric dipeptide isosteres. J Med Chem. 2007 Sep 6;50(18):4316-28. Epub 2007 Aug 16.","parent_key":"BE0004854"}
{"ref-id":"A12847","pubmed-id":11151088,"citation":"Authors unspecified: Lopinavir/ritonavir: a protease inhibitor combination. Med Lett Drugs Ther. 2001 Jan 8;43(1095):1-2.","parent_key":"BE0004854"}
{"ref-id":"A15451","pubmed-id":18220957,"citation":"Sun S, Rao NL, Venable J, Thurmond R, Karlsson L: TLR7/9 antagonists as therapeutics for immune-mediated inflammatory disorders. Inflamm Allergy Drug Targets. 2007 Dec;6(4):223-35.","parent_key":"BE0001171"}
{"ref-id":"A12837","pubmed-id":17164136,"citation":"Capone ML, Tacconelli S, Di Francesco L, Sacchetti A, Sciulli MG, Patrignani P: Pharmacodynamic of cyclooxygenase inhibitors in humans. Prostaglandins Other Lipid Mediat. 2007 Jan;82(1-4):85-94. Epub 2006 Jul 3.","parent_key":"BE0000262"}
{"ref-id":"A12838","pubmed-id":17573128,"citation":"FitzGerald GA: COX-2 in play at the AHA and the FDA. Trends Pharmacol Sci. 2007 Jul;28(7):303-7. Epub 2007 Jun 18.","parent_key":"BE0000262"}
{"ref-id":"A12839","pubmed-id":17691997,"citation":"Yuan Y, Hunt RH: Global gastrointestinal safety profile of etoricoxib and lumiracoxib. Curr Pharm Des. 2007;13(22):2237-47.","parent_key":"BE0000262"}
{"ref-id":"A2558","pubmed-id":17937610,"citation":"van Guldener C, Nanayakkara PW, Stehouwer CD: Homocysteine and asymmetric dimethylarginine (ADMA): biochemically linked but differently related to vascular disease in chronic kidney disease. Clin Chem Lab Med. 2007;45(12):1683-7.","parent_key":"BE0000005"}
{"ref-id":"A18294","pubmed-id":17591676,"citation":"Kohalmy K, Tamasi V, Kobori L, Sarvary E, Pascussi JM, Porrogi P, Rozman D, Prough RA, Meyer UA, Monostory K: Dehydroepiandrosterone induces human CYP2B6 through the constitutive androstane receptor. Drug Metab Dispos. 2007 Sep;35(9):1495-501. Epub 2007 Jun 25.","parent_key":"BE0000071"}
{"ref-id":"A18295","pubmed-id":18079279,"citation":"Tamasi V, Miller KK, Ripp SL, Vila E, Geoghagen TE, Prough RA: Modulation of receptor phosphorylation contributes to activation of peroxisome proliferator activated receptor alpha by dehydroepiandrosterone and other peroxisome proliferators. Mol Pharmacol. 2008 Mar;73(3):968-76. Epub 2007 Dec 13.","parent_key":"BE0000071"}
{"ref-id":"A18294","pubmed-id":17591676,"citation":"Kohalmy K, Tamasi V, Kobori L, Sarvary E, Pascussi JM, Porrogi P, Rozman D, Prough RA, Meyer UA, Monostory K: Dehydroepiandrosterone induces human CYP2B6 through the constitutive androstane receptor. Drug Metab Dispos. 2007 Sep;35(9):1495-501. Epub 2007 Jun 25.","parent_key":"BE0000956"}
{"ref-id":"A1713","pubmed-id":17139284,"citation":"Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.","parent_key":"BE0000807"}
{"ref-id":"A1715","pubmed-id":17016423,"citation":"Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.","parent_key":"BE0000807"}
{"ref-id":"A1991","pubmed-id":10592235,"citation":"Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H, Shindyalov IN, Bourne PE: The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42.","parent_key":"BE0000807"}
{"ref-id":"A1713","pubmed-id":17139284,"citation":"Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.","parent_key":"BE0000005"}
{"ref-id":"A1715","pubmed-id":17016423,"citation":"Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.","parent_key":"BE0000005"}
{"ref-id":"A1991","pubmed-id":10592235,"citation":"Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H, Shindyalov IN, Bourne PE: The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42.","parent_key":"BE0000005"}
{"ref-id":"A1991","pubmed-id":10592235,"citation":"Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H, Shindyalov IN, Bourne PE: The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42.","parent_key":"BE0000017"}
{"ref-id":"A1713","pubmed-id":17139284,"citation":"Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.","parent_key":"BE0000071"}
{"ref-id":"A1715","pubmed-id":17016423,"citation":"Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.","parent_key":"BE0000071"}
{"ref-id":"A1713","pubmed-id":17139284,"citation":"Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.","parent_key":"BE0000956"}
{"ref-id":"A1715","pubmed-id":17016423,"citation":"Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.","parent_key":"BE0000956"}
{"ref-id":"A15289","pubmed-id":7864817,"citation":"Ouellet M, Percival MD: Effect of inhibitor time-dependency on selectivity towards cyclooxygenase isoforms. Biochem J. 1995 Feb 15;306 ( Pt 1):247-51.","parent_key":"BE0000262"}
{"ref-id":"A15289","pubmed-id":7864817,"citation":"Ouellet M, Percival MD: Effect of inhibitor time-dependency on selectivity towards cyclooxygenase isoforms. Biochem J. 1995 Feb 15;306 ( Pt 1):247-51.","parent_key":"BE0000017"}
{"ref-id":"A14018","pubmed-id":17694093,"citation":"Xu WS, Parmigiani RB, Marks PA: Histone deacetylase inhibitors: molecular mechanisms of action. Oncogene. 2007 Aug 13;26(37):5541-52.","parent_key":"BE0002365"}
{"ref-id":"A9","pubmed-id":11752352,"citation":"Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5.","parent_key":"BE0002365"}
{"ref-id":"A19911","pubmed-id":15194485,"citation":"Ramesh Babu PB, Chidekel A, Utidjian L, Shaffer TH: Regulation of apical surface fluid and protein secretion in human airway epithelial cell line Calu-3. Biochem Biophys Res Commun. 2004 Jul 9;319(4):1132-7.","parent_key":"BE0001195"}
{"ref-id":"A20225","pubmed-id":24454499,"citation":"Konno H, Kanai Y, Katagiri M, Watanabe T, Mori A, Ikuta T, Tani H, Fukushima S, Tatefuji T, Shirasawa T: Melinjo (Gnetum gnemon L.) Seed Extract Decreases Serum Uric Acid Levels in Nonobese Japanese Males: A Randomized Controlled Study. Evid Based Complement Alternat Med. 2013;2013:589169. doi: 10.1155/2013/589169. Epub 2013 Dec 17.","parent_key":"BE0000071"}
{"ref-id":"A20225","pubmed-id":24454499,"citation":"Konno H, Kanai Y, Katagiri M, Watanabe T, Mori A, Ikuta T, Tani H, Fukushima S, Tatefuji T, Shirasawa T: Melinjo (Gnetum gnemon L.) Seed Extract Decreases Serum Uric Acid Levels in Nonobese Japanese Males: A Randomized Controlled Study. Evid Based Complement Alternat Med. 2013;2013:589169. doi: 10.1155/2013/589169. Epub 2013 Dec 17.","parent_key":"BE0000215"}
{"ref-id":"A20201","pubmed-id":23843199,"citation":"Sarath Josh MK, Pradeep S, Vijayalekshmi Amma KS, Balachandran S, Abdul Jaleel UC, Doble M, Spener F, Benjamin S: Phthalates efficiently bind to human peroxisome proliferator activated receptor and retinoid X receptor alpha, beta, gamma subtypes: an in silico approach. J Appl Toxicol. 2014 Jul;34(7):754-65. doi: 10.1002/jat.2902. Epub 2013 Jul 11.","parent_key":"BE0000071"}
{"ref-id":"A20201","pubmed-id":23843199,"citation":"Sarath Josh MK, Pradeep S, Vijayalekshmi Amma KS, Balachandran S, Abdul Jaleel UC, Doble M, Spener F, Benjamin S: Phthalates efficiently bind to human peroxisome proliferator activated receptor and retinoid X receptor alpha, beta, gamma subtypes: an in silico approach. J Appl Toxicol. 2014 Jul;34(7):754-65. doi: 10.1002/jat.2902. Epub 2013 Jul 11.","parent_key":"BE0000215"}
{"ref-id":"A1713","pubmed-id":17139284,"citation":"Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.","parent_key":"BE0000163"}
{"ref-id":"A1715","pubmed-id":17016423,"citation":"Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.","parent_key":"BE0000163"}
{"ref-id":"A1991","pubmed-id":10592235,"citation":"Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H, Shindyalov IN, Bourne PE: The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42.","parent_key":"BE0000163"}
{"ref-id":"A1991","pubmed-id":10592235,"citation":"Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H, Shindyalov IN, Bourne PE: The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42.","parent_key":"BE0000262"}
{"ref-id":"A20234","pubmed-id":24998974,"citation":"Zhang L, Ren XM, Wan B, Guo LH: Structure-dependent binding and activation of perfluorinated compounds on human peroxisome proliferator-activated receptor gamma. Toxicol Appl Pharmacol. 2014 Sep 15;279(3):275-83. doi: 10.1016/j.taap.2014.06.020. Epub 2014 Jul 3.","parent_key":"BE0000215"}
{"ref-id":"A19372","pubmed-id":24986106,"citation":"Liu M, Montgomery MK, Fiveash CE, Osborne B, Cooney GJ, Bell-Anderson K, Turner N: PPARalpha-independent actions of omega-3 PUFAs contribute to their beneficial effects on adiposity and glucose homeostasis. Sci Rep. 2014 Jul 2;4:5538. doi: 10.1038/srep05538.","parent_key":"BE0000071"}
{"ref-id":"A19371","pubmed-id":19585164,"citation":"Rudkowska I, Garenc C, Couture P, Vohl MC: Omega-3 fatty acids regulate gene expression levels differently in subjects carrying the PPARalpha L162V polymorphism. Genes Nutr. 2009 Sep;4(3):199-205. doi: 10.1007/s12263-009-0129-2. Epub 2009 Jul  8.","parent_key":"BE0000071"}
{"ref-id":"A19365","pubmed-id":21382489,"citation":"Varga T, Czimmerer Z, Nagy L: PPARs are a unique set of fatty acid regulated transcription factors controlling both lipid metabolism and inflammation. Biochim Biophys Acta. 2011 Aug;1812(8):1007-22. doi: 10.1016/j.bbadis.2011.02.014. Epub 2011 Mar 5.","parent_key":"BE0000215"}
{"ref-id":"A19366","pubmed-id":18769551,"citation":"Edwards IJ, O'Flaherty JT: Omega-3 Fatty Acids and PPARgamma in Cancer. PPAR Res. 2008;2008:358052. doi: 10.1155/2008/358052.","parent_key":"BE0000215"}
{"ref-id":"A20255","pubmed-id":26238175,"citation":"Lau AJ, Chang TK: 3-Hydroxyflavone and structural analogues differentially activate pregnane X receptor: Implication for inflammatory bowel disease. Pharmacol Res. 2015 Oct;100:64-72. doi: 10.1016/j.phrs.2015.07.031. Epub 2015 Jul 31.","parent_key":"BE0000956"}
{"ref-id":"A19809","pubmed-id":15491415,"citation":"Downie MM, Sanders DA, Maier LM, Stock DM, Kealey T: Peroxisome proliferator-activated receptor and farnesoid X receptor ligands differentially regulate sebaceous differentiation in human sebaceous gland organ cultures in vitro. Br J Dermatol. 2004 Oct;151(4):766-75.","parent_key":"BE0000071"}
{"ref-id":"A1991","pubmed-id":10592235,"citation":"Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H, Shindyalov IN, Bourne PE: The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42.","parent_key":"BE0000215"}
{"ref-id":"A1991","pubmed-id":10592235,"citation":"Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H, Shindyalov IN, Bourne PE: The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42.","parent_key":"BE0001195"}
{"ref-id":"A1991","pubmed-id":10592235,"citation":"Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H, Shindyalov IN, Bourne PE: The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42.","parent_key":"BE0003756"}
{"ref-id":"A12938","pubmed-id":16301791,"citation":"Jabeen T, Singh N, Singh RK, Sharma S, Somvanshi RK, Dey S, Singh TP: Non-steroidal anti-inflammatory drugs as potent inhibitors of phospholipase A2: structure of the complex of phospholipase A2 with niflumic acid at 2.5 Angstroms resolution. Acta Crystallogr D Biol Crystallogr. 2005 Dec;61(Pt 12):1579-86. Epub 2005 Nov 19.","parent_key":"BE0000262"}
{"ref-id":"A16868","pubmed-id":17485303,"citation":"Diao HL, Zhu H, Ma H, Tan HN, Cong J, Su RW, Yang ZM: Rat ovulation, implantation and decidualization are severely compromised by COX-2 inhibitors. Front Biosci. 2007 May 1;12:3333-42.","parent_key":"BE0000262"}
{"ref-id":"A16869","pubmed-id":17098211,"citation":"Alpert E, Gruzman A, Tennenbaum T, Sasson S: Selective cyclooxygenase-2 inhibitors stimulate glucose transport in L6 myotubes in a protein kinase Cdelta-dependent manner. Biochem Pharmacol. 2007 Feb 1;73(3):368-77. Epub 2006 Oct 13.","parent_key":"BE0000262"}
{"ref-id":"A17586","pubmed-id":21600945,"citation":"Talbot S, Lin JC, Lahjouji K, Roy JP, Senecal J, Morin A, Couture R: Cigarette smoke-induced kinin B1 receptor promotes NADPH oxidase activity in cultured human alveolar epithelial cells. Peptides. 2011 Jul;32(7):1447-56. doi: 10.1016/j.peptides.2011.05.005. Epub 2011  May 11.","parent_key":"BE0000017"}
{"ref-id":"A19855","pubmed-id":11861974,"citation":"Wilson VS, Bobseine K, Lambright CR, Gray LE Jr: A novel cell line, MDA-kb2, that stably expresses an androgen- and glucocorticoid-responsive reporter for the detection of hormone receptor agonists and antagonists. Toxicol Sci. 2002 Mar;66(1):69-81.","parent_key":"BE0000794"}
{"ref-id":"A13626","pubmed-id":17015640,"citation":"Vidal C, Gomez-Hernandez A, Sanchez-Galan E, Gonzalez A, Ortega L, Gomez-Gerique JA, Tunon J, Egido J: Licofelone, a balanced inhibitor of cyclooxygenase and 5-lipoxygenase, reduces inflammation in a rabbit model of atherosclerosis. J Pharmacol Exp Ther. 2007 Jan;320(1):108-16. Epub 2006 Oct 2.","parent_key":"BE0000262"}
{"ref-id":"A13590","pubmed-id":16846549,"citation":"Rainsford KD: Nimesulide -- a multifactorial approach to inflammation and pain: scientific and clinical consensus. Curr Med Res Opin. 2006 Jun;22(6):1161-70.","parent_key":"BE0000262"}
{"ref-id":"A1713","pubmed-id":17139284,"citation":"Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.","parent_key":"BE0000911"}
{"ref-id":"A1715","pubmed-id":17016423,"citation":"Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.","parent_key":"BE0000911"}
{"ref-id":"A9","pubmed-id":11752352,"citation":"Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5.","parent_key":"BE0000911"}
{"ref-id":"A12953","pubmed-id":19098484,"citation":"Levy JA: HIV pathogenesis: 25 years of progress and persistent challenges. AIDS. 2009 Jan 14;23(2):147-60. doi: 10.1097/QAD.0b013e3283217f9f.","parent_key":"BE0000911"}
{"ref-id":"A12954","pubmed-id":19692476,"citation":"Agrawal-Gamse C, Lee FH, Haggarty B, Jordan AP, Yi Y, Lee B, Collman RG, Hoxie JA, Doms RW, Laakso MM: Adaptive mutations in a human immunodeficiency virus type 1 envelope protein with a truncated V3 loop restore function by improving interactions with CD4. J Virol. 2009 Nov;83(21):11005-15. doi: 10.1128/JVI.01238-09. Epub 2009 Aug 19.","parent_key":"BE0000911"}
{"ref-id":"A12955","pubmed-id":16298345,"citation":"Napier C, Sale H, Mosley M, Rickett G, Dorr P, Mansfield R, Holbrook M: Molecular cloning and radioligand binding characterization of the chemokine receptor CCR5 from rhesus macaque and human. Biochem Pharmacol. 2005 Dec 19;71(1-2):163-72. Epub 2005 Nov 18.","parent_key":"BE0000911"}
{"ref-id":"A7607","pubmed-id":24189255,"citation":"Balasubramanian V, Solapure S, Iyer H, Ghosh A, Sharma S, Kaur P, Deepthi R, Subbulakshmi V, Ramya V, Ramachandran V, Balganesh M, Wright L, Melnick D, Butler SL, Sambandamurthy VK: Bactericidal activity and mechanism of action of AZD5847, a novel oxazolidinone for treatment of tuberculosis. Antimicrob Agents Chemother. 2014;58(1):495-502. doi: 10.1128/AAC.01903-13. Epub  2013 Nov 4.","parent_key":"BE0004800"}
{"ref-id":"A20102","pubmed-id":28165287,"citation":"Walker CS, Raddant AC, Woolley MJ, Russo AF, Hay DL: CGRP receptor antagonist activity of olcegepant depends on the signalling pathway measured. Cephalalgia. 2017 Jan 1:333102417691762. doi: 10.1177/0333102417691762.","parent_key":"BE0009009"}
{"ref-id":"A2828","pubmed-id":17620375,"citation":"Hazen R, Harvey R, Ferris R, Craig C, Yates P, Griffin P, Miller J, Kaldor I, Ray J, Samano V, Furfine E, Spaltenstein A, Hale M, Tung R, St Clair M, Hanlon M, Boone L: In vitro antiviral activity of the novel, tyrosyl-based human immunodeficiency virus (HIV) type 1 protease inhibitor brecanavir (GW640385) in combination with other antiretrovirals and against a panel of protease inhibitor-resistant HIV. Antimicrob Agents Chemother. 2007 Sep;51(9):3147-54. Epub 2007 Jul 9.","parent_key":"BE0004854"}
{"ref-id":"A2831","pubmed-id":16723584,"citation":"Ford SL, Reddy YS, Anderson MT, Murray SC, Fernandez P, Stein DS, Johnson MA: Single-dose safety and pharmacokinetics of brecanavir, a novel human immunodeficiency virus protease inhibitor. Antimicrob Agents Chemother. 2006 Jun;50(6):2201-6.","parent_key":"BE0004854"}
{"ref-id":"A2830","pubmed-id":17261626,"citation":"Reddy YS, Ford SL, Anderson MT, Murray SC, Ng-Cashin J, Johnson MA: Safety and pharmacokinetics of brecanavir, a novel human immunodeficiency virus type 1 protease inhibitor, following repeat administration with and without ritonavir in healthy adult subjects. Antimicrob Agents Chemother. 2007 Apr;51(4):1202-8. Epub 2007 Jan 29.","parent_key":"BE0004854"}
{"ref-id":"A20155","pubmed-id":21115097,"citation":"Kojima H, Sata F, Takeuchi S, Sueyoshi T, Nagai T: Comparative study of human and mouse pregnane X receptor agonistic activity in 200 pesticides using in vitro reporter gene assays. Toxicology. 2011 Feb 27;280(3):77-87. doi: 10.1016/j.tox.2010.11.008. Epub 2010 Nov 27.","parent_key":"BE0000956"}
{"ref-id":"A14145","pubmed-id":19808995,"citation":"Tradtrantip L, Namkung W, Verkman AS: Crofelemer, an antisecretory antidiarrheal proanthocyanidin oligomer extracted from Croton lechleri, targets two distinct intestinal chloride channels. Mol Pharmacol. 2010 Jan;77(1):69-78. doi: 10.1124/mol.109.061051. Epub 2009 Oct 6.","parent_key":"BE0001195"}
{"ref-id":"A3062","pubmed-id":10829362,"citation":"Vincent JL: Afelimomab. Int J Clin Pract. 2000 Apr;54(3):190-3.","parent_key":"BE0000704"}
{"ref-id":"A3200","pubmed-id":15481993,"citation":"Almansa C, Bartroli J, Belloc J, Cavalcanti FL, Ferrando R, Gomez LA, Ramis I, Carceller E, Merlos M, Garcia-Rafanell J: New water-soluble sulfonylphosphoramidic acid derivatives of the COX-2 selective inhibitor cimicoxib. A novel approach to sulfonamide prodrugs. J Med Chem. 2004 Oct 21;47(22):5579-82.","parent_key":"BE0000262"}
{"ref-id":"A3678","pubmed-id":17929306,"citation":"McHutchison JG, Bacon BR, Gordon SC, Lawitz E, Shiffman M, Afdhal NH, Jacobson IM, Muir A, Al-Adhami M, Morris ML, Lekstrom-Himes JA, Efler SM, Davis HL: Phase 1B, randomized, double-blind, dose-escalation trial of CPG 10101 in patients with chronic hepatitis C virus. Hepatology. 2007 Nov;46(5):1341-9.","parent_key":"BE0001171"}
{"ref-id":"A36696","pubmed-id":25521244,"citation":"Weiss J, Theile D, Dvorak Z, Haefeli WE: Interaction potential of the multitargeted receptor tyrosine kinase inhibitor dovitinib with drug transporters and drug metabolising enzymes assessed in vitro. Pharmaceutics. 2014 Dec 16;6(4):632-50. doi: 10.3390/pharmaceutics6040632.","parent_key":"BE0000956"}
{"ref-id":"A192843","pubmed-id":31903790,"citation":"Miao M, De Clercq E, Li G: Clinical significance of chemokine receptor antagonists. Expert Opin Drug Metab Toxicol. 2020 Jan;16(1):11-30. doi: 10.1080/17425255.2020.1711884. Epub 2020 Jan 17.","parent_key":"BE0000911"}
{"ref-id":"A3922","pubmed-id":11134270,"citation":"Trkola A, Ketas TJ, Nagashima KA, Zhao L, Cilliers T, Morris L, Moore JP, Maddon PJ, Olson WC: Potent, broad-spectrum inhibition of human immunodeficiency virus type 1 by the CCR5 monoclonal antibody PRO 140. J Virol. 2001 Jan;75(2):579-88.","parent_key":"BE0000911"}
{"ref-id":"A4008","pubmed-id":21587264,"citation":"VanderMolen KM, McCulloch W, Pearce CJ, Oberlies NH: Romidepsin (Istodax, NSC 630176, FR901228, FK228, depsipeptide): a natural product recently approved for cutaneous T-cell lymphoma. J Antibiot (Tokyo). 2011 Aug;64(8):525-31. doi: 10.1038/ja.2011.35. Epub 2011 May 18.","parent_key":"BE0002365"}
{"ref-id":"A1991","pubmed-id":10592235,"citation":"Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H, Shindyalov IN, Bourne PE: The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42.","parent_key":"BE0000770"}
{"ref-id":"A1991","pubmed-id":10592235,"citation":"Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H, Shindyalov IN, Bourne PE: The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42.","parent_key":"BE0000420"}
{"ref-id":"A4092","pubmed-id":15956985,"citation":"Ingman K, Hagelberg N, Aalto S, Nagren K, Juhakoski A, Karhuvaara S, Kallio A, Oikonen V, Hietala J, Scheinin H: Prolonged central mu-opioid receptor occupancy after single and repeated nalmefene dosing. Neuropsychopharmacology. 2005 Dec;30(12):2245-53.","parent_key":"BE0000420"}
{"ref-id":"A31301","pubmed-id":25187751,"citation":"Paille F, Martini H: Nalmefene: a new approach to the treatment of alcohol dependence. Subst Abuse Rehabil. 2014 Aug 8;5:87-94. doi: 10.2147/SAR.S45666. eCollection 2014.","parent_key":"BE0000420"}
{"ref-id":"A14356","pubmed-id":17490919,"citation":"Sommer D, Bogdan R, Berger J, Peters DM, Morty RE, Clauss WG, Fronius M: CFTR-dependent Cl- secretion in Xenopus laevis lung epithelium. Respir Physiol Neurobiol. 2007 Aug 15;158(1):97-106. Epub 2007 Apr 5.","parent_key":"BE0001195"}
{"ref-id":"A14360","pubmed-id":16899109,"citation":"Smolen JS, Maini RN: Interleukin-6: a new therapeutic target. Arthritis Res Ther. 2006;8 Suppl 2:S5. Epub 2006 Jul 28.","parent_key":"BE0002859"}
{"ref-id":"A193263","pubmed-id":21940820,"citation":"Betts BC, St Angelo ET, Kennedy M, Young JW: Anti-IL6-receptor-alpha (tocilizumab) does not inhibit human monocyte-derived dendritic cell maturation or alloreactive T-cell responses. Blood. 2011 Nov 10;118(19):5340-3. doi: 10.1182/blood-2011-06-363390. Epub 2011 Sep 22.","parent_key":"BE0002859"}
{"ref-id":"A14616","pubmed-id":17909271,"citation":"Kraft MD: Emerging pharmacologic options for treating postoperative ileus. Am J Health Syst Pharm. 2007 Oct 15;64(20 Suppl 13):S13-20.","parent_key":"BE0000770"}
{"ref-id":"A6740","pubmed-id":19086236,"citation":"Buchler MW, Seiler CM, Monson JR, Flamant Y, Thompson-Fawcett MW, Byrne MM, Mortensen ER, Altman JF, Williamson R: Clinical trial: alvimopan for the management of post-operative ileus after abdominal surgery: results of an international randomized, double-blind, multicentre, placebo-controlled clinical study. Aliment Pharmacol Ther. 2008 Aug 1;28(3):312-25.","parent_key":"BE0000770"}
{"ref-id":"A14617","pubmed-id":16597533,"citation":"Saufl NM, Strzyzewski N: Nurses are everywhere: a practical perspective on the surgical team in managing postoperative ileus. J Perianesth Nurs. 2006 Apr;21(2A Suppl):S24-9.","parent_key":"BE0000770"}
{"ref-id":"A14618","pubmed-id":15882122,"citation":"Neary P, Delaney CP: Alvimopan. Expert Opin Investig Drugs. 2005 Apr;14(4):479-88.","parent_key":"BE0000770"}
{"ref-id":"A14619","pubmed-id":11755894,"citation":"Schmidt WK: Alvimopan* (ADL 8-2698) is a novel peripheral opioid antagonist. Am J Surg. 2001 Nov;182(5A Suppl):27S-38S.","parent_key":"BE0000770"}
{"ref-id":"A14618","pubmed-id":15882122,"citation":"Neary P, Delaney CP: Alvimopan. Expert Opin Investig Drugs. 2005 Apr;14(4):479-88.","parent_key":"BE0000420"}
{"ref-id":"A16930","pubmed-id":17340127,"citation":"Beattie DT, Cheruvu M, Mai N, O'Keefe M, Johnson-Rabidoux S, Peterson C, Kaufman E, Vickery R: The in vitro pharmacology of the peripherally restricted opioid receptor antagonists, alvimopan, ADL 08-0011 and methylnaltrexone. Naunyn Schmiedebergs Arch Pharmacol. 2007 May;375(3):205-20. Epub 2007 Mar 6.","parent_key":"BE0000420"}
{"ref-id":"A1991","pubmed-id":10592235,"citation":"Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H, Shindyalov IN, Bourne PE: The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42.","parent_key":"BE0000246"}
{"ref-id":"A203369","pubmed-id":23463743,"citation":"Mansour H, Chahine EB, Karaoui LR, El-Lababidi RM: Cethromycin: a new ketolide antibiotic. Ann Pharmacother. 2013 Mar;47(3):368-79. doi: 10.1345/aph.1R435. Epub 2013 Mar 5.","parent_key":"BE0004800"}
{"ref-id":"A203417","pubmed-id":12177734,"citation":"Champney WS, Pelt J: The ketolide antibiotic ABT-773 is a specific inhibitor of translation and 50S ribosomal subunit formation in Streptococcus pneumoniae cells. Curr Microbiol. 2002 Sep;45(3):155-60. doi: 10.1007/s00284-001-0110-9.","parent_key":"BE0004800"}
{"ref-id":"A203420","pubmed-id":15469510,"citation":"Vimberg V, Xiong L, Bailey M, Tenson T, Mankin A: Peptide-mediated macrolide resistance reveals possible specific interactions in the nascent peptide exit tunnel. Mol Microbiol. 2004 Oct;54(2):376-85. doi: 10.1111/j.1365-2958.2004.04290.x.","parent_key":"BE0004800"}
{"ref-id":"A14633","pubmed-id":10202976,"citation":"Leker RR, Shohami E, Abramsky O, Ovadia H: Dexanabinol; a novel neuroprotective drug in experimental focal cerebral ischemia. J Neurol Sci. 1999 Jan 15;162(2):114-9.","parent_key":"BE0000704"}
{"ref-id":"A14634","pubmed-id":14664914,"citation":"Trembovler V, Abu-Raya S, Shohami E: Synergism between tumor necrosis factor-alpha and H2O2 enhances cell damage in rat PC12 cells. Neurosci Lett. 2003 Dec 19;353(2):115-8.","parent_key":"BE0000704"}
{"ref-id":"A14650","pubmed-id":15475571,"citation":"Erbe DV, Wang S, Zhang YL, Harding K, Kung L, Tam M, Stolz L, Xing Y, Furey S, Qadri A, Klaman LD, Tobin JF: Ertiprotafib improves glycemic control and lowers lipids via multiple mechanisms. Mol Pharmacol. 2005 Jan;67(1):69-77. Epub 2004 Oct 8.","parent_key":"BE0000071"}
{"ref-id":"A14650","pubmed-id":15475571,"citation":"Erbe DV, Wang S, Zhang YL, Harding K, Kung L, Tam M, Stolz L, Xing Y, Furey S, Qadri A, Klaman LD, Tobin JF: Ertiprotafib improves glycemic control and lowers lipids via multiple mechanisms. Mol Pharmacol. 2005 Jan;67(1):69-77. Epub 2004 Oct 8.","parent_key":"BE0000215"}
{"ref-id":"A14654","pubmed-id":12970088,"citation":"Chakrabarti R, Vikramadithyan RK, Misra P, Hiriyan J, Raichur S, Damarla RK, Gershome C, Suresh J, Rajagopalan R: Ragaglitazar: a novel PPAR alpha PPAR gamma agonist with potent lipid-lowering and insulin-sensitizing efficacy in animal models. Br J Pharmacol. 2003 Oct;140(3):527-37. Epub 2003 Sep 1.","parent_key":"BE0000071"}
{"ref-id":"A14655","pubmed-id":16240504,"citation":"Egerod FL, Nielsen HS, Iversen L, Thorup I, Storgaard T, Oleksiewicz MB: Biomarkers for early effects of carcinogenic dual-acting PPAR agonists in rat urinary bladder urothelium in vivo. Biomarkers. 2005 Jul-Aug;10(4):295-309.","parent_key":"BE0000071"}
{"ref-id":"A14654","pubmed-id":12970088,"citation":"Chakrabarti R, Vikramadithyan RK, Misra P, Hiriyan J, Raichur S, Damarla RK, Gershome C, Suresh J, Rajagopalan R: Ragaglitazar: a novel PPAR alpha PPAR gamma agonist with potent lipid-lowering and insulin-sensitizing efficacy in animal models. Br J Pharmacol. 2003 Oct;140(3):527-37. Epub 2003 Sep 1.","parent_key":"BE0000215"}
{"ref-id":"A14655","pubmed-id":16240504,"citation":"Egerod FL, Nielsen HS, Iversen L, Thorup I, Storgaard T, Oleksiewicz MB: Biomarkers for early effects of carcinogenic dual-acting PPAR agonists in rat urinary bladder urothelium in vivo. Biomarkers. 2005 Jul-Aug;10(4):295-309.","parent_key":"BE0000215"}
{"ref-id":"A14656","pubmed-id":16168052,"citation":"Tenenbaum A, Motro M, Fisman EZ: Dual and pan-peroxisome proliferator-activated receptors (PPAR) co-agonism: the bezafibrate lessons. Cardiovasc Diabetol. 2005 Sep 16;4:14.","parent_key":"BE0000071"}
{"ref-id":"A31531","pubmed-id":20347527,"citation":"Seimetz D, Lindhofer H, Bokemeyer C: Development and approval of the trifunctional antibody catumaxomab (anti-EpCAM x anti-CD3) as a targeted cancer immunotherapy. Cancer Treat Rev. 2010 Oct;36(6):458-67. doi: 10.1016/j.ctrv.2010.03.001. Epub 2010 Mar 27.","parent_key":"BE0002098"}
{"ref-id":"A31531","pubmed-id":20347527,"citation":"Seimetz D, Lindhofer H, Bokemeyer C: Development and approval of the trifunctional antibody catumaxomab (anti-EpCAM x anti-CD3) as a targeted cancer immunotherapy. Cancer Treat Rev. 2010 Oct;36(6):458-67. doi: 10.1016/j.ctrv.2010.03.001. Epub 2010 Mar 27.","parent_key":"BE0002097"}
{"ref-id":"A31531","pubmed-id":20347527,"citation":"Seimetz D, Lindhofer H, Bokemeyer C: Development and approval of the trifunctional antibody catumaxomab (anti-EpCAM x anti-CD3) as a targeted cancer immunotherapy. Cancer Treat Rev. 2010 Oct;36(6):458-67. doi: 10.1016/j.ctrv.2010.03.001. Epub 2010 Mar 27.","parent_key":"BE0000710"}
{"ref-id":"A14688","pubmed-id":18523657,"citation":"Dejneka NS, Wan S, Bond OS, Kornbrust DJ, Reich SJ: Ocular biodistribution of bevasiranib following a single intravitreal injection to rabbit eyes. Mol Vis. 2008 May 28;14:997-1005.","parent_key":"BE0000163"}
{"ref-id":"A14691","pubmed-id":17243065,"citation":"Wilkin TJ, Su Z, Kuritzkes DR, Hughes M, Flexner C, Gross R, Coakley E, Greaves W, Godfrey C, Skolnik PR, Timpone J, Rodriguez B, Gulick RM: HIV type 1 chemokine coreceptor use among antiretroviral-experienced patients screened for a clinical trial of a CCR5 inhibitor: AIDS Clinical Trial Group A5211. Clin Infect Dis. 2007 Feb 15;44(4):591-5. Epub 2007 Jan 17.","parent_key":"BE0000911"}
{"ref-id":"A14692","pubmed-id":18495779,"citation":"Tsibris AM, Sagar M, Gulick RM, Su Z, Hughes M, Greaves W, Subramanian M, Flexner C, Giguel F, Leopold KE, Coakley E, Kuritzkes DR: In vivo emergence of vicriviroc resistance in a human immunodeficiency virus type 1 subtype C-infected subject. J Virol. 2008 Aug;82(16):8210-4. doi: 10.1128/JVI.00444-08. Epub 2008 May 21.","parent_key":"BE0000911"}
{"ref-id":"A17984","pubmed-id":21079302,"citation":"Mittal M, Raychaudhuri SP: Golimumab and certolizumab: the two new anti-tumor necrosis factor kids on the block. Indian J Dermatol Venereol Leprol. 2010 Nov-Dec;76(6):602-8; quiz 609. doi: 10.4103/0378-6323.72445.","parent_key":"BE0000704"}
{"ref-id":"A15720","pubmed-id":20399943,"citation":"Renner RM, Jensen JT, Nichols MD, Edelman AB: Pain control in first-trimester surgical abortion: a systematic review of randomized controlled trials. Contraception. 2010 May;81(5):372-88. doi: 10.1016/j.contraception.2009.12.008. Epub 2010 Jan 27.","parent_key":"BE0000017"}
{"ref-id":"A15721","pubmed-id":10450786,"citation":"Berg J, Fellier H, Christoph T, Grarup J, Stimmeder D: The analgesic NSAID lornoxicam inhibits cyclooxygenase (COX)-1/-2, inducible nitric oxide synthase (iNOS), and the formation of interleukin (IL)-6 in vitro. Inflamm Res. 1999 Jul;48(7):369-79.","parent_key":"BE0000017"}
{"ref-id":"A15722","pubmed-id":17516707,"citation":"Rose P, Steinhauser C: Comparison of Lornoxicam and Rofecoxib in Patients with Activated Osteoarthritis (COLOR Study). Clin Drug Investig. 2004;24(4):227-36.","parent_key":"BE0000017"}
{"ref-id":"A15723","pubmed-id":11846620,"citation":"Bianchi M, Panerai AE: Effects of lornoxicam, piroxicam, and meloxicam in a model of thermal hindpaw hyperalgesia induced by formalin injection in rat tail. Pharmacol Res. 2002 Feb;45(2):101-5.","parent_key":"BE0000017"}
{"ref-id":"A15720","pubmed-id":20399943,"citation":"Renner RM, Jensen JT, Nichols MD, Edelman AB: Pain control in first-trimester surgical abortion: a systematic review of randomized controlled trials. Contraception. 2010 May;81(5):372-88. doi: 10.1016/j.contraception.2009.12.008. Epub 2010 Jan 27.","parent_key":"BE0000262"}
{"ref-id":"A15721","pubmed-id":10450786,"citation":"Berg J, Fellier H, Christoph T, Grarup J, Stimmeder D: The analgesic NSAID lornoxicam inhibits cyclooxygenase (COX)-1/-2, inducible nitric oxide synthase (iNOS), and the formation of interleukin (IL)-6 in vitro. Inflamm Res. 1999 Jul;48(7):369-79.","parent_key":"BE0000262"}
{"ref-id":"A15722","pubmed-id":17516707,"citation":"Rose P, Steinhauser C: Comparison of Lornoxicam and Rofecoxib in Patients with Activated Osteoarthritis (COLOR Study). Clin Drug Investig. 2004;24(4):227-36.","parent_key":"BE0000262"}
{"ref-id":"A15723","pubmed-id":11846620,"citation":"Bianchi M, Panerai AE: Effects of lornoxicam, piroxicam, and meloxicam in a model of thermal hindpaw hyperalgesia induced by formalin injection in rat tail. Pharmacol Res. 2002 Feb;45(2):101-5.","parent_key":"BE0000262"}
{"ref-id":"A19667","pubmed-id":15163279,"citation":"Legrand E: Aceclofenac in the management of inflammatory pain. Expert Opin Pharmacother. 2004 Jun;5(6):1347-57.","parent_key":"BE0000262"}
{"ref-id":"A19667","pubmed-id":15163279,"citation":"Legrand E: Aceclofenac in the management of inflammatory pain. Expert Opin Pharmacother. 2004 Jun;5(6):1347-57.","parent_key":"BE0000017"}
{"ref-id":"A18118","pubmed-id":8878254,"citation":"Kristensen K, Christensen CB, Christrup LL, Nielsen LC: The mu1 and mu2 opioid receptor binding of ketobemidone, norketobemidone and 3-dimethylamino-1,1-diphenylbutene. Pharmacol Toxicol. 1996 Aug;79(2):103-4.","parent_key":"BE0000770"}
{"ref-id":"A18119","pubmed-id":8153059,"citation":"Christensen CB: The opioid receptor binding profiles of ketobemidone and morphine. Pharmacol Toxicol. 1993 Dec;73(6):344-5.","parent_key":"BE0000770"}
{"ref-id":"A18119","pubmed-id":8153059,"citation":"Christensen CB: The opioid receptor binding profiles of ketobemidone and morphine. Pharmacol Toxicol. 1993 Dec;73(6):344-5.","parent_key":"BE0000420"}
{"ref-id":"A20251","pubmed-id":25765238,"citation":"Kennedy RK, Naik PR, Veena V, Lakshmi BS, Lakshmi P, Krishna R, Sakthivel N: 5-Methyl phenazine-1-carboxylic acid: a novel bioactive metabolite by a rhizosphere soil bacterium that exhibits potent antimicrobial and anticancer activities. Chem Biol Interact. 2015 Apr 25;231:71-82. doi: 10.1016/j.cbi.2015.03.002. Epub 2015 Mar 9.","parent_key":"BE0000246"}
{"ref-id":"A20070","pubmed-id":17963371,"citation":"Katona BW, Cummins CL, Ferguson AD, Li T, Schmidt DR, Mangelsdorf DJ, Covey DF: Synthesis, characterization, and receptor interaction profiles of enantiomeric bile acids. J Med Chem. 2007 Nov 29;50(24):6048-58. Epub 2007 Oct 27.","parent_key":"BE0000956"}
{"ref-id":"A17287","pubmed-id":21091776,"citation":"Norrby K, Nordenhem A: Dalteparin, a low-molecular-weight heparin, promotes angiogenesis mediated by heparin-binding VEGF-A in vivo. APMIS. 2010 Dec;118(12):949-57. doi: 10.1111/j.1600-0463.2010.02635.x. Epub 2010  Oct 12.","parent_key":"BE0000163"}
{"ref-id":"A17288","pubmed-id":17692905,"citation":"Marchetti M, Vignoli A, Russo L, Balducci D, Pagnoncelli M, Barbui T, Falanga A: Endothelial capillary tube formation and cell proliferation induced by tumor cells are affected by low molecular weight heparins and unfractionated heparin. Thromb Res. 2008;121(5):637-45. Epub 2007 Aug 10.","parent_key":"BE0000163"}
{"ref-id":"A17289","pubmed-id":16041398,"citation":"Takahashi H, Ebihara S, Okazaki T, Asada M, Sasaki H, Yamaya M: A comparison of the effects of unfractionated heparin, dalteparin and danaparoid on vascular endothelial growth factor-induced tumour angiogenesis and heparanase activity. Br J Pharmacol. 2005 Oct;146(3):333-43.","parent_key":"BE0000163"}
{"ref-id":"A7077","pubmed-id":19668594,"citation":"Jamal KN, Callanan DG: The role of difluprednate ophthalmic emulsion in clinical practice. Clin Ophthalmol. 2009;3:381-90. Epub 2009 Jun 29.","parent_key":"BE0000794"}
{"ref-id":"A16915","pubmed-id":20509750,"citation":"Tajika T, Takahashi H, Sakai Y, Fujii H, Isowaki A, Sakaki H: Metabolic profiles of difluprednate in rabbit ocular tissues after instillation of difluprednate ophthalmic emulsion. Xenobiotica. 2010 Aug;40(8):569-77. doi: 10.3109/00498254.2010.490308.","parent_key":"BE0000794"}
{"ref-id":"A17900","pubmed-id":17504835,"citation":"Yuan CS: Methylnaltrexone mechanisms of action and effects on opioid bowel dysfunction and other opioid adverse effects. Ann Pharmacother. 2007 Jun;41(6):984-93. Epub 2007 May 15.","parent_key":"BE0000770"}
{"ref-id":"A7106","pubmed-id":10850857,"citation":"Gamache DA, Graff G, Brady MT, Spellman JM, Yanni JM: Nepafenac, a unique nonsteroidal prodrug with potential utility in the treatment of trauma-induced ocular inflammation: I. Assessment of anti-inflammatory efficacy. Inflammation. 2000 Aug;24(4):357-70.","parent_key":"BE0000017"}
{"ref-id":"A7106","pubmed-id":10850857,"citation":"Gamache DA, Graff G, Brady MT, Spellman JM, Yanni JM: Nepafenac, a unique nonsteroidal prodrug with potential utility in the treatment of trauma-induced ocular inflammation: I. Assessment of anti-inflammatory efficacy. Inflammation. 2000 Aug;24(4):357-70.","parent_key":"BE0000262"}
{"ref-id":"A1991","pubmed-id":10592235,"citation":"Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H, Shindyalov IN, Bourne PE: The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42.","parent_key":"BE0000956"}
{"ref-id":"A1991","pubmed-id":10592235,"citation":"Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H, Shindyalov IN, Bourne PE: The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42.","parent_key":"BE0000071"}
{"ref-id":"A1991","pubmed-id":10592235,"citation":"Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H, Shindyalov IN, Bourne PE: The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42.","parent_key":"BE0003801"}
{"ref-id":"A1991","pubmed-id":10592235,"citation":"Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H, Shindyalov IN, Bourne PE: The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42.","parent_key":"BE0001092"}
{"ref-id":"A18383","pubmed-id":10794682,"citation":"Talley JJ, Bertenshaw SR, Brown DL, Carter JS, Graneto MJ, Kellogg MS, Koboldt CM, Yuan J, Zhang YY, Seibert K: N-[[(5-methyl-3-phenylisoxazol-4-yl)-phenyl]sulfonyl]propanamide, sodium salt, parecoxib sodium: A potent and selective inhibitor of COX-2 for parenteral administration. J Med Chem. 2000 May 4;43(9):1661-3.","parent_key":"BE0000262"}
{"ref-id":"A20239","pubmed-id":25314719,"citation":"Fang M, Webster TF, Ferguson PL, Stapleton HM: Characterizing the peroxisome proliferator-activated receptor (PPARgamma) ligand binding potential of several major flame retardants, their metabolites, and chemical mixtures in house dust. Environ Health Perspect. 2015 Feb;123(2):166-72. doi: 10.1289/ehp.1408522. Epub 2014 Oct 14.","parent_key":"BE0000215"}
{"ref-id":"A7336","pubmed-id":19465361,"citation":"Anninos H, Andrikopoulos G, Pastromas S, Sakellariou D, Theodorakis G, Vardas P: Triflusal: an old drug in modern antiplatelet therapy. Review of its action, use, safety and effectiveness. Hellenic J Cardiol. 2009 May-Jun;50(3):199-207.","parent_key":"BE0000017"}
{"ref-id":"A17414","pubmed-id":3838919,"citation":"Dominguez MJ, Vacas M, Saez Y, Olabarria I, Velasco A, Iriarte JA, Forn J: Effects of triflusal in patients with prosthetic heart valves. Clin Ther. 1985;7(3):357-60.","parent_key":"BE0000017"}
{"ref-id":"A7336","pubmed-id":19465361,"citation":"Anninos H, Andrikopoulos G, Pastromas S, Sakellariou D, Theodorakis G, Vardas P: Triflusal: an old drug in modern antiplatelet therapy. Review of its action, use, safety and effectiveness. Hellenic J Cardiol. 2009 May-Jun;50(3):199-207.","parent_key":"BE0000005"}
{"ref-id":"A17418","pubmed-id":9551715,"citation":"Sanchez de Miguel L, Casado S, Farre J, Garcia-Duran M, Rico LA, Monton M, Romero J, Bellver T, Sierra MP, Guerra JI, Mata P, Esteban A, Lopez-Farre A: Comparison of in vitro effects of triflusal and acetysalicylic acid on nitric oxide synthesis by human neutrophils. Eur J Pharmacol. 1998 Feb 5;343(1):57-65.","parent_key":"BE0000005"}
{"ref-id":"A17419","pubmed-id":10998082,"citation":"De Miguel LS, Jimenez A, Monton M, Farre J, Del Mar Arriero M, Rodriguez-Feo JA, Garcia-Canete J, Rico L, Gomez J, Nunez A, Casado S, Farre AL: A 4-trifluoromethyl derivative of salicylate, triflusal, stimulates nitric oxide production by human neutrophils: role in platelet function. Eur J Clin Invest. 2000 Sep;30(9):811-7.","parent_key":"BE0000005"}
{"ref-id":"A7340","pubmed-id":16939630,"citation":"Gonzalez-Correa JA, De La Cruz JP: Triflusal: an antiplatelet drug with a neuroprotective effect? Cardiovasc Drug Rev. 2006 Spring;24(1):11-24.","parent_key":"BE0000005"}
{"ref-id":"A17564","pubmed-id":22293084,"citation":"Yu H, Burton B, Huang CJ, Worley J, Cao D, Johnson JP Jr, Urrutia A, Joubran J, Seepersaud S, Sussky K, Hoffman BJ, Van Goor F: Ivacaftor potentiation of multiple CFTR channels with gating mutations. J Cyst Fibros. 2012 May;11(3):237-45. doi: 10.1016/j.jcf.2011.12.005. Epub 2012 Jan 30.","parent_key":"BE0001195"}
{"ref-id":"A179674","pubmed-id":27636560,"citation":"Fohner AE, McDonagh EM, Clancy JP, Whirl Carrillo M, Altman RB, Klein TE: PharmGKB summary: ivacaftor pathway, pharmacokinetics/pharmacodynamics. Pharmacogenet Genomics. 2017 Jan;27(1):39-42. doi: 10.1097/FPC.0000000000000246.","parent_key":"BE0001195"}
{"ref-id":"A17927","pubmed-id":23583259,"citation":"Sharma D, Lau AJ, Sherman MA, Chang TK: Agonism of human pregnane X receptor by rilpivirine and etravirine: comparison with first generation non-nucleoside reverse transcriptase inhibitors. Biochem Pharmacol. 2013 Jun 1;85(11):1700-11. doi: 10.1016/j.bcp.2013.04.002. Epub 2013 Apr 9.","parent_key":"BE0000956"}
{"ref-id":"A7426","pubmed-id":23437846,"citation":"Gemzell-Danielsson K, Rabe T, Cheng L: Emergency contraception. Gynecol Endocrinol. 2013 Mar;29 Suppl 1:1-14. doi: 10.3109/09513590.2013.774591.","parent_key":"BE0000794"}
{"ref-id":"A17921","pubmed-id":23579459,"citation":"Zu Heringdorf DM, Ihlefeld K, Pfeilschifter J: Pharmacology of the sphingosine-1-phosphate signalling system. Handb Exp Pharmacol. 2013;(215):239-53. doi: 10.1007/978-3-7091-1368-4_13.","parent_key":"BE0002432"}
{"ref-id":"A17922","pubmed-id":23579456,"citation":"Bhabak KP, Arenz C: Novel drugs targeting sphingolipid metabolism. Handb Exp Pharmacol. 2013;(215):187-96. doi: 10.1007/978-3-7091-1368-4_10.","parent_key":"BE0002432"}
{"ref-id":"A20231","pubmed-id":24859201,"citation":"Hait NC, Wise LE, Allegood JC, O'Brien M, Avni D, Reeves TM, Knapp PE, Lu J, Luo C, Miles MF, Milstien S, Lichtman AH, Spiegel S: Active, phosphorylated fingolimod inhibits histone deacetylases and facilitates fear extinction memory. Nat Neurosci. 2014 Jul;17(7):971-80. doi: 10.1038/nn.3728. Epub 2014 May 25.","parent_key":"BE0002365"}
{"ref-id":"A192816","pubmed-id":26053034,"citation":"Hait NC, Avni D, Yamada A, Nagahashi M, Aoyagi T, Aoki H, Dumur CI, Zelenko Z, Gallagher EJ, Leroith D, Milstien S, Takabe K, Spiegel S: The phosphorylated prodrug FTY720 is a histone deacetylase inhibitor that reactivates ERalpha expression and enhances hormonal therapy for breast cancer. Oncogenesis. 2015 Jun 8;4:e156. doi: 10.1038/oncsis.2015.16.","parent_key":"BE0002365"}
{"ref-id":"A192819","pubmed-id":31826690,"citation":"Perla AS, Fratini L, Cardoso PS, de Farias CB, da Cunha Jaeger M, Roesler R: Fingolimod (FTY720) reduces viability and survival and increases histone H3 acetylation in medulloblastoma cells. Pediatr Hematol Oncol. 2020 Mar;37(2):170-175. doi: 10.1080/08880018.2019.1699213. Epub 2019 Dec 11.","parent_key":"BE0002365"}
{"ref-id":"A38022","pubmed-id":22149256,"citation":"David OJ, Kovarik JM, Schmouder RL: Clinical pharmacokinetics of fingolimod. Clin Pharmacokinet. 2012 Jan 1;51(1):15-28. doi: 10.2165/11596550-000000000-00000.","parent_key":"BE0008652"}
{"ref-id":"A38022","pubmed-id":22149256,"citation":"David OJ, Kovarik JM, Schmouder RL: Clinical pharmacokinetics of fingolimod. Clin Pharmacokinet. 2012 Jan 1;51(1):15-28. doi: 10.2165/11596550-000000000-00000.","parent_key":"BE0009882"}
{"ref-id":"A38022","pubmed-id":22149256,"citation":"David OJ, Kovarik JM, Schmouder RL: Clinical pharmacokinetics of fingolimod. Clin Pharmacokinet. 2012 Jan 1;51(1):15-28. doi: 10.2165/11596550-000000000-00000.","parent_key":"BE0009881"}
{"ref-id":"A3006","pubmed-id":15313917,"citation":"Kuznetsov G, Towle MJ, Cheng H, Kawamura T, TenDyke K, Liu D, Kishi Y, Yu MJ, Littlefield BA: Induction of morphological and biochemical apoptosis following prolonged mitotic blockage by halichondrin B macrocyclic ketone analog E7389. Cancer Res. 2004 Aug 15;64(16):5760-6.","parent_key":"BE0000246"}
{"ref-id":"A17944","pubmed-id":22813448,"citation":"Browning DJ, Kaiser PK, Rosenfeld PJ, Stewart MW: Aflibercept for age-related macular degeneration: a game-changer or quiet addition? Am J Ophthalmol. 2012 Aug;154(2):222-6. doi: 10.1016/j.ajo.2012.04.020.","parent_key":"BE0000163"}
{"ref-id":"A7485","pubmed-id":23620660,"citation":"Chimenti MS, Saraceno R, Chiricozzi A, Giunta A, Chimenti S, Perricone R: Profile of certolizumab and its potential in the treatment of psoriatic arthritis. Drug Des Devel Ther. 2013 Apr 15;7:339-48. doi: 10.2147/DDDT.S31658. Print 2013.","parent_key":"BE0000704"}
{"ref-id":"A176585","pubmed-id":28976302,"citation":"Corbett M, Chehadah F, Biswas M, Moe-Byrne T, Palmer S, Soares M, Walton M, Harden M, Ho P, Woolacott N, Bojke L: Certolizumab pegol and secukinumab for treating active psoriatic arthritis following inadequate response to disease-modifying antirheumatic drugs: a systematic review and economic evaluation. Health Technol Assess. 2017 Oct;21(56):1-326. doi: 10.3310/hta21560.","parent_key":"BE0000704"}
{"ref-id":"A7493","pubmed-id":22917017,"citation":"Gertz MA: Pomalidomide and myeloma meningitis. Leuk Lymphoma. 2013 Apr;54(4):681-2. doi: 10.3109/10428194.2012.723708. Epub 2013 Jan 2.","parent_key":"BE0000704"}
{"ref-id":"A17981","pubmed-id":17308870,"citation":"Ferguson GD, Jensen-Pergakes K, Wilkey C, Jhaveri U, Richard N, Verhelle D, De Parseval LM, Corral LG, Xie W, Morris CL, Brady H, Chan K: Immunomodulatory drug CC-4047 is a cell-type and stimulus-selective transcriptional inhibitor of cyclooxygenase 2. J Clin Immunol. 2007 Mar;27(2):210-20. Epub 2007 Feb 17.","parent_key":"BE0000262"}
{"ref-id":"A17988","pubmed-id":20653327,"citation":"Cavender MA, Lincoff AM: Therapeutic potential of aleglitazar, a new dual PPAR-alpha/gamma agonist: implications for cardiovascular disease in patients with diabetes mellitus. Am J Cardiovasc Drugs. 2010;10(4):209-16. doi: 10.2165/11539500-000000000-00000.","parent_key":"BE0000071"}
{"ref-id":"A17988","pubmed-id":20653327,"citation":"Cavender MA, Lincoff AM: Therapeutic potential of aleglitazar, a new dual PPAR-alpha/gamma agonist: implications for cardiovascular disease in patients with diabetes mellitus. Am J Cardiovasc Drugs. 2010;10(4):209-16. doi: 10.2165/11539500-000000000-00000.","parent_key":"BE0000215"}
{"ref-id":"A19851","pubmed-id":11779144,"citation":"Inoue I, Itoh F, Aoyagi S, Tazawa S, Kusama H, Akahane M, Mastunaga T, Hayashi K, Awata T, Komoda T, Katayama S: Fibrate and statin synergistically increase the transcriptional activities of PPARalpha/RXRalpha and decrease the transactivation of NFkappaB. Biochem Biophys Res Commun. 2002 Jan 11;290(1):131-9.","parent_key":"BE0000215"}
{"ref-id":"A199077","pubmed-id":18757750,"citation":"Wilson DN, Schluenzen F, Harms JM, Starosta AL, Connell SR, Fucini P: The oxazolidinone antibiotics perturb the ribosomal peptidyl-transferase center and effect tRNA positioning. Proc Natl Acad Sci U S A. 2008 Sep 9;105(36):13339-44. doi: 10.1073/pnas.0804276105. Epub 2008 Aug 29.","parent_key":"BE0004800"}
{"ref-id":"A199080","pubmed-id":17499045,"citation":"Leach KL, Swaney SM, Colca JR, McDonald WG, Blinn JR, Thomasco LM, Gadwood RC, Shinabarger D, Xiong L, Mankin AS: The site of action of oxazolidinone antibiotics in living bacteria and in human mitochondria. Mol Cell. 2007 May 11;26(3):393-402. doi: 10.1016/j.molcel.2007.04.005.","parent_key":"BE0004800"}
{"ref-id":"A199083","pubmed-id":9333037,"citation":"Shinabarger DL, Marotti KR, Murray RW, Lin AH, Melchior EP, Swaney SM, Dunyak DS, Demyan WF, Buysse JM: Mechanism of action of oxazolidinones: effects of linezolid and eperezolid on translation reactions. Antimicrob Agents Chemother. 1997 Oct;41(10):2132-6.","parent_key":"BE0004800"}
{"ref-id":"A7653","pubmed-id":25471070,"citation":"Leonard J, Baker DE: Naloxegol: treatment for opioid-induced constipation in chronic non-cancer pain. Ann Pharmacother. 2015 Mar;49(3):360-5. doi: 10.1177/1060028014560191. Epub 2014  Dec 3.","parent_key":"BE0000770"}
{"ref-id":"A31555","pubmed-id":26264914,"citation":"Ibeas Bih C, Chen T, Nunn AV, Bazelot M, Dallas M, Whalley BJ: Molecular Targets of Cannabidiol in Neurological Disorders. Neurotherapeutics. 2015 Oct;12(4):699-730. doi: 10.1007/s13311-015-0377-3.","parent_key":"BE0000420"}
{"ref-id":"A31555","pubmed-id":26264914,"citation":"Ibeas Bih C, Chen T, Nunn AV, Bazelot M, Dallas M, Whalley BJ: Molecular Targets of Cannabidiol in Neurological Disorders. Neurotherapeutics. 2015 Oct;12(4):699-730. doi: 10.1007/s13311-015-0377-3.","parent_key":"BE0000770"}
{"ref-id":"A31555","pubmed-id":26264914,"citation":"Ibeas Bih C, Chen T, Nunn AV, Bazelot M, Dallas M, Whalley BJ: Molecular Targets of Cannabidiol in Neurological Disorders. Neurotherapeutics. 2015 Oct;12(4):699-730. doi: 10.1007/s13311-015-0377-3.","parent_key":"BE0000215"}
{"ref-id":"A33357","pubmed-id":24288245,"citation":"Scuderi C, Steardo L, Esposito G: Cannabidiol promotes amyloid precursor protein ubiquitination and reduction of beta amyloid expression in SHSY5YAPP+ cells through PPARgamma involvement. Phytother Res. 2014 Jul;28(7):1007-13. doi: 10.1002/ptr.5095. Epub 2013 Nov 28.","parent_key":"BE0000215"}
{"ref-id":"A31555","pubmed-id":26264914,"citation":"Ibeas Bih C, Chen T, Nunn AV, Bazelot M, Dallas M, Whalley BJ: Molecular Targets of Cannabidiol in Neurological Disorders. Neurotherapeutics. 2015 Oct;12(4):699-730. doi: 10.1007/s13311-015-0377-3.","parent_key":"BE0000017"}
{"ref-id":"A31555","pubmed-id":26264914,"citation":"Ibeas Bih C, Chen T, Nunn AV, Bazelot M, Dallas M, Whalley BJ: Molecular Targets of Cannabidiol in Neurological Disorders. Neurotherapeutics. 2015 Oct;12(4):699-730. doi: 10.1007/s13311-015-0377-3.","parent_key":"BE0000262"}
{"ref-id":"A19688","pubmed-id":1963196,"citation":"Kaneto H, Takahashi M, Watanabe J: The opioid receptor selectivity for trimebutine in isolated tissues experiments and receptor binding studies. J Pharmacobiodyn. 1990 Jul;13(7):448-53.","parent_key":"BE0000770"}
{"ref-id":"A31449","pubmed-id":16604091,"citation":"Barnes PJ: How corticosteroids control inflammation: Quintiles Prize Lecture 2005. Br J Pharmacol. 2006 Jun;148(3):245-54. doi: 10.1038/sj.bjp.0706736.","parent_key":"BE0000794"}
{"ref-id":"A31458","pubmed-id":23213332,"citation":"Uva L, Miguel D, Pinheiro C, Antunes J, Cruz D, Ferreira J, Filipe P: Mechanisms of action of topical corticosteroids in psoriasis. Int J Endocrinol. 2012;2012:561018. doi: 10.1155/2012/561018. Epub 2012 Nov 5.","parent_key":"BE0000794"}
{"ref-id":"A18396","pubmed-id":23896281,"citation":"Gao M: Antiviral activity and resistance of HCV NS5A replication complex inhibitors. Curr Opin Virol. 2013 Oct;3(5):514-20. doi: 10.1016/j.coviro.2013.06.014. Epub 2013 Jul 27.","parent_key":"BE0008651"}
{"ref-id":"A18411","pubmed-id":20446681,"citation":"Bolli MH, Abele S, Binkert C, Bravo R, Buchmann S, Bur D, Gatfield J, Hess P, Kohl C, Mangold C, Mathys B, Menyhart K, Muller C, Nayler O, Scherz M, Schmidt G, Sippel V, Steiner B, Strasser D, Treiber A, Weller T: 2-imino-thiazolidin-4-one derivatives as potent, orally active S1P1 receptor agonists. J Med Chem. 2010 May 27;53(10):4198-211. doi: 10.1021/jm100181s.","parent_key":"BE0008652"}
{"ref-id":"A18412","pubmed-id":21345969,"citation":"Piali L, Froidevaux S, Hess P, Nayler O, Bolli MH, Schlosser E, Kohl C, Steiner B, Clozel M: The selective sphingosine 1-phosphate receptor 1 agonist ponesimod protects against lymphocyte-mediated tissue inflammation. J Pharmacol Exp Ther. 2011 May;337(2):547-56. doi: 10.1124/jpet.110.176487. Epub  2011 Feb 23.","parent_key":"BE0008652"}
{"ref-id":"A19833","pubmed-id":15359738,"citation":"Smith SD, She YM, Roberts EA, Sarkar B: Using immobilized metal affinity chromatography, two-dimensional electrophoresis and mass spectrometry to identify hepatocellular proteins with copper-binding ability. J Proteome Res. 2004 Jul-Aug;3(4):834-40.","parent_key":"BE0000143"}
{"ref-id":"A182060","pubmed-id":28807672,"citation":"Baumann MH, Majumdar S, Le Rouzic V, Hunkele A, Uprety R, Huang XP, Xu J, Roth BL, Pan YX, Pasternak GW: Pharmacological characterization of novel synthetic opioids (NSO) found in the recreational drug marketplace. Neuropharmacology. 2018 May 15;134(Pt A):101-107. doi: 10.1016/j.neuropharm.2017.08.016. Epub 2017 Aug 12.","parent_key":"BE0000770"}
{"ref-id":"A182060","pubmed-id":28807672,"citation":"Baumann MH, Majumdar S, Le Rouzic V, Hunkele A, Uprety R, Huang XP, Xu J, Roth BL, Pan YX, Pasternak GW: Pharmacological characterization of novel synthetic opioids (NSO) found in the recreational drug marketplace. Neuropharmacology. 2018 May 15;134(Pt A):101-107. doi: 10.1016/j.neuropharm.2017.08.016. Epub 2017 Aug 12.","parent_key":"BE0000420"}
{"ref-id":"A19749","pubmed-id":25648999,"citation":"Lee JH, Noh CK, Yim CS, Jeong YS, Ahn SH, Lee W, Kim DD, Chung SJ: Kinetics of the Absorption, Distribution, Metabolism, and Excretion of Lobeglitazone, a Novel Activator of Peroxisome Proliferator-Activated Receptor Gamma in Rats. J Pharm Sci. 2015 Sep;104(9):3049-59. doi: 10.1002/jps.24378. Epub 2015 Feb 3.","parent_key":"BE0000215"}
{"ref-id":"A19861","pubmed-id":12391285,"citation":"Wick M, Hurteau G, Dessev C, Chan D, Geraci MW, Winn RA, Heasley LE, Nemenoff RA: Peroxisome proliferator-activated receptor-gamma is a target of nonsteroidal anti-inflammatory drugs mediating cyclooxygenase-independent inhibition of lung cancer cell growth. Mol Pharmacol. 2002 Nov;62(5):1207-14.","parent_key":"BE0000215"}
{"ref-id":"A27797","pubmed-id":14980665,"citation":"Riendeau D, Salem M, Styhler A, Ouellet M, Mancini JA, Li CS: Evaluation of loxoprofen and its alcohol metabolites for potency and selectivity of inhibition of cyclooxygenase-2. Bioorg Med Chem Lett. 2004 Mar 8;14(5):1201-3.","parent_key":"BE0000262"}
{"ref-id":"A27797","pubmed-id":14980665,"citation":"Riendeau D, Salem M, Styhler A, Ouellet M, Mancini JA, Li CS: Evaluation of loxoprofen and its alcohol metabolites for potency and selectivity of inhibition of cyclooxygenase-2. Bioorg Med Chem Lett. 2004 Mar 8;14(5):1201-3.","parent_key":"BE0000017"}
{"ref-id":"A19257","pubmed-id":28009827,"citation":"Ashraf Z, Alamgeer, Rasool R, Hassan M, Ahsan H, Afzal S, Afzal K, Cho H, Kim SJ: Synthesis, Bioevaluation and Molecular Dynamic Simulation Studies of Dexibuprofen-Antioxidant Mutual Prodrugs. Int J Mol Sci. 2016 Dec 21;17(12). pii: E2151. doi: 10.3390/ijms17122151.","parent_key":"BE0000262"}
{"ref-id":"A19257","pubmed-id":28009827,"citation":"Ashraf Z, Alamgeer, Rasool R, Hassan M, Ahsan H, Afzal S, Afzal K, Cho H, Kim SJ: Synthesis, Bioevaluation and Molecular Dynamic Simulation Studies of Dexibuprofen-Antioxidant Mutual Prodrugs. Int J Mol Sci. 2016 Dec 21;17(12). pii: E2151. doi: 10.3390/ijms17122151.","parent_key":"BE0000017"}
{"ref-id":"A31527","pubmed-id":3278945,"citation":"Esteve J, Farre AJ, Roser R: Pharmacological profile of droxicam. Gen Pharmacol. 1988;19(1):49-54.","parent_key":"BE0000017"}
{"ref-id":"A31527","pubmed-id":3278945,"citation":"Esteve J, Farre AJ, Roser R: Pharmacological profile of droxicam. Gen Pharmacol. 1988;19(1):49-54.","parent_key":"BE0000262"}
{"ref-id":"A31842","pubmed-id":9638074,"citation":"Lees P, McKellar QA, Foot R, Gettinby G: Pharmacodynamics and pharmacokinetics of tolfenamic acid in ruminating calves: evaluation in models of acute inflammation. Vet J. 1998 May;155(3):275-88.","parent_key":"BE0000017"}
{"ref-id":"A31843","pubmed-id":8200415,"citation":"McKellar QA, Lees P, Gettinby G: Pharmacodynamics of tolfenamic acid in dogs. Evaluation of dose response relationships. Eur J Pharmacol. 1994 Mar 3;253(3):191-200.","parent_key":"BE0000017"}
{"ref-id":"A31824","pubmed-id":6691890,"citation":"Tokola RA, Neuvonen PJ: Effects of migraine attack and metoclopramide on the absorption of tolfenamic acid. Br J Clin Pharmacol. 1984 Jan;17(1):67-75.","parent_key":"BE0000017"}
{"ref-id":"A31842","pubmed-id":9638074,"citation":"Lees P, McKellar QA, Foot R, Gettinby G: Pharmacodynamics and pharmacokinetics of tolfenamic acid in ruminating calves: evaluation in models of acute inflammation. Vet J. 1998 May;155(3):275-88.","parent_key":"BE0000262"}
{"ref-id":"A31843","pubmed-id":8200415,"citation":"McKellar QA, Lees P, Gettinby G: Pharmacodynamics of tolfenamic acid in dogs. Evaluation of dose response relationships. Eur J Pharmacol. 1994 Mar 3;253(3):191-200.","parent_key":"BE0000262"}
{"ref-id":"A31824","pubmed-id":6691890,"citation":"Tokola RA, Neuvonen PJ: Effects of migraine attack and metoclopramide on the absorption of tolfenamic acid. Br J Clin Pharmacol. 1984 Jan;17(1):67-75.","parent_key":"BE0000262"}
{"ref-id":"A18385","pubmed-id":15077695,"citation":"McCann ME, Andersen DR, Zhang D, Brideau C, Black WC, Hanson PD, Hickey GJ: In vitro effects and in vivo efficacy of a novel cyclooxygenase-2 inhibitor in dogs with experimentally induced synovitis. Am J Vet Res. 2004 Apr;65(4):503-12.","parent_key":"BE0000262"}
{"ref-id":"A188877","pubmed-id":23959544,"citation":"He Y, Si D, Yang C, Ni L, Li B, Ding M, Yang P: The effects of amlodipine and S(-)-amlodipine on vascular endothelial function in patients with hypertension. Am J Hypertens. 2014 Jan;27(1):27-31. doi: 10.1093/ajh/hpt138. Epub 2013 Aug 19.","parent_key":"BE0000005"}
{"ref-id":"A7880","pubmed-id":25261794,"citation":"Fujita W, Gomes I, Dove LS, Prohaska D, McIntyre G, Devi LA: Molecular characterization of eluxadoline as a potential ligand targeting mu-delta opioid receptor heteromers. Biochem Pharmacol. 2014 Dec 1;92(3):448-56. doi: 10.1016/j.bcp.2014.09.015. Epub  2014 Sep 28.","parent_key":"BE0000770"}
{"ref-id":"A7878","pubmed-id":23583433,"citation":"Dove LS, Lembo A, Randall CW, Fogel R, Andrae D, Davenport JM, McIntyre G, Almenoff JS, Covington PS: Eluxadoline benefits patients with irritable bowel syndrome with diarrhea in a phase 2 study. Gastroenterology. 2013 Aug;145(2):329-38.e1. doi: 10.1053/j.gastro.2013.04.006. Epub 2013 Apr 9.","parent_key":"BE0000770"}
{"ref-id":"A7880","pubmed-id":25261794,"citation":"Fujita W, Gomes I, Dove LS, Prohaska D, McIntyre G, Devi LA: Molecular characterization of eluxadoline as a potential ligand targeting mu-delta opioid receptor heteromers. Biochem Pharmacol. 2014 Dec 1;92(3):448-56. doi: 10.1016/j.bcp.2014.09.015. Epub  2014 Sep 28.","parent_key":"BE0000420"}
{"ref-id":"A18395","pubmed-id":26416827,"citation":"Kuk K, Taylor-Cousar JL: Lumacaftor and ivacaftor in the management of patients with cystic fibrosis: current evidence and future prospects. Ther Adv Respir Dis. 2015 Dec;9(6):313-26. doi: 10.1177/1753465815601934. Epub 2015 Sep 28.","parent_key":"BE0001195"}
{"ref-id":"A33314","pubmed-id":25026323,"citation":"Gassaway MM, Rives ML, Kruegel AC, Javitch JA, Sames D: The atypical antidepressant and neurorestorative agent tianeptine is a mu-opioid receptor agonist. Transl Psychiatry. 2014 Jul 15;4:e411. doi: 10.1038/tp.2014.30.","parent_key":"BE0000770"}
{"ref-id":"A33316","pubmed-id":28303899,"citation":"Samuels BA, Nautiyal KM, Kruegel AC, Levinstein MR, Magalong VM, Gassaway MM, Grinnell SG, Han J, Ansonoff MA, Pintar JE, Javitch JA, Sames D, Hen R: The Behavioral Effects of the Antidepressant Tianeptine Require the Mu-Opioid Receptor. Neuropsychopharmacology. 2017 Sep;42(10):2052-2063. doi: 10.1038/npp.2017.60. Epub 2017 Mar 17.","parent_key":"BE0000770"}
{"ref-id":"A18453","pubmed-id":24400777,"citation":"DeGoey DA, Randolph JT, Liu D, Pratt J, Hutchins C, Donner P, Krueger AC, Matulenko M, Patel S, Motter CE, Nelson L, Keddy R, Tufano M, Caspi DD, Krishnan P, Mistry N, Koev G, Reisch TJ, Mondal R, Pilot-Matias T, Gao Y, Beno DW, Maring CJ, Molla A, Dumas E, Campbell A, Williams L, Collins C, Wagner R, Kati WM: Discovery of ABT-267, a pan-genotypic inhibitor of HCV NS5A. J Med Chem. 2014 Mar 13;57(5):2047-57. doi: 10.1021/jm401398x. Epub 2014 Jan 15.","parent_key":"BE0008651"}
{"ref-id":"A19921","pubmed-id":15385557,"citation":"Nandini CD, Mikami T, Ohta M, Itoh N, Akiyama-Nambu F, Sugahara K: Structural and functional characterization of oversulfated chondroitin sulfate/dermatan sulfate hybrid chains from the notochord of hagfish. Neuritogenic and binding activities for growth factors and neurotrophic factors. J Biol Chem. 2004 Dec 3;279(49):50799-809. Epub 2004 Sep 22.","parent_key":"BE0000163"}
{"ref-id":"A14340","pubmed-id":18084610,"citation":"Loberg RD, McGregor N, Ying C, Sargent E, Pienta KJ: In vivo evaluation of AT-101 (R-(-)-gossypol acetic acid) in androgen-independent growth of VCaP prostate cancer cells in combination with surgical castration. Neoplasia. 2007 Dec;9(12):1030-7.","parent_key":"BE0000246"}
{"ref-id":"A19591","pubmed-id":16651709,"citation":"Nishimura M, Yamaguchi M, Naito S, Yamauchi A: Soybean oil fat emulsion to prevent TPN-induced liver damage: possible molecular mechanisms and clinical implications. Biol Pharm Bull. 2006 May;29(5):855-62.","parent_key":"BE0000071"}
{"ref-id":"A32722","pubmed-id":8872359,"citation":"Kobayashi T, Ikeda K, Ichikawa T, Togashi S, Kumanishi T: Effects of sigma ligands on the cloned mu-, delta- and kappa-opioid receptors co-expressed with G-protein-activated K+ (GIRK) channel in Xenopus oocytes. Br J Pharmacol. 1996 Sep;119(1):73-80.","parent_key":"BE0000770"}
{"ref-id":"A33093","pubmed-id":10339595,"citation":"Cronstein BN, Montesinos MC, Weissmann G: Salicylates and sulfasalazine, but not glucocorticoids, inhibit leukocyte accumulation by an adenosine-dependent mechanism that is independent of inhibition of prostaglandin synthesis and p105 of NFkappaB. Proc Natl Acad Sci U S A. 1999 May 25;96(11):6377-81.","parent_key":"BE0000017"}
{"ref-id":"A33093","pubmed-id":10339595,"citation":"Cronstein BN, Montesinos MC, Weissmann G: Salicylates and sulfasalazine, but not glucocorticoids, inhibit leukocyte accumulation by an adenosine-dependent mechanism that is independent of inhibition of prostaglandin synthesis and p105 of NFkappaB. Proc Natl Acad Sci U S A. 1999 May 25;96(11):6377-81.","parent_key":"BE0000262"}
{"ref-id":"A32963","pubmed-id":7437270,"citation":"Levy G: Clinical pharmacokinetics of salicylates: a re-assessment. Br J Clin Pharmacol. 1980 Oct;10 Suppl 2:285S-290S.","parent_key":"BE0000017"}
{"ref-id":"A32963","pubmed-id":7437270,"citation":"Levy G: Clinical pharmacokinetics of salicylates: a re-assessment. Br J Clin Pharmacol. 1980 Oct;10 Suppl 2:285S-290S.","parent_key":"BE0000262"}
{"ref-id":"A18415","pubmed-id":23410971,"citation":"Davids MS, Letai A: ABT-199: taking dead aim at BCL-2. Cancer Cell. 2013 Feb 11;23(2):139-41. doi: 10.1016/j.ccr.2013.01.018.","parent_key":"BE0000246"}
{"ref-id":"A18565","pubmed-id":23291630,"citation":"Souers AJ, Leverson JD, Boghaert ER, Ackler SL, Catron ND, Chen J, Dayton BD, Ding H, Enschede SH, Fairbrother WJ, Huang DC, Hymowitz SG, Jin S, Khaw SL, Kovar PJ, Lam LT, Lee J, Maecker HL, Marsh KC, Mason KD, Mitten MJ, Nimmer PM, Oleksijew A, Park CH, Park CM, Phillips DC, Roberts AW, Sampath D, Seymour JF, Smith ML, Sullivan GM, Tahir SK, Tse C, Wendt MD, Xiao Y, Xue JC, Zhang H, Humerickhouse RA, Rosenberg SH, Elmore SW: ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets. Nat Med. 2013 Feb;19(2):202-8. doi: 10.1038/nm.3048. Epub 2013 Jan 6.","parent_key":"BE0000246"}
{"ref-id":"A40022","pubmed-id":28056525,"citation":"King AC, Peterson TJ, Horvat TZ, Rodriguez M, Tang LA: Venetoclax: A First-in-Class Oral BCL-2 Inhibitor for the Management of Lymphoid Malignancies. Ann Pharmacother. 2017 May;51(5):410-416. doi: 10.1177/1060028016685803. Epub 2017 Jan 6.","parent_key":"BE0000246"}
{"ref-id":"A19609","pubmed-id":11988537,"citation":"Urizar NL, Liverman AB, Dodds DT, Silva FV, Ordentlich P, Yan Y, Gonzalez FJ, Heyman RA, Mangelsdorf DJ, Moore DD: A natural product that lowers cholesterol as an antagonist ligand for FXR. Science. 2002 May 31;296(5573):1703-6. Epub 2002 May 2.","parent_key":"BE0000956"}
{"ref-id":"A19609","pubmed-id":11988537,"citation":"Urizar NL, Liverman AB, Dodds DT, Silva FV, Ordentlich P, Yan Y, Gonzalez FJ, Heyman RA, Mangelsdorf DJ, Moore DD: A natural product that lowers cholesterol as an antagonist ligand for FXR. Science. 2002 May 31;296(5573):1703-6. Epub 2002 May 2.","parent_key":"BE0000071"}
{"ref-id":"A20257","pubmed-id":26340163,"citation":"Ravindra KC, Ho WE, Cheng C, Godoy LC, Wishnok JS, Ong CN, Wong WS, Wogan GN, Tannenbaum SR: Untargeted Proteomics and Systems-Based Mechanistic Investigation of Artesunate in Human Bronchial Epithelial Cells. Chem Res Toxicol. 2015 Oct 19;28(10):1903-13. doi: 10.1021/acs.chemrestox.5b00105. Epub 2015 Sep 21.","parent_key":"BE0000143"}
{"ref-id":"A32631","pubmed-id":8663038,"citation":"Rai SS, Wolff J: Localization of the vinblastine-binding site on beta-tubulin. J Biol Chem. 1996 Jun 21;271(25):14707-11.","parent_key":"BE0000143"}
{"ref-id":"A32632","pubmed-id":19455242,"citation":"Huzil JT, Chen K, Kurgan L, Tuszynski JA: The roles of beta-tubulin mutations and isotype expression in acquired drug resistance. Cancer Inform. 2007 Apr 27;3:159-81.","parent_key":"BE0000143"}
{"ref-id":"A32626","pubmed-id":28042310,"citation":"Gerullis H, Wawroschek F, Kohne CH, Ecke TH: Vinflunine in the treatment of advanced urothelial cancer: clinical evidence and experience. Ther Adv Urol. 2017 Jan;9(1):28-35. doi: 10.1177/1756287216677903. Epub 2016 Nov  21.","parent_key":"BE0000143"}
{"ref-id":"A19943","pubmed-id":15713005,"citation":"Nishiyama T, Mae T, Kishida H, Tsukagawa M, Mimaki Y, Kuroda M, Sashida Y, Takahashi K, Kawada T, Nakagawa K, Kitahara M: Curcuminoids and sesquiterpenoids in turmeric (Curcuma longa L.) suppress an increase in blood glucose level in type 2 diabetic KK-Ay mice. J Agric Food Chem. 2005 Feb 23;53(4):959-63.","parent_key":"BE0000215"}
{"ref-id":"A191622","pubmed-id":29864447,"citation":"Westover JB, Mathis A, Taylor R, Wandersee L, Bailey KW, Sefing EJ, Hickerson BT, Jung KH, Sheridan WP, Gowen BB: Galidesivir limits Rift Valley fever virus infection and disease in Syrian golden hamsters. Antiviral Res. 2018 Aug;156:38-45. doi: 10.1016/j.antiviral.2018.05.013. Epub 2018 Jun 1.","parent_key":"BE0009862"}
{"ref-id":"A191769","pubmed-id":31142664,"citation":"Eyer L, Nougairede A, Uhlirova M, Driouich JS, Zouharova D, Valdes JJ, Haviernik J, Gould EA, De Clercq E, de Lamballerie X, Ruzek D: An E460D Substitution in the NS5 Protein of Tick-Borne Encephalitis Virus Confers Resistance to the Inhibitor Galidesivir (BCX4430) and Also Attenuates the Virus for Mice. J Virol. 2019 Jul 30;93(16). pii: JVI.00367-19. doi: 10.1128/JVI.00367-19. Print 2019 Aug 15.","parent_key":"BE0009862"}
{"ref-id":"A32090","pubmed-id":28930490,"citation":"Donaldson SH, Pilewski JM, Griese M, Cooke J, Viswanathan L, Tullis E, Davies JC, Lekstrom-Himes JA, Wang LT: Tezacaftor/Ivacaftor in Subjects with Cystic Fibrosis and F508del/F508del-CFTR or F508del/G551D-CFTR. Am J Respir Crit Care Med. 2018 Jan 15;197(2):214-224. doi: 10.1164/rccm.201704-0717OC.","parent_key":"BE0001195"}
{"ref-id":"A32093","pubmed-id":29099344,"citation":"Taylor-Cousar JL, Munck A, McKone EF, van der Ent CK, Moeller A, Simard C, Wang LT, Ingenito EP, McKee C, Lu Y, Lekstrom-Himes J, Elborn JS: Tezacaftor-Ivacaftor in Patients with Cystic Fibrosis Homozygous for Phe508del. N Engl J Med. 2017 Nov 23;377(21):2013-2023. doi: 10.1056/NEJMoa1709846. Epub 2017 Nov 3.","parent_key":"BE0001195"}
{"ref-id":"A20298","pubmed-id":27714410,"citation":"Saint-Criq V, Gray MA: Role of CFTR in epithelial physiology. Cell Mol Life Sci. 2017 Jan;74(1):93-115. doi: 10.1007/s00018-016-2391-y. Epub 2016 Oct 6.","parent_key":"BE0001195"}
{"ref-id":"A19363","pubmed-id":2211617,"citation":"Bai RL, Pettit GR, Hamel E: Binding of dolastatin 10 to tubulin at a distinct site for peptide antimitotic agents near the exchangeable nucleotide and vinca alkaloid sites. J Biol Chem. 1990 Oct 5;265(28):17141-9.","parent_key":"BE0000143"}
{"ref-id":"A19364","pubmed-id":27518442,"citation":"Waight AB, Bargsten K, Doronina S, Steinmetz MO, Sussman D, Prota AE: Structural Basis of Microtubule Destabilization by Potent Auristatin Anti-Mitotics. PLoS One. 2016 Aug 12;11(8):e0160890. doi: 10.1371/journal.pone.0160890. eCollection 2016.","parent_key":"BE0000143"}
{"ref-id":"A199215","pubmed-id":14581379,"citation":"De Lorenzo MS, Yamaguchi K, Subbaramaiah K, Dannenberg AJ: Bryostatin-1 stimulates the transcription of cyclooxygenase-2: evidence for an activator protein-1-dependent mechanism. Clin Cancer Res. 2003 Oct 15;9(13):5036-43.","parent_key":"BE0000262"}
{"ref-id":"A199221","pubmed-id":25808573,"citation":"Kedei N, Kraft MB, Keck GE, Herald CL, Melody N, Pettit GR, Blumberg PM: Neristatin 1 provides critical insight into bryostatin 1 structure-function relationships. J Nat Prod. 2015 Apr 24;78(4):896-900. doi: 10.1021/acs.jnatprod.5b00094. Epub 2015 Mar 26.","parent_key":"BE0000704"}
{"ref-id":"A27262","pubmed-id":24297381,"citation":"Huizinga TW, Fleischmann RM, Jasson M, Radin AR, van Adelsberg J, Fiore S, Huang X, Yancopoulos GD, Stahl N, Genovese MC: Sarilumab, a fully human monoclonal antibody against IL-6Ralpha in patients with rheumatoid arthritis and an inadequate response to methotrexate: efficacy and safety results from the randomised SARIL-RA-MOBILITY Part A trial. Ann Rheum Dis. 2014 Sep;73(9):1626-34. doi: 10.1136/annrheumdis-2013-204405. Epub 2013 Dec 2.","parent_key":"BE0002859"}
{"ref-id":"A27269","pubmed-id":27464017,"citation":"June RR, Olsen NJ: Room for more IL-6 blockade? Sarilumab for the treatment of rheumatoid arthritis. Expert Opin Biol Ther. 2016 Oct;16(10):1303-9. doi: 10.1080/14712598.2016.1217988. Epub 2016 Aug 8.","parent_key":"BE0002859"}
{"ref-id":"A27270","pubmed-id":28264816,"citation":"Smolen JS, Landewe R, Bijlsma J, Burmester G, Chatzidionysiou K, Dougados M, Nam J, Ramiro S, Voshaar M, van Vollenhoven R, Aletaha D, Aringer M, Boers M, Buckley CD, Buttgereit F, Bykerk V, Cardiel M, Combe B, Cutolo M, van Eijk-Hustings Y, Emery P, Finckh A, Gabay C, Gomez-Reino J, Gossec L, Gottenberg JE, Hazes JMW, Huizinga T, Jani M, Karateev D, Kouloumas M, Kvien T, Li Z, Mariette X, McInnes I, Mysler E, Nash P, Pavelka K, Poor G, Richez C, van Riel P, Rubbert-Roth A, Saag K, da Silva J, Stamm T, Takeuchi T, Westhovens R, de Wit M, van der Heijde D: EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2016 update. Ann Rheum Dis. 2017 Jun;76(6):960-977. doi: 10.1136/annrheumdis-2016-210715. Epub 2017 Mar 6.","parent_key":"BE0002859"}
{"ref-id":"A27271","pubmed-id":28707587,"citation":"Kampan NC, Xiang SD, McNally OM, Stephens AN, Quinn MA, Plebanski M: Immunotherapeutic Interleukin-6 or Interleukin-6 receptor blockade in cancer: challenges and opportunities. Curr Med Chem. 2017 Jul 12. doi: 10.2174/0929867324666170712160621.","parent_key":"BE0002859"}
{"ref-id":"A27272","pubmed-id":26392750,"citation":"Lin P: Targeting interleukin-6 for noninfectious uveitis. Clin Ophthalmol. 2015 Sep 11;9:1697-702. doi: 10.2147/OPTH.S68595. eCollection 2015.","parent_key":"BE0002859"}
{"ref-id":"A14305","pubmed-id":17519293,"citation":"Chang F, Jaber LA, Berlie HD, O'Connell MB: Evolution of peroxisome proliferator-activated receptor agonists. Ann Pharmacother. 2007 Jun;41(6):973-83. Epub 2007 May 22.","parent_key":"BE0000215"}
{"ref-id":"A3704","pubmed-id":17455259,"citation":"Beckers T, Burkhardt C, Wieland H, Gimmnich P, Ciossek T, Maier T, Sanders K: Distinct pharmacological properties of second generation HDAC inhibitors with the benzamide or hydroxamate head group. Int J Cancer. 2007 Sep 1;121(5):1138-48.","parent_key":"BE0002365"}
{"ref-id":"A3705","pubmed-id":17868033,"citation":"Khan N, Jeffers M, Kumar S, Hackett C, Boldog F, Khramtsov N, Qian X, Mills E, Berghs SC, Carey N, Finn PW, Collins LS, Tumber A, Ritchie JW, Jensen PB, Lichenstein HS, Sehested M: Determination of the class and isoform selectivity of small-molecule histone deacetylase inhibitors. Biochem J. 2008 Jan 15;409(2):581-9.","parent_key":"BE0002365"}
{"ref-id":"A18725","pubmed-id":7494809,"citation":"Mollmann H, Hochhaus G, Rohatagi S, Barth J, Derendorf H: Pharmacokinetic/pharmacodynamic evaluation of deflazacort in comparison to methylprednisolone and prednisolone. Pharm Res. 1995 Jul;12(7):1096-100.","parent_key":"BE0000794"}
{"ref-id":"A33111","pubmed-id":12730403,"citation":"Mezei O, Banz WJ, Steger RW, Peluso MR, Winters TA, Shay N: Soy isoflavones exert antidiabetic and hypolipidemic effects through the PPAR pathways in obese Zucker rats and murine RAW 264.7 cells. J Nutr. 2003 May;133(5):1238-43. doi: 10.1093/jn/133.5.1238.","parent_key":"BE0000071"}
{"ref-id":"A33111","pubmed-id":12730403,"citation":"Mezei O, Banz WJ, Steger RW, Peluso MR, Winters TA, Shay N: Soy isoflavones exert antidiabetic and hypolipidemic effects through the PPAR pathways in obese Zucker rats and murine RAW 264.7 cells. J Nutr. 2003 May;133(5):1238-43. doi: 10.1093/jn/133.5.1238.","parent_key":"BE0000215"}
{"ref-id":"A31293","pubmed-id":22136436,"citation":"Ghazi A, Trikha A, Calhoun WJ: Benralizumab--a humanized mAb to IL-5Ralpha with enhanced antibody-dependent cell-mediated cytotoxicity--a novel approach for the treatment of asthma. Expert Opin Biol Ther. 2012 Jan;12(1):113-8. doi: 10.1517/14712598.2012.642359. Epub 2011 Dec 5.","parent_key":"BE0002097"}
{"ref-id":"A31294","pubmed-id":23866823,"citation":"Laviolette M, Gossage DL, Gauvreau G, Leigh R, Olivenstein R, Katial R, Busse WW, Wenzel S, Wu Y, Datta V, Kolbeck R, Molfino NA: Effects of benralizumab on airway eosinophils in asthmatic patients with sputum eosinophilia. J Allergy Clin Immunol. 2013 Nov;132(5):1086-1096.e5. doi: 10.1016/j.jaci.2013.05.020. Epub 2013 Jul 16.","parent_key":"BE0002097"}
{"ref-id":"A31297","pubmed-id":28109128,"citation":"Wang B, Yan L, Yao Z, Roskos LK: Population Pharmacokinetics and Pharmacodynamics of Benralizumab in Healthy Volunteers and Patients With Asthma. CPT Pharmacometrics Syst Pharmacol. 2017 Apr;6(4):249-257. doi: 10.1002/psp4.12160. Epub 2017 Jan 21.","parent_key":"BE0002097"}
{"ref-id":"A14334","pubmed-id":17505826,"citation":"Li J, Viallet J, Haura EB: A small molecule pan-Bcl-2 family inhibitor, GX15-070, induces apoptosis and enhances cisplatin-induced apoptosis in non-small cell lung cancer cells. Cancer Chemother Pharmacol. 2008 Mar;61(3):525-34. Epub 2007 May 16.","parent_key":"BE0000246"}
{"ref-id":"A14335","pubmed-id":17227835,"citation":"Perez-Galan P, Roue G, Villamor N, Campo E, Colomer D: The BH3-mimetic GX15-070 synergizes with bortezomib in mantle cell lymphoma by enhancing Noxa-mediated activation of Bak. Blood. 2007 May 15;109(10):4441-9. Epub 2007 Jan 16.","parent_key":"BE0000246"}
{"ref-id":"A20103","pubmed-id":20573757,"citation":"Chan KY, Edvinsson L, Eftekhari S, Kimblad PO, Kane SA, Lynch J, Hargreaves RJ, de Vries R, Garrelds IM, van den Bogaerdt AJ, Danser AH, Maassenvandenbrink A: Characterization of the calcitonin gene-related peptide receptor antagonist telcagepant (MK-0974) in human isolated coronary arteries. J Pharmacol Exp Ther. 2010 Sep 1;334(3):746-52. doi: 10.1124/jpet.110.165993. Epub 2010 Jun 23.","parent_key":"BE0009009"}
{"ref-id":"A14333","pubmed-id":16505100,"citation":"Hari M, Loganzo F, Annable T, Tan X, Musto S, Morilla DB, Nettles JH, Snyder JP, Greenberger LM: Paclitaxel-resistant cells have a mutation in the paclitaxel-binding region of beta-tubulin (Asp26Glu) and less stable microtubules. Mol Cancer Ther. 2006 Feb;5(2):270-8.","parent_key":"BE0000143"}
{"ref-id":"A176525","pubmed-id":29138536,"citation":"Gajofatto A: Spotlight on siponimod and its potential in the treatment of secondary progressive multiple sclerosis: the evidence to date. Drug Des Devel Ther. 2017 Nov 2;11:3153-3157. doi: 10.2147/DDDT.S122249. eCollection 2017.","parent_key":"BE0002432"}
{"ref-id":"A176528","pubmed-id":29735753,"citation":"Glaenzel U, Jin Y, Nufer R, Li W, Schroer K, Adam-Stitah S, Peter van Marle S, Legangneux E, Borell H, James AD, Meissner A, Camenisch G, Gardin A: Metabolism and Disposition of Siponimod, a Novel Selective S1P1/S1P5 Agonist, in Healthy Volunteers and In Vitro Identification of Human Cytochrome P450 Enzymes Involved in Its Oxidative Metabolism. Drug Metab Dispos. 2018 Jul;46(7):1001-1013. doi: 10.1124/dmd.117.079574. Epub 2018 May 7.","parent_key":"BE0002432"}
{"ref-id":"A176531","pubmed-id":26856814,"citation":"O'Sullivan C, Schubart A, Mir AK, Dev KK: The dual S1PR1/S1PR5 drug BAF312 (Siponimod) attenuates demyelination in organotypic slice cultures. J Neuroinflammation. 2016 Feb 8;13:31. doi: 10.1186/s12974-016-0494-x.","parent_key":"BE0002432"}
{"ref-id":"A176519","pubmed-id":24900670,"citation":"Pan S, Gray NS, Gao W, Mi Y, Fan Y, Wang X, Tuntland T, Che J, Lefebvre S, Chen Y, Chu A, Hinterding K, Gardin A, End P, Heining P, Bruns C, Cooke NG, Nuesslein-Hildesheim B: Discovery of BAF312 (Siponimod), a Potent and Selective S1P Receptor Modulator. ACS Med Chem Lett. 2013 Jan 4;4(3):333-7. doi: 10.1021/ml300396r. eCollection 2013 Mar 14.","parent_key":"BE0008652"}
{"ref-id":"A176522","pubmed-id":517042,"citation":"Gianguzza M, Dolcemascolo G: On the ultrastructure of the test cells of Ascidia malaca during oogenesis. Acta Embryol Exp (Palermo). 1979;(2):173-89.","parent_key":"BE0008652"}
{"ref-id":"A176525","pubmed-id":29138536,"citation":"Gajofatto A: Spotlight on siponimod and its potential in the treatment of secondary progressive multiple sclerosis: the evidence to date. Drug Des Devel Ther. 2017 Nov 2;11:3153-3157. doi: 10.2147/DDDT.S122249. eCollection 2017.","parent_key":"BE0008652"}
{"ref-id":"A20342","pubmed-id":16961726,"citation":"Gresele P, Momi S: Pharmacologic profile and therapeutic potential of NCX 4016, a nitric oxide-releasing aspirin, for cardiovascular disorders. Cardiovasc Drug Rev. 2006 Summer;24(2):148-68.","parent_key":"BE0000017"}
{"ref-id":"A33150","pubmed-id":16144976,"citation":"Corazzi T, Leone M, Maucci R, Corazzi L, Gresele P: Direct and irreversible inhibition of cyclooxygenase-1 by nitroaspirin (NCX 4016). J Pharmacol Exp Ther. 2005 Dec;315(3):1331-7. doi: 10.1124/jpet.105.089896. Epub 2005 Sep 6.","parent_key":"BE0000017"}
{"ref-id":"A189330","pubmed-id":31291516,"citation":"Lipton RB, Croop R, Stock EG, Stock DA, Morris BA, Frost M, Dubowchik GM, Conway CM, Coric V, Goadsby PJ: Rimegepant, an Oral Calcitonin Gene-Related Peptide Receptor Antagonist, for Migraine. N Engl J Med. 2019 Jul 11;381(2):142-149. doi: 10.1056/NEJMoa1811090.","parent_key":"BE0009009"}
{"ref-id":"A189207","pubmed-id":31081399,"citation":"Negro A, Martelletti P: Gepants for the treatment of migraine. Expert Opin Investig Drugs. 2019 Jun;28(6):555-567. doi: 10.1080/13543784.2019.1618830. Epub 2019 May 17.","parent_key":"BE0009009"}
{"ref-id":"A191721","pubmed-id":30724789,"citation":"Hayden FG, Shindo N: Influenza virus polymerase inhibitors in clinical development. Curr Opin Infect Dis. 2019 Apr;32(2):176-186. doi: 10.1097/QCO.0000000000000532.","parent_key":"BE0009866"}
{"ref-id":"A20198","pubmed-id":23707768,"citation":"Wang YM, Lin W, Chai SC, Wu J, Ong SS, Schuetz EG, Chen T: Piperine activates human pregnane X receptor to induce the expression of cytochrome P450 3A4 and multidrug resistance protein 1. Toxicol Appl Pharmacol. 2013 Oct 1;272(1):96-107. doi: 10.1016/j.taap.2013.05.014. Epub 2013 May 22.","parent_key":"BE0000956"}
{"ref-id":"A189318","pubmed-id":31492652,"citation":"Cohen JA, Comi G, Selmaj KW, Bar-Or A, Arnold DL, Steinman L, Hartung HP, Montalban X, Kubala Havrdova E, Cree BAC, Sheffield JK, Minton N, Raghupathi K, Huang V, Kappos L: Safety and efficacy of ozanimod versus interferon beta-1a in relapsing multiple sclerosis (RADIANCE): a multicentre, randomised, 24-month, phase 3 trial. Lancet Neurol. 2019 Nov;18(11):1021-1033. doi: 10.1016/S1474-4422(19)30238-8. Epub 2019 Sep 3.","parent_key":"BE0008652"}
{"ref-id":"A189321","pubmed-id":28398597,"citation":"Tran JQ, Hartung JP, Peach RJ, Boehm MF, Rosen H, Smith H, Brooks JL, Timony GA, Olson AD, Gujrathi S, Frohna PA: Results From the First-in-Human Study With Ozanimod, a Novel, Selective Sphingosine-1-Phosphate Receptor Modulator. J Clin Pharmacol. 2017 Aug;57(8):988-996. doi: 10.1002/jcph.887. Epub 2017 Apr 11.","parent_key":"BE0008652"}
{"ref-id":"A189333","pubmed-id":29125718,"citation":"Tran JQ, Hartung JP, Tompkins CA, Frohna PA: Effects of High- and Low-Fat Meals on the Pharmacokinetics of Ozanimod, a Novel Sphingosine-1-Phosphate Receptor Modulator. Clin Pharmacol Drug Dev. 2018 Aug;7(6):634-640. doi: 10.1002/cpdd.409. Epub 2017 Nov 10.","parent_key":"BE0008652"}
{"ref-id":"A189318","pubmed-id":31492652,"citation":"Cohen JA, Comi G, Selmaj KW, Bar-Or A, Arnold DL, Steinman L, Hartung HP, Montalban X, Kubala Havrdova E, Cree BAC, Sheffield JK, Minton N, Raghupathi K, Huang V, Kappos L: Safety and efficacy of ozanimod versus interferon beta-1a in relapsing multiple sclerosis (RADIANCE): a multicentre, randomised, 24-month, phase 3 trial. Lancet Neurol. 2019 Nov;18(11):1021-1033. doi: 10.1016/S1474-4422(19)30238-8. Epub 2019 Sep 3.","parent_key":"BE0002432"}
{"ref-id":"A189321","pubmed-id":28398597,"citation":"Tran JQ, Hartung JP, Peach RJ, Boehm MF, Rosen H, Smith H, Brooks JL, Timony GA, Olson AD, Gujrathi S, Frohna PA: Results From the First-in-Human Study With Ozanimod, a Novel, Selective Sphingosine-1-Phosphate Receptor Modulator. J Clin Pharmacol. 2017 Aug;57(8):988-996. doi: 10.1002/jcph.887. Epub 2017 Apr 11.","parent_key":"BE0002432"}
{"ref-id":"A189333","pubmed-id":29125718,"citation":"Tran JQ, Hartung JP, Tompkins CA, Frohna PA: Effects of High- and Low-Fat Meals on the Pharmacokinetics of Ozanimod, a Novel Sphingosine-1-Phosphate Receptor Modulator. Clin Pharmacol Drug Dev. 2018 Aug;7(6):634-640. doi: 10.1002/cpdd.409. Epub 2017 Nov 10.","parent_key":"BE0002432"}
{"ref-id":"A19942","pubmed-id":15705660,"citation":"Schaaf MJ, Lewis-Tuffin LJ, Cidlowski JA: Ligand-selective targeting of the glucocorticoid receptor to nuclear subdomains is associated with decreased receptor mobility. Mol Endocrinol. 2005 Jun;19(6):1501-15. Epub 2005 Feb 10.","parent_key":"BE0000794"}
{"ref-id":"A203246","pubmed-id":24856378,"citation":"Rakanovic-Todic M, Burnazovic-Ristic L, Ibrulj S, Mulbegovic N: Effect of met-enkephalin on chromosomal aberrations in the lymphocytes of the peripheral blood of patients with multiple sclerosis. Bosn J Basic Med Sci. 2014 May;14(2):75-80. doi: 10.17305/bjbms.2014.2267.","parent_key":"BE0000420"}
{"ref-id":"A203246","pubmed-id":24856378,"citation":"Rakanovic-Todic M, Burnazovic-Ristic L, Ibrulj S, Mulbegovic N: Effect of met-enkephalin on chromosomal aberrations in the lymphocytes of the peripheral blood of patients with multiple sclerosis. Bosn J Basic Med Sci. 2014 May;14(2):75-80. doi: 10.17305/bjbms.2014.2267.","parent_key":"BE0000770"}
{"ref-id":"A19937","pubmed-id":15677712,"citation":"Yoshikawa N, Yamamoto K, Shimizu N, Yamada S, Morimoto C, Tanaka H: The distinct agonistic properties of the phenylpyrazolosteroid cortivazol reveal interdomain communication within the glucocorticoid receptor. Mol Endocrinol. 2005 May;19(5):1110-24. Epub 2005 Jan 27.","parent_key":"BE0000794"}
{"ref-id":"A18893","pubmed-id":241595,"citation":"Thomas GM, Rees P, Dippy JE, Maddock J: Simultaneous pharmacokinetics of alclofenace in plasma and synovial fluid in patients with rheumatoid arthritis. Curr Med Res Opin. 1975;3(5):264-7.","parent_key":"BE0000262"}
{"ref-id":"A27192","pubmed-id":1204506,"citation":"Brogden RN, Pinder RM, Sawyer PR, Speight TM, Avery GS: Bufexamac: a review of its pharmacological properties and therapeutic efficacy in inflammatory dermatoses. Drugs. 1975;10(5-6):351-6.","parent_key":"BE0000017"}
{"ref-id":"A27192","pubmed-id":1204506,"citation":"Brogden RN, Pinder RM, Sawyer PR, Speight TM, Avery GS: Bufexamac: a review of its pharmacological properties and therapeutic efficacy in inflammatory dermatoses. Drugs. 1975;10(5-6):351-6.","parent_key":"BE0000262"}
{"ref-id":"A33062","pubmed-id":24963489,"citation":"Li JY, Cao HY, Liu P, Cheng GH, Sun MY: Glycyrrhizic acid in the treatment of liver diseases: literature review. Biomed Res Int. 2014;2014:872139. doi: 10.1155/2014/872139. Epub 2014 May 13.","parent_key":"BE0000704"}
{"ref-id":"A32945","pubmed-id":22393325,"citation":"Visioli F, Giordano E, Nicod NM, Davalos A: Molecular targets of omega 3 and conjugated linoleic Fatty acids - \"micromanaging\" cellular response. Front Physiol. 2012 Feb 29;3:42. doi: 10.3389/fphys.2012.00042. eCollection 2012.","parent_key":"BE0000262"}
{"ref-id":"A32946","pubmed-id":28760435,"citation":"Rodriguez-Cruz M, Serna DS: Nutrigenomics of omega-3 fatty acids: Regulators of the master transcription factors. Nutrition. 2017 Sep;41:90-96. doi: 10.1016/j.nut.2017.04.012. Epub 2017 May 2.","parent_key":"BE0000071"}
{"ref-id":"A32946","pubmed-id":28760435,"citation":"Rodriguez-Cruz M, Serna DS: Nutrigenomics of omega-3 fatty acids: Regulators of the master transcription factors. Nutrition. 2017 Sep;41:90-96. doi: 10.1016/j.nut.2017.04.012. Epub 2017 May 2.","parent_key":"BE0000215"}
{"ref-id":"A33078","pubmed-id":1588563,"citation":"Hulin B, Clark DA, Goldstein SW, McDermott RE, Dambek PJ, Kappeler WH, Lamphere CH, Lewis DM, Rizzi JP: Novel thiazolidine-2,4-diones as potent euglycemic agents. J Med Chem. 1992 May 15;35(10):1853-64.","parent_key":"BE0000215"}
{"ref-id":"A34016","pubmed-id":28778859,"citation":"Miyazaki T, Choi IY, Rubas W, Anand NK, Ali C, Evans J, Gursahani H, Hennessy M, Kim G, McWeeney D, Pfeiffer J, Quach P, Gauvin D, Riley TA, Riggs JA, Gogas K, Zalevsky J, Doberstein SK: NKTR-181: A Novel Mu-Opioid Analgesic with Inherently Low Abuse Potential. J Pharmacol Exp Ther. 2017 Oct;363(1):104-113. doi: 10.1124/jpet.117.243030. Epub 2017 Aug 4.","parent_key":"BE0000770"}
{"ref-id":"A34016","pubmed-id":28778859,"citation":"Miyazaki T, Choi IY, Rubas W, Anand NK, Ali C, Evans J, Gursahani H, Hennessy M, Kim G, McWeeney D, Pfeiffer J, Quach P, Gauvin D, Riley TA, Riggs JA, Gogas K, Zalevsky J, Doberstein SK: NKTR-181: A Novel Mu-Opioid Analgesic with Inherently Low Abuse Potential. J Pharmacol Exp Ther. 2017 Oct;363(1):104-113. doi: 10.1124/jpet.117.243030. Epub 2017 Aug 4.","parent_key":"BE0000420"}
{"ref-id":"A193497","pubmed-id":29616828,"citation":"Zhang L, Zhang J, Jiang Q, Zhang L, Song W: Zinc binding groups for histone deacetylase inhibitors. J Enzyme Inhib Med Chem. 2018 Dec;33(1):714-721. doi: 10.1080/14756366.2017.1417274.","parent_key":"BE0002365"}
{"ref-id":"A193431","pubmed-id":7332580,"citation":"Boyle MD: Inhibition by zinc of the binding of C1 to antigen-antibody complexes. Biochem Biophys Res Commun. 1981 Dec 15;103(3):856-62. doi: 10.1016/0006-291x(81)90889-5.","parent_key":"BE0002095"}
{"ref-id":"A193431","pubmed-id":7332580,"citation":"Boyle MD: Inhibition by zinc of the binding of C1 to antigen-antibody complexes. Biochem Biophys Res Commun. 1981 Dec 15;103(3):856-62. doi: 10.1016/0006-291x(81)90889-5.","parent_key":"BE0002096"}
{"ref-id":"A37090","pubmed-id":19434887,"citation":"Sitruk-Ware R: Pharmacological profile of progestins. Maturitas. 2008 Sep-Oct;61(1-2):151-7.","parent_key":"BE0000794"}
{"ref-id":"A191400","pubmed-id":29511076,"citation":"Agostini ML, Andres EL, Sims AC, Graham RL, Sheahan TP, Lu X, Smith EC, Case JB, Feng JY, Jordan R, Ray AS, Cihlar T, Siegel D, Mackman RL, Clarke MO, Baric RS, Denison MR: Coronavirus Susceptibility to the Antiviral Remdesivir (GS-5734) Is Mediated by the Viral Polymerase and the Proofreading Exoribonuclease. mBio. 2018 Mar 6;9(2). pii: mBio.00221-18. doi: 10.1128/mBio.00221-18.","parent_key":"BE0003801"}
{"ref-id":"A191451","pubmed-id":30987343,"citation":"Tchesnokov EP, Feng JY, Porter DP, Gotte M: Mechanism of Inhibition of Ebola Virus RNA-Dependent RNA Polymerase by Remdesivir. Viruses. 2019 Apr 4;11(4). pii: v11040326. doi: 10.3390/v11040326.","parent_key":"BE0009862"}
{"ref-id":"A188976","pubmed-id":31047803,"citation":"Tamura K, Tsurutani J, Takahashi S, Iwata H, Krop IE, Redfern C, Sagara Y, Doi T, Park H, Murthy RK, Redman RA, Jikoh T, Lee C, Sugihara M, Shahidi J, Yver A, Modi S: Trastuzumab deruxtecan (DS-8201a) in patients with advanced HER2-positive breast cancer previously treated with trastuzumab emtansine: a dose-expansion, phase 1 study. Lancet Oncol. 2019 Jun;20(6):816-826. doi: 10.1016/S1470-2045(19)30097-X. Epub 2019 Apr 29.","parent_key":"BE0000710"}
{"ref-id":"A188979","pubmed-id":30351177,"citation":"Nagai Y, Oitate M, Shiozawa H, Ando O: Comprehensive preclinical pharmacokinetic evaluations of trastuzumab deruxtecan (DS-8201a), a HER2-targeting antibody-drug conjugate, in cynomolgus monkeys. Xenobiotica. 2019 Sep;49(9):1086-1096. doi: 10.1080/00498254.2018.1531158. Epub 2019 Jan 4.","parent_key":"BE0000710"}
{"ref-id":"A191751","pubmed-id":17562848,"citation":"Markowitz CE: Interferon-beta: mechanism of action and dosing issues. Neurology. 2007 Jun 12;68(24 Suppl 4):S8-11. doi: 10.1212/01.wnl.0000277703.74115.d2.","parent_key":"BE0000661"}
{"ref-id":"A191814","pubmed-id":25356432,"citation":"Kasper LH, Reder AT: Immunomodulatory activity of interferon-beta. Ann Clin Transl Neurol. 2014 Aug;1(8):622-31. doi: 10.1002/acn3.84. Epub 2014 Jul 23.","parent_key":"BE0000661"}
{"ref-id":"A191817","pubmed-id":27572132,"citation":"Haji Abdolvahab M, Mofrad MR, Schellekens H: Interferon Beta: From Molecular Level to Therapeutic Effects. Int Rev Cell Mol Biol. 2016;326:343-72. doi: 10.1016/bs.ircmb.2016.06.001. Epub 2016 Jul 20.","parent_key":"BE0000661"}
{"ref-id":"A191820","pubmed-id":23913971,"citation":"Kole A, He J, Rivollier A, Silveira DD, Kitamura K, Maloy KJ, Kelsall BL: Type I IFNs regulate effector and regulatory T cell accumulation and anti-inflammatory cytokine production during T cell-mediated colitis. J Immunol. 2013 Sep 1;191(5):2771-9. doi: 10.4049/jimmunol.1301093. Epub 2013 Aug 2.","parent_key":"BE0000661"}
{"ref-id":"A192717","pubmed-id":2322310,"citation":"Hastie SB, Macdonald TL: Binding of colchiceine to tubulin. Mechanisms of ligand association with tubulin. Biochem Pharmacol. 1990 Apr 15;39(8):1271-6. doi: 10.1016/0006-2952(90)90002-3.","parent_key":"BE0000143"}
{"ref-id":"A191640","pubmed-id":24121757,"citation":"Hoetelmans RM, Dierynck I, Smyej I, Meyvisch P, Jacquemyn B, Marien K, Simmen K, Verloes R: Safety and pharmacokinetics of the HIV-1 protease inhibitor TMC310911 coadministered with ritonavir in healthy participants: results from 2 phase 1 studies. J Acquir Immune Defic Syndr. 2014 Mar 1;65(3):299-305. doi: 10.1097/QAI.0000000000000011.","parent_key":"BE0000664"}
{"ref-id":"A191637","pubmed-id":21896904,"citation":"Dierynck I, Van Marck H, Van Ginderen M, Jonckers TH, Nalam MN, Schiffer CA, Raoof A, Kraus G, Picchio G: TMC310911, a novel human immunodeficiency virus type 1 protease inhibitor, shows in vitro an improved resistance profile and higher genetic barrier to resistance compared with current protease inhibitors. Antimicrob Agents Chemother. 2011 Dec;55(12):5723-31. doi: 10.1128/AAC.00748-11. Epub 2011 Sep 6.","parent_key":"BE0000664"}
{"ref-id":"A192426","pubmed-id":15492138,"citation":"Huentelman MJ, Zubcevic J, Hernandez Prada JA, Xiao X, Dimitrov DS, Raizada MK, Ostrov DA: Structure-based discovery of a novel angiotensin-converting enzyme 2 inhibitor. Hypertension. 2004 Dec;44(6):903-6. doi: 10.1161/01.HYP.0000146120.29648.36. Epub 2004 Oct 18.","parent_key":"BE0000982"}
{"ref-id":"A188982","pubmed-id":31825192,"citation":"Modi S, Saura C, Yamashita T, Park YH, Kim SB, Tamura K, Andre F, Iwata H, Ito Y, Tsurutani J, Sohn J, Denduluri N, Perrin C, Aogi K, Tokunaga E, Im SA, Lee KS, Hurvitz SA, Cortes J, Lee C, Chen S, Zhang L, Shahidi J, Yver A, Krop I: Trastuzumab Deruxtecan in Previously Treated HER2-Positive Breast Cancer. N Engl J Med. 2019 Dec 11. doi: 10.1056/NEJMoa1914510.","parent_key":"BE0009862"}